<SEC-DOCUMENT>0001819790-21-000027.txt : 20210805
<SEC-HEADER>0001819790-21-000027.hdr.sgml : 20210805
<ACCEPTANCE-DATETIME>20210804174028
ACCESSION NUMBER:		0001819790-21-000027
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		57
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210805
DATE AS OF CHANGE:		20210804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tarsus Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001819790
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				814717861
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39614
		FILM NUMBER:		211145350

	BUSINESS ADDRESS:	
		STREET 1:		15440 LAGUNA CANYON ROAD
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
		BUSINESS PHONE:		(949) 409-9820

	MAIL ADDRESS:	
		STREET 1:		15440 LAGUNA CANYON ROAD
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tars-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:1b782ba2-cb83-443a-9650-7dcdabbf6aa7,g:fefcf97f-7929-4215-bb38-a69760b7d0fa,d:8b61561133ed4a6b868d8d2b5a1f9640--><html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:tars="http://tarsusrx.com/20210630" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>tars-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80L2ZyYWc6Mjc4ZjIwYjU4ZDJhNDZiZmIwNjE5MDRmYTJkZmI0MzYvdGFibGU6YWVkOWUyMzg3OTUyNDQwNjg0ZTcwNGI3MTRiYTk4NTQvdGFibGVyYW5nZTphZWQ5ZTIzODc5NTI0NDA2ODRlNzA0YjcxNGJhOTg1NF8yLTEtMS0xLTA_84d11653-d924-4d1a-ac32-795f6a5d946c">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80L2ZyYWc6Mjc4ZjIwYjU4ZDJhNDZiZmIwNjE5MDRmYTJkZmI0MzYvdGFibGU6YWVkOWUyMzg3OTUyNDQwNjg0ZTcwNGI3MTRiYTk4NTQvdGFibGVyYW5nZTphZWQ5ZTIzODc5NTI0NDA2ODRlNzA0YjcxNGJhOTg1NF8zLTEtMS0xLTA_37178177-d779-4341-833c-42969a8dadb5">0001819790</ix:nonNumeric><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80L2ZyYWc6Mjc4ZjIwYjU4ZDJhNDZiZmIwNjE5MDRmYTJkZmI0MzYvdGFibGU6YWVkOWUyMzg3OTUyNDQwNjg0ZTcwNGI3MTRiYTk4NTQvdGFibGVyYW5nZTphZWQ5ZTIzODc5NTI0NDA2ODRlNzA0YjcxNGJhOTg1NF80LTEtMS0xLTA_f48c5241-710b-436e-8fae-f2359b47ee2f">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80L2ZyYWc6Mjc4ZjIwYjU4ZDJhNDZiZmIwNjE5MDRmYTJkZmI0MzYvdGFibGU6YWVkOWUyMzg3OTUyNDQwNjg0ZTcwNGI3MTRiYTk4NTQvdGFibGVyYW5nZTphZWQ5ZTIzODc5NTI0NDA2ODRlNzA0YjcxNGJhOTg1NF81LTEtMS0xLTA_cf28cb98-f47c-4753-b0c4-7c0a56cfef1e">2021</ix:nonNumeric><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80L2ZyYWc6Mjc4ZjIwYjU4ZDJhNDZiZmIwNjE5MDRmYTJkZmI0MzYvdGFibGU6YWVkOWUyMzg3OTUyNDQwNjg0ZTcwNGI3MTRiYTk4NTQvdGFibGVyYW5nZTphZWQ5ZTIzODc5NTI0NDA2ODRlNzA0YjcxNGJhOTg1NF82LTEtMS0xLTA_5f241fdf-4a2a-4b26-b073-97d454a42923">Q2</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i63a91755fb3d4006a2cc404a6ded9de0_D20201008-20201008" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNy9mcmFnOmMzZDRmYzhjNDYxNjRmZGY5NGFkZjZhN2M2NTEwMmZlL3RhYmxlOjE0YjRiZTM2OWUzMDRjNDBhNjc3NmZlYTU2OGNmZGIxL3RhYmxlcmFuZ2U6MTRiNGJlMzY5ZTMwNGM0MGE2Nzc2ZmVhNTY4Y2ZkYjFfMi0xLTEtMS0w_66f369b2-bdaf-4da0-bdfd-b2a996bef3d2">0.1346</ix:nonFraction><ix:nonNumeric contextRef="iae02a45997884de49225d614d0b8bfcf_D20210101-20210630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfMjM4Ng_487f5d4f-2795-4d06-a86b-a0f73cdced0d">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="tars-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="id418552000374cee91d2f152ebbeefbf_I20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id5386c319aba4c61a7bf6efd8331dd95_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6a6d638fd8024fb489c508a2ffc1d40a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia569047a0bf44c6a9285af3f2ca01975_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia277d64b3cf54f299bea0e672deb68c6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b407322af7f46eca61e30b4fecffe2b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i844a21cea71e4d1bae8b39773824d43d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i631be233d7544546b6561e0e68e759a9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaa5350dda6d437da5ff9a746dca6f3b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47131aae4502439b84e481d0cd4795aa_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1e17b2b90194854a0c1f35b7f7a220c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cfb8f7666f5404697abaf42468b411d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f0a7226965f407bb1332105daf637d9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i883f70c143b9443d8fd6e696331febda_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb7ee0d743be4e14b1401f1d0a96ec6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52e734a7761645e48b189cb6e2b8421e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac09cf4a066646c188469b8b5c55183e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad26ed4c0a904b1db84e266a4d16a1b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23ecbbc22f4540cd8bcea0e396ba673e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a28ec4e85d84692b4ca6a32628fa4be_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc512caba35a452c8e9461069e750305_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4ab6ac8e8814105820d3a3d650f85f6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i739e66a8b2094324ad392839b69d2eec_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33759a7e324e4a7d9618b0aaa5838ece_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fb433c2724c4c6e91eb08e2465af045_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47b0c69c412247c68a44124006cf6612_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17e969dac4d6411dbb826ee3db9998d9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a8d4c6166724c9dba7245924538fd86_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i345e2829049d4416bf301cc23ac6a406_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0634e483f0f4516a460bacff8b51bcc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4426dbfe40cc497ab87fc456c68f513e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5291f4b8a4e24019929680d04b243c5f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1f9f9fed4d646e2b0a01016693eec81_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaeccdc12ddfa46af872eef01caec5973_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i582e67cbd8fa41379c4ab2acf8ad6e1c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94907dbf7f4947419d7e95e4a21fe043_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18065d30bf104e29b2ef78dd078ba467_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fb6e623368041f9a2fada37f7f956b8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib35a7e25ebbe4fc381478dbc1dc8dbd3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54f251974ca94b0e9b65707daf81e0f4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d8683a7d9e14fe9abbd3f6a5c86c6f6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f0da49422cc4c05b2cba9c4406d801a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice41973b875c464a83d520944c39c4eb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58d0bbc40e024b4bab78c783704a7261_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1195e7340d234c54a47b573024044888_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i940347dc2e60436481e72725ac419fe5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i211c6caec1a14d17bb9a07d1b78206cc_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i760234fe991c4dce8f6fcb5f097fe516_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1b6177ab72f41b8a0277863efcf4f48_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6dea8e6a4a44ea8b8d16ccb73c60507_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff82cd871b884faca9901b82ef49823f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc3a3e1730b5474fb6d19a4e8ace2be6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5b15cc9e2f848be9dcc3c45f2dcb249_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id44cd453c94c48e99a7b9568be7f73e7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37397987845b4ff0830e35dfd25588e8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id299c065b2574582a3d3a576ee8241d8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefff22de6102436b99e849ce51fd5afa_D20201020-20201020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-20</xbrli:startDate><xbrli:endDate>2020-10-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92fe8dadc41449e49b3e9e72a278675a_I20201020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia81ce0ad42d6478f8526933a9dce6e9d_D20201020-20201020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-20</xbrli:startDate><xbrli:endDate>2020-10-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>tars:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i63a91755fb3d4006a2cc404a6ded9de0_D20201008-20201008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-08</xbrli:startDate><xbrli:endDate>2020-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i366691130c6c4705a075c2827729e560_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c14c67cea444f0bb19eaae7c5445028_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i652b87a7987044cca7f42704ba156268_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9b8f6a5a48541248c73d37edf6dcbae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ad7dbb20ff542cab6548bbf1e554538_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifac36b8ba5a54e45b43ad3707581ea5e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia344278fd11e4e599d06a16dbef3dac0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9254bbc4390429eadabae632a1ee8ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>tars:vote</xbrli:measure></xbrli:unit><xbrli:context id="i4fa02c7ace144c81a2fd09a81a1d827c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i160de614ede245e3b4a8318dd5566a1f_I20201020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4417090679e84025a7090d9e6076ba21_I20201020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide340ac61efb43b08434911f4db98e68_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70a7676a97b848b1a1f7a3665d148983_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae02a45997884de49225d614d0b8bfcf_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1441e738b9045918e9a7e31197dd133_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id52f2032269a4f819d15bd4d1e161a3b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia382e48d34b4428fafebec87724739c8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09be892cb78f4a5492f5791c5d513c0a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54c21ad7a9fe43c996fb0628c1fd4ac4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie004d19f0fd443d5b88f07a7468ee270_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaa289cd736c437987015fee0950c75c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42649f1122f8480785c73d82be5bd8dc_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52aedec7a8084e91bca615af7ebec95a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icea321863db444169b622b85850d6e55_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00691ca440da494bb30506de043894c3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib790f0e6092341f4a52bec6af062bad6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bb4eaa3ec8e4dea84b9f3711947b2e3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41b874cb3c6a4ec08fed9386a1952c2d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09d03f0a6dbb451781fd862327cdf06f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i676991ec719542d787676a12566ca054_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia30cf1b452db4f2ab51f825c5ca653f5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEarlyExercisedOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i219f4b1f55974121826108795989b54f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEarlyExercisedOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddbd54b520554e4eba813e5be9dfdf7d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09a13b7525134e7abe18f464f8248af4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53e1600dba1b4b808a42c009c3b3eaa9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1923bd29bb5b417abd997b0aed3bc467_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia46c6f317af64f7caba90357c4e57a2d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62e01287e81647ce9087b8b1ff3d25cf_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i220d03846323467db8c56663c9a2e8df_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i229e0511be204ad18d91926584e23767_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6a8425d752d4893941d5870ecfeb307_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8de5698c138449598b8e67a58294917_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7356e8595ea47819751082d1cbcd009_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i739167d612a94c119439e7d8a3bb2b98_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7653af8a6494075bf51541661c26fca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dd90741d4ee44c0912e3f9f2224b6b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i531e6f9904f341b0bf1f8a0e802a62ba_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabd2ce550eaa434ea84c33a084eae37b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:NonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="contract"><xbrli:measure>tars:contract</xbrli:measure></xbrli:unit><xbrli:context id="icb3da3b8c1a44b60becc387206f9893f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tars:IrvineOfficeAndFacilitiesLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie05ece3c0fcc4ccaa63406a8de30a51b_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie13dc8d045254f7482573f832793430f_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1452c0961726458e8ba94815bf62b628_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tars:OtherFacilityLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2b5fae2eaf5463c9ec06e5004104176_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f5e022e1a4a4c389fd70f2fdd2953e1_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i120ab40354ce4e18abe9a05184afca4c_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93cd1b65dc5e40239017d30da180b216_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d2fb7b171a54a6d88b68e421934e6d8_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad5ec97fc35d4af183d9972de8c93b10_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CommercialAndSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70b499fd960e46b6927230aed1207cbd_D20210401-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie07d05df956f4d13b7387802ceea7fc8_D20210401-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id78fdaf99d664fb88506c79ba98fab86_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i984e3a65060c4cfeb572fc37ad5c4a4b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1af047204199476fbf9fa4a0c7a282ea_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CommercialAndSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82afa114a25e4157b2a2b9dd666cfc9c_D20200903-20200903"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-03</xbrli:startDate><xbrli:endDate>2020-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="arrangement"><xbrli:measure>tars:arrangement</xbrli:measure></xbrli:unit><xbrli:context id="i0574c418228c4e3ab5c608032507de3f_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99377563ab2d44c1b8761203fb868e37_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7f0a54579764e34bd42dd790ba99ef4_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16f2fabfc6b747e5837e0174609fcc2b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa0fee81cd004ce9a21528b56b335914_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2e854be994f41e6972a64d241a91f47_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:SalesMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4ad4f4b71ae44b283fcc4fb9a913a39_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id305f2fec3554db090e0b6fe23e91f04_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i597fcedd8e7a4ac5ad1d8f9599d89d31_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cb967d1c1e54bef8b85105752dc7964_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:110%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:110%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:110%">FORM <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTU2_06a445eb-0151-4cb2-803d-81790ec23f47">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:0.1%"></td><td style="width:2.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6ZTNlMmE2MDMzZTgyNDUyNGE3OTY0NGRjMDM1OTkzZWQvdGFibGVyYW5nZTplM2UyYTYwMzNlODI0NTI0YTc5NjQ0ZGMwMzU5OTNlZF8wLTAtMS0xLTA_51ab11d3-401f-478c-87f5-73d27504c368">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:15pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">For the quarterly period ended <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xMjk_17c0ba77-177e-41d8-9d82-f9a3afc25bb7">June&#160;30, 2021</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:0.1%"></td><td style="width:2.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6OWM2OWUwZWUwN2VlNGZkOWFiZDQxZTcyNDVkNTk5ZGYvdGFibGVyYW5nZTo5YzY5ZTBlZTA3ZWU0ZmQ5YWJkNDFlNzI0NWQ1OTlkZl8wLTAtMS0xLTA_e4af4ebb-2bc2-4b1c-98b2-56ddfe6e0289">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:9pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">For the transition period from _____</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%;text-decoration:underline">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">to ____</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%;text-decoration:underline">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:110%">&#160;</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number:  <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTU3_ffd9a4e2-bec4-47a0-8e07-42f464b9a81c">001-39614</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:110%"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTU4_46b849f2-c212-473d-b9ca-c2858a202ea6">TARSUS PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:110%">(Exact name of Registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:48.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6ODlmMDhmNzJhYWNlNDBlNDk1NGE0MzQ2ZGI5OWZhYTAvdGFibGVyYW5nZTo4OWYwOGY3MmFhY2U0MGU0OTU0YTQzNDZkYjk5ZmFhMF8wLTAtMS0xLTA_8b5f7623-0be6-4aae-9aaa-6e22ff64d79e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6ODlmMDhmNzJhYWNlNDBlNDk1NGE0MzQ2ZGI5OWZhYTAvdGFibGVyYW5nZTo4OWYwOGY3MmFhY2U0MGU0OTU0YTQzNDZkYjk5ZmFhMF8wLTItMS0xLTA_e55fd141-cb54-426b-a6fd-79cefd21c1ca">81-4717861</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:48.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6OGFlM2M0MGU1NmQ5NDkwNGJmMmNjYWI3NzdmYWUwMDQvdGFibGVyYW5nZTo4YWUzYzQwZTU2ZDk0OTA0YmYyY2NhYjc3N2ZhZTAwNF8wLTAtMS0xLTA_1e9b37ea-35c5-4f45-a2d3-3583777e8d63">15440 Laguna Canyon Road, Suite 160</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6OGFlM2M0MGU1NmQ5NDkwNGJmMmNjYWI3NzdmYWUwMDQvdGFibGVyYW5nZTo4YWUzYzQwZTU2ZDk0OTA0YmYyY2NhYjc3N2ZhZTAwNF8xLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGNhN2Q2NjliNGU0M2JhOGZmYzdkY2VkMGNmMGI3OV80_a50560a9-95ca-4f0f-a6e0-154acc5c3b46">Irvine</ix:nonNumeric>, <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6OGFlM2M0MGU1NmQ5NDkwNGJmMmNjYWI3NzdmYWUwMDQvdGFibGVyYW5nZTo4YWUzYzQwZTU2ZDk0OTA0YmYyY2NhYjc3N2ZhZTAwNF8xLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGNhN2Q2NjliNGU0M2JhOGZmYzdkY2VkMGNmMGI3OV84_093fef0c-de7e-4d18-a022-01285d9ba5ba">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6OGFlM2M0MGU1NmQ5NDkwNGJmMmNjYWI3NzdmYWUwMDQvdGFibGVyYW5nZTo4YWUzYzQwZTU2ZDk0OTA0YmYyY2NhYjc3N2ZhZTAwNF8xLTItMS0xLTA_9fcec914-6836-4be4-86af-5c48652ce73f">92618</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:110%"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTQ5_10fa9e51-c992-4ab4-be18-c4b103281dd5">(949)</ix:nonNumeric> <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTU5_9affb116-d6ef-4aeb-ae8e-d0e5b06a4eb2">409-9820</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:110%">(Registrant's telephone number, including area code)</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.216%"><tr><td style="width:1.0%"></td><td style="width:40.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6MTAxMDc0NDFiMmJlNDFjOTkyNzhkOTY0MjJhYzMyZTgvdGFibGVyYW5nZToxMDEwNzQ0MWIyYmU0MWM5OTI3OGQ5NjQyMmFjMzJlOF8xLTAtMS0xLTA_2b1fdb65-9e12-4fe3-a32b-c1652962d18c">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6MTAxMDc0NDFiMmJlNDFjOTkyNzhkOTY0MjJhYzMyZTgvdGFibGVyYW5nZToxMDEwNzQ0MWIyYmU0MWM5OTI3OGQ5NjQyMmFjMzJlOF8xLTEtMS0xLTA_67db0491-b88f-4bc2-9741-2d29fa0a6bdf">TARS</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The Nasdaq Global Market LLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6MTAxMDc0NDFiMmJlNDFjOTkyNzhkOTY0MjJhYzMyZTgvdGFibGVyYW5nZToxMDEwNzQ0MWIyYmU0MWM5OTI3OGQ5NjQyMmFjMzJlOF8xLTItMS0xLTAvdGV4dHJlZ2lvbjowY2JjMjFmMTZiYWM0MzM3YmM2OWMyZmVkMzNkZmNkNF8zNA_c0a1e3a1-669f-4e27-80bd-1347600a10ea">Nasdaq Global Select Market</ix:nonNumeric>)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;<ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTYw_df7fce16-bd60-4a52-b6d8-1f60bd6f3bf3">Yes</ix:nonNumeric> &#9746;  No &#9744;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTUw_587e28da-ba00-48c1-b9ad-552f23d4ef97">Yes</ix:nonNumeric> &#9746;  No &#9744;</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:14.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.228%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6YjVjZGM1YjFkODZlNDUxOWE1MDI4ZmJkNjAxN2QwMWMvdGFibGVyYW5nZTpiNWNkYzViMWQ4NmU0NTE5YTUwMjhmYmQ2MDE3ZDAxY18xLTAtMS0xLTA_16ada236-9cd2-4703-b303-6400f42cd18b">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" format="ixt:booleantrue" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6YjVjZGM1YjFkODZlNDUxOWE1MDI4ZmJkNjAxN2QwMWMvdGFibGVyYW5nZTpiNWNkYzViMWQ4NmU0NTE5YTUwMjhmYmQ2MDE3ZDAxY18xLTQtMS0xLTA_6ec54770-cfc3-4feb-9f53-4275c79071e0">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6YjVjZGM1YjFkODZlNDUxOWE1MDI4ZmJkNjAxN2QwMWMvdGFibGVyYW5nZTpiNWNkYzViMWQ4NmU0NTE5YTUwMjhmYmQ2MDE3ZDAxY18yLTQtMS0xLTA_ff6455fe-07a1-4011-91be-023d4d360a47">&#9746;</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#160;<ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTUx_a364930c-8300-4599-a74a-a24477f7b9de">&#9746;</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:49.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTUy_c37e4d73-e501-4247-b8d5-962190dfff99">&#9744;</ix:nonNumeric>  No &#9746;</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id418552000374cee91d2f152ebbeefbf_I20210801" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTUz_2270f95c-66e5-4ea7-a5ee-d910aada5f23">20,574,104</ix:nonFraction> shares of common stock, $0.0001 par value, outstanding as of August 1, 2021.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:94.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_10">Part I - Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8b61561133ed4a6b868d8d2b5a1f9640_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_13">Item 1. Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8b61561133ed4a6b868d8d2b5a1f9640_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_67">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8b61561133ed4a6b868d8d2b5a1f9640_67">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_70">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8b61561133ed4a6b868d8d2b5a1f9640_70">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_73">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8b61561133ed4a6b868d8d2b5a1f9640_73">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_76">Part II - Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8b61561133ed4a6b868d8d2b5a1f9640_76">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_79">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8b61561133ed4a6b868d8d2b5a1f9640_79">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_82">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8b61561133ed4a6b868d8d2b5a1f9640_82">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_85">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8b61561133ed4a6b868d8d2b5a1f9640_85">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_88">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8b61561133ed4a6b868d8d2b5a1f9640_88">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_91">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8b61561133ed4a6b868d8d2b5a1f9640_91">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_94">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8b61561133ed4a6b868d8d2b5a1f9640_94">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_97">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8b61561133ed4a6b868d8d2b5a1f9640_97">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_100">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8b61561133ed4a6b868d8d2b5a1f9640_100">38</a></span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_13"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item I. Financial Statements (Unaudited)</span></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_16"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO THE FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:93.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.025%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pages</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_19">Condensed Balance Sheets</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_22">Condensed Statements of Operations and Comprehensive Income (Loss</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_25">Condensed Statements of Preferred Stock and Stockholders&#8217; Equity (Deficit</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_28">Condensed Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_31">Notes to Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-6</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and par value amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfNS0xLTEtMS0w_b93f53b6-1b66-4145-87e6-503f1391cfa7">176,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfNS0zLTEtMS0w_05b8c81b-a1eb-46a0-ade3-57b32b51ba6f">168,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfNi0xLTEtMS0w_a71daa03-67e0-4546-a101-72a8a3e5acc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfNi0zLTEtMS0w_b061e4fe-5fef-4278-92a7-79f3572f0f57">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfNy0xLTEtMS0w_11b146db-a55f-40cd-bf22-6c59f4c32c8e">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfNy0zLTEtMS0w_e881c4c1-9f00-460c-b268-89c9dafea2c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfOS0xLTEtMS0w_095fefac-479b-4d02-ba9f-488bdfa7f221">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfOS0zLTEtMS0w_a0eab939-2329-43ab-b9fc-402643d8fd13">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTAtMS0xLTEtMA_36c9faaf-dfc9-460a-bf17-c5c75b375eb9">4,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTAtMy0xLTEtMA_0065d50a-0f4c-4b56-8c13-0ce007294864">2,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTEtMS0xLTEtMA_696d4a8b-a027-460c-a3cf-fd7c9254faf8">200,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTEtMy0xLTEtMA_4796ac8e-debf-4621-83da-e3d4ff509058">170,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTItMS0xLTEtMA_85d55cd3-6136-4041-bea2-6ada956ed7a6">481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTItMy0xLTEtMA_3e7b0add-3341-44bd-b83c-a76d248e7454">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTMtMS0xLTEtMA_105b67c2-9e10-4a90-b948-4f986852054e">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTMtMy0xLTEtMA_e5c00147-73d0-4911-ad1c-5129681eb7c0">688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTQtMS0xLTEtMA_a23d1f65-bae0-4a60-a85c-dc4d10828846">1,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTQtMy0xLTEtMA_c9b13836-4a65-4aff-afed-7df3288d9875">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTUtMS0xLTEtMA_487703e6-373b-4824-80b5-756e32d3237f">203,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTUtMy0xLTEtMA_37dd3429-606e-45d2-97b5-0563d688abc6">171,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES, PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTgtMS0xLTEtMA_9c0cafdb-5994-42f1-b9b5-0fa5345d9e38">8,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTgtMy0xLTEtMA_b5e8fe1b-b91a-445f-94a2-8fd753f696d1">4,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTktMS0xLTEtMA_6dbe1670-220b-48eb-b68c-120d3a97a065">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTktMy0xLTEtMA_32174082-8ae7-4047-8330-67ce381df99b">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjAtMS0xLTEtMA_f09f7202-c914-40e9-b9cf-9ac695f74505">10,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjAtMy0xLTEtMA_c1379362-9260-4f82-b3d1-313196ab3bfc">5,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjEtMS0xLTEtMA_f6d2730b-a8d0-4229-aab5-0573a6e12d13">524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjEtMy0xLTEtMA_2d5f92f3-4020-433d-87cd-3afca012a586">605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjItMS0xLTEtMA_bdbcfb72-d620-4029-a1ae-3e72925addd7">10,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjItMy0xLTEtMA_d872d732-3c6d-4b74-a547-6ef0d8d47913">5,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commitments and contingencies (Note 9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjMtMS0xLTEtMA_ff8e9991-c46e-4997-abfb-6c3978440e2a"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjMtMy0xLTEtMA_ab547e5e-b5ce-4089-8fb9-0eee6dbb009e"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjc0N2Y0NjA5YzY0ZDRkOTJhN2RmNjViOTJiYjRlMzk1XzIx_1c33b3da-2bed-47ed-803a-596e18e69167"><ix:nonFraction unitRef="usdPerShare" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjc0N2Y0NjA5YzY0ZDRkOTJhN2RmNjViOTJiYjRlMzk1XzIx_ad73728f-6f51-4d21-bb74-49ed143a5fe5">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjc0N2Y0NjA5YzY0ZDRkOTJhN2RmNjViOTJiYjRlMzk1XzM1_142c8167-7280-4acd-96b0-20459b42a9fb"><ix:nonFraction unitRef="shares" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjc0N2Y0NjA5YzY0ZDRkOTJhN2RmNjViOTJiYjRlMzk1XzM1_3d4074ca-10a7-4982-bc49-9476853c6292">10,000,000</ix:nonFraction></ix:nonFraction> authorized at June&#160;30, 2021 and December&#160;31, 2020; <ix:nonFraction unitRef="shares" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjc0N2Y0NjA5YzY0ZDRkOTJhN2RmNjViOTJiYjRlMzk1XzYz_3109f0cd-0a8d-439e-a752-12aa1b6a3094"><ix:nonFraction unitRef="shares" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjc0N2Y0NjA5YzY0ZDRkOTJhN2RmNjViOTJiYjRlMzk1XzYz_dc7f3be3-0fc0-4af9-9cc3-85212e86fe2c"><ix:nonFraction unitRef="shares" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjc0N2Y0NjA5YzY0ZDRkOTJhN2RmNjViOTJiYjRlMzk1XzYz_ed0a2b68-9132-4128-95ef-5e8a96eff919"><ix:nonFraction unitRef="shares" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjc0N2Y0NjA5YzY0ZDRkOTJhN2RmNjViOTJiYjRlMzk1XzYz_fcc716db-3377-4aa3-a926-b5ba678c8770">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2021 and December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMS0xLTEtMA_686aaed6-31cf-462d-921e-e19060027ce7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMy0xLTEtMA_cda21b4f-4a62-4af5-8700-fbab6af604d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzE4_10b1a972-207f-49ea-b81a-e327899e2548"><ix:nonFraction unitRef="usdPerShare" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzE4_bcdce746-b25f-4487-828c-0f2ae9f1f50c">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzMy_6647eb2b-cf56-4445-abf2-6947dd9f2c6f"><ix:nonFraction unitRef="shares" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzMy_6eafa6d2-c149-4573-9493-63c32f499c25">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzU0_3fdaf6af-2418-46b1-b960-fe24e85fc202">20,704,104</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzc1_a914b6f9-2e67-4d76-9fe3-69ae22fc1dfb">20,573,951</ix:nonFraction> outstanding, which excludes <ix:nonFraction unitRef="shares" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="INF" format="ixt:numdotdecimal" name="tars:CommonStockSharesSubjectToRepurchase" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzEwNg_081b566f-3519-43c7-8702-6162b61cdca4">130,153</ix:nonFraction> shares subject to repurchase at June&#160;30, 2021 (unaudited); <ix:nonFraction unitRef="shares" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzE1Nw_c67bffe7-91a9-4790-9562-4bfebe158574">20,502,576</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzE3OA_2bc01189-9494-4c98-b2ea-07bccf9d4b3b">20,323,301</ix:nonFraction> outstanding, which excludes <ix:nonFraction unitRef="shares" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="INF" format="ixt:numdotdecimal" name="tars:CommonStockSharesSubjectToRepurchase" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzIwOQ_5e725829-2849-4bcf-8524-ca0775d7da88">179,375</ix:nonFraction> shares subject to repurchase at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMS0xLTEtMA_b2594554-ced0-48f0-b4ab-cb63435af61e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMy0xLTEtMA_a9906ce6-b223-455a-b6ac-3df7e2e6fb70">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjctMS0xLTEtMA_a6ab4622-a6db-4807-a912-1fc3e8a398fa">208,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjctMy0xLTEtMA_10d70464-ed35-4378-8853-9188e9db4571">198,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjgtMS0xLTEtMA_51b22389-7ee9-4264-bd25-027edda1e42f">16,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjgtMy0xLTEtMA_badf3259-3e32-4bb7-b351-34d4bf1c00fe">32,845</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjktMS0xLTEtMA_6aa902f5-f972-4d4f-b2dd-e44bd8d963f0">192,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjktMy0xLTEtMA_22e2b0bd-fec2-4ff1-aa68-6df4a83e6b55">165,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities, preferred stock and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMzAtMS0xLTEtMA_d3387889-ecc6-4d41-9095-656d58dbb127">203,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMzAtMy0xLTEtMA_849269d1-bb4f-49a1-bb0e-cf52a82b14f0">171,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fees</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a6d638fd8024fb489c508a2ffc1d40a_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMy0xLTEtMS0w_9b8514fd-de00-4594-8d3c-74162d07560c">19,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia569047a0bf44c6a9285af3f2ca01975_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMy0zLTEtMS0w_570dbb04-2e11-457e-a26e-16f3f726d290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia277d64b3cf54f299bea0e672deb68c6_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMy01LTEtMS05Ng_e8d2ffc8-8501-4b28-aeaa-8f0b1b149cf7">52,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b407322af7f46eca61e30b4fecffe2b_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMy03LTEtMS05Ng_d5093507-857d-4905-bba2-d7494f51d4b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844a21cea71e4d1bae8b39773824d43d_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNC0xLTEtMS0w_aecdde0e-7795-4268-b200-358be11a4e16">2,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i631be233d7544546b6561e0e68e759a9_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNC0zLTEtMS0w_beb9ac29-ea38-435b-9717-a68c5890de88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaa5350dda6d437da5ff9a746dca6f3b_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNC01LTEtMS05Ng_ad9179fe-75a8-4e84-a5bb-61ac9e6ef343">3,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47131aae4502439b84e481d0cd4795aa_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNC03LTEtMS05Ng_0d8f974e-4f97-435f-8833-d9e799fd3747">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNS0xLTEtMS0w_aae40a09-a1b8-46a4-b4ba-4a439bc6b501">22,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNS0zLTEtMS0w_b64067d2-b8c4-4744-8d1d-f9e6b34e2152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNS01LTEtMS05Ng_71eb3ace-8374-4aea-a3cd-28b677201c2b">55,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNS03LTEtMS05Ng_b8f108dd-54a8-480c-89d2-1e0e8aa5cbee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of license fees and collaboration revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1e17b2b90194854a0c1f35b7f7a220c_D20210401-20210630" decimals="-3" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNy0xLTEtMS0w_cca63b31-caa7-4d8b-98d5-19db1790c454">737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cfb8f7666f5404697abaf42468b411d_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNy0zLTEtMS0w_df61b935-36bc-4e94-b9e6-14b371b0c034">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f0a7226965f407bb1332105daf637d9_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNy01LTEtMS05Ng_10e74731-41d3-4e02-9439-1b84c2960c5b">2,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i883f70c143b9443d8fd6e696331febda_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNy03LTEtMS05Ng_7e459764-83ce-4dd5-ad70-df963c084d86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfOC0xLTEtMS0w_804b7db7-173f-4fd7-9294-242b2c554051">7,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfOC0zLTEtMS0w_a2534c24-6f5f-409c-b99e-9bc8dfc4fc8f">1,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfOC01LTEtMS0w_002392f4-3a06-47f5-8ae7-46eb8682fa69">23,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfOC03LTEtMS0w_24ba5bda-28c1-4b23-bdaf-9ef45d125a44">3,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfOS0xLTEtMS0w_4796e55a-e748-4a4c-aa3e-5b373b31572d">6,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfOS0zLTEtMS0w_09d0717b-161c-4e4e-a907-43c6e21109a0">1,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfOS01LTEtMS0w_13072813-8c6b-476c-9026-3b174085d9a3">11,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfOS03LTEtMS0w_44db3898-8bd8-45f5-9b8d-c0cea98c9ebe">2,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTAtMS0xLTEtMA_f195776e-16dc-4efc-911c-bc96fd1f8d4e">14,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTAtMy0xLTEtMA_91c63b2e-e570-4841-a720-702f8400f99a">3,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTAtNS0xLTEtMA_d3f0ca83-b1fd-4627-84e3-b512fd43d66b">37,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTAtNy0xLTEtMA_c19054c2-6c9e-4f4f-884a-af5e873c7f5b">5,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations before other (expense) income and income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTEtMS0xLTEtMA_64a6c741-07de-4062-86cc-b72f2d24e7be">7,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTEtMy0xLTEtMA_7434e458-bdec-42df-a45c-16c1c98d6e54">3,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTEtNS0xLTEtMA_34869f7b-b1f0-462b-8183-7341a0cf47c8">17,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTEtNy0xLTEtMA_48eedfe3-983e-4871-9667-6feda8817d1e">5,381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTMtMS0xLTEtMA_142bb2f1-1d3f-458f-b3e4-2a1e4cb8f317">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTMtMy0xLTEtMA_9d627109-ac5a-44b4-b5c1-0f6888904954">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTMtNS0xLTEtMA_2c226a93-7092-4d12-aa0e-6876e8e29402">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTMtNy0xLTEtMA_f7d3ba37-f16f-4496-aedf-4f81d3faecd8">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTQtMS0xLTEtMA_6478fc64-905e-4ef8-ba0c-9c735310948b">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTQtMy0xLTEtMA_8626dc28-61f4-4078-8eb9-7ab50991cfc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTQtNS0xLTEtOTY_ec3cd70f-c2aa-4906-bcc1-1879ecae56c4">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTQtNy0xLTEtOTY_1a9b8414-0fcc-4deb-ac5d-cf5592b6ee3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of equity warrant rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTYtMS0xLTEtMA_9ce4d0f6-c461-4a20-87cf-2bc5254650ae">876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTYtMy0xLTEtMA_21a549e4-7dae-4c25-8d0f-30beeccf1b4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTYtNS0xLTEtMA_cb615e21-ad54-466c-9dbb-daef133eabcd">876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTYtNy0xLTEtMA_01356b32-2c25-411d-91d0-d4bfda60d00b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTctMS0xLTEtMA_71890427-d9d9-44d6-a780-da637bf8511c">908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTctMy0xLTEtMA_1a3a3d67-98c1-488e-ae73-05083398acd1">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTctNS0xLTEtMA_8b49e7ca-c9f1-43e1-a238-58633c92f7c3">933</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTctNy0xLTEtMA_fe763f07-4a8e-4049-a6eb-dcd2c88b3395">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTgtMS0xLTEtMA_627e9853-0623-47c3-ad7e-0ab4b70e81e8">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTgtMy0xLTEtMA_980b116d-6f9c-42d4-8dc5-8a5078f368c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTgtNS0xLTEtMA_b2404bce-88ea-42c8-99ff-e7041ce270a6">342</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTgtNy0xLTEtMA_4b9db744-546f-47db-b6d5-3655f93af453">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) and comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTktMS0xLTEtMA_2275d7ae-1e40-4e3f-81c4-f6c3ec09f21d"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTktMS0xLTEtMA_6f265270-5938-475d-a5b8-9e985315fcbb">6,345</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTktMy0xLTEtMA_618bdf6b-e049-4661-828d-7a3fc70e9588"><ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTktMy0xLTEtMA_7b277b4e-a332-4a91-a14a-13fbc900bda0">3,250</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTktNS0xLTEtMA_175cd416-6007-4df2-81ee-08a6315f7343"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTktNS0xLTEtMA_9beee3be-798b-4a2d-a774-87458c85b95b">16,721</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTktNy0xLTEtMA_79619b0d-452e-4be5-bcf3-24a002ba63fc"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTktNy0xLTEtMA_a24b4c98-6472-44c6-82ed-ba6caa96cf51">5,207</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjEtMS0xLTEtMA_21f2cda2-4417-4f1d-8e97-2c1e61b3f3b1">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjEtMy0xLTEtMA_3022bbc2-170e-4e14-9272-74bfed0a75b9">1.23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjEtNS0xLTEtMA_12e50fed-15bc-4123-9bec-138b1b8ad6cc">0.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjEtNy0xLTEtMA_0b4db2a8-d3b2-4369-8fec-66e9e6c0243c">1.96</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjItMS0xLTEtMA_173ce298-3a1a-431f-9cad-f903ae41a483">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjItMy0xLTEtMA_ee7a3611-a44d-4701-896f-2816428d6c43">1.23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjItNS0xLTEtOTY_afe7b8b4-eb67-40e2-b971-fbb13b9e1746">0.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjItNy0xLTEtOTY_e998afb3-d468-4e31-bfbc-a73ff1f61190">1.96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjQtMS0xLTEtMA_fcfdeb60-ad1d-44bc-99ca-7b6c50502649">20,555,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjQtMy0xLTEtMA_1c1d762c-fd50-481c-93aa-6311a8f90f9a">2,651,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjQtNS0xLTEtMA_6f3cd9f7-10cf-4a60-9dfd-7fc7df5d4379">20,446,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjQtNy0xLTEtMA_0f9edd7a-23fd-41b0-9edf-50aff9cd7728">2,650,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjUtMS0xLTEtMA_fb2e1a59-5dd5-42ec-9fe5-7aa36dc5c8aa">21,966,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjUtMy0xLTEtMA_05f417be-5bb4-41cb-9c5e-a18dbbb89d6f">2,651,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjUtNS0xLTEtOTY_e5d419e4-2a7a-4407-bae9-325ed51deeb8">21,895,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjUtNy0xLTEtOTY_ab2535c3-b959-498e-980b-ef552e224e9a">2,650,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.266%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb7ee0d743be4e14b1401f1d0a96ec6d_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMi0xLTEtMS0w_6c8e0c6b-7f8b-4e5a-9380-aee6b8ccd93c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb7ee0d743be4e14b1401f1d0a96ec6d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMi0zLTEtMS0w_b0ffb336-03b8-4163-80da-3dadf3e3033e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52e734a7761645e48b189cb6e2b8421e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMi01LTEtMS0w_9a1d42e0-85f5-40e4-a2ad-9fc548a5a1b6">20,323,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52e734a7761645e48b189cb6e2b8421e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMi03LTEtMS0w_582c8c87-ab4d-4136-a51a-4e5a99194387">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac09cf4a066646c188469b8b5c55183e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMi05LTEtMS0w_48c9d725-c819-4e77-85b4-cc3fb526354e">198,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad26ed4c0a904b1db84e266a4d16a1b4_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMi0xMS0xLTEtMA_1ddc4c45-7965-4aed-8538-7a61b4834604">32,845</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMi0xMy0xLTEtMA_81f8066b-aba1-4ec5-8768-bb2858b96627">165,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23ecbbc22f4540cd8bcea0e396ba673e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMy0xMS0xLTEtMA_68043025-3979-468e-94eb-8fdd6ae6bf79">10,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a28ec4e85d84692b4ca6a32628fa4be_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMy0xMy0xLTEtMA_014d250c-ac7b-42a3-883d-d802cb89207f">10,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Recognition of stock-based compensation expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc512caba35a452c8e9461069e750305_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNC05LTEtMS0w_d07e32f4-f20b-46b5-a98b-478b7622eec6">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a28ec4e85d84692b4ca6a32628fa4be_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNC0xMy0xLTEtMA_6b40b18d-1158-4b9a-87f1-2c3fe39a7cd1">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Exercise of vested stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4ab6ac8e8814105820d3a3d650f85f6_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNS01LTEtMS0w_6c68f9e0-344d-49dc-8232-75ef9c233ab0">13,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc512caba35a452c8e9461069e750305_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNS05LTEtMS0w_31f537db-3a6e-487c-a199-6299f612cf24">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a28ec4e85d84692b4ca6a32628fa4be_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNS0xMy0xLTEtMA_7b865052-dbaf-4a74-abc5-3ed368f84057">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Shares issued as consideration for in-license rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4ab6ac8e8814105820d3a3d650f85f6_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNi01LTEtMS0w_fb68a2e1-0be4-4617-b499-38f233a92109">187,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc512caba35a452c8e9461069e750305_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNi05LTEtMS0w_b85123b6-36bd-4af7-87ba-34250621af9d">5,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a28ec4e85d84692b4ca6a32628fa4be_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNi0xMy0xLTEtMA_7647b6ba-59e0-44c3-86f7-de89f296052f">5,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance as of March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i739e66a8b2094324ad392839b69d2eec_I20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNy0xLTEtMS0w_cfe28d5c-5b27-4c46-8e90-93280909a59d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739e66a8b2094324ad392839b69d2eec_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNy0zLTEtMS0w_d06a3acb-846c-4321-9b0f-33436181a835">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33759a7e324e4a7d9618b0aaa5838ece_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNy01LTEtMS0w_4ee06dd8-6ec5-4b36-bd3d-1f71acd900ec">20,524,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33759a7e324e4a7d9618b0aaa5838ece_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNy03LTEtMS0w_84d74651-29d1-49e5-92cf-59febc95cac0">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fb433c2724c4c6e91eb08e2465af045_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNy05LTEtMS0w_3d632238-5f7b-4946-bf66-530502ad98fc">205,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47b0c69c412247c68a44124006cf6612_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNy0xMS0xLTEtMA_de6a1e15-7277-48fd-8e79-ace4b1b7312f">22,469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e969dac4d6411dbb826ee3db9998d9_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNy0xMy0xLTEtMA_f3dd8648-894b-4ed1-94e5-bb50355da195">183,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a8d4c6166724c9dba7245924538fd86_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfOC0xMS0xLTEtMA_24d476ae-f166-4d70-9e1b-ca911e98ba75">6,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfOC0xMy0xLTEtMA_5377d3a8-aa42-4ed1-ba56-eef096f8c38b">6,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Recognition of stock-based compensation expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i345e2829049d4416bf301cc23ac6a406_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfOS05LTEtMS0w_d7e0841b-34a0-4306-b004-5e6637d47891">2,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfOS0xMy0xLTEtMA_f75eba29-6255-45b3-a26b-bb0821405e8e">2,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Lapse of repurchase rights related to common stock issued pursuant to early exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0634e483f0f4516a460bacff8b51bcc_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="tars:StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTAtNS0xLTEtNTA4_8e943125-5c33-4e7f-9f11-6bc8f0f811e7">49,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i345e2829049d4416bf301cc23ac6a406_D20210401-20210630" decimals="-3" name="tars:StockIssuedDuringPeriodValueLapseOfRepurchaseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTAtOS0xLTEtNTA4_cc020d5e-4515-40d1-8fc6-0ea15b6ec137">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" name="tars:StockIssuedDuringPeriodValueLapseOfRepurchaseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTAtMTMtMS0xLTUwOA_ac3c56ae-070b-4c44-8e6e-b1864c4bbdfe">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Exercise of vested stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0634e483f0f4516a460bacff8b51bcc_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTAtNS0xLTEtMA_dc50171b-6c0f-495b-b727-5daf2fbbe045">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i345e2829049d4416bf301cc23ac6a406_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTAtOS0xLTEtMA_68df2839-466f-448f-9636-e2f9e821a5a0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTAtMTMtMS0xLTA_1cac080b-e4e2-466e-a01a-2b0d6b78db76">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance as of June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4426dbfe40cc497ab87fc456c68f513e_I20210630" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTEtMS0xLTEtMA_6f716cb1-40bf-4454-8174-b32ce78cba5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4426dbfe40cc497ab87fc456c68f513e_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTEtMy0xLTEtMA_874bc423-c438-4a05-b952-b877a81b9dfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5291f4b8a4e24019929680d04b243c5f_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTEtNS0xLTEtMA_e4604830-c128-4656-8104-a95c8dd27cb0">20,573,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5291f4b8a4e24019929680d04b243c5f_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTEtNy0xLTEtMA_c46ca175-714d-47d2-8d7f-491c45656a2e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f9f9fed4d646e2b0a01016693eec81_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTEtOS0xLTEtMA_98701c1e-fe1d-4d2e-9b1a-ae4626d1ae32">208,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeccdc12ddfa46af872eef01caec5973_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTEtMTEtMS0xLTA_96a76ad7-2c22-4a04-8c4c-4f6b6b96585a">16,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTEtMTMtMS0xLTA_79ef90bf-60ec-4689-bb44-7ba15c99cddd">192,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.266%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Deficit</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i582e67cbd8fa41379c4ab2acf8ad6e1c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMi0xLTEtMS0w_e09e1a56-54cf-4625-9c0c-210193d92770">8,249,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i582e67cbd8fa41379c4ab2acf8ad6e1c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMi0zLTEtMS0w_e65fc16e-f7b0-4863-a388-980d2ab70b92">63,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94907dbf7f4947419d7e95e4a21fe043_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMi01LTEtMS0w_221ec691-26eb-4611-9241-bb3c8d459090">2,646,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94907dbf7f4947419d7e95e4a21fe043_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMi03LTEtMS0w_85ee3678-74d4-458f-b107-45846e624185">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18065d30bf104e29b2ef78dd078ba467_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMi05LTEtMS0w_a32453e0-1f5a-4cdf-a6b9-d9944ee4bd35">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fb6e623368041f9a2fada37f7f956b8_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMi0xMS0xLTEtMA_f9aa4739-3e36-40a2-8623-fe2fa859a00b">6,034</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib35a7e25ebbe4fc381478dbc1dc8dbd3_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMi0xMy0xLTEtMA_96d8a7e0-a708-47eb-8e23-0a9c35061035">6,005</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54f251974ca94b0e9b65707daf81e0f4_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMy0xMS0xLTEtMA_b0bc399e-80b7-4510-a69c-34e541fa3e96">1,957</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d8683a7d9e14fe9abbd3f6a5c86c6f6_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMy0xMy0xLTEtMA_a1a4dee3-4516-4b28-84ca-e9addd65f468">1,957</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Recognition of stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f0da49422cc4c05b2cba9c4406d801a_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNC05LTEtMS0w_f5af8887-d51e-496e-9457-c1906a99bd22">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d8683a7d9e14fe9abbd3f6a5c86c6f6_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNC0xMy0xLTEtMA_dbe2c13c-adff-43eb-895b-c3d5f6c9995f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Lapse of repurchase rights related to common stock issued pursuant to early exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice41973b875c464a83d520944c39c4eb_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="tars:StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNS01LTEtMS0w_f18c92c5-6225-4ab9-9106-25927914b777">4,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance as of March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i58d0bbc40e024b4bab78c783704a7261_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNi0xLTEtMS0w_56bd92b7-3dab-41da-b6a3-df9d73107c1c">8,249,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58d0bbc40e024b4bab78c783704a7261_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNi0zLTEtMS0w_131856f0-139b-4d7f-b099-df5bb4268eab">63,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1195e7340d234c54a47b573024044888_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNi01LTEtMS0w_ac56d540-3cb8-4718-ae23-fcd8c91c33a9">2,650,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1195e7340d234c54a47b573024044888_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNi03LTEtMS0w_50d50729-7e36-462d-b27e-4759c068375b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940347dc2e60436481e72725ac419fe5_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNi05LTEtMS0w_4868b42b-a796-4d85-a7cf-95136fb4258d">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i211c6caec1a14d17bb9a07d1b78206cc_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNi0xMS0xLTEtMA_e8cd9824-0fd2-43b5-bd33-45a5beee8de7">7,991</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i760234fe991c4dce8f6fcb5f097fe516_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNi0xMy0xLTEtMA_4c0bb48b-1ec7-4829-97e3-edda471f928d">7,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1b6177ab72f41b8a0277863efcf4f48_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNy0xMS0xLTEtMA_1ac828a7-ef17-4685-b5d6-ec1495ea4ac4">3,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNy0xMy0xLTEtMA_6a1d3aa9-7416-439c-b05c-2f387b417769">3,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Recognition of stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6dea8e6a4a44ea8b8d16ccb73c60507_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfOC05LTEtMS0w_ecab0105-5942-43f1-bbe3-7ba1f52080df">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfOC0xMy0xLTEtMA_017c6968-d348-4e5e-817b-9682266a9f31">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Exercise of vested stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff82cd871b884faca9901b82ef49823f_D20200401-20200630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfOS01LTEtMS0w_085f6184-5ecd-4511-81e0-c52c088c10af">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance as of June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc3a3e1730b5474fb6d19a4e8ace2be6_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMTAtMS0xLTEtMA_7e9af184-63ae-479e-b9b5-2c2264116c58">8,249,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3a3e1730b5474fb6d19a4e8ace2be6_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMTAtMy0xLTEtMA_21c96ef4-99cc-4f02-9cb3-0381c87e18f1">63,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5b15cc9e2f848be9dcc3c45f2dcb249_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMTAtNS0xLTEtMA_36ce95ee-b7d1-4b36-b114-0465ed9962c5">2,651,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5b15cc9e2f848be9dcc3c45f2dcb249_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMTAtNy0xLTEtMA_0ce6dc7c-9e16-4522-9165-0f223d6ad1d8">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id44cd453c94c48e99a7b9568be7f73e7_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMTAtOS0xLTEtMA_f7a1061e-3d0f-4cad-a075-4d348b81a75b">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37397987845b4ff0830e35dfd25588e8_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMTAtMTEtMS0xLTA_bb87001c-5287-42f5-aeb4-14ed70892506">11,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id299c065b2574582a3d3a576ee8241d8_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMTAtMTMtMS0xLTA_e03e0675-7d4e-43bf-b9a2-340aa084cd0f">11,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMy0xLTEtMS0w_96e60902-94fb-45b2-b7e5-964082eaa404">16,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMy0zLTEtMS0w_cc527f07-4092-4fe0-847c-5939477bca40">5,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNS0xLTEtMS0w_77b3fd66-02ae-4599-ad82-35c775af9e58">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNS0zLTEtMS0w_12365984-3755-4787-9066-8508e830d7c1">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNi0xLTEtMS0w_1292826a-60b3-4add-81be-76eff7282a41">4,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNi0zLTEtMS0w_e18aa851-0402-4d8b-8893-9e89e0fbe9a9">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use asset </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNy0xLTEtMS0w_e0cba69d-14ae-495c-b9e9-4deab0d0a8b7">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNy0zLTEtMS0w_25c69677-a7ec-4ccc-9896-57eec79c3a2e">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfOC0xLTEtMS0w_857c77f3-b247-448a-8354-51647352393e">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfOC0zLTEtMS0w_b2dcc368-5895-4d8d-8eb0-2e17b7d4393f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on lease termination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GainLossOnTerminationOfLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfOS0xLTEtMS0w_f95b7368-3739-4f9c-937c-2d384f14e047">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnTerminationOfLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfOS0zLTEtMS0w_9701b101-0aca-46c9-b623-a69f598f55fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTAtMS0xLTEtMA_239cfdde-5458-47d7-8058-8fdf4fa3a9ee">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTAtMy0xLTEtMA_b6d0b118-13bd-47f2-bc98-baa62f393719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain from transactions denominated in a foreign currency</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTMtMS0xLTEtMA_5d5cc9cd-b5c5-46ab-9ec4-1d6e1369eeb2">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTMtMy0xLTEtMA_e918b626-5755-42ab-bb57-4321c1ac98c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock pursuant to in-license agreement </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTQtMS0xLTEtMA_3a594081-aca9-4cbb-b9e1-2116f57a1555">5,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTQtMy0xLTEtMA_686e16f6-da07-4ea9-91fd-cf25e3d4b3a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTYtMS0xLTEtMA_bc426e57-503f-4270-bc00-c6e6b2daf6d7">20,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTYtMy0xLTEtMA_f2d6e759-56dd-4980-b6be-eeb815b44a9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTgtMS0xLTEtMA_9399b8e9-30a5-47a9-a550-c71f9e4e4cc9">137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTgtMy0xLTEtMA_926058ab-a47a-4222-a1bb-d7876bf50277">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTktMS0xLTEtMA_b944cba1-8696-4b14-bd15-5098629fec8f">1,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTktMy0xLTEtMA_6e6529a8-2830-4616-9a1c-bcd5116d5702">1,526</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjAtMS0xLTEtMA_58a28c9d-54dd-4ad2-a09e-931c5abfe791">2,326</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjAtMy0xLTEtMA_1f3d2979-6965-42f5-9a37-acebf5280445">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjEtMS0xLTEtMA_57141a4b-0f3e-481e-b2fc-3a9efbf868d2">4,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjEtMy0xLTEtMA_9db995ce-8a80-4a81-bef1-2643444a974f">1,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjItMS0xLTEtMA_4acf8bce-c836-4a79-912c-76c82588bf20">430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjItMy0xLTEtMA_1f4c9de5-3b5b-4d04-8a33-335ecf11583f">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjMtMS0xLTEtMA_dc093c5f-46a6-4725-873d-a9684cf6e09a">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjMtMy0xLTEtMA_d2bab856-5ca3-4816-91c5-99fb0c69b8be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjQtMS0xLTEtMA_d3bbb145-d71a-4aa4-ba27-8b0f30225e30">8,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjQtMy0xLTEtMA_880e19fb-9e12-4627-b2e0-2c4026f1f549">4,553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjYtMS0xLTEtMA_9581ee92-d2e8-430f-8942-a6cb0c3054d4">191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjYtMy0xLTEtMA_ca364933-f2dd-433b-ba5a-536db7a6d4ee">371</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjctMS0xLTEtMA_bb49da71-34a2-44a5-9d82-7a2a2120ed98">191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjctMy0xLTEtMA_3a50655e-498f-484f-8e09-5ca7a2cf25f7">371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of Series B Preferred Stock, net of issuance costs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzAtMS0xLTEtMA_8968fb7e-dbb3-4c30-8632-b586f42fe83e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzAtMy0xLTEtMA_e1730463-fe6a-4ea1-9b0b-5f9d3bba020a">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of vested stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzQtMS0xLTEtMA_fb3d3261-3182-49b9-8c6e-c74795371a4e">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzQtMy0xLTEtMA_f9405d35-999b-4f66-aa28-04652af0069c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options prior to vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="tars:ProceedsFromEarlyExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzUtMS0xLTEtMA_f58d23ef-1116-4314-90c1-67f01ba4e0c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" name="tars:ProceedsFromEarlyExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzUtMy0xLTEtMA_f4566b7f-d588-4355-b39e-25c983192514">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzYtMS0xLTEtMA_95262383-935d-49a2-ad7c-5068f8580795">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzYtMy0xLTEtMA_a1b8ba66-b048-421f-827f-2ca7321cdcb5">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzctMS0xLTEtMA_77906b0d-60c3-4daf-a343-cc6f77be3ef1">8,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzctMy0xLTEtMA_f18329e1-d921-4073-83cb-e6070801a0ec">4,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash &#8212; beginning of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzgtMS0xLTEtMA_1cbe9e44-a9fd-4bc3-97d5-55a699bad419">168,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib35a7e25ebbe4fc381478dbc1dc8dbd3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzgtMy0xLTEtMA_1825bcf4-9369-468e-95b8-e121fc20c108">57,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash &#8212; end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzktMS0xLTEtMA_96d13c3e-d8fc-41b4-99b4-e822ed1979ec">176,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id299c065b2574582a3d3a576ee8241d8_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzktMy0xLTEtMA_cd78796a-28c7-49da-980e-2f6fc0b0d3bd">53,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDEtMS0xLTEtMA_0b25b5db-e79a-4f4b-8b6c-c9e73ade8558">176,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id299c065b2574582a3d3a576ee8241d8_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDEtMy0xLTEtMA_ed0fe2b4-d976-4a13-b00c-76612c42c39e">53,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDItMS0xLTEtMA_c304a508-329e-48db-bd1a-330797f2eca2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id299c065b2574582a3d3a576ee8241d8_I20200630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDItMy0xLTEtMA_d3f79c1c-68af-464f-802f-8bdfbe8cd873">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDMtMS0xLTEtMA_fa4cf1ac-e3a8-416b-b3ad-37b43c46f204">176,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id299c065b2574582a3d3a576ee8241d8_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDMtMy0xLTEtMA_b3ccb8bb-6289-43d8-89e6-04652cdac634">53,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental Disclosures Noncash Investing and Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset obtained in exchange for operating lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDUtMS0xLTEtMA_3c093b03-8f97-4726-8e63-1c6e77eab02f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDUtMy0xLTEtMA_955163a5-602e-42f9-8253-62489ba45d01">767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions of property and equipment in accounts payable and other accrued liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDctMS0xLTEtMA_0635d8ee-8b4c-4cd4-9b8e-8574c038152b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDctMy0xLTEtMA_63c96b1b-d94d-4dd1-ba99-8d1c1d0f741c">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derecognition of right-of-use asset upon lease termination</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" name="tars:DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDgtMS0xLTEtMA_23c92bb1-c209-41ce-966e-d0cb53bf0ade">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="tars:DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDgtMy0xLTEtMA_028d3f26-0fcc-4029-a486-cf6b9cd01986">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock issued to licensor pursuant to execution of out-license agreement</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDktMS0xLTEtMA_513fa855-e253-494e-99e7-daec9d5a3963">5,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDktMy0xLTEtMA_69083b28-d36f-4eac-8b33-bf07cf1976d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_31"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfNjU1Mg_071ecf7d-490a-4b87-a448-c9b660192a14" continuedAt="i879eb372eceb4f08802c984db8db7ac2" escape="true">DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS</ix:nonNumeric></span></div><ix:continuation id="i879eb372eceb4f08802c984db8db7ac2" continuedAt="i97ae9ee0d3034cbaaa3fa78c8a2fc498"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Description of Business</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tarsus Pharmaceuticals, Inc. (&#8220;Tarsus&#8221; or the &#8220;Company&#8221;) is a late clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutic candidates to address large market opportunities initially in ophthalmic conditions where there are limited treatment alternatives.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b) Reverse Stock Split and Initial Public Offering </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 8, 2020, the Tarsus Board of Directors approved a 1-for-7.4276 reverse stock split and a certificate of amendment was filed to amend the Company's certificate of incorporation to effect this reverse split.  The par value was not adjusted as a result of the reverse stock split.  All share and per share information included in the accompanying financial statements give retroactive effect to this reverse stock split for all periods presented.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 20, 2020, the Company completed its initial public offering ("IPO") through an underwritten sale of <ix:nonFraction unitRef="shares" contextRef="iefff22de6102436b99e849ce51fd5afa_D20201020-20201020" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfNTc1_07f71ba9-9c52-4a03-b66e-ef04aff39930">6,325,000</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sh</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ares of its common stock at a price </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of $<ix:nonFraction unitRef="usdPerShare" contextRef="i92fe8dadc41449e49b3e9e72a278675a_I20201020" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfNjE5_68bb533e-beb4-4cdb-974a-ae20c6507e1f">16.00</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> per share, inclusive of an additional <ix:nonFraction unitRef="shares" contextRef="ia81ce0ad42d6478f8526933a9dce6e9d_D20201020-20201020" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfNjYw_1542edb3-7b81-4edc-a5a0-6c151ebc5ce6">825,000</ix:nonFraction> shares of its common stock sold upon the full exercise of the underwriters&#8217; purchase option. The aggregate net proceeds by the Company from the offering totaled $<ix:nonFraction unitRef="usd" contextRef="iefff22de6102436b99e849ce51fd5afa_D20201020-20201020" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfODEx_a635d44c-73a3-4875-aecc-7437971fb3ba">91.7</ix:nonFraction> million, after deducting underwriting discounts and commissions and other offering expenses.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Concurrent with the closing of the Company's IPO, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">all then-outstanding shares of its convertible preferred stock (see </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 4</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) were automatically converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i92fe8dadc41449e49b3e9e72a278675a_I20201020" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfMTA3NQ_609c36dd-20d9-49ee-ac15-15eeae8469cf">11,107,018</ix:nonFraction> issued shares of common stock. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">(c)  Liquidity</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has no product sales, and since inception, has accumulated losses and negative cash flows from operations (other than consideration received from an out-licensing agreement, as discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), resulting in an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfMTc0Ng_fae5374f-b6d6-48ff-834a-5e6d0ac9d000">16.1</ix:nonFraction> million as of June&#160;30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfMTc2Mg_d1e8642f-0ece-4a36-bc45-bb78066af103">32.8</ix:nonFraction> million as of December&#160;31, 2020. The Company&#8217;s cash and cash equivalents were $<ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfMTgxOQ_2bbea0db-33c3-453f-8299-8d19d388cd02">176.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfMTgyNg_bb023032-b322-4d6e-bda7-0b6167516ac9">168.1</ix:nonFraction> million as of June&#160;30, 2021 and December&#160;31, 2020, respectively. The Company has funded its inception-to-date operations primarily through equity capital raises and proceeds from its out-license agreement.  The Company believes that its existing capital resources will be sufficient to meet projected operating requirements beyond at least 12 months from the August 5, 2021 filing date of this Form 10-Q.  Accordingly, the accompanying financial statements in this Form 10-Q have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operations currently consist of its corporate organization build-out, intellectual property licensing activities, and conducting preclinical and clinical studies. The Company faces the clinical, business, and liquidity risks that are typically associated with early-stage biotechnology companies; it must complete expensive research and development activities, achieve research and development outcomes that are inherently uncertain, recruit and retain skilled personnel (including executive management), and build and defend its intellectual property rights.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company&#8217;s research and development activities and other operating expenses.  The Company will be required to raise additional capital to fund its future operations, however, no assurance can be given as to whether financing will be available on terms acceptable to the Company, if at all.  If the Company raises additional funds by issuing equity securities, its stockholders may experience dilution. Any future debt financing into which the Company enters may impose additional covenants that restrict operations, including limitations on its ability to incur liens or additional debt, pay dividends, repurchase common stock, make certain investments, or engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity raise may contain terms that are not favorable to the Company or its stockholders. The Company&#8217;s potential inability to raise capital when needed could have a negative impact on its financial condition and ability to pursue planned business strategies. If the Company is unable to raise additional funds as required, it may need to delay, reduce, or terminate some or all </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i97ae9ee0d3034cbaaa3fa78c8a2fc498"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">its development programs and clinical trials. The Company may also be required to sell or license its rights to product candidates in certain territories or indications that it would otherwise prefer to develop and commercialize on its own. If the Company is required to enter into collaborations and other arrangements to address its liquidity needs, it may have to give up certain rights that limit its ability to develop and commercialize product candidates or may have other terms that are not favorable to the Company or its stockholders, which could materially and adversely affect its business and financial prospects. These factors may adversely impact the Company's ability to achieve its business objectives and would likely have an adverse effect on its future business prospects, or even its ability to remain a going concern. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d) Operating Segment  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfNjU1Mw_6d3f8bf1-7e59-4070-bc14-30c089202573" escape="true">To date, the Company has operated and managed its business and financial information on an aggregate basis for the purposes of evaluating financial performance and the allocation of capital and personnel resources. Accordingly, the Company&#8217;s management determined that it operates in <ix:nonFraction unitRef="segment" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfNTc3NA_c1d1f0e8-7bc0-4cea-bd62-bc2303c689dd">one</ix:nonFraction> reportable operating segment.  This single segment is focused exclusively on developing pharmaceutical products for eventual commercialization.</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e) Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has irrevocably elected to not take this exemption and, as a result, will adopt new or revised accounting standards on the relevant effective dates on which adoption of such standards is required for other public companies that are not emerging growth companies.</span></div></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_40"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NTE_5d69ce5f-7b32-4674-9ff3-04b452c88d49" continuedAt="ieeee3af9a9c74e81bb0ce7dac5131f1f" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES</ix:nonNumeric></span></div><ix:continuation id="ieeee3af9a9c74e81bb0ce7dac5131f1f" continuedAt="ifc45771df96448a8b0581264a60e2d11"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i) <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NDc_e0779ffa-d53f-4127-a959-a0f8d408f3a5" continuedAt="icf31e790a46742d1b804d65d14beb7b6" escape="true">Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="icf31e790a46742d1b804d65d14beb7b6"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information and pursuant to Form 10-Q and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Article 10 of Regulation S-X </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, the accompanying condensed financial statements do not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim condensed balance sheet as of June&#160;30, 2021, and the interim condensed statements of operations and comprehensive income (loss), changes in preferred stock and stockholders&#8217; equity and cash flows for the three and six months ended June&#160;30, 2021 and 2020 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes related to the three and six-month periods are also unaudited. The condensed balance sheet as of December 31, 2020 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three and six months ended June&#160;30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021 or any other interim or annual period. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed financial statements should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2020 in the Company&#8217;s Annual Report on Form 10-K (&#8220;Annual Report&#8221;) for the fiscal year ended December 31, 2020, as filed with the SEC on March 31, 2021.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These amounts may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an on-going basis, management evaluates its most critical estimates and assumptions, including those related to the (i)&#160;fair value of equity-based awards and periodic recognition of stock-based compensation, (ii)&#160;the realization of income tax assets and estimates of tax liabilities, and (iii)&#160;expense accruals related to research and development activities, including clinical trials.  The accounting policies and estimates that most significantly impact the presented amounts within the accompanying condensed financial statements are further described below:</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(ii) <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NTI_ed4ab0bc-466c-4545-9017-79c1319a3bdd" continuedAt="i9f12ae74d7334012b1d11adfac5beaab" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9f12ae74d7334012b1d11adfac5beaab">Cash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, with original maturities of three months or less from the purchase date.</ix:continuation></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(iii) <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NTM_d423c302-92e7-4463-b271-62705c227132" continuedAt="i52c34e8f136c4c90a1641635b02f9dde" escape="true">Restricted Cash</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i52c34e8f136c4c90a1641635b02f9dde">Restricted cash represents cash held as collateral for the Company&#8217;s corporate credit card program. Any cash that is legally or contractually restricted from immediate use is classified as restricted cash.</ix:continuation></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(iv) <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NDU_6a9dd9ac-b3ee-4554-af91-842b6f0ade08" continuedAt="i979be9ca07cc42ff990447ce6535dd2c" escape="true">Concentration of Credit Risk and Other Risks and Uncertainties</ix:nonNumeric></span></div><ix:continuation id="i979be9ca07cc42ff990447ce6535dd2c" continuedAt="ie1f8a563babf4b91a682161f3ef379c9"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents in deposits at financial institutions that exceed federally insured limits.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared a pandemic related to the global novel coronavirus disease 2019 (&#8220;COVID-19&#8221;) outbreak. To date, the Company&#8217;s operations have not been significantly impacted by the COVID-19 </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ifc45771df96448a8b0581264a60e2d11" continuedAt="i29403eaf7f7d4f5fbbc59559b2a8a71b"><ix:continuation id="ie1f8a563babf4b91a682161f3ef379c9"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pandemic, though the Company continues to monitor the potential impact COVID-19 may have on its ongoing and planned clinical trials. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak may have on these activities or its financial condition.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results of operations involve numerous risks and uncertainties. Factors that could adversely impact the Company&#8217;s operating results and business objectives include, but are not limited to, (1) uncertainty of results of clinical trials, (2) uncertainty of regulatory approval of the Company&#8217;s potential product candidates, including TP-03 for ophthalmic conditions, TP-04 for treatment of skin conditions and TP-05 for prophylaxis of Lyme and community malaria reduction, (3) uncertainty of market acceptance of its product candidates, (4) competition from substitute products and other companies, (5) securing and protecting proprietary technology and strategic relationships, and (6) and dependence on key individuals and sole source suppliers.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s product candidates require approvals from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive these necessary approvals. If the Company is denied approval, approval is delayed, or is unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company's business.</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(v) <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NTQ_db62fcb6-6c52-48db-aeda-73fa06757fbb" continuedAt="i7f6efdbd74a64dbc803a394196742d0e" escape="true">Property and Equipment</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7f6efdbd74a64dbc803a394196742d0e">Property and equipment is stated at historical cost and is depreciated on a straight-line basis over an estimated useful life that corresponds with its designated asset category. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of &#8220;long-lived assets&#8221; (which includes property and equipment) whenever events or changes in circumstances in the business indicate that the asset&#8217;s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value.</ix:continuation> Other than the right-of-use ("ROU") asset impairment discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were no events or changes in business circumstances during the three and six months ended June 30, 2021 or year ended December&#160;31, 2020 that indicated the carrying amounts of any long-lived assets were not fully recoverable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(vi) <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NDY_26419d4a-f46e-4808-8fc4-8e38a7529d8c" continuedAt="i7d1e6deb335642698b8705b0534eb793" escape="true">Revenue Recognition for Out-License Arrangements</ix:nonNumeric></span></div><ix:continuation id="i7d1e6deb335642698b8705b0534eb793" continuedAt="ib08a5a62c540446ea4f98805c4af357b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview </span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has one out-license arrangement that allows the licensee to market the Company&#8217;s TP-03 product (representing "functional intellectual property") in certain territories for a certain field of use and for a stated term - see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract, (b) the contract&#8217;s transaction price for allocation (including variable consideration), (c) the stand-alone selling price for each identified performance obligation, and (d) the timing and amount of  revenue recognition in each period. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's out-license arrangement, as described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was analyzed under GAAP to determine whether the promised goods or services (which include the license, and know-how, data, and information necessary or reasonably useful for the research, development, manufacture, or commercialization of any license product, and governance committee services) are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is considered to not be distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's out-license arrangement is in exchange for the following forms of consideration: (i) upfront cash payments, (ii) equity-based consideration, (iii) sales royalties, (iv) sales threshold milestones, (v) development milestone fees, and (vi) regulatory milestone fees.  Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied.   The Company evaluates the progress related to each milestone at each reporting </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i29403eaf7f7d4f5fbbc59559b2a8a71b" continuedAt="i7dc921a369eb4ca3973a541d9080690c"><ix:continuation id="ib08a5a62c540446ea4f98805c4af357b" continuedAt="ia6ec7983b52e40959843cd4c74e4956c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period and, if necessary, also adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Terms for Receipt of Payments</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual terms that establish the Company&#8217;s right to collect specified amounts from its customers and the require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, as follows:</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Upfront License Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company determines whether non-refundable license consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the out-license.  The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company utilizes the &#8220;most likely amount&#8221; method to estimate the amount of consideration to which it will be entitled for achievement of development milestones. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint.  At each reporting period, the Company re-evaluates this associated revenue recognition constraint.  Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, thus reflected in the financial statements in the period of adjustment. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company utilizes the &#8220;most likely amount&#8221; method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied). Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are constrained for revenue recognition until achievement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the "sales-or-usage-based royalty exception" the Company recognizes revenue based on the contractual percentage of the licensee&#8217;s sales to its customers at the later of (i) the occurrence of the related sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from its out-licensing arrangements.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><ix:continuation id="ia6ec7983b52e40959843cd4c74e4956c" continuedAt="i82b47e616f9e466ba169047081d4d077"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Threshold Milestones:</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i82b47e616f9e466ba169047081d4d077"> Similar to royalties, applying the "sales-or-usage-based royalty exception", the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from out-licensing arrangements.</ix:continuation> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(vii) <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NDg_6eb49c77-8cb0-490c-ba5d-53a37beb2bc1" continuedAt="ib6e728e6f0974efa8506383ed9d2dfae" escape="true">Research and Development Costs</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib6e728e6f0974efa8506383ed9d2dfae" continuedAt="ib723aa2da346434b9358f0bc26780400">Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. These expenses also include internal costs directly attributable to in-development programs, including cost of certain salaries, payroll taxes, employee benefits, and stock-based compensation expense, as well as laboratory and clinical supplies, pre-clinical and clinical trial related expenses, and the cost of services provided by outside contractors. The Company recognizes expense for pre-clinical studies and clinical trial activities performed by these third parties. This is typically based upon estimates of the proportion of work completed over the term of the individual study or trial, as well as patient enrollment and dosing events in accordance with agreements established with clinical research organizations ("CROs") and clinical trial or pre-clinical study sites.</ix:continuation></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i7dc921a369eb4ca3973a541d9080690c" continuedAt="iaf27adc07b664c37ab0ec53033a34a3b"><div style="margin-top:12pt;text-indent:49.5pt"><ix:continuation id="ib723aa2da346434b9358f0bc26780400"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered, and may continue to enter into, license agreements to access and utilize intellectual property for drug development. In each case, the Company evaluates if the assets acquired in a transaction represent the acquisition of an as</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">set or a business, as defined under applicable GAAP. The Company&#8217;s executed in-license agreements (see </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8(b)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) were evaluated and determined to represent asset acquisitions. Because these assets have not yet received regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and have no alternative future uses, the purchase price for each was immediately recognized as research and development expense. In addition, any future milestone payments (whether in the form of cash or stock) made before product regulatory approval (that do not meet the definition of a derivative) will also be immediately recognized as research and development expense when paid or becomes payable, provided there is no alternative future use of the rights in other research and development projects.</span></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(viii) <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NDM_ab101c56-a7c3-4c2f-b8e1-1a91bf2dce65" continuedAt="ie517df549c9f4843a51e76dc60d35d72" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="ie517df549c9f4843a51e76dc60d35d72"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is recognized for all equity awards granted to employees, consultants, and members of the Company&#8217;s Board of Directors and is recognized at fair value. For stock-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date is the date of grant and the related expense is recognized on a straight-line basis over each award&#8217;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes compensation cost if and when it concludes that it is probable that the performance condition will be achieved and the related expense is recognized on an accelerated attribution method. As applicable, the Company reverses previously recognized expense for forfeitures of unvested awards in the period of occurrence. The Company uses the Black-Scholes pricing model to estimate the fair value of stock option awards as of the date of grant.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement of the fair value of stock-based awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#8217;s judgment, including (a)&#160;the fair value of the Company&#8217;s common stock on the date of the option grant, (b)&#160;the expected term of the stock option until its exercise by the recipient, (c)&#160;stock price volatility over the expected term, (d)&#160;the prevailing risk-free interest rate over the expected term, and (e)&#160;expected dividend payments over the expected term.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management estimates the expected term of awarded stock options utilizing the &#8220;simplified method&#8221; for awards as the Company does not yet have sufficient exercise history since its November 2016 formation. Further, prior to the IPO, the Company was privately-held and therefore lacked company-specific historical and implied volatility information of its stock.&#160;Accordingly, management estimated this expected volatility based on a designated peer-group of publicly-traded companies for a look-back period, as of the date of grant, that corresponded with the expected term of the awarded stock option. The Company estimates the risk-free interest rate based upon the U.S. Department of the Treasury yield curve in effect at award grant for time periods that correspond with the expected term of the awarded stock option. The Company&#8217;s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the IPO, given the absence of a public trading market, the Company&#8217;s Board of Directors, with input from management, considered numerous objective and subjective factors to determine the fair value of its common stock. The factors included: (i)&#160;third-party valuations of the Company&#8217;s common stock; (ii)&#160;the Company&#8217;s stage of development; (iii)&#160;the status of research and development efforts; (iv)&#160;the rights, preferences and privileges of the Company&#8217;s preferred stock relative to common stock; (v)&#160;the Company&#8217;s operating results and financial condition, including the Company&#8217;s levels of available capital resources; (vi)&#160;equity market conditions affecting comparable public companies; (vii)&#160;general U.S. market conditions; and (viii)&#160;the lack of current marketability of the Company&#8217;s common stock. Subsequent to the IPO, the fair value of the Company&#8217;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of grant.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based compensation expense is reported in the Statements of Operations and Comprehensive Income (Loss) within "research and development" expense or "general and administrative" expense, based upon the assigned department of the award recipient.</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(ix) <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NTU_73b2f569-2b26-4a01-9f30-c9bda0ea4487" continuedAt="i00ea6425433d40e1be1840cc8cfedd87" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i00ea6425433d40e1be1840cc8cfedd87" continuedAt="i78e7fe684cfd4226b00143d46ea0a97d">Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts </ix:continuation></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="iaf27adc07b664c37ab0ec53033a34a3b" continuedAt="i532ab0d555c44d25ae93fe0d8f789280"><ix:continuation id="i78e7fe684cfd4226b00143d46ea0a97d"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reported in the financial statements, as well as operating losses and tax credit carryforwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain due to the Company&#8217;s historical operating performance and recorded cumulative net losses in prior fiscal periods.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded to reduce deferred tax assets, because based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If and when the Company were to determine that deferred tax assets are realizable, an adjustment to the corresponding valuation allowance would increase the net income in the period that such determination was made.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that the Company is assessed interest and/or penalties from taxing authorities that have not been previously accrued, such amounts would be included as a component of &#8220;income tax expense&#8221; within the Statements of Operations and Comprehensive Income (Loss) in the period the notice was received. To date there have been no interest or penalties charged.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2019-12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> removes certain exceptions for performing intraperiod tax allocations, recognizing deferred taxes for investments, and calculating income taxes in interim periods.  The guidance also simplifies the accounting for franchise taxes, transactions that result in a step-up in the tax basis of goodwill, and the effect of enacted changes in tax laws or rates in interim periods.  The Company adopted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2019-12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the first quarter of 2021, which had no material impact to its financial statements.</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(x) <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NDk_14547057-bae4-465e-8fec-219844c4d25a" continuedAt="i6d645b150a6649aa94bdfa0ad3c1df43" escape="true">Net Income (Loss) per Share Attributable to Common Stockholders</ix:nonNumeric></span></div><ix:continuation id="i6d645b150a6649aa94bdfa0ad3c1df43"><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share attributable to common stockholders is calculated by dividing the net income (loss) by the weighted-average number of shares of common stock outstanding for the period, without the consideration for potential dilutive shares of common stock. Diluted net income (loss) per share is computed by dividing the net income (loss) by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method, as applicable. The Company&#8217;s participating securities include unvested common stock awards issued upon early exercise of certain stock options, as early exercised unvested common stock awards have a non-forfeitable right to dividends. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses, so in periods of net losses, the two-class method of calculating basic and diluted earnings per share is not required. In periods of net income, basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. In periods of net income, net income is attributed to both common stockholders and participating security holders, and therefore, net income is allocated to shares of common stock and participating securities, as if all of the earnings for the period had been distributed. Diluted earnings per share under the two-class method is calculated using the more dilutive of the treasury stock or the two-class method. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to a net loss for the three and six months ended June 30, 2020, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in these periods.</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(xi) <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NTA_dc25356d-e96b-48f0-922b-21c93e12fc5a" continuedAt="i73b7cf800e35466b9e6d62ec1a78e628" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i73b7cf800e35466b9e6d62ec1a78e628" continuedAt="i33d6fc89486e49bea25bc73aaba6d234">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</ix:continuation></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i532ab0d555c44d25ae93fe0d8f789280"><ix:continuation id="i33d6fc89486e49bea25bc73aaba6d234"><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to their short maturities. Derivative instruments (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) are carried at fair value based on unobservable market inputs.</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(xii) <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NTY_3b04349d-9d16-45bf-a797-bcba80846f7c" continuedAt="ia91294eb5b094b86acc6450ccb0acbce" escape="true">Comprehensive Income (Loss)</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia91294eb5b094b86acc6450ccb0acbce">Comprehensive income (loss) represents all changes in stockholders&#8217; equity (deficit), except those resulting from distributions to stockholders. For all periods presented, comprehensive income (loss) was the same as reported net income (loss).</ix:continuation></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(xiii) <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NDQ_c590390f-0e7a-4185-82a0-13b81a0a1b0d" continuedAt="ief55f5f167614beab63a0e492bb5979b" escape="true">Recently Issued or Effective Accounting Standards</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ief55f5f167614beab63a0e492bb5979b">Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#8217;s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these condensed financial statements have been determined by the Company&#8217;s management to have no impact, or an immaterial impact, on its current and expected future financial position, results of operations, or cash flows.</ix:continuation></span></div></ix:continuation><div id="i8b61561133ed4a6b868d8d2b5a1f9640_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RleHRyZWdpb246MmU2ZGQ3YTJkNmU0NDBmMzg3M2UyOTVlN2NiOWNhOWFfMjQyNw_f5b58195-50d5-42a1-ba65-7cc03d8d15f8" continuedAt="i93d98baffb75498d9d0adbbb84da7f2f" escape="true">BALANCE SHEET ACCOUNT DETAIL</ix:nonNumeric></span></div><ix:continuation id="i93d98baffb75498d9d0adbbb84da7f2f" continuedAt="i28fab78c67ad4fdfa20c0792d42b6de7"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of selected financial statement captions that comprise the accompanying balance sheets are summarized below: </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Property and Equipment, net of Accumulated Depreciation</span></div><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RleHRyZWdpb246MmU2ZGQ3YTJkNmU0NDBmMzg3M2UyOTVlN2NiOWNhOWFfMjQyOA_2b2442d0-72e9-420f-a3eb-8bbf7a43ecfd" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Property and equipment, net of accumulated depreciation&#8221; consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:75.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.334%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i366691130c6c4705a075c2827729e560_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfMS0xLTEtMS0w_ad074135-8986-4ad1-8517-a84b05c79f0f">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c14c67cea444f0bb19eaae7c5445028_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfMS0zLTEtMS0w_423611db-6fec-48d1-b0b6-7a871ff16d2f">294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i652b87a7987044cca7f42704ba156268_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfMi0xLTEtMS0w_1a55f26d-2535-47c7-a113-fd41526a9e9b">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b8f6a5a48541248c73d37edf6dcbae_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfMi0zLTEtMS0w_5339ff47-55bf-4fe4-9f78-8aa17b7dcb6d">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad7dbb20ff542cab6548bbf1e554538_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfMy0xLTEtMS0w_1f3cfe7e-0cb5-4aaf-b7a8-1058d3fc1404">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac36b8ba5a54e45b43ad3707581ea5e_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfMy0zLTEtMS0w_60e3ceef-a28c-44e5-885b-f59e04e8b506">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia344278fd11e4e599d06a16dbef3dac0_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfNC0xLTEtMS0w_7d35b09b-3df3-47ab-bf50-1897634cea95">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9254bbc4390429eadabae632a1ee8ce_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfNC0zLTEtMS0w_854a0a6e-995d-4de8-bd85-9c8446064600">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfNS0xLTEtMS0w_5f9f303a-fa9c-48b6-880a-89d889734f2e">747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfNS0zLTEtMS0w_44a1265a-67c6-4241-ac16-de73766203ae">682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Less): Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfNi0xLTEtMS0w_1f7e0fe8-9ad9-4ed2-8a3f-5186ee92645c">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfNi0zLTEtMS0w_2f1d4e6e-c6ed-4570-b48e-a17ba20b64da">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation and amortization</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfNy0xLTEtMS0w_f2969bd5-dcb3-4864-a19c-e8ebbc39df38">481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfNy0zLTEtMS0w_7174105e-5679-47e9-aff7-ab40ce56ebca">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense (included within &#8220;total operating expenses&#8221; in the accompanying Statements of Operations and Comprehensive Income (Loss)) for the three months ended June 30, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RleHRyZWdpb246MmU2ZGQ3YTJkNmU0NDBmMzg3M2UyOTVlN2NiOWNhOWFfMjE5OTAyMzI1ODAyOA_09bc6c84-feec-4ce3-8be3-a89b8046c2a1">125</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RleHRyZWdpb246MmU2ZGQ3YTJkNmU0NDBmMzg3M2UyOTVlN2NiOWNhOWFfMzI5ODUzNDg4NTkyNA_d509aae5-9c19-4f0d-bff6-435b83854047">17</ix:nonFraction> thousand, respectively, and for the six months ended June 30, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RleHRyZWdpb246MmU2ZGQ3YTJkNmU0NDBmMzg3M2UyOTVlN2NiOWNhOWFfMzI5ODUzNDg4NTkxOQ_905fd9f6-1f33-4415-a9ac-dcc043feaee9">189</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RleHRyZWdpb246MmU2ZGQ3YTJkNmU0NDBmMzg3M2UyOTVlN2NiOWNhOWFfNDgz_f0c1c76d-ad0e-4159-9c65-06038d0b563a">32</ix:nonFraction> thousand, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b) Other Assets</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i28fab78c67ad4fdfa20c0792d42b6de7"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RleHRyZWdpb246MmU2ZGQ3YTJkNmU0NDBmMzg3M2UyOTVlN2NiOWNhOWFfMjQyNA_0bc157f1-36dd-47b1-ad54-257ed6e8685d" continuedAt="iebaf13fd4d264eacb456b7d0a4f7471c" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"Other assets" consists of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:DepositAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmZiY2Q3Yjc2NDUzODQ0MmQ5ZGFmZTE1MzEzZGMzOTFhL3RhYmxlcmFuZ2U6ZmJjZDdiNzY0NTM4NDQyZDlkYWZlMTUzMTNkYzM5MWFfMS0xLTEtMS0w_50629ea0-968e-4619-89ed-6ec5f5873094">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" name="us-gaap:DepositAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmZiY2Q3Yjc2NDUzODQ0MmQ5ZGFmZTE1MzEzZGMzOTFhL3RhYmxlcmFuZ2U6ZmJjZDdiNzY0NTM4NDQyZDlkYWZlMTUzMTNkYzM5MWFfMS0zLTEtMS0w_33051b02-45c3-496f-81e7-85dac14ebe3b">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity warrant rights*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="tars:EquityWarrantRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmZiY2Q3Yjc2NDUzODQ0MmQ5ZGFmZTE1MzEzZGMzOTFhL3RhYmxlcmFuZ2U6ZmJjZDdiNzY0NTM4NDQyZDlkYWZlMTUzMTNkYzM5MWFfMi0xLTEtMS0w_5654109f-37f5-4ce9-ab59-28ada0fa532f">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:zerodash" name="tars:EquityWarrantRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmZiY2Q3Yjc2NDUzODQ0MmQ5ZGFmZTE1MzEzZGMzOTFhL3RhYmxlcmFuZ2U6ZmJjZDdiNzY0NTM4NDQyZDlkYWZlMTUzMTNkYzM5MWFfMi0zLTEtMS0w_ba50d641-e390-4ffa-b578-0e704564de66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmZiY2Q3Yjc2NDUzODQ0MmQ5ZGFmZTE1MzEzZGMzOTFhL3RhYmxlcmFuZ2U6ZmJjZDdiNzY0NTM4NDQyZDlkYWZlMTUzMTNkYzM5MWFfMy0xLTEtMS0w_f87d5839-2d8a-457d-8a1c-3443bec2cf2c">422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmZiY2Q3Yjc2NDUzODQ0MmQ5ZGFmZTE1MzEzZGMzOTFhL3RhYmxlcmFuZ2U6ZmJjZDdiNzY0NTM4NDQyZDlkYWZlMTUzMTNkYzM5MWFfMy0zLTEtMS0w_5e099a0b-7d81-4edc-be0e-6365c83131eb">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmZiY2Q3Yjc2NDUzODQ0MmQ5ZGFmZTE1MzEzZGMzOTFhL3RhYmxlcmFuZ2U6ZmJjZDdiNzY0NTM4NDQyZDlkYWZlMTUzMTNkYzM5MWFfNC0xLTEtMS0w_b9d766ec-64a7-42a3-9c6f-368654fb8410">1,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmZiY2Q3Yjc2NDUzODQ0MmQ5ZGFmZTE1MzEzZGMzOTFhL3RhYmxlcmFuZ2U6ZmJjZDdiNzY0NTM4NDQyZDlkYWZlMTUzMTNkYzM5MWFfNC0zLTEtMS0w_d65c8cdc-b889-4c4e-b1dc-6166ec24d50f">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><ix:continuation id="iebaf13fd4d264eacb456b7d0a4f7471c" continuedAt="i7a95e84261814ea1a79eb4824de3fa53"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">              *In January 2020, the FASB issued </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Update No. 2020-01, Investments&#8212;Equity Securities (Topic 321), &#160;&#160;&#160;&#160;                   Investments&#8212;Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)&#8212;Clarifying the Interactions between Topic 321, Topic 323, and Topic 815</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i7a95e84261814ea1a79eb4824de3fa53"> (a consensus of the Emerging Issues Task Force), which clarifies the interaction of the accounting for equity securities, investments accounted for under the equity method, and certain forward contracts and purchased options. This update is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The Company is in the process of determining the impact the adoption will have on its financial statements, beginning as of and for the three months ending March 31, 2022.</ix:continuation>  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c) Accounts Payable and Other Accrued Liabilities&#160;</span></div><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RleHRyZWdpb246MmU2ZGQ3YTJkNmU0NDBmMzg3M2UyOTVlN2NiOWNhOWFfMjQyNQ_701698e7-46a4-4f92-98ae-be626f6a433a" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Accounts payable and other accrued liabilities&#8221; consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable and other</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfMS0xLTEtMS0w_2691d613-c2f4-473b-bbd5-6744820811e4">3,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfMS0zLTEtMS0w_8975a806-6aae-4d03-bef5-511641eb0363">2,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfMy0xLTEtMS0w_b7e575d8-d280-4293-8789-fed2b272668a">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfMy0zLTEtMS0w_d8825308-a670-4fd9-8b09-8e172bafd1f5">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical studies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="tars:AccruedClinicalStudiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNC0xLTEtMS0w_1deab10f-8534-462d-96f8-c14865c355bc">3,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:numdotdecimal" name="tars:AccruedClinicalStudiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNC0zLTEtMS0w_1e79202c-a47b-43e7-9aa4-285b04b0406d">1,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNS0xLTEtMS03NzI_d763681d-6e89-44af-a6d4-1c78aad93858">1,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNS0zLTEtMS03NzI_668f1060-60bd-42ce-9bab-0662664748e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNS0xLTEtMS0w_10d008ce-fff3-46fe-8572-33195733a66e">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNS0zLTEtMS0w_2b043429-0b7f-4332-9584-f474061978e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock option early exercise liability, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNi0xLTEtMS0w_df58449e-3da6-4d80-977b-f821a4cb9df0">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNi0zLTEtMS0w_1292f6ca-0d79-48e8-a585-6476716e170d">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNy0xLTEtMS0w_a58fe3ec-5d22-471c-95e2-49d377697405">8,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNy0zLTEtMS0w_ff2aef19-acd0-4b22-bc01-03cecfd0c123">4,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d) Other Long-Term Liabilities</span></div><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:OtherLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RleHRyZWdpb246MmU2ZGQ3YTJkNmU0NDBmMzg3M2UyOTVlN2NiOWNhOWFfMjQyNg_45483a33-d8e8-40c8-8fe8-04705152a523" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Other long-term liabilities&#8221; consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, non-current portion</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjExMGMyYzg1Y2Q5NjQ1YjJiZmI0MmQ4MDc2MmI3MTdhL3RhYmxlcmFuZ2U6MTEwYzJjODVjZDk2NDViMmJmYjQyZDgwNzYyYjcxN2FfMS0xLTEtMS0w_7dc22164-bc4b-4590-b9e9-351648b5f429">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjExMGMyYzg1Y2Q5NjQ1YjJiZmI0MmQ4MDc2MmI3MTdhL3RhYmxlcmFuZ2U6MTEwYzJjODVjZDk2NDViMmJmYjQyZDgwNzYyYjcxN2FfMS0zLTEtMS0w_b76ae388-a1e8-445c-b6fe-77e6f3d9eb9b">549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjExMGMyYzg1Y2Q5NjQ1YjJiZmI0MmQ4MDc2MmI3MTdhL3RhYmxlcmFuZ2U6MTEwYzJjODVjZDk2NDViMmJmYjQyZDgwNzYyYjcxN2FfMi0xLTEtMS0w_d95f776a-2ecb-4c59-954a-1443545b1c80">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjExMGMyYzg1Y2Q5NjQ1YjJiZmI0MmQ4MDc2MmI3MTdhL3RhYmxlcmFuZ2U6MTEwYzJjODVjZDk2NDViMmJmYjQyZDgwNzYyYjcxN2FfMi0zLTEtMS0w_3c955c6a-4fb3-42f1-ad47-0448dafbd977">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock option early exercise liability, non-current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjExMGMyYzg1Y2Q5NjQ1YjJiZmI0MmQ4MDc2MmI3MTdhL3RhYmxlcmFuZ2U6MTEwYzJjODVjZDk2NDViMmJmYjQyZDgwNzYyYjcxN2FfMy0xLTEtMS0w_8df2c36c-1405-4392-b712-4cb189383e2f">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjExMGMyYzg1Y2Q5NjQ1YjJiZmI0MmQ4MDc2MmI3MTdhL3RhYmxlcmFuZ2U6MTEwYzJjODVjZDk2NDViMmJmYjQyZDgwNzYyYjcxN2FfMy0zLTEtMS0w_cccc86ca-5be9-453d-8a2f-138e08077232">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjExMGMyYzg1Y2Q5NjQ1YjJiZmI0MmQ4MDc2MmI3MTdhL3RhYmxlcmFuZ2U6MTEwYzJjODVjZDk2NDViMmJmYjQyZDgwNzYyYjcxN2FfNC0xLTEtMS0w_d427eeea-a81a-4f34-9fa2-6e369932cf1d">524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjExMGMyYzg1Y2Q5NjQ1YjJiZmI0MmQ4MDc2MmI3MTdhL3RhYmxlcmFuZ2U6MTEwYzJjODVjZDk2NDViMmJmYjQyZDgwNzYyYjcxN2FfNC0zLTEtMS0w_c4a4e73a-de26-423c-a3a1-6b1c8eaf9f21">605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8b61561133ed4a6b868d8d2b5a1f9640_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfOTQ1_79553214-ba04-4e62-a44d-c504c5c4d77b" continuedAt="i4e2dae23a98f416598ded4dd6a753b90" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="i4e2dae23a98f416598ded4dd6a753b90" continuedAt="i7c82d4abef5045c08c28ff0ab81ef7cd"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Authorized Stock</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the October 2020 Amended and Restated Certificate of Incorporation, the Company is authorized to issue two classes of stock: common and preferred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The total number of shares authorized for issuance is <ix:nonFraction unitRef="shares" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfMjUz_e91d157c-a432-47e7-ba55-161de67616bf">200.0</ix:nonFraction> million shares of common stock and <ix:nonFraction unitRef="shares" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfMjgz_b0c07bcb-d2c3-4f35-ad50-8133c976ad41">10.0</ix:nonFraction> million shares of preferred stock.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i7c82d4abef5045c08c28ff0ab81ef7cd"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Overview and Reserve for Future Issuance</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stockholders have <ix:nonFraction unitRef="vote" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="tars:CommonStockNumberOfVotes" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfMzky_ea9e56a1-8b06-4705-b601-7cd304f3fd80">one</ix:nonFraction> vote for each share of common stock held and are entitled to receive any dividends declared by the Company&#8217;s Board of Directors when legally available for distribution, then-subject to the dividend rights of the holders of preferred stock. For the three and six months ended June 30, 2021 and for the year ended December&#160;31, 2020, <ix:nonFraction unitRef="usdPerShare" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfNjcz_65a27fb3-bada-49d3-b392-6316edb168d8"><ix:nonFraction unitRef="usdPerShare" contextRef="i4fa02c7ace144c81a2fd09a81a1d827c_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfNjcz_c565af56-f8aa-4992-b41c-a4c1a02f721e">no</ix:nonFraction></ix:nonFraction> dividends were declared.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021 and December&#160;31, 2020, the Company had <ix:nonFraction unitRef="shares" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfNzM0_062ae3ec-888a-41e5-96b6-20e06fd9da3b">20.7</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfNzQx_74df4529-d006-4c4e-a40e-16acf193f112">20.5</ix:nonFraction> million shares of common stock issued, respectively. At June&#160;30, 2021 and December&#160;31, 2020, the Company had <ix:nonFraction unitRef="shares" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfODE5_1ff6a610-76f1-42a9-a776-8c736b097da0">20.6</ix:nonFraction> million, an</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d <ix:nonFraction unitRef="shares" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfODI3_c8652c4a-acb6-4bb7-8047-6189c31fe34b">20.3</ix:nonFraction> million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock outstanding, respectively. <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfOTQ2_c59639bb-fded-4fc2-bf34-665d7a688d27" continuedAt="ibcc05a11be0d49c088990b3985f4b5ad" escape="true">The following shares of common stock were reserved for issuance:</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><ix:continuation id="ibcc05a11be0d49c088990b3985f4b5ad"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options issued and outstanding </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="INF" format="ixt:numdotdecimal" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RhYmxlOjYwMTliYzg3MGY5MTQ2Y2JhM2VjNDExYmNlMzQxODM4L3RhYmxlcmFuZ2U6NjAxOWJjODcwZjkxNDZjYmEzZWM0MTFiY2UzNDE4MzhfMi0xLTEtMS0w_01fec5a0-61f8-4195-b037-f8dbeb964981">2,598,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="INF" format="ixt:numdotdecimal" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RhYmxlOjYwMTliYzg3MGY5MTQ2Y2JhM2VjNDExYmNlMzQxODM4L3RhYmxlcmFuZ2U6NjAxOWJjODcwZjkxNDZjYmEzZWM0MTFiY2UzNDE4MzhfMi0zLTEtMS0w_cd92b9ba-2cdd-48f2-8baa-e0494c9e6b52">1,836,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock awards reserved for future grant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="INF" format="ixt:numdotdecimal" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RhYmxlOjYwMTliYzg3MGY5MTQ2Y2JhM2VjNDExYmNlMzQxODM4L3RhYmxlcmFuZ2U6NjAxOWJjODcwZjkxNDZjYmEzZWM0MTFiY2UzNDE4MzhfMy0xLTEtMS0w_3bc3c577-8a77-4117-90b8-9a362f63706f">9,451,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="INF" format="ixt:numdotdecimal" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RhYmxlOjYwMTliYzg3MGY5MTQ2Y2JhM2VjNDExYmNlMzQxODM4L3RhYmxlcmFuZ2U6NjAxOWJjODcwZjkxNDZjYmEzZWM0MTFiY2UzNDE4MzhfMy0zLTEtMS0w_e9ea2c81-cf25-4692-90a9-3b8c190bebce">9,414,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="INF" format="ixt:numdotdecimal" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RhYmxlOjYwMTliYzg3MGY5MTQ2Y2JhM2VjNDExYmNlMzQxODM4L3RhYmxlcmFuZ2U6NjAxOWJjODcwZjkxNDZjYmEzZWM0MTFiY2UzNDE4MzhfNC0xLTEtMS03NTY_f42ea0d3-67cb-4d21-b0c4-1b7236a22429">4,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="INF" format="ixt:zerodash" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RhYmxlOjYwMTliYzg3MGY5MTQ2Y2JhM2VjNDExYmNlMzQxODM4L3RhYmxlcmFuZ2U6NjAxOWJjODcwZjkxNDZjYmEzZWM0MTFiY2UzNDE4MzhfNC0zLTEtMS03NTY_6c9317e4-3a10-406f-89c2-bbb6cbe4b9e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shares of common stock reserved</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RhYmxlOjYwMTliYzg3MGY5MTQ2Y2JhM2VjNDExYmNlMzQxODM4L3RhYmxlcmFuZ2U6NjAxOWJjODcwZjkxNDZjYmEzZWM0MTFiY2UzNDE4MzhfNC0xLTEtMS0w_5d90fafa-451d-40ae-b30e-10c5990ed32b">12,054,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RhYmxlOjYwMTliYzg3MGY5MTQ2Y2JhM2VjNDExYmNlMzQxODM4L3RhYmxlcmFuZ2U6NjAxOWJjODcwZjkxNDZjYmEzZWM0MTFiY2UzNDE4MzhfNC0zLTEtMS0w_a7183d9e-63cb-4695-bbd2-2963b6e31750">11,250,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i8b61561133ed4a6b868d8d2b5a1f9640_49"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfNDM0MA_bcf124fa-ca6a-4a79-989f-3d3f2abf259b" continuedAt="ia272a6689cd743119394e3129222f095" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="ia272a6689cd743119394e3129222f095" continuedAt="ifd8a0d81e0084d92996a4137c16163c6"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 and 2016 Equity Incentive Plans</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Board of Directors and stockholders adopted and approved the Company's 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) on October 8, 2020. The 2020 Plan replaced the Company's 2016 Equity Incentive Plan that was earlier adopted in December 2016 (the &#8220;2016 Plan&#8221;).  However, awards outstanding under the 2016 Plan will continue to be governed by its original terms. The number of shares of the Company's common stock that were initially available for issuance under the 2020 Plan equaled the initial sum of <ix:nonFraction unitRef="shares" contextRef="i160de614ede245e3b4a8318dd5566a1f_I20201020" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfNTcy_ff74eef3-7928-4b65-968e-47478a2a5d6a">9,000,000</ix:nonFraction> shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">plus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="i4417090679e84025a7090d9e6076ba21_I20201020" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfNTg3_61d4f3d3-7b2e-485a-8716-c7b0945ce471">2,432,980</ix:nonFraction> shares that were then available for issuance under the 2016 Plan. The 2020 Plan provides for the following types of awards: incentive and non-statutory stock options, stock appreciation rights, restricted shares, and restricted stock units.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of common stock reserved for issuance under the 2020 Plan are increased automatically on the first business day of each fiscal year, commencing in 2021 and ending in 2030, by a number equal to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">lesser of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: (i) <ix:nonFraction unitRef="number" contextRef="ide340ac61efb43b08434911f4db98e68_I20210630" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfMTA2NQ_8aaedf96-c9d3-4206-b31a-f84faf634546">4</ix:nonFraction>% of the shares of common stock outstanding on the last day of the prior fiscal year; or (ii) the number of shares determined by the Company's Board of Directors. In general, to the extent that any awards under the 2020 Plan are forfeited, terminate, expire or lapse without the issuance of shares, or if the Company reacquires the shares subject to awards granted under the 2020 Plan, those shares will again become available for issuance under the 2020 Plan, as will shares applied to pay the exercise or purchase price of an award or to satisfy tax withholding obligations related to any award.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards are governed by agreements between the Company and the recipients. Incentive stock options and nonqualified stock options may be granted under the 2020 Plan (and previously the 2016 Plan) at an exercise price of not less than <ix:nonFraction unitRef="number" contextRef="i70a7676a97b848b1a1f7a3665d148983_D20210101-20210630" decimals="INF" name="tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfMTkxOA_4a498b1a-439a-44d6-90f6-885d29221fae">100</ix:nonFraction>% of the fair market value of common stock on the respective date of grant.  The grant date is the date the terms of the award are formally approved by the Company&#8217;s Board of Directors or its designee. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through June&#160;30, 2021, all awards issued under the 2020 Plan and 2016 Plan were in the form of stock options and restricted stock units. These stock award agreements have service and/or performance conditions for vesting, unless immediately vested on the date of grant. Stock awards granted typically have <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfMjM4Ng_487f5d4f-2795-4d06-a86b-a0f73cdced0d">one</span> to <ix:nonNumeric contextRef="ia1441e738b9045918e9a7e31197dd133_D20210101-20210630" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfNDM0MQ_42dd39d3-bd70-4e8c-af3f-9f3617a29a50">four-year</ix:nonNumeric> service conditions for full vesting. The performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ifd8a0d81e0084d92996a4137c16163c6" continuedAt="ic916030c25ca4bc988e5e725450936dc"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options must be exercised, if at all, no later than <ix:nonNumeric contextRef="id52f2032269a4f819d15bd4d1e161a3b_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfMjY3NA_929eda63-9311-4495-8e4c-aa2dbcc391b3">10</ix:nonNumeric> years from the date of grant. Upon termination of employment, vested stock options may be exercised within <ix:nonNumeric contextRef="id52f2032269a4f819d15bd4d1e161a3b_D20210101-20210630" format="ixt-sec:durmonth" name="tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfMjc3OA_1df8e417-a4dc-4144-9b72-5abc3c8bbd34">12</ix:nonNumeric> months after the date of termination upon death, <ix:nonNumeric contextRef="id52f2032269a4f819d15bd4d1e161a3b_D20210101-20210630" format="ixt-sec:durwordsen" name="tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfMjgyMw_c0d5c0f5-addf-4e48-89de-bf27df09541f">six months</ix:nonNumeric> after the date of termination upon disability, and <ix:nonNumeric contextRef="id52f2032269a4f819d15bd4d1e161a3b_D20210101-20210630" format="ixt-sec:durwordsen" name="tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfMjg3Nw_9f5089e1-6e38-4eea-8ba9-2c7486eb680b">three months</ix:nonNumeric> after the date of termination for all other separations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Summary</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is recorded in the accompanying condensed statements of operations and comprehensive income (loss) based on the assigned or designated department of the award recipient. <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfNDM0Mg_b3068d9c-15af-4c66-b6e6-272ce167eef8" continuedAt="icb69ba316b76498eabe329b5cd9bfb30" escape="true">Stock-based compensation expense for the three and six months ended June 30, 2021 and 2020 was as follows:</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><ix:continuation id="icb69ba316b76498eabe329b5cd9bfb30"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:45.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia382e48d34b4428fafebec87724739c8_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfMi0xLTEtMS0w_3726f7ed-9381-486c-9487-612663cac5b9">427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09be892cb78f4a5492f5791c5d513c0a_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfMi0zLTEtMS0w_44d6b5d7-13a8-401b-9dc6-3895980e9c1b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c21ad7a9fe43c996fb0628c1fd4ac4_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfMi01LTEtMS0w_5106e14f-6b9a-4f3d-b2cb-7c5e3baca061">771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie004d19f0fd443d5b88f07a7468ee270_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfMi03LTEtMS0w_fb289f83-db6d-46ab-8a10-257100fd0465">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaa289cd736c437987015fee0950c75c_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfMy0xLTEtMS0w_144ed55f-605a-439f-96c8-33b02ba1c38c">2,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42649f1122f8480785c73d82be5bd8dc_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfMy0zLTEtMS0w_a39ec3a6-4d9e-4590-8b40-6f75d994e244">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52aedec7a8084e91bca615af7ebec95a_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfMy01LTEtMS0w_d1634125-6554-4a3c-82ed-4395397488d4">3,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea321863db444169b622b85850d6e55_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfMy03LTEtMS0w_96229abc-5dd2-40fa-903a-948c3ec8e49a">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfNC0xLTEtMS0w_09c7fb07-5693-4134-a965-fc81194e6015">2,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfNC0zLTEtMS0w_1219d366-cfab-4f00-9161-9e0b3402a035">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfNC01LTEtMS0w_be3d9e83-3aba-4db2-9926-59c99058b419">4,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfNC03LTEtMS0w_8b2e5a69-c01f-47a6-bbc0-2090d4407378">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pre-Vesting Exercise Feature of Certain Stock Options </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Plan permitted certain option holders to exercise awarded options prior to vesting. Upon this early exercise, the options became subject to a restricted stock agreement and remain subject to the same vesting provisions in the corresponding stock option award. These unvested options are subject to repurchase by the Company upon employee termination at the same price exercised. These unvested shares of common stock are reported as issued (but not outstanding) on the accompanying Balance Sheets while subject to repurchase by the Company. These shares are also excluded from the basic net income (loss) per share until the repurchase right lapses upon vesting, but are included in the diluted net income per share for the three and six months ended June&#160;30, 2021.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic916030c25ca4bc988e5e725450936dc">The Company initially records a liability for these early exercises that is subsequently reclassified into stockholders&#8217; equity on a pro rata basis as vesting occurs. As of June&#160;30, 2021 and December&#160;31, 2020, the Company recorded the unvested portion of the exercise proceeds of $<ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfNDI2Mw_6486e611-a8d4-4c30-9b0a-3848f7ee2546">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfMzI5ODUzNDg4NzY5OA_944d7725-f495-4329-9d90-4858b078a279">0.4</ix:nonFraction> million, respectively, as a liability from the early exercise in the accompanying Balance Sheets.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_52"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMTQxMw_a9b1bd36-ca20-435e-961a-4a6c4d1265d9" continuedAt="i9ffd7c499dba4fb38c957128392610e2" escape="true">NET INCOME (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i9ffd7c499dba4fb38c957128392610e2" continuedAt="id822ddb7a9ed4506bc486cdfcfca395a"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMTQxNA_5018d555-827d-4aab-9820-ad15f52b4450" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company permits certain option holders to exercise awarded options prior to vesting (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Upon this early exercise, these options become subject to a restricted stock agreement and remain subject to the same vesting provisions in the corresponding stock option award. These early exercised options are considered to be "participating securities" due to non-forfeitable right to dividends (i.e., even prior to vesting). For the three and six months ended June 30, 2021, the "two-class method" was utilized to calculate diluted net income per share as it was more dilutive than the "treasury stock metho</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d". Due to a net loss for the three months ended March 31, 2020, all otherwise potentially dilutive securities are antidilutive. Accordingly, basic net loss per share equals diluted net loss per share for the three and six months ended June 30, 2020. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> table sets forth the computation of basic and diluted net loss per share attributable to common stockholders:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.212%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.127%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic EPS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMy0xLTEtMS0w_ac7ae272-dbd0-4fa4-8497-7cc7946cc346">6,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMy0zLTEtMS0w_97e4bab8-8966-41f7-8427-0c018af94d38">3,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMy00LTEtMS0yMzM_1f17aae9-411f-4445-be0e-7ddb4c5b819c">16,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMy02LTEtMS0yMzM_9796aa65-7800-41b6-a5b8-b891a19259be">5,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: undistributed income allocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNC0xLTEtMS0w_2125bdd1-625a-4867-b59f-85b333d949f3">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNC0zLTEtMS0w_370d64b0-3527-4bbb-88dd-94703b0ba7f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNC00LTEtMS0yMzM_174faf28-566e-4fed-b8ed-5957f08f20ea">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNC02LTEtMS0yMzM_e4e3c53f-a64f-4132-b124-afaef271d712">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available to common shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNS0xLTEtMS0w_35536ffb-6540-4e0d-ac16-31b4c9961b82">6,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNS0zLTEtMS0w_9d968104-c43c-4ce5-aa67-c41cae620cd7">3,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNS00LTEtMS0yMzM_877e254c-6b11-4a3f-818a-f42db2ccac0f">16,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNS02LTEtMS0yMzM_9794bbce-a1ea-4792-b314-1d21c9c32a00">5,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNy0xLTEtMS0w_355fc19c-11eb-4eda-b947-6342e7accd3e">20,555,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNy0zLTEtMS0w_0e9fdad5-deea-49ca-a617-9eb750676020">2,651,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNy00LTEtMS0yMzM_1561c451-3bb6-4812-9289-a269c61620f2">20,446,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNy02LTEtMS0yMzM_d7650d30-4e5d-4c2e-9bd7-fff9adede115">2,650,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to common stockholders&#8212;basic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfOC0xLTEtMS0w_21f2cda2-4417-4f1d-8e97-2c1e61b3f3b1">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfOC0zLTEtMS0w_3022bbc2-170e-4e14-9272-74bfed0a75b9">1.23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfOC00LTEtMS0yMzM_12e50fed-15bc-4123-9bec-138b1b8ad6cc">0.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfOC02LTEtMS0yMzM_0b4db2a8-d3b2-4369-8fec-66e9e6c0243c">1.96</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTEtMS0xLTEtMA_1b61195b-ea97-4fcd-9e1e-240bbeb56189">6,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTEtMy0xLTEtMA_e9a39d48-6f08-4fc6-a152-6821b60a9810">3,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTEtNC0xLTEtMjMz_c260c080-c7c4-4b12-8bcc-7563cd13fc8a">16,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTEtNi0xLTEtMjMz_03aec959-260a-41c2-9c49-3567233bf924">5,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: undistributed income reallocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTItMS0xLTEtMA_3fe5e88b-e4ff-496e-a106-e50761af0924">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTItMy0xLTEtMA_07f54a22-b43a-4d62-9149-cd652dfd206d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTItNC0xLTEtMjMz_b653c796-535b-4d04-bf93-1abb94ccdca3">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTItNi0xLTEtMjMz_c55bb573-1647-4316-ab3d-0a1455fbb9dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available to common shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTMtMS0xLTEtMA_040b60c3-d7d3-4252-942e-7f6d5b078f1d">6,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTMtMy0xLTEtMA_85ed6cf2-e44a-45f6-8c30-543cd6dff3d8">3,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTMtNC0xLTEtMjMz_761e88e1-69e0-4be3-a1b0-6e494ab03d7f">16,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTMtNi0xLTEtMjMz_20e55b47-5fa4-4786-9fc6-e9831e94b157">5,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTUtMS0xLTEtMA_a7c172a3-eead-4e22-a017-4a309b6abaff">20,555,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTUtMy0xLTEtMA_485abf2c-5d68-466d-89cd-f7560335fca3">2,651,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTUtNC0xLTEtMjMz_5bcb81fa-0f8e-409e-83bb-348e00feb64b">20,446,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTUtNi0xLTEtMjMz_866010be-4253-45dc-b360-41ac8febae12">2,650,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTctMS0xLTEtMA_8b1bb7f3-17c4-4dfe-b74a-ae806b7a0514">1,411,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTctMy0xLTEtMA_73712614-fc32-449f-ac1e-a0ef99a072e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTctNC0xLTEtMjMz_48f6a817-487b-46c9-a765-70b9221b3caa">1,449,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTctNi0xLTEtMjMz_7ff6da4d-7c63-4494-8e21-d02fa7c370fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTgtMS0xLTEtMA_51348066-daa5-4823-8c0a-b4d8a8aed62d">21,966,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTgtMy0xLTEtMA_44ff5838-4ade-419f-b4fb-2e75088afbbb">2,651,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTgtNC0xLTEtMjMz_64193a56-6b56-4cef-aecc-8f3bcd24cd09">21,895,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTgtNi0xLTEtMjMz_1b846402-1da9-4439-b84b-a6e153d580d3">2,650,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to common stockholders&#8212;diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTktMS0xLTEtMA_173ce298-3a1a-431f-9cad-f903ae41a483">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTktMy0xLTEtMA_ee7a3611-a44d-4701-896f-2816428d6c43">1.23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTktNC0xLTEtMjMz_afe7b8b4-eb67-40e2-b971-fbb13b9e1746">0.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTktNi0xLTEtMjMz_e998afb3-d468-4e31-bfbc-a73ff1f61190">1.96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-indent:49.5pt"><ix:continuation id="id822ddb7a9ed4506bc486cdfcfca395a" continuedAt="i776956203ac44b40a52c9d01b53dab10"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> three and six months ended June&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="shares" contextRef="i00691ca440da494bb30506de043894c3_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMzI5ODUzNDg4NTIyNw_15fdab91-ac05-4f30-be82-2cafab290482"><ix:nonFraction unitRef="shares" contextRef="ib790f0e6092341f4a52bec6af062bad6_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMzI5ODUzNDg4NTIyNw_92732721-12da-4c82-86f8-55d5b3f44456">0.8</ix:nonFraction></ix:nonFraction>&#160;million unexercised stock options were excluded from the computation of n</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">et income per share because the effect would have been anti-dilutive. Additionally, during the three and six months ended June 30, 2020, <ix:nonFraction unitRef="shares" contextRef="i4bb4eaa3ec8e4dea84b9f3711947b2e3_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMTEzOA_5bb9db16-3bf1-4595-ae3a-0d6ee6faad1e"><ix:nonFraction unitRef="shares" contextRef="i41b874cb3c6a4ec08fed9386a1952c2d_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMTEzOA_a3074bfa-615d-45cd-8519-64fc9604d2db">1.2</ix:nonFraction></ix:nonFraction>&#160;million unexercised stock options, <ix:nonFraction unitRef="shares" contextRef="i09d03f0a6dbb451781fd862327cdf06f_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMTE3MQ_21b9509f-0b77-4e64-8e8d-4f5cdaabfd6f"><ix:nonFraction unitRef="shares" contextRef="i676991ec719542d787676a12566ca054_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMTE3MQ_d3bdb04a-6ab1-4c58-9e42-90ca4a49eef6">8.2</ix:nonFraction></ix:nonFraction>&#160;million shares of preferred stock, and <ix:nonFraction unitRef="shares" contextRef="ia30cf1b452db4f2ab51f825c5ca653f5_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMTA5OTUxMTYzMDcyNg_1ee9ffd0-5b0d-4091-adca-91ac215fe429"><ix:nonFraction unitRef="shares" contextRef="i219f4b1f55974121826108795989b54f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMTA5OTUxMTYzMDcyNg_d984e477-e88e-4222-a850-a139a492a2ac">67</ix:nonFraction></ix:nonFraction>&#160;thousand early-exercised and unvested stock options were excluded from the calculation of diluted net loss per share attributable to common stockholders because their impact under the &#8220;treasury stock method&#8221; and "if-converted metho</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i776956203ac44b40a52c9d01b53dab10">d" would have been anti-dilutive.</ix:continuation> </span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_55"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RleHRyZWdpb246NzNiNzMxZjBlYWY0NDNmN2E1Zjc1ZDYzOWM3MmU0NmRfMjE3OA_66e5d7a9-1526-4843-af12-30d7d7c500c2" continuedAt="ifea9c476325a44ae8564be33b8db4d75" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="ifea9c476325a44ae8564be33b8db4d75" continuedAt="i72d851fe8f22428c8826842da1c3a62b"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RleHRyZWdpb246NzNiNzMxZjBlYWY0NDNmN2E1Zjc1ZDYzOWM3MmU0NmRfMjE3OQ_1d8017f7-dfb7-48fa-8648-23d653d8c5e0" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes certain financial instruments measured at fair value that are included within the accompanying balance sheets, and their designation among the three fair value measurement categories (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2(xiii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddbd54b520554e4eba813e5be9dfdf7d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMy0xLTEtMS0w_eb85d47f-16c7-4d1c-be23-325eb7a7517b">176,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09a13b7525134e7abe18f464f8248af4_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMy0zLTEtMS0w_cd565e43-c9ea-40be-93ac-3e7e24bb0897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53e1600dba1b4b808a42c009c3b3eaa9_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMy01LTEtMS0w_600c173c-6392-48b1-982f-7ac512eba50e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1923bd29bb5b417abd997b0aed3bc467_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMy03LTEtMS0w_921d19fe-9a01-4fa3-8e54-9d96e38369d4">176,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity warrant rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddbd54b520554e4eba813e5be9dfdf7d_I20210630" decimals="-3" format="ixt:zerodash" name="tars:EquityWarrantsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfNC0xLTEtMS0w_e85b6da2-2361-4b90-89a1-d7714b3672e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09a13b7525134e7abe18f464f8248af4_I20210630" decimals="-3" format="ixt:zerodash" name="tars:EquityWarrantsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfNC0zLTEtMS0w_da733db8-5911-48f3-a64e-b8f07bfd37b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53e1600dba1b4b808a42c009c3b3eaa9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="tars:EquityWarrantsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfNC01LTEtMS0w_b7d7d382-c33c-45e0-9886-f17c58600647">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1923bd29bb5b417abd997b0aed3bc467_I20210630" decimals="-3" format="ixt:numdotdecimal" name="tars:EquityWarrantsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfNC03LTEtMS0w_61dac780-f1aa-45e6-97b8-a9cd6300a923">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia46c6f317af64f7caba90357c4e57a2d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfNS0xLTEtMS0w_908ee0ee-787b-4ff9-8cb7-11bc20f1d36c">176,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62e01287e81647ce9087b8b1ff3d25cf_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfNS0zLTEtMS0w_79f4e01a-a603-4e4a-b7c6-c0190608b49f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i220d03846323467db8c56663c9a2e8df_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfNS01LTEtMS0w_f9aae14d-b31f-48bf-9c90-512122767e39">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfNS03LTEtMS0w_4f9a3844-388e-4277-a09e-98a703f2ff67">177,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i229e0511be204ad18d91926584e23767_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMTAtMS0xLTEtMA_89a22bab-2096-42dd-8558-858c3de16f99">168,129</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6a8425d752d4893941d5870ecfeb307_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMTAtMy0xLTEtMA_b350f4ea-4f3a-416a-8e7c-2e5c837616fd">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8de5698c138449598b8e67a58294917_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMTAtNS0xLTEtMA_de9a4b6a-c4cc-4e96-a262-4f7924eb5ed4">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7356e8595ea47819751082d1cbcd009_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMTAtNy0xLTEtMA_919ec3e9-2384-48f1-9094-bbd951c0f57b">168,129</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739167d612a94c119439e7d8a3bb2b98_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMTEtMS0xLTEtMA_9b461914-04a8-4c63-a909-8665423da8f9">168,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7653af8a6494075bf51541661c26fca_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMTEtMy0xLTEtMA_fd82b46d-5161-4f27-bf41-41d1b47a4eb3">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dd90741d4ee44c0912e3f9f2224b6b6_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMTEtNS0xLTEtMA_1492a209-5dfe-42e6-9bb4-e0392ce28a67">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMTEtNy0xLTEtMA_93dd28bb-ef2c-4057-b379-59e5cfb11ae1">168,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Money Market Funds</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market fund holdings are included in "cash and cash equivalents" on the accompanying Balance Sheets and are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the fair value hierarchy because of their readily-available market prices in active markets that are publicly accessible at the measurement date. These money market funds are invested in U.S. Treasury, bills, notes, and other obligations issued or guaranteed as to principal and interest by the U.S. Government or its agencies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Warrant Rights</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, contemporaneous with the China Out-License transaction (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Company and LianBio Ophthalmology Limited (&#8220;LianBio&#8221;), executed a warrant agreement for the Company to purchase a stated number of equity securities of LianBio, a privately-held China-focused pharmaceutical company, at fair value (on a per share basis at the time of issuance).  The warrants will vest upon the achievement of certain clinical and regulatory events. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These warrants are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the fair value measurement hierarchy. The most significant assumptions  used in the option pricing valuation model to determine fair value include: the estimated current fair value of LianBio common stock, LianBio stock volatility (based on the historical volatility of similar companies), and the probability of achievement of discrete clinical and regulatory milestones for the vesting of each of the three warrants.  As of June&#160;30, 2021, one of these three milestones was met for vesting of the respective warrant.   </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These warrant agreements allow for "noncash settlement" and therefore met the criteria to be recognized as a "derivative asset" on the accompanying Condensed Balance Sheets and are presented within "other assets" as of June&#160;30, 2021 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). These warrants will be remeasured with a corresponding amount reported in "other (expense) income, net" on the Statement of Operations and Comprehensive Income (Loss) at each reporting date, until exercised or expired. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RleHRyZWdpb246NzNiNzMxZjBlYWY0NDNmN2E1Zjc1ZDYzOWM3MmU0NmRfMTA5OTUxMTYzMTYzNw_c186b359-d699-4183-b25e-038713eb4233" continuedAt="id75bb28ac2d64215bb29aeb0f4880432" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in fair value of the equity warrant rights presented in "other assets" on the accompanying Condensed Balance Sheets. The measurement of the equity warrant rights represents a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> financial instrument:</span></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt;text-align:center"><ix:continuation id="i72d851fe8f22428c8826842da1c3a62b"><ix:continuation id="id75bb28ac2d64215bb29aeb0f4880432"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"></td><td style="width:82.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Warrant Rights, presented in "other assets" within the Condensed Consolidated Balance Sheets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOjM2M2VhOTUyZjA0YzQyZmM4NDQyNWU3NzZkNTFmMjE2L3RhYmxlcmFuZ2U6MzYzZWE5NTJmMDRjNDJmYzg0NDI1ZTc3NmQ1MWYyMTZfMS0xLTEtMS0yNjIx_a697765b-c56a-41d9-b986-ce00d06a54cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Initial fair value estimate of equity warrant rights upon issuance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a28ec4e85d84692b4ca6a32628fa4be_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOjM2M2VhOTUyZjA0YzQyZmM4NDQyNWU3NzZkNTFmMjE2L3RhYmxlcmFuZ2U6MzYzZWE5NTJmMDRjNDJmYzg0NDI1ZTc3NmQ1MWYyMTZfMi0xLTEtMS0yNjIx_2e5e3e11-ee9f-4b01-8480-6da414a006ed">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e969dac4d6411dbb826ee3db9998d9_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOjM2M2VhOTUyZjA0YzQyZmM4NDQyNWU3NzZkNTFmMjE2L3RhYmxlcmFuZ2U6MzYzZWE5NTJmMDRjNDJmYzg0NDI1ZTc3NmQ1MWYyMTZfMy0xLTEtMS0yNjk0_e6be9fca-1c02-465f-b2a8-334ef35ce3f2">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revaluation of equity warrant rights upon achievement of first development milestone, included in "license fees"  within the Condensed Statement of Operations for the three months ended June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531e6f9904f341b0bf1f8a0e802a62ba_D20210401-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOjM2M2VhOTUyZjA0YzQyZmM4NDQyNWU3NzZkNTFmMjE2L3RhYmxlcmFuZ2U6MzYzZWE5NTJmMDRjNDJmYzg0NDI1ZTc3NmQ1MWYyMTZfMy0xLTEtMS0yNjIx_b33c56ab-67fe-4234-ba55-ed0ddc130ff5">719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revaluation of equity warrant rights included in "other income (expense), net" within the Condensed Statement of Operations for the three months ended June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabd2ce550eaa434ea84c33a084eae37b_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOjM2M2VhOTUyZjA0YzQyZmM4NDQyNWU3NzZkNTFmMjE2L3RhYmxlcmFuZ2U6MzYzZWE5NTJmMDRjNDJmYzg0NDI1ZTc3NmQ1MWYyMTZfNC0xLTEtMS0yNjIx_63287854-6b17-416e-b1fd-eeff1781d39d">876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of June 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOjM2M2VhOTUyZjA0YzQyZmM4NDQyNWU3NzZkNTFmMjE2L3RhYmxlcmFuZ2U6MzYzZWE5NTJmMDRjNDJmYzg0NDI1ZTc3NmQ1MWYyMTZfNS0xLTEtMS0yNjIx_1636279c-f42e-4cd0-b899-4dbe0977b571">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfODEzMw_5ce997f8-8dd2-4c14-a4ed-03c38ac81bae" continuedAt="iaaab4458d18d4cccbdb9aa2c53154469" escape="true">COMMITMENTS&#160;&amp; CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="iaaab4458d18d4cccbdb9aa2c53154469" continuedAt="id5ddca70b98d4c989ecb4e7f93873f6a"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Facility Leases </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company enters lease agreements with unaffiliated parties for the use of office and laboratory facilities and office equipment. As of December&#160;31, 2020, the Company had <ix:nonFraction unitRef="contract" contextRef="icb3da3b8c1a44b60becc387206f9893f_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="tars:LesseeOperatingLeaseNumberOfLeaseContracts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMjYw_ea15f790-8022-4e2c-ada0-6b93da7c71d5">three</ix:nonFraction> active facility leases in Irvine, California.  Separately in January 2021, the Company entered into a <ix:nonNumeric contextRef="ie05ece3c0fcc4ccaa63406a8de30a51b_I20210131" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfODEzNA_54989a69-8225-4acb-a0dd-599234e777af">six-month</ix:nonNumeric> lease for an additional adjacent administrative office suite that was not capitalized due to its under 12-month term.  In December 2020, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="ie13dc8d045254f7482573f832793430f_D20201201-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNTM1_fd445a49-b74d-403b-b1b5-51d0f2e5e553">15</ix:nonFraction> thousand impairment of its "operating lease right-of-use lease asset" in connection with its decision to early terminate one of the leases, which was completed in January 2021.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's remaining <ix:nonFraction unitRef="contract" contextRef="i1452c0961726458e8ba94815bf62b628_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="tars:LesseeOperatingLeaseNumberOfContractsNotImpaired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNzMw_ea92f822-745d-42ab-9733-50b5d4146e14">two</ix:nonFraction> capitalized facility leases for adjacent administrative and laboratory suites in Irvine, California commenced on June&#160;1, 2020. These leases each expire on January&#160;31, 2024 and one includes a renewal option that was not reasonably certain to be exercised at the time of lease commencement for purposes of its associated accounting for  capitalized "operating lease right-of-use asset" and accompanying lease liability included within "accounts payable and other accrued liabilities" and "other long-term liabilities" on the accompanying Condensed Balance Sheets, amounting to an aggregate $<ix:nonFraction unitRef="usd" contextRef="if2b5fae2eaf5463c9ec06e5004104176_D20200601-20200601" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMTMyMQ_823886d0-9076-4688-bfe5-234ead1f3ca7">0.6</ix:nonFraction> million.  These operating leases have annual rent that is payable monthly and carry fixed annual increases. Also, under these arrangements, real estate taxes, certain operating expenses, and common area maintenance are paid by the Company; since these costs are variable in nature, they are excluded from the measurement of the reported right-of-use asset and liability and are expensed as incurred. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020 and for the three and six months ended June 30, 2021, the Company had no sublease arrangements with it as lessor.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Components of Lease Expense</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liability associated with each lease is amortized over the respective lease term using the &#8220;effective interest rate method.&#8221; The Company&#8217;s right-of-use asset is amortized over the lease term on a straight-line basis to lease expense, as reported on an allocated basis within &#8220;research and development&#8221; and &#8220;general and administrative&#8221; expenses on the accompanying Statements of Operations and Comprehensive Income (Loss). <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfODEzNQ_820f1956-119c-4272-ae62-691576d67b1a" continuedAt="i0aec4f099554428cba17427d4558181e" escape="true">The components of lease cost were as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="id5ddca70b98d4c989ecb4e7f93873f6a" continuedAt="iebd69f69150b4fe8bd62fbde0b696fe0"><div style="margin-top:12pt;text-align:center;text-indent:49.5pt"><ix:continuation id="i0aec4f099554428cba17427d4558181e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:40.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.816%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfMi0xLTEtMS0w_801a107a-0ea5-4d8b-ba63-147681e9f7bc">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfMi0zLTEtMS0w_ae35960c-c05c-454d-adf2-eec3be2cb0b6">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfMi00LTEtMS0yNjg_d94946f0-7854-4057-a640-4c278c085135">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfMi02LTEtMS0yNjg_c8e7e006-3fea-458e-9a55-be65b70b8378">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfMy0xLTEtMS0w_664a8e0b-d1fa-46cb-923b-f3c4dcc046cf">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfMy0zLTEtMS0w_04516645-7a31-4e16-a149-c24f725ff339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfMy00LTEtMS0yNjg_530e1df1-ecf2-4f06-a333-a7370831aa88">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfMy02LTEtMS0yNjg_1e5c61d8-8977-4559-9067-8d41584a9320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfNC0xLTEtMS0w_eaa611b4-f24c-4a75-b241-ac9032742825">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfNC0zLTEtMS0w_9d0649ed-8a74-4e68-96ba-4c98cc24bafd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfNC00LTEtMS0yNjg_29f07f8d-8d0a-4f31-b99e-48d08873319d">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfNC02LTEtMS0yNjg_c711a02f-c447-4099-b451-e73e08551bf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfNS0xLTEtMS0w_fab3a2cd-97bd-42b1-9566-ec1ffcd13fee">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfNS0zLTEtMS0w_8ab7078d-def1-4acb-8735-ee91f65627a8">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfNS00LTEtMS0yNjg_4a7c5097-74d9-4bc8-9038-fe24790a970f">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfNS02LTEtMS0yNjg_b10deac2-7722-41f4-966d-c00d6bd7b8b0">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Weighted-Average Remaining Lease Term and Applied Discount Rate as of June 30, 2021 and December 31, 2020</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021 and December&#160;31, 2020, the Company's active facility leases had a weighted average remaining lease term of <ix:nonNumeric contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" format="ixt-sec:durwordsen" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMjU0MQ_64afe2ed-e0e4-4e1a-be26-b89b43deb093">2 years, 7 months</ix:nonNumeric> and <ix:nonNumeric contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231" format="ixt-sec:durwordsen" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMjU0OA_510984bb-2d6f-4211-b3b9-65ec4540e9a5">2 years, 10 months</ix:nonNumeric>, respectively.  The weighted average estimated incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMjYyOA_6020a409-1beb-4ecf-9936-f567cb7c6ae0">10</ix:nonFraction>% was utilized to present value future minimum lease payments since an implicit interest rate was not readily determinable. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Contractual Lease Payments as of June&#160;30, 2021</span></div><ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfODEzMg_b1de9a3c-4cf5-410e-980a-854e956bc8a8" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below table summarizes the (i)&#160;minimum lease payments over the next five years and thereafter, (ii)&#160;lease arrangement imputed interest, and (iii)&#160;present value of future lease payments:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases - future payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining six months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOjczZDYxNDVmYWM1YjQxNTA4ZjU1NTg4ZTcyZjlkMDg5L3RhYmxlcmFuZ2U6NzNkNjE0NWZhYzViNDE1MDhmNTU1ODhlNzJmOWQwODlfMS0xLTEtMS0w_7e4e8bad-f042-42f4-a4d4-03ded5031d18">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOjczZDYxNDVmYWM1YjQxNTA4ZjU1NTg4ZTcyZjlkMDg5L3RhYmxlcmFuZ2U6NzNkNjE0NWZhYzViNDE1MDhmNTU1ODhlNzJmOWQwODlfMi0xLTEtMS0w_95078064-f26c-4902-802e-176f095a8328">271</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOjczZDYxNDVmYWM1YjQxNTA4ZjU1NTg4ZTcyZjlkMDg5L3RhYmxlcmFuZ2U6NzNkNjE0NWZhYzViNDE1MDhmNTU1ODhlNzJmOWQwODlfMy0xLTEtMS0w_f586095c-27ab-4fa6-aa96-a3025546da59">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOjczZDYxNDVmYWM1YjQxNTA4ZjU1NTg4ZTcyZjlkMDg5L3RhYmxlcmFuZ2U6NzNkNjE0NWZhYzViNDE1MDhmNTU1ODhlNzJmOWQwODlfNC0xLTEtMS0w_21f89ead-8738-4fae-b418-88bc243f6d3b">25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOjczZDYxNDVmYWM1YjQxNTA4ZjU1NTg4ZTcyZjlkMDg5L3RhYmxlcmFuZ2U6NzNkNjE0NWZhYzViNDE1MDhmNTU1ODhlNzJmOWQwODlfNS0xLTEtMS0w_f28ca2a0-9a4b-4e5f-bb94-1ce6d91b38c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future lease payments, undiscounted</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOjczZDYxNDVmYWM1YjQxNTA4ZjU1NTg4ZTcyZjlkMDg5L3RhYmxlcmFuZ2U6NzNkNjE0NWZhYzViNDE1MDhmNTU1ODhlNzJmOWQwODlfNi0xLTEtMS0w_8d1fb3a8-91ab-42f9-856f-6aee248c4e29">717</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Less): Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOjczZDYxNDVmYWM1YjQxNTA4ZjU1NTg4ZTcyZjlkMDg5L3RhYmxlcmFuZ2U6NzNkNjE0NWZhYzViNDE1MDhmNTU1ODhlNzJmOWQwODlfNy0xLTEtMS0w_51f307e6-5e78-41a7-bf3c-0d31f5e6a82c">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease payments</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOjczZDYxNDVmYWM1YjQxNTA4ZjU1NTg4ZTcyZjlkMDg5L3RhYmxlcmFuZ2U6NzNkNjE0NWZhYzViNDE1MDhmNTU1ODhlNzJmOWQwODlfOC0xLTEtMS0w_298cb424-8bd1-4a52-8a7c-416e7f87bef4">634</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) In-License Agreements for Lotilaner</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agreement for Skin and Eye Disease or Conditions in Humans</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, the Company entered into an in-license agreement with Elanco Tiergesundheit AG (&#8220;Elanco&#8221;) for exclusive worldwide rights to certain intellectual property for the development and commercialization of lotilaner in the treatment or cure of any eye or skin disease or condition in humans (the "January 2019 Agreement"). The Company has sole financial responsibility for related development, regulatory, and commercialization activities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made a $<ix:nonFraction unitRef="usd" contextRef="i4f5e022e1a4a4c389fd70f2fdd2953e1_D20190101-20190131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMzU1Nw_be96ac2d-00ff-4ff8-8568-ea60dc4e0311">1.0</ix:nonFraction> million upfront payment at execution of the January 2019 Agreement. In September 2020, the Company made a required $<ix:nonFraction unitRef="usd" contextRef="i120ab40354ce4e18abe9a05184afca4c_D20200901-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMzY2Nw_11d69842-ccce-4398-b903-f6d5d5a2888c">1.0</ix:nonFraction> million clinical milestone payment associated with the first of two U.S. pivotal trials for the treatment of Demodex blepharitis.  The Company recognized an additional $<ix:nonFraction unitRef="usd" contextRef="i93cd1b65dc5e40239017d30da180b216_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMzgzMA_3660a3c8-0582-4b2c-9383-9f9a294fc9fd">2.0</ix:nonFraction> million expense for its second pivotal trial milestone in the three and six months ended June 30, 2021, which was paid in April 2021.  These amounts are presented in the applicable period within "research and development" expense in the accompanying Statements of Operations and Comprehensive Income (Loss). </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may make further cash payments to Elanco under this January 2019 Agreement upon the achievement of certain clinical milestones in the treatment of human skin diseases using lotilaner for an aggregate maximum of $<ix:nonFraction unitRef="usd" contextRef="i0d2fb7b171a54a6d88b68e421934e6d8_I20190131" decimals="INF" format="ixt:numdotdecimal" name="tars:CollaborativeArrangementMaximumMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNDMxOQ_7c27c262-fbf3-4f08-83a9-9326e06669e3">3.0</ix:nonFraction> million and various commercial and sales threshold milestones for an aggregate maximum of $<ix:nonFraction unitRef="usd" contextRef="iad5ec97fc35d4af183d9972de8c93b10_I20190131" decimals="INF" format="ixt:numdotdecimal" name="tars:CollaborativeArrangementMaximumMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNDQwNA_7625aa99-d718-406d-8dad-f24fa90828c1">79.0</ix:nonFraction> million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its net sales. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="iebd69f69150b4fe8bd62fbde0b696fe0"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">double-digits of such proceeds, except for territories in which the Company achieved applicable regulatory approval prior to sublicense execution.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the China Out-License discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company made a required contractual payment in the amount of $<ix:nonFraction unitRef="usd" contextRef="i70b499fd960e46b6927230aed1207cbd_D20210401-20210531" decimals="-5" format="ixt:numdotdecimal" name="tars:UpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMTA5OTUxMTYzNjc5OQ_bbff749b-5fd5-4a18-975b-f37f86808c41">2.5</ix:nonFraction> million to Elanco as part of the receipt of $<ix:nonFraction unitRef="usd" contextRef="ie07d05df956f4d13b7387802ceea7fc8_D20210401-20210531" decimals="INF" format="ixt:numdotdecimal" name="tars:UpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMTA5OTUxMTYzNjgxMw_4661fc08-cd37-45a8-97e0-9c35dcd76adf">25</ix:nonFraction> million of initial proceeds from LianBio during the three months ended June 30, 2021.  </span></div><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agreement for All Other Diseases or Conditions in Humans</span></div><div style="text-indent:56.55pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2020, the Company executed an expanded license agreement with Elanco, granting it a worldwide  license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention, or cure of "all other" diseases and conditions in humans (i.e., beyond that of the eye or skin, the &#8220;September 2020 Agreement&#8221;).  The Company issued Elanco <ix:nonFraction unitRef="shares" contextRef="i120ab40354ce4e18abe9a05184afca4c_D20200901-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNTI5MA_857be988-f4a6-4ff4-b88c-8008e95100f6">222,460</ix:nonFraction> shares of its common stock at the execution of the September 2020 Agreement. The value of these shares was $<ix:nonFraction unitRef="usd" contextRef="i120ab40354ce4e18abe9a05184afca4c_D20200901-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNTQwMA_f6c2ba98-8ace-4fd8-94d7-64841b494ee8">3.1</ix:nonFraction> million ($<ix:nonFraction unitRef="usdPerShare" contextRef="id78fdaf99d664fb88506c79ba98fab86_I20210630" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNTQwNA_0e17868a-15f9-498a-bafa-ca74fb7cf5de">14.0003</ix:nonFraction> per share, approximating the issuance price of the Company's Series C preferred stock in September 2020).  </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is required to make further cash payments to Elanco under the September 2020 Agreement upon the achievement of various clinical milestones for an aggregate maximum of $<ix:nonFraction unitRef="usd" contextRef="i984e3a65060c4cfeb572fc37ad5c4a4b_I20210630" decimals="INF" format="ixt:numdotdecimal" name="tars:CollaborativeArrangementMaximumMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMzI5ODUzNDg5MjY1OA_6b6c2806-b78f-4230-b00a-e6dded9dbe54">4.5</ix:nonFraction> million and various commercial and sales threshold milestones for an aggregate maximum of $<ix:nonFraction unitRef="usd" contextRef="i1af047204199476fbf9fa4a0c7a282ea_I20210630" decimals="INF" format="ixt:numdotdecimal" name="tars:CollaborativeArrangementMaximumMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMzI5ODUzNDg5Mjc0NA_27f94f9c-d2ce-4a9c-b571-fc5fc7557871">77.0</ix:nonFraction> million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its net sales. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, except for territories in which the Company achieved applicable regulatory approval prior to sublicense execution.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, the Company entered into an out-license agreement with LianBio (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">), which  obligated it to grant Elanco an additional fixed <ix:nonFraction unitRef="shares" contextRef="i120ab40354ce4e18abe9a05184afca4c_D20200901-20200930" decimals="INF" format="ixt:numdotdecimal" name="tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNTY3MQ_336ff7ed-1841-4ebb-82f3-7f637e38a11b">187,500</ix:nonFraction> shares of the Company's common stock that were otherwise required to be granted no later than the 18-month anniversary of the September 2020 Agreement for the Company's continued license exclusivity.  These additional shares were valued at $<ix:nonFraction unitRef="usd" contextRef="i82afa114a25e4157b2a2b9dd666cfc9c_D20200903-20200903" decimals="INF" format="ixt:numdotdecimal" name="tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNTkxNA_c08e2184-2c05-439a-a3a1-46784acb3927">5.5</ix:nonFraction> million based on the Company's stock closing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i120ab40354ce4e18abe9a05184afca4c_D20200901-20200930" decimals="INF" name="tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNTk2Mw_ce380c9a-b3ec-4efd-93b8-669cbc2352f7">29.30</ix:nonFraction> per share (on the date the issuance became contractually required) and is reported within "research and development" expense within the accompanying Statements of Operations and Comprehensive Income (Loss) for the three and six months ended June 30, 2021.  </span></div><div style="text-indent:56.55pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c) Employment Agreements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements with <ix:nonFraction unitRef="arrangement" contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="tars:NumberOfEmploymentArrangementsWithExecutiveOfficers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNjk1OQ_784070a2-7ea7-4151-8a71-e2d984c8ac58">six</ix:nonFraction> of its named executive officers. These agreements provide for the payment of certain benefits upon separation of employment under specified circumstances, such as termination without cause, or termination in connection with a change in control event.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Litigation Contingencies</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company is currently not aware of any such matters where there is at least a reasonable probability that a material loss, if any, has been or will be incurred for financial statement recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e) Indemnities and Guarantees</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain indemnity commitments, under which it may be required to make payments to its officers and directors in relation to certain transactions to the maximum extent permitted under applicable laws. The duration of these indemnities varies, and in certain cases, is indefinite and does not provide for any limitation of maximum payments. The Company has not been obligated to make any such payments to date and no liabilities have been recorded for this contingency in the accompanying Condensed Balance Sheets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_64"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 9. <ix:nonNumeric contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfMjM1Nw_899b30ba-53cb-46fc-a031-eae274079e9b" continuedAt="i5270c4584b134021a64a5a3559521f43" escape="true">OUT-LICENSE AGREEMENT</ix:nonNumeric></span></div><ix:continuation id="i5270c4584b134021a64a5a3559521f43" continuedAt="i2e1369d0119e4e478439c36e456cd72b"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License of TP-03 Commercial Rights in Greater China in March 2021</span></div><div><span><br/></span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 26, 2021, the Company entered into an out-license agreement with LianBio for its exclusive development and commercialization rights of TP-03 (lotilaner ophthalmic solution, 0.25%) in the People&#8217;s Republic of China, Hong Kong, Macau, and Taiwan (the &#8220;China Territory&#8221;) for the treatment of Demodex blepharitis and Meibomian Gland Disease (the &#8220;China Out-License&#8221;).  LianBio is contractually responsible for all clinical development and commercialization activities and costs within the China Territory.</span></div><div><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company received payments from LianBio of $<ix:nonFraction unitRef="usd" contextRef="i0574c418228c4e3ab5c608032507de3f_D20210401-20210430" decimals="INF" format="ixt:numdotdecimal" name="tars:UpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfNjQz_50e2a13f-815f-449e-ad10-58c041ad1539">15.0</ix:nonFraction> million in April 2021 and $<ix:nonFraction unitRef="usd" contextRef="i99377563ab2d44c1b8761203fb868e37_D20210501-20210531" decimals="INF" format="ixt:numdotdecimal" name="tars:UpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfNjY1_d51c523a-645c-4b49-9ce8-03de6aa28964">10.0</ix:nonFraction> million in May 2021 as initial consideration, and $<ix:nonFraction unitRef="usd" contextRef="ib7f0a54579764e34bd42dd790ba99ef4_D20210601-20210630" decimals="INF" format="ixt:numdotdecimal" name="tars:UpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfMTA5OTUxMTYzMDM3MQ_b1587176-cfbc-4b70-ad4c-f67daeca5a57">10.0</ix:nonFraction>&#160;million in June 2021 for the achievement of a clinical development milestone.  </span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also is eligible to receive other payments and consideration from LianBio upon achievement of certain additional milestones, including: (i) TP-03 clinical development and regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i16f2fabfc6b747e5837e0174609fcc2b_I20210630" decimals="INF" format="ixt:numdotdecimal" name="tars:CollaborativeArrangementMaximumMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfMzI5ODUzNDg4NTkxNg_8b6ce761-5352-42ac-8e1c-8a4c5c93c133">65.0</ix:nonFraction>&#160;million (including $<ix:nonFraction unitRef="usd" contextRef="iaa0fee81cd004ce9a21528b56b335914_D20210601-20210630" decimals="-6" format="ixt:numdotdecimal" name="tars:CollaborativeArrangementMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfMTA5OTUxMTYzMzU4NA_d740f419-f1aa-49a2-9c3a-ffddc2dd3d2f">20</ix:nonFraction>&#160;million for the achievement of a clinical milestone in June 2021 that is presented within "accounts receivable" on the accompanying Condensed Balance Sheets), (ii) TP-03 sales-based milestones for the China Territory of up to  $<ix:nonFraction unitRef="usd" contextRef="ie2e854be994f41e6972a64d241a91f47_I20210630" decimals="INF" format="ixt:numdotdecimal" name="tars:CollaborativeArrangementMaximumMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfNzk4_9dd7ebe0-1b95-4be6-b420-86ecfcbab9cd">100.0</ix:nonFraction> million, (iii) tiered mid-to-high-teen royalties for China Territory TP-03 sales, and (iv) equity warrants issued to the Company in March 2021 for purchase of LianBio equity securities, subject to TP-03 clinical/regulatory achievements for vesting. </span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized "license fees" and "collaboration revenue" for the three months ended June 30, 2021 of $<ix:nonFraction unitRef="usd" contextRef="ib4ad4f4b71ae44b283fcc4fb9a913a39_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfMTQzMQ_84a4595b-a061-49c2-b04c-03cb7dbe7f5e">19.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id305f2fec3554db090e0b6fe23e91f04_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfMTQzOA_d0acf4ec-e5c6-4ade-884e-b98b17a1e9d7">3.0</ix:nonFraction> million, respectively, in the accompanying Condensed Statements of Operations and Comprehensive Income (Loss), in accordance with the revenue recognition accounting policy described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2(vi).  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These amounts represent separately valued "performance obligations" in the China Out-License</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i597fcedd8e7a4ac5ad1d8f9599d89d31_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfMTA5OTUxMTYzNDI3OA_27d7b450-855c-4efc-917f-07043ec6bf77">52.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6cb967d1c1e54bef8b85105752dc7964_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfMTA5OTUxMTYzNDI4Mw_40ffaf1d-6812-43a8-8885-17f8c27500ca">3.1</ix:nonFraction> million, respectively, for "license fees" and "collaboration revenue".</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These revenue amounts were each recognized upon (i) the transfer of TP-03 license rights in the China Territory to LianBio and (ii) the actual or partial completion of clinical activities and related data for the Company's pivotal trials of TP-03 in the treatment of Demodex blepharitis (each representing separately valued "performance obligations" in the China Out-License).  As part of this revenue recognition model, the Company was required to value the LianBio equity warrant, applying a discounted cash flow model with highly subjective inputs for this pre-revenue company, and to also consider the probability of achievement of requisite vesting events.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2e1369d0119e4e478439c36e456cd72b">In future periods, the Company may recognize additional revenue from contractual receipts due from LianBio as (1) performance obligations are satisfied related to the completion of the TP-03 pivotal trial and as associated clinical data and reports are delivered, (2) regulatory approval events are achieved, and (3) LianBio has sales of TP-03 in the China Territory.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note Regarding Forward-Looking Statements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains certain forward-looking statements. All statements other than statements of historical facts contained in this report, including statements regarding our future results of operations and financial position, future revenue, business strategy, prospects, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; or &#8220;would,&#8221; or the negative of these terms or other similar expressions are intended to identify forward looking statements. Forward-looking statements contained in this report include, but are not limited to, statements about:</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the likelihood of our clinical trials demonstrating safety and efficacy of our product candidates, and other positive results;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and progress of our current clinical trials and timing of initiation of our future clinical trials, and the reporting of data from our current and future trials;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to the clinical development of our current and future product candidates, including the size, number and disease areas to be evaluated;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence of Demodex blepharitis and the size of the market opportunity for our product candidates;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our product candidates;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to commercializing our product candidates, if approved, including sales strategy;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of COVID-19 on our business and operations;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing therapies that are or may become available;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of the number of patients in the United States or globally, as applicable, who suffer from Demodex blepharitis, Meibomian Gland Disease ("MGD"), rosacea, Lyme disease and malaria and the number of patients that will enroll in our clinical trials;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the beneficial characteristics, safety, efficacy, therapeutic effects and potential advantages of our product candidates;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing or likelihood of regulatory filings and approval for our product candidates;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of our product candidates and our product candidates to meet existing or future regulatory standards;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to the further development and manufacturing of our product candidates, including additional indications for which we may pursue;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify additional products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected potential benefits of strategic collaborations with third parties (including, for example, the receipt of payments, achievement and timing of milestones under license agreements, and the ability of our third party collaborators to commercialize our product candidates in the territories under license) and our ability to attract collaborators with development, regulatory and commercialization expertise;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">existing regulations and regulatory developments in the United States and other jurisdictions;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to hire additional personnel, in particular sales personnel, and our ability to attract and retain such personnel;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditure requirements;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act; and</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our anticipated use of our existing resources and the proceeds from our IPO.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the section titled &#8220;Risk Factors&#8221; elsewhere in this report. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, advancements, discoveries, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this report and the documents that we reference in this report and have filed with the SEC as exhibits to this report with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of our Business</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions where there are limited treatment alternatives. Our lead product candidate, TP-03, is a novel therapeutic in Phase 3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. Blepharitis ("Blephar" is a reference to eyelid and &#8220;itis&#8221; is a reference to inflammation) is a condition characterized by inflammation of the eyelid margin, redness and ocular irritation, including a specific type of eyelash dandruff called collarettes. The healthy interaction of the eyelid and the surface of the eye is crucial to ocular health. Poorly controlled and progressive blepharitis can lead to worsening of corneal damage over time and, in extreme cases, blindness.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> According to published studies, there are an estimated 20&#160;million patients in the United States who suffer from blepharitis, with approximately 45% or nine million of cases caused by Demodex infestation. Further, our estimates indicate the possible number of Demodex blepharitis cases may be as high as approximately 25&#160;million, based on our internal research indicating approximately 58% of patients presenting to eye care clinics have collarettes and a published study estimating that at least 45&#160;million people annually visit an eye care clinic. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that TP-03 has the potential to be the first therapeutic approved by the United States Food and Drug Administration ("FDA") for the treatment of Demodex blepharitis and become the standard of care.  The active pharmaceutical ingredient ("API") of TP-03, lotilaner, is designed to paralyze and eradicate mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GABA-Cl") channels.  </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, we have completed four Phase 2 trials and one Phase 2b/3 trial for TP-03 in Demodex blepharitis, all of which met their primary, secondary and/or exploratory endpoints, as applicable, and during which TP-03 was well tolerated.  Our Phase 2b/3 trial, Saturn-1, met all pre-specified primary and secondary endpoints, as announced in June 2021.  We commenced our second pivotal trial, Saturn-2, in May 2021.  Saturn-2 has primary and secondary endpoints consistent with Saturn-1.  These TP-03 pivotal trials are expected to support our submission of a new drug application ("NDA") with the FDA for TP-03 for the treatment of Demodex blepharitis during the first half of 2022.  </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to further advance our pipeline with the lotilaner API to address several diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases.  These targeted diseases with high unmet medical needs currently include TP-03 for the treatment of MGD, TP-04 for the potential treatment of rosacea and TP-05 for the potential Lyme disease prophylaxis and community malaria reduction.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Business and Clinical Highlights </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">TP-03 Demodex Blepharitis Pivotal Trials, Saturn-1 &amp; Saturn-2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">: On June 21, 2021, we announced positive results of the pivotal Phase 2b/3 Saturn-1 pivotal trial.  All pre-specified primary and secondary endpoints were met, and complete resolution of Demodex blepharitis signs was demonstrated in patients treated with TP-03 (lotilaner ophthalmic solution, 0.25%). </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">81% of patients on TP-03 achieved a clinically meaningful collarette cure, defined as 0-10 collarettes per lid at day 43 compared to 23% of those on vehicle (p&lt;0.0001). </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">44% of patients on TP-03 achieved the primary endpoint of complete collarette cure, defined as 0-2 collarettes per lid at day 43, compared to 7% on vehicle (p&lt;0.0001).</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">68% of patients on TP-03 achieved mite eradication defined as 0 mites per lash at day 43, compared to 18% on vehicle (p&lt;0.0001).</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Additionally, significant efficacy in lid erythema (redness) was demonstrated across multiple measures including complete and clinically meaningful composite cures, and in erythema alone. Results showed 45 % of patients improved erythema by one (1) grade or more (compared to 28% of patients on vehicle, p=0.0002) and 19% of patients on TP-03 achieved a complete erythema cure (compared to 7% of patients on vehicle, p&lt;0.0001).</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">TP-03 was well tolerated with a safety profile similar to the vehicle group. Additionally, most TP-03 patients (92%) reported that the drop comfort was neutral to very comfortable. There were no serious treatment-related adverse events nor any treatment-related adverse events leading to treatment discontinuation. </span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 6, 2021, we announced the commencement of our second pivotal trial, Saturn-2.  This Phase 3 trial is substantially identical in design to Saturn-1 (same primary and secondary endpoints) and is expected to enroll approximately 418 participants.  We expect to report topline data results from Saturn-2 in the first quarter of 2022.  If Saturn-2 results are positive, we expect to use the data from the Saturn-1 and Saturn-2 trials to support our submission of an NDA with the FDA for TP-03 for the treatment of Demodex blepharitis in the first half of 2022.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">TP-03 China Territory Out-License</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On March 26, 2021, we executed an out-license agreement (the "China Out-License") with LianBio Ophthalmology Limited ("LianBio"), granting exclusive commercial rights to TP-03 for the treatment of Demodex blepharitis and MGD within The People&#8217;s Republic of China, Macau, Hong Kong, and Taiwan (the "China Territory"). </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have received contractual proceeds of $35 million from LianBio during the three months ended June 30, 2021 and expect to receive an additional $20 million by September 30, 2021 for a recently achieved Saturn-1 clinical milestone.  In March 2021, also as part of the China Out-License, we received warrant rights in LianBio, subject to clinical and regulatory vesting provisions.   </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are further eligible to receive (i) Saturn-2 clinical milestone of $15 million (expected achievement by March 31, 2022), (ii) China-based clinical and regulatory milestones totaling $30 million, and (iii) China Territory sales threshold milestones totaling $100 million.  We are also entitled to receive tiered royalties in the low double-digits on the net sales of TP-03 within the China Territory.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">TP-05 Initiation of Phase 1 Trial, Callisto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: On June 16, 2021, we announced that we initiated dosing participants in our first clinical trial for TP-05, a novel, oral, non-vaccine therapeutic, for the prevention of Lyme disease and malaria. The Phase 1 Callisto trial is a single ascending dose and multiple ascending dose trial to evaluate the safety, tolerability and pharmacokinetics ("PK") of TP-05 in healthy volunteers. There are currently no FDA-approved pharmacological prophylactic options for Lyme disease, which is the most common vector-borne disease in the United States, transmitted to humans via Borrelia burgdorferi bacterium infection following the bite of a tick vector.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe TP-05 is currently the only non-vaccine, drug-based, preventive therapeutic in development that targets the ticks, and potentially prevents Lyme disease transmission. It is designed to rapidly provide systemic blood levels of lotilaner potentially sufficient to kill infected ticks attached to the human body before they can transmit the Borrelia bacteria that causes Lyme disease. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">New Saturn-1 Data Presented at ASCRS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">:  On July 24, 2021, we presented new Saturn-1 data at the American Society of Cataract and Refractive Surgery ("ASCRS") 2021 Annual Meeting.  The new Saturn-1 data demonstrated a strong patient responder rate, in addition to achieving all primary and secondary endpoints; nearly all Demodex blepharitis patients studied experienced a significant response to treatment with TP-03. These findings indicate the substantial potential impact this treatment may have for both patients and eye care professionals, including meaningful improvement in reducing the number of mites per lash and collarette grade reduction.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to this new data presented at the ASCRS meeting, on July 24, 2021 we also announced results from additional Saturn-1 safety analysis, which revealed that TP-03 had no clinically significant adverse effect on multiple safety measures including Corrected Distance Visual Acuity ("CDVA"), corneal staining, and intraocular pressure ("IOP"), and no significant findings from slit lamp biomicroscopy or fundus exam. In addition, no impact to endothelial cell density ("ECD") was seen in a subset of 21 patients. ECD will be further evaluated as part of the Saturn-2 trial plan. We believe that the results from our Saturn-1 clinical trial, along with previously announced data, reinforces that TP-03 is potentially safe to use in a broad patient population.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Atlas and Europa Studies Presented at ARVO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On May 3, 2021, we released the results of the Atlas study at the virtual Association for Research in Vision and Ophthalmology ("ARVO") 2021 Annual Meeting. The Atlas study is what we believe is the first multi-center observational study to evaluate the functional and psychosocial impact of Demodex blepharitis.  The study also provided insights on the clinical manifestations of Demodex blepharitis in adult patients. Overall, the study showed that Demodex blepharitis is associated with a significant symptomatic and psychosocial burden, negatively affecting daily life in the majority (80%) of patients. We also presented complete efficacy and safety data from our Phase 2b Europa trial, which consisted of positive trial results that were used as the basis for our Saturn-1 and 2 pivotal trial designs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate and Financial Overview</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated as a Delaware corporation in November 2016, and our headquarters is located in Irvine, California. Since our inception in November 2016, we have devoted substantially all of our resources to organizing and staffing our company, acquiring intellectual property, clinical development of our product candidates, building our research and development capabilities, raising capital, and enhancing our corporate infrastructure. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have financed our operations through private placements of preferred stock, convertible promissory notes, the net proceeds from our IPO (as defined below), and out-licensing arrangements. From inception through June 2021, we raised net proceeds of approximately $103.2&#160;million through private placements of preferred stock. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In advance of our IPO, on October 8, 2020, our board of directors approved a 1-for-7.4276 reverse stock split of our capital stock.  All share and per share information included in the accompanying financial statements has been adjusted to reflect this reverse stock split.  On October 20, 2020, we completed our initial public offering ("IPO") through an underwritten sale of 6,325,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sh</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares of our common stock at a price </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $16.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share, inclusive of an additional 825,000 shares of common stock sold upon the full exercise of the underwriters&#8217; purchase option. The aggregate net proceeds from the offering after deducting underwriting discounts and commissions and other offering expenses were $91.7 million.  Concurrent with the IPO, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all then-outstanding shares of our convertible preferred stock automatically converted into an aggregate of 11,107,018 issued shares of common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, we executed an out-license of TP-03 for the China Territory (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">).  During the six months ended June 30, 2021, we received cash proceeds of $35.0 million from our licensee.  We expect to receive additional cash proceeds from our licensee totaling $35.0 million by March 31, 2022 (for first-year consideration of $70 million), assuming all of our TP-03 U.S. clinical milestones are achieved (including $20 million that became payable upon the achievement of a milestone in June 2021 and is pending receipt).</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have incurred significant net operating losses in every year since our inception and expect to continue to incur significant operating expenses and, other than the effect of license fee revenue from the China Out-License Agreement, increasing operating losses for the foreseeable future. Our net income (losses) were $6.3 million and $(3.3) million for the three months ended June 30, 2021 and 2020, respectively, and $16.7 million and $(5.2) million for the six months ended<br/>June 30, 2021 and 2020, respectively. Our net losses and any net income we may generate may fluctuate significantly from quarter to quarter and year to year and could be substantial. As of June&#160;30, 2021 and December&#160;31, 2020, we had an accumulated deficit of $16.1 million and $32.8 million, respectively, from research and development and general and administrative activities since our inception. We anticipate that our operating expenses will increase significantly as we:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct clinical trials of our lead product candidate, TP-03, for the treatment of Demodex blepharitis including our Phase 3 trial, Saturn-2;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance the clinical development of TP-03 for the treatment of MGD, TP-04 for the potential treatment of rosacea and TP-05 for potential Lyme prophylaxis and community malaria reduction;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory and marketing approvals for product candidates that successfully complete clinical development, if any;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish our own sales force in the United States to commercialize our products for which we obtain regulatory approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage with contract manufacturers to ensure a sufficient supply chain capacity to provide commercial quantities of any products for which we may obtain marketing approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional staff, including clinical, scientific, technical, regulatory, marketing, operations, financial, and other support personnel, to execute our business plan; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add information systems and personnel to support our product development and potential future commercialization efforts, and to enable us to operate as a public company.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any products approved for sale and we have not yet generated any revenue from product sales. However, we recognized "license fee revenue" and "collaboration revenue" from our China Out-License for the three and six months ended June 30, 2021 of an aggregate $22.0 million and $55.4 million, respectively (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and expect to recognize additional revenue under these captions from this arrangement in future periods.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate revenues from product sales unless and until we successfully complete clinical development and obtain regulatory approval for a product candidate and commercially launch such product. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through private or public equity or debt financings, or collaborations, strategic alliances, or licensing arrangements with third parties. Adequate funding may not be available to us when needed on acceptable terms, or at all. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional capital or enter into such agreements as and when needed, we could be forced to significantly delay, scale back, or discontinue our product development and/or commercialization plans, which would negatively and adversely affect our financial condition.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with drug product development, we are unable to accurately predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, our aggregate cash and cash equivalents was $176.7&#160;million &#8211; see the section below titled &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations &#8212; Liquidity and Capital Resources.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic on our Operations</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to contain the spread of COVID-19 in the United States (including in California where our corporate headquarters and laboratory facility are located) and other countries have included quarantines, shelter-in-place orders, and various other government restrictions in order to control the spread of this virus.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been carefully monitoring the COVID-19 pandemic as it continues to progress and its potential impact on our business. We have taken important steps to ensure the workplace safety of our employees when working within our laboratory and administrative offices, or when traveling to our clinical trial sites. We have also implemented a vaccination policy and we may take further actions as may be required by federal, state or local authorities.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, we have been able to continue our key business activities and advance our clinical programs. However, in the future, it is possible that our clinical development timelines and business plans could be adversely affected. We maintain regular communication with our vendors and clinical sites to appropriately plan for, and mitigate, the impact of the COVID-19 pandemic on our operations. Specifically, for our Phase 3 Saturn-2 trial, we have instituted various protocols for our sites, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">including increasing health screening of individuals and providing enhanced communication and training to staff regarding COVID-19. However, the ultimate effect from this pandemic on our development timelines for TP-03 and our other product candidates is inherently uncertain.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the section titled &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 31, 2021, for a further discussion of the potential adverse impact of COVID-19 on our business, results of operations and financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Result of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended June&#160;30, 2021&#160;and 2020</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods indicated:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fees and collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,017&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,017&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of license fees and collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,735&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,263&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,472&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations before other (expense) income and income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,263)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,545&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of equity warrant rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(876)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(876)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(908)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(921)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,345&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,250)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,595&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Fees and Collaboration Revenue </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and collaboration revenue was $22.0 million for the three months ended June 30, 2021, of which $19.0 million was attributable to license fees and $3.0 million of which was attributable to collaboration revenue.  These revenue amounts are attributable to the portion of the China Out-License (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) contractual milestones that were fully or partially complete by June 30, 2021.  These amounts respectively represent the satisfaction of the transfer of license rights to LianBio and the partial completion of clinical-related "performance obligations" stated in the China Out-License.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will recognize additional "license fee and collaboration revenue" as these performance obligations are further satisfied or other events occur, specifically related to (i) milestone payments upon TP-03 pivotal trial completion and the delivery of associated clinical data and reports to our licensee, (ii) achievement of regulatory events that trigger milestone payments, and (iii) sales by our licensee of TP-03 in the China Territory. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of License Fees and Collaboration Revenue</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of license fees and collaboration revenue was $0.7 million for the three months ended June&#160;30, 2021.  Under the terms of the China Out-License and our in-license agreement for lotilaner (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), we recognized $0.7 million of associated expense in proportion to our recognized "license fee" and "collaboration revenue" in the same period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $5.5 million for the three months ended June&#160;30, 2021 as compared to the prior year period.  The increase was primarily due to (i) increased clinical and preclinical study costs of $2.7 million, (ii) increased manufacturing and formulation costs of $1.0&#160;million, and (iii)&#160;increased payroll and personnel-related costs, including stock-based compensation, of $1.3&#160;million for additional employees to drive our product development initiatives.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $5.3 million for the three months ended June&#160;30, 2021, as compared to the prior year period. The increase was primarily due to (i) $3.5&#160;million increase in payroll and personnel-related costs, including stock-based compensation, for employee additions, (ii) increased insurance and other administrative costs of $0.8 million, (iii) increased professional fees of $0.6&#160;million, and (iv) increased commercial and market research costs of $0.3 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a full "valuation allowance" against our net deferred tax assets as of June&#160;30, 2021 and 2020 since we cannot conclude that these future benefits will be realized through the offset of our potential taxable income in the future. For the three months ended June 30, 2021, we recorded income tax expense of $29 thousand attributable to current federal and state income tax expense as a result of taxable income in those jurisdictions which cannot be fully offset by available net operating losses and credits. We used the year-to-date "effective tax rate method" to determine our interim income tax expense for federal and state jurisdictions where a reliable estimate of the annual effective tax rate could not be made. For the three and six months ended June 30, 2020, we did not record any income tax expense due to our incurred losses in that period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Six Months Ended June&#160;30, 2021&#160;and 2020</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods indicated:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fees and collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of license fees and collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,453&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,381&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,072&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations before other income (expense) and income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,381)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of equity warrant rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(876)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(876)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(933)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,107)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,721&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,207)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Fees and Collaboration Revenue </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and collaboration revenue was $55.4 million for the six months ended June&#160;30, 2021, of which $52.4 million was attributable to license fees and $3.1 million was attributable to collaboration revenue. These revenue amounts are attributable to the portion of the China Out-License (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) contractual milestones that are fully or partially complete by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021.  These amounts respectively represent the satisfaction of the transfer of license rights to LianBio and the partial completion of clinical-related "performance obligations" stated in the China Out-License.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will recognize additional "license fee and collaboration revenue" as these performance obligations are further satisfied or other events occur, specifically related to (i) milestone payments upon TP-03 pivotal trial completion and the delivery of associated clinical data and reports to our licensee, (ii) achievement of regulatory events that trigger milestone payments, and (iii) our licensee's sales of TP-03 in the China Territory. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of License Fees and Collaboration Revenue</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of license fees and collaboration revenue was $2.0 million for the six months ended June&#160;30, 2021.  Under the terms of the China Out-License, and our in-license agreement for lotilaner (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), we recognized $2.0 million of associated expense in proportion to our recognized "license fee" and "collaboration revenue" in the same period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $20.2 million for the six months ended June&#160;30, 2021 as compared to the prior year period.  The increase was primarily due to (i)&#160;payment to our licensor in the form of issuance of 187,500 shares of our common stock valued at $5.5 million in March 2021 (at our early-extension of exclusive rights to lotilaner in "all other" diseases and conditions in humans), (ii) clinical milestone expense of $2.0 million that became payable in March 2021 to our licensor in connection with the commencement of Saturn-2, our second U.S. pivotal trial for the treatment of Demodex blepharitis, (iii) increased clinical and preclinical study costs of $7.9 million, (iv) increased manufacturing and formulation costs of $2.2&#160;million, and (v)&#160;increased payroll and personnel-related costs, including stock-based compensation, of $2.2&#160;million for additional employees to drive our product development initiatives.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $9.8 million for the six months ended June&#160;30, 2021. The increase was primarily due to (i) $5.4&#160;million increase in payroll and personnel-related costs, including stock-based compensation, for employee additions, (ii) increased insurance and other administrative costs of $1.7 million, (iii) increased professional fees of $1.3&#160;million, and (iv) increased commercial and market research costs of $1.3 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense) Income, Net</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in other (expense) income, net of $1.1 million was primarily due to lower interest income on our U.S. Treasury money market funds and removal of capitalized leasehold improvements for a terminated lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a full "valuation allowance" against our net deferred tax assets as of June&#160;30, 2021 and 2020 since we cannot conclude that these future benefits will be realized through the offset of our potential taxable income in the future. For the six months ended June 30, 2021, we recorded income tax expense of $0.3 million attributable to current federal and state income tax expense as a result of taxable income in those jurisdictions which cannot be fully offset by available net operating losses and credits. We used the year-to-date "effective tax rate method" to determine our interim income tax expense for federal and state jurisdictions where a reliable estimate of the annual effective tax rate could not be made. For the three and six months ended June 30, 2020, we did not record any income tax expense due to our incurred losses in that period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to be dependent upon equity, debt financing, and/or other forms of capital raises at least until we are able to generate significant ongoing positive cash flows from our operations. As of June&#160;30, 2021, we had cash and cash equivalents of $176.7 million and accounts receivable from our licensee of $20 million for a clinical milestone achieved in June 2021 and expect collection by September 30, 2021. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2016 through June&#160;30, 2021, our operations have been substantially financed by cash proceeds from private placements of preferred stock, our IPO proceeds, and China Out-License consideration.  As part of our IPO, we sold 6,325,000 shares of our common stock (inclusive of the full exercise of the underwriters&#8217; option to purchase an </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional 825,000 shares of our common stock).  After deducting underwriting discounts and commissions and other related expenses, our IPO proceeds were $91.7 million. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April and May 2021, we received $25 million of initial proceeds from our licensee as part of the execution of our China Out-License (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and received an additional $10 million in June 2021 for the achievement of a clinical milestone.  We expect to receive an additional $20 million by September 30, 2021 and $15 million by March 31, 2022, for $70 million in aggregate proceeds within 12 months following agreement execution.  The remaining $130 million of potential milestones  under this license will be received upon future clinical/regulatory and sales achievements within the China Territory. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no ongoing material financing commitments, such as lines of credit or guarantees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current cash balance funds our operating expenditures and other working capital requirements.  Our operating expenditures currently consist of research and development expenses (including activities within our preclinical, clinical, regulatory, and drug manufacturing initiatives) and general and administrative expenses. Our use of cash is impacted by the timing and extent of payments for each of these activities and other business requirements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash and cash equivalents of $176.7 million as of June&#160;30, 2021 and our expected total $35 million of additional proceeds from the China Out-Licensee by March 2022 will enable us to fund our operating expenses and capital expenditure requirements into the first half of 2023.  We have based this cash runway estimate on our current assumptions that may require future adjustments as part of our ongoing business decisions within pipeline development and our other corporate initiatives. Accordingly, we may require additional capital resources earlier than we currently expect.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any product sales (separate from our reported "license fee and collaboration revenue" discussed above). We do not expect to report any product revenue unless and until we (1)&#160;complete development of any of our product candidates; (2)&#160;obtain applicable regulatory approvals; and then (3)&#160;successfully commercialize or enter into other collaborative agreements for our product candidates with third parties. We do not know with certainty when, or if, any of these items will ultimately occur.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant operating losses for the foreseeable future, and expect these losses to further increase, as we ramp up our clinical development programs and begin activities for commercial launch readiness. We may also encounter unforeseen expenses, difficulties, complications, delays and other currently unknown factors that could adversely affect our business. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require additional capital to fully develop our product candidates and to execute our business strategy. Our requirements of a future capital raise will depend on many factors, including:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, timing, rate of progress and costs of our drug discovery efforts, preclinical development activities, laboratory testing and clinical trials for our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and scope of clinical programs we decide to pursue;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost, timing and outcome of preparing for and undergoing regulatory review of our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and costs of development and commercial manufacturing activities;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing associated with commercializing our product candidates, if they receive marketing approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we might have at such time;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or in-license other product candidates and technologies;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent and trademark applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates and, ultimately, the sale of our products, following FDA approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our implementation of various computerized information systems;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impact of COVID-19 on our clinical development or operations; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with being a public company.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adequate funding may not be available to us on acceptable terms or at all. Our potential inability to raise capital when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. If we are unable to raise additional funds as required, we may need to delay, reduce, or terminate some or all development programs and clinical trials. We may also be required to sell or license our rights to product candidates in certain territories or indications that we would otherwise prefer to develop and commercialize ourselves. If we are required to enter into collaborations and other arrangements to address our liquidity needs, we may have to give up certain rights that limit our ability to develop and commercialize our product candidates or may have other terms that are not favorable to us or our stockholders, which could materially and adversely affect our business and financial prospects. See the section titled &#8220;Risk Factors&#8221; in this report for additional risks associated with our substantial capital requirements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary Statement of Cash Flows</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the primary sources and uses of cash, cash equivalents and restricted cash for each of the periods presented below:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,757&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,553)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,586&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,817)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by (Used in) Operating Activities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities was $8.8 million for the six months ended June 30, 2021.  We recognized $55.4 million of license fee and collaboration revenue, though we received $35 million in cash in the current six-month period in connection with the China Out-License transaction.  In the current six-month period, our cash payments to vendors for our operating activities totaled $17.4 million and payroll-related cash payments (inclusive of 2020 bonus payouts) totaled $4.6 million. In addition, we made contractual payments of $4.5 million to our intellectual property licensor (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $4.6 million for the six months ended June 30, 2020 and primarily represented a net loss of $5.2 million associated with our operating expenses in that period.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Investing Activities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $0.2 million for the six months ended June 30, 2021, which consisted of leasehold improvements for our laboratory and administrative offices and various purchases of property and equipment.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $0.4 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the six months ended June 30, 2020, which consisted of various purchases of property and equipment.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $20 thousand and $0.1 million for the six months ended June 30, 2021 and 2020, respectively, and was attributable to proceeds from the exercises of stock options in each period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies, Significant Judgments and Use of Estimates</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of our condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and notes to the financial statements.  Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates are different assumptions and conditions.  A summary of our critical accounting policies is presented in our filed Annual Report on Form 10-K for the year ended December 31, 2020.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no material changes to our previously reported "Critical Accounting Policies" during the three and six months ended June 30, 2021, except for:</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition for Out-Licenses and Collaborative Agreements </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The terms of our out-licenses and collaborative agreements include upfront license fees, milestones, and other contingent payments for the achievement of defined development, regulatory and sales-based events, as well as royalties on sales of commercialized products. Arrangements that include upfront payments may require deferral of revenue recognition to a future period until we perform obligations under these arrangements. The event-based milestone and other contingent payments represent variable consideration, and we use the "most likely amount method" to estimate this variable consideration. Given the high degree of uncertainty around the occurrence of these events, we determine the milestone and other contingent amounts to be "constrained" until the uncertainty associated with these payments is resolved. We will recognize revenue from sales-based royalty payments when or as our licensee sales occur. We will re-evaluate our determined "transaction price" in each reporting period as uncertain events are resolved and other changes in circumstances occur.  A "performance obligation" is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract&#8217;s "transaction price" is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of recent accounting pronouncements that may potentially impact our financial position, results of operations or cash flows are disclosed in the footnote to which each relates within these accompanying Condensed Financial Statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                There have been no material changes outside the ordinary course of business to the Company&#8217;s contractual obligations disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification Agreements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law and in accordance with our amended and restated bylaws, we indemnify our officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. We are also party to indemnification agreements with our officers and directors. We believe the fair value of the indemnification rights and agreements is minimal. Accordingly, we have not recorded any liabilities for these indemnification rights and agreements as of June&#160;30, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act Accounting Election</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Jumpstart Our Business Startups Act of 2012, as amended (the "JOBS Act") permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have irrevocably elected to opt out of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain an emerging growth company until the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">earliest of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (1)&#160;the last day of our first fiscal year (a)&#160;following the fifth anniversary of the completion of our IPO, (b)&#160;in which we have total annual gross revenues of at least $1.07&#160;billion or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700&#160;million of the prior June 30th and (2)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period.</span></div><div style="margin-top:12pt;text-align:center;text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center;text-indent:49.5pt"><span><br/></span></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of June&#160;30, 2021, we had cash and cash equivalents of $176.7 million, consisting of interest-bearing money market accounts, for which the fair market value would be affected by changes in the general level of United States interest rates. However, due to the short-term maturities and the low-risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash and cash equivalents.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that inflation, interest rate changes, or foreign currency exchange rate fluctuations had a significant impact on our results of operations for any periods presented herein.</span></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended ("Exchange Act")) as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, do not expect that our disclosure controls or our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_79"></div><div style="margin-top:17pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.</span></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_82"></div><div style="margin-top:17pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this filing, there have been no material changes to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on March 31, 2021.</span></div><div><span><br/></span></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth information regarding all unregistered securities sold by us from April 1, 2021 through June 30, 2021. No underwriters were involved in the sales and the certificates representing the securities sold and issued contain legends restricting transfer of the securities without registration under the Securities Act or an applicable exemption from registration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">          </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the China Out-License, in May 2021, we issued 187,500 shares of our common stock to Elanco as consideration for continued license exclusivity under the License Agreement with Elanco, dated September 3, 2020. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of these securities was exempt from </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">registration under the Securities Act under Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder as transactions by an issuer not involving a public offering. The recipient of securities in this transaction acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions. The recipient of these securities is an accredited person and had adequate access, through employment, business or other relationships, to information about the registrant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in the planned use of proceeds from our IPO as described in the Registration Statement on Form S-1 (File No. 333-249076), declared effective by the SEC on October 15, 2020, and the related final prospectus, dated October 15, 2020, filed with the SEC on October 16, 2020, pursuant to Rule 424(b) of the Securities Act.</span></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:17pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.947%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Herewith</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1819790/000119312520272900/d11649dex31.htm">Amended and Restated Certificate of Incorporation of Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39614</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/20/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1819790/000119312520272900/d11649dex32.htm">Amended and Restated Bylaws of Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39614</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/20/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1819790/000119312520267327/d30607dex42.htm">Amended and Restated Investors&#8217; Rights Agreement, dated September 24, 2020, by and among the Registrant and the other parties thereto.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-249076</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/09/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31111.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31211.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32111.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32211.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Tarsus Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.</span></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i8b61561133ed4a6b868d8d2b5a1f9640_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8b61561133ed4a6b868d8d2b5a1f9640_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.473%"><tr><td style="width:1.0%"></td><td style="width:29.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 5, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                         </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.368%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TARSUS PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Bobak Azamian, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bobak Azamian, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Director)</span></td></tr></table></div><div style="margin-top:12pt;text-align:right;text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.473%"><tr><td style="width:1.0%"></td><td style="width:29.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 5, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                         </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.368%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Leonard M. Greenstein</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard M. Greenstein</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit31111.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4e9861181b7b4d75a98831414244998a_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">I, Bobak Azamian, M.D., Ph.D., certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">I have reviewed this Quarterly Report on Form 10-Q of Tarsus Pharmaceuticals, Inc&#59;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact &#160;&#160;&#160;&#160;necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred &#160;&#160;&#160;&#160;during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.452%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Date&#58; August&#160;5, 2021</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">By&#58;</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#47;s&#47; Bobak Azamian, M.D., Ph.D.</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bobak Azamian, M.D., Ph.D.</font></div><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">President and Chief Executive Officer</font></div><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit31211.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie61002608bc8460f9de688c6c0dd5470_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">I, Leo M. Greenstein, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">I have reviewed this Quarterly Report on Form 10-Q of Tarsus Pharmaceuticals, Inc&#59;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact &#160;&#160;&#160;&#160;necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred &#160;&#160;&#160;&#160;during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.452%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Date&#58; August&#160;5, 2021</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">By&#58;</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#47;s&#47; Leo M. Greenstein</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Leo M. Greenstein</font></div><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Chief Financial Officer</font></div><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Principal Financial Officer and Principal Accounting Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit32111.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ida7aebccd8b44b07bf2b10ae227d14c9_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 32.1 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-indent:32.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Quarterly Report of Tarsus Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Bobak Azamian, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.249%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.985%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.119%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act</font></div><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of 1934, as amended&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.730%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information contained in the Report fairly presents, in all material respects, the financial condition and</font></div><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">result of operations of the Company.</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.371%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; August&#160;5, 2021</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bobak Azamian, M.D., Ph.D.</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bobak Azamian, M.D., Ph.D.</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President and Chief Executive Officer</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit32211.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if0c1a4965f4447e9ac01ac2bf67f1615_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 32.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-indent:32.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Quarterly Report of Tarsus Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Leo M. Greenstein, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.249%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.985%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.119%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act</font></div><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of 1934, as amended&#59; and</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.730%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information contained in the Report fairly presents, in all material respects, the financial condition and</font></div><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">result of operations of the Company.</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.371%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; August&#160;5, 2021</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Leo M. Greenstein</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Leo M. Greenstein</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>tars-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1b782ba2-cb83-443a-9650-7dcdabbf6aa7,g:fefcf97f-7929-4215-bb38-a69760b7d0fa-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:tars="http://tarsusrx.com/20210630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://tarsusrx.com/20210630">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tars-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tars-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tars-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tars-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://tarsusrx.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheets" roleURI="http://tarsusrx.com/role/CondensedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsParenthetical" roleURI="http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofOperationsandComprehensiveLoss" roleURI="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Condensed Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofPreferredStockandStockholdersEquityDeficit" roleURI="http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit">
        <link:definition>1004005 - Statement - Condensed Statements of Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofCashFlows" roleURI="http://tarsusrx.com/role/CondensedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandPresentationofFinancialStatements" roleURI="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements">
        <link:definition>2101101 - Disclosure - Description of Business and Presentation of Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandPresentationofFinancialStatementsDetails" roleURI="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails">
        <link:definition>2402401 - Disclosure - Description of Business and Presentation of Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandUseofEstimates" roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetail" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetail">
        <link:definition>2105103 - Disclosure - Balance Sheet Account Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailTables" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailTables">
        <link:definition>2306301 - Disclosure - Balance Sheet Account Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails">
        <link:definition>2407402 - Disclosure - Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailOtherAssetsDetails" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails">
        <link:definition>2408403 - Disclosure - Balance Sheet Account Detail - Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails">
        <link:definition>2409404 - Disclosure - Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails">
        <link:definition>2410405 - Disclosure - Balance Sheet Account Detail - Other Long-Term Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://tarsusrx.com/role/StockholdersEquity">
        <link:definition>2111104 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://tarsusrx.com/role/StockholdersEquityTables">
        <link:definition>2312302 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetails" roleURI="http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails">
        <link:definition>2413406 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySharesReservedforIssuanceDetails" roleURI="http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails">
        <link:definition>2414407 - Disclosure - Stockholders' Equity - Shares Reserved for Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://tarsusrx.com/role/StockBasedCompensation">
        <link:definition>2115105 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://tarsusrx.com/role/StockBasedCompensationTables">
        <link:definition>2316303 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>2417408 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationExpenseDetails" roleURI="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails">
        <link:definition>2418409 - Disclosure - Stock-Based Compensation - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShare" roleURI="http://tarsusrx.com/role/NetIncomeLossPerShare">
        <link:definition>2119106 - Disclosure - Net Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareTables" roleURI="http://tarsusrx.com/role/NetIncomeLossPerShareTables">
        <link:definition>2320304 - Disclosure - Net Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareDetails" roleURI="http://tarsusrx.com/role/NetIncomeLossPerShareDetails">
        <link:definition>2421410 - Disclosure - Net Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareAntidilutiveSecuritiesDetails" roleURI="http://tarsusrx.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesDetails">
        <link:definition>2422411 - Disclosure - Net Income (Loss) Per Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://tarsusrx.com/role/FairValueMeasurements">
        <link:definition>2123107 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://tarsusrx.com/role/FairValueMeasurementsTables">
        <link:definition>2324305 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" roleURI="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails">
        <link:definition>2425412 - Disclosure - Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails" roleURI="http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails">
        <link:definition>2426413 - Disclosure - Fair Value Measurements - Changes in Fair Value of Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingencies" roleURI="http://tarsusrx.com/role/CommitmentContingencies">
        <link:definition>2127108 - Disclosure - Commitment &amp; Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesTables" roleURI="http://tarsusrx.com/role/CommitmentContingenciesTables">
        <link:definition>2328306 - Disclosure - Commitment &amp; Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesFacilityLeasesDetails" roleURI="http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails">
        <link:definition>2429414 - Disclosure - Commitment &amp; Contingencies - Facility Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesFacilityLeasesDetails_1" roleURI="http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails_1">
        <link:definition>2429414 - Disclosure - Commitment &amp; Contingencies - Facility Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesLeaseCostDetails" roleURI="http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails">
        <link:definition>2430415 - Disclosure - Commitment &amp; Contingencies - Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesInLicenseAgreementforLotilanerDetails" roleURI="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails">
        <link:definition>2431416 - Disclosure - Commitment &amp; Contingencies - In-License Agreement for Lotilaner (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesEmploymentArrangementsDetails" roleURI="http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails">
        <link:definition>2432417 - Disclosure - Commitment &amp; Contingencies - Employment Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OutLicenseAgreement" roleURI="http://tarsusrx.com/role/OutLicenseAgreement">
        <link:definition>2133109 - Disclosure - Out-License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OutLicenseAgreementDetails" roleURI="http://tarsusrx.com/role/OutLicenseAgreementDetails">
        <link:definition>2434418 - Disclosure - Out-License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="tars_IrvineOfficeAndFacilitiesLeaseMember" abstract="true" name="IrvineOfficeAndFacilitiesLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_ClinicalMilestonesMember" abstract="true" name="ClinicalMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_CommercialAndSalesMilestonesMember" abstract="true" name="CommercialAndSalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_SalesMilestoneMember" abstract="true" name="SalesMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_ElancoMember" abstract="true" name="ElancoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" abstract="false" name="AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="tars_CommonStockNumberOfVotes" abstract="false" name="CommonStockNumberOfVotes" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_ProceedsFromEarlyExerciseOfStockOptions" abstract="false" name="ProceedsFromEarlyExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="tars_CollaborationMember" abstract="true" name="CollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_EquityWarrantsFairValueDisclosure" abstract="false" name="EquityWarrantsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CommonStockSharesSubjectToRepurchase" abstract="false" name="CommonStockSharesSubjectToRepurchase" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_EquityIncentivePlan2020Member" abstract="true" name="EquityIncentivePlan2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_DevelopmentAndRegulatoryMilestoneMember" abstract="true" name="DevelopmentAndRegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_CollaborativeArrangementMaximumMilestonePayment" abstract="false" name="CollaborativeArrangementMaximumMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" abstract="false" name="StockIssuedDuringPeriodValueLapseOfRepurchaseRights" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_OtherFacilityLeasesMember" abstract="true" name="OtherFacilityLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_LesseeOperatingLeaseNumberOfContractsNotImpaired" abstract="false" name="LesseeOperatingLeaseNumberOfContractsNotImpaired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_CollaborativeArrangementMilestonePayment" abstract="false" name="CollaborativeArrangementMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_LesseeOperatingLeaseNumberOfLeaseContracts" abstract="false" name="LesseeOperatingLeaseNumberOfLeaseContracts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" abstract="false" name="StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_EquityIncentivePlan2016Member" abstract="true" name="EquityIncentivePlan2016Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" abstract="false" name="AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" abstract="false" name="NumberOfEmploymentArrangementsWithExecutiveOfficers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="tars_UpfrontPayment" abstract="false" name="UpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_LianBioMember" abstract="true" name="LianBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_EquityWarrantRights" abstract="false" name="EquityWarrantRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination" abstract="false" name="DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" abstract="true" name="ShareBasedPaymentArrangementEarlyExercisedOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" abstract="false" name="AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_LicenseAndCollaborationMember" abstract="true" name="LicenseAndCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_AccruedClinicalStudiesCurrent" abstract="false" name="AccruedClinicalStudiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>tars-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1b782ba2-cb83-443a-9650-7dcdabbf6aa7,g:fefcf97f-7929-4215-bb38-a69760b7d0fa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="tars-20210630.xsd#CondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d4a1a9ef-2596-4602-a9b4-1e1f4b3b2164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bd463b6f-3b45-479e-beb4-3dde60cdc39e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d4a1a9ef-2596-4602-a9b4-1e1f4b3b2164" xlink:to="loc_us-gaap_AssetsCurrent_bd463b6f-3b45-479e-beb4-3dde60cdc39e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9b0d89b7-4017-43c6-89c1-fba3390b9e45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d4a1a9ef-2596-4602-a9b4-1e1f4b3b2164" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9b0d89b7-4017-43c6-89c1-fba3390b9e45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6d90ee49-e933-4128-8c3d-179fb343dca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d4a1a9ef-2596-4602-a9b4-1e1f4b3b2164" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6d90ee49-e933-4128-8c3d-179fb343dca9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_47a8b8da-f290-4fd4-9d0c-6c9ed7ee953a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d4a1a9ef-2596-4602-a9b4-1e1f4b3b2164" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_47a8b8da-f290-4fd4-9d0c-6c9ed7ee953a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0a06caf3-b051-4037-bc9a-9c94680a0592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_7737b8c5-2fb4-4ef8-b117-83cf5536e4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0a06caf3-b051-4037-bc9a-9c94680a0592" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_7737b8c5-2fb4-4ef8-b117-83cf5536e4b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_46c8f050-6fc0-4968-94cc-d80d50e07728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0a06caf3-b051-4037-bc9a-9c94680a0592" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_46c8f050-6fc0-4968-94cc-d80d50e07728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_78fc7c83-2e21-4aa7-a265-8eb6119a7eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2aebfeeb-13af-4c15-8184-ea6568fb94e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_78fc7c83-2e21-4aa7-a265-8eb6119a7eb4" xlink:to="loc_us-gaap_LiabilitiesCurrent_2aebfeeb-13af-4c15-8184-ea6568fb94e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e8d93da4-43f7-4ace-8498-1a291688b479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_78fc7c83-2e21-4aa7-a265-8eb6119a7eb4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e8d93da4-43f7-4ace-8498-1a291688b479" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c4d519be-a945-4b62-9fa4-221eb48ce738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f818c79f-db2c-4ba7-aa22-fa61bd95b384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c4d519be-a945-4b62-9fa4-221eb48ce738" xlink:to="loc_us-gaap_Liabilities_f818c79f-db2c-4ba7-aa22-fa61bd95b384" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c758d878-b023-43bc-b2a9-c37b731e9352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c4d519be-a945-4b62-9fa4-221eb48ce738" xlink:to="loc_us-gaap_StockholdersEquity_c758d878-b023-43bc-b2a9-c37b731e9352" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_41125a19-2e79-4d5a-aebc-113c5f2d8d70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c4d519be-a945-4b62-9fa4-221eb48ce738" xlink:to="loc_us-gaap_CommitmentsAndContingencies_41125a19-2e79-4d5a-aebc-113c5f2d8d70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_25e35e29-0b35-4118-92c3-b7b05466e12d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dd036de3-db55-454b-94bd-a055a462d92f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25e35e29-0b35-4118-92c3-b7b05466e12d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dd036de3-db55-454b-94bd-a055a462d92f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b701df53-2783-4328-9fa3-b6f872e6ad50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25e35e29-0b35-4118-92c3-b7b05466e12d" xlink:to="loc_us-gaap_CommonStockValue_b701df53-2783-4328-9fa3-b6f872e6ad50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_44ffa8b9-0e77-4632-a011-7c0fc845b5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25e35e29-0b35-4118-92c3-b7b05466e12d" xlink:to="loc_us-gaap_PreferredStockValue_44ffa8b9-0e77-4632-a011-7c0fc845b5ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4e228ca2-3c58-417c-9ac9-8a2f82f12431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25e35e29-0b35-4118-92c3-b7b05466e12d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4e228ca2-3c58-417c-9ac9-8a2f82f12431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f049ef0b-39b3-4bae-9088-97be45233f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_68bc820f-9785-4eae-bb0c-0d99c5591b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f049ef0b-39b3-4bae-9088-97be45233f8b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_68bc820f-9785-4eae-bb0c-0d99c5591b95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_765040f0-363d-43a0-82d2-89bdc96c01bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f049ef0b-39b3-4bae-9088-97be45233f8b" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_765040f0-363d-43a0-82d2-89bdc96c01bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4d758295-8ac3-47e3-a9f3-26f2856255c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f049ef0b-39b3-4bae-9088-97be45233f8b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4d758295-8ac3-47e3-a9f3-26f2856255c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_d3c1f1e3-ae6f-4d82-a104-3b4f70b3f886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f049ef0b-39b3-4bae-9088-97be45233f8b" xlink:to="loc_us-gaap_RestrictedCashCurrent_d3c1f1e3-ae6f-4d82-a104-3b4f70b3f886" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0acabc1d-dd6b-40e1-9b7c-708531e82ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f049ef0b-39b3-4bae-9088-97be45233f8b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0acabc1d-dd6b-40e1-9b7c-708531e82ce9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="tars-20210630.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ff1eaa55-9ccf-46e9-afd2-6ae5cb87e545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_6462ee10-d5eb-43b7-90d2-6aeea9208b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ff1eaa55-9ccf-46e9-afd2-6ae5cb87e545" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_6462ee10-d5eb-43b7-90d2-6aeea9208b8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fbbbc7d4-8f2e-4ea6-bde8-54704fa434d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ff1eaa55-9ccf-46e9-afd2-6ae5cb87e545" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fbbbc7d4-8f2e-4ea6-bde8-54704fa434d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_000b00ba-6661-47c2-b4f9-8ec585ae61d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ff1eaa55-9ccf-46e9-afd2-6ae5cb87e545" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_000b00ba-6661-47c2-b4f9-8ec585ae61d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0379d587-5ba0-40c7-943d-ffb072be5f18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cb437667-0cd6-418b-9af5-426e59640359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0379d587-5ba0-40c7-943d-ffb072be5f18" xlink:to="loc_us-gaap_OperatingExpenses_cb437667-0cd6-418b-9af5-426e59640359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a38d0f98-60e2-4690-ac42-5e50b6a5500f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0379d587-5ba0-40c7-943d-ffb072be5f18" xlink:to="loc_us-gaap_Revenues_a38d0f98-60e2-4690-ac42-5e50b6a5500f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c2339114-28b6-4b27-a44c-943ef3bd13bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f83a0e7a-2dec-4d6e-b1e8-8ab2a0dfc438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c2339114-28b6-4b27-a44c-943ef3bd13bc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f83a0e7a-2dec-4d6e-b1e8-8ab2a0dfc438" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_04cce0a3-f606-4e15-b33c-3e57ff133c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c2339114-28b6-4b27-a44c-943ef3bd13bc" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_04cce0a3-f606-4e15-b33c-3e57ff133c89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_066e2c44-3f42-4217-ae29-cdb883bc40a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c2339114-28b6-4b27-a44c-943ef3bd13bc" xlink:to="loc_us-gaap_OperatingIncomeLoss_066e2c44-3f42-4217-ae29-cdb883bc40a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_87a094a4-d6bd-401d-aa3c-3039495dd467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1c057fad-505e-4e52-84a0-3a79f1ca825f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_87a094a4-d6bd-401d-aa3c-3039495dd467" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1c057fad-505e-4e52-84a0-3a79f1ca825f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e8aa6ef4-a9da-4651-bd4f-5ebd662c9450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_87a094a4-d6bd-401d-aa3c-3039495dd467" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e8aa6ef4-a9da-4651-bd4f-5ebd662c9450" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_f5e7ab29-2d82-4585-807a-24c999113ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_87a094a4-d6bd-401d-aa3c-3039495dd467" xlink:to="loc_us-gaap_CostOfRevenue_f5e7ab29-2d82-4585-807a-24c999113ba9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="tars-20210630.xsd#CondensedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e045fa7e-14c6-404e-a884-9020f3a2642b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7b342d29-1115-4197-94b6-6b6561ada681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e045fa7e-14c6-404e-a884-9020f3a2642b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7b342d29-1115-4197-94b6-6b6561ada681" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_67f24e3c-99d9-4ef3-a556-b07976423f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0b5a6fb0-1bdc-4263-a882-f7132f8ac852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_67f24e3c-99d9-4ef3-a556-b07976423f8f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0b5a6fb0-1bdc-4263-a882-f7132f8ac852" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f07d2154-3ce5-4cf3-aa23-fbd9cc8673b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_67f24e3c-99d9-4ef3-a556-b07976423f8f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f07d2154-3ce5-4cf3-aa23-fbd9cc8673b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab4b731b-97db-44bc-ba4f-a0fe18b53f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_67f24e3c-99d9-4ef3-a556-b07976423f8f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab4b731b-97db-44bc-ba4f-a0fe18b53f2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_91ea82c3-13a4-4380-9a35-a87b8f59301b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fa24d55e-1766-4165-aca3-95d9be7ee2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_91ea82c3-13a4-4380-9a35-a87b8f59301b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fa24d55e-1766-4165-aca3-95d9be7ee2bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_d095784a-cade-4ccc-ade5-3437a06f2d79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_91ea82c3-13a4-4380-9a35-a87b8f59301b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_d095784a-cade-4ccc-ade5-3437a06f2d79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a433598-12ef-4db7-813c-4997d95b3a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_4d61f665-8665-4d97-a2da-a532814ae2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a433598-12ef-4db7-813c-4997d95b3a6d" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_4d61f665-8665-4d97-a2da-a532814ae2d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_7c9843c3-6d2a-4748-b878-45e23c26e8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a433598-12ef-4db7-813c-4997d95b3a6d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_7c9843c3-6d2a-4748-b878-45e23c26e8c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ProceedsFromEarlyExerciseOfStockOptions_fa193e25-a664-43b1-85a5-081aa72d59f6" xlink:href="tars-20210630.xsd#tars_ProceedsFromEarlyExerciseOfStockOptions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a433598-12ef-4db7-813c-4997d95b3a6d" xlink:to="loc_tars_ProceedsFromEarlyExerciseOfStockOptions_fa193e25-a664-43b1-85a5-081aa72d59f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f1bdde-5b14-4641-8dc7-03fa986419d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ad80a9ce-9ba7-4a0a-9105-30e57bff8ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f1bdde-5b14-4641-8dc7-03fa986419d9" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ad80a9ce-9ba7-4a0a-9105-30e57bff8ba7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_d8f20a26-7666-43c7-ae69-db167114da8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f1bdde-5b14-4641-8dc7-03fa986419d9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_d8f20a26-7666-43c7-ae69-db167114da8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_184372dd-cc93-4c23-a025-77ff7bf7af9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f1bdde-5b14-4641-8dc7-03fa986419d9" xlink:to="loc_us-gaap_NetIncomeLoss_184372dd-cc93-4c23-a025-77ff7bf7af9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_34d72cda-54ba-4203-b026-308899c53f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f1bdde-5b14-4641-8dc7-03fa986419d9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_34d72cda-54ba-4203-b026-308899c53f4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_fc976611-2878-4441-bded-8b6fdd698956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f1bdde-5b14-4641-8dc7-03fa986419d9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_fc976611-2878-4441-bded-8b6fdd698956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ae8d77ea-7648-4ff4-a861-74b0d2ad6776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f1bdde-5b14-4641-8dc7-03fa986419d9" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ae8d77ea-7648-4ff4-a861-74b0d2ad6776" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_7605bc51-8724-4e38-88cb-a4569536602f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f1bdde-5b14-4641-8dc7-03fa986419d9" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_7605bc51-8724-4e38-88cb-a4569536602f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_1b5d1c21-b203-4364-9311-a673e2236bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f1bdde-5b14-4641-8dc7-03fa986419d9" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_1b5d1c21-b203-4364-9311-a673e2236bcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_cf511863-2d97-492f-8e98-3c639aabcfa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f1bdde-5b14-4641-8dc7-03fa986419d9" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_cf511863-2d97-492f-8e98-3c639aabcfa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_0a048699-06e4-42aa-9bee-a98e9d4f54de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f1bdde-5b14-4641-8dc7-03fa986419d9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_0a048699-06e4-42aa-9bee-a98e9d4f54de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_74c7800a-77b9-47cc-9f83-99d618e4f747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f1bdde-5b14-4641-8dc7-03fa986419d9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_74c7800a-77b9-47cc-9f83-99d618e4f747" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_06ff8396-f198-446d-b2db-20e49678faad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f1bdde-5b14-4641-8dc7-03fa986419d9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_06ff8396-f198-446d-b2db-20e49678faad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7a4f7792-1511-453a-a87a-29359a41535e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f1bdde-5b14-4641-8dc7-03fa986419d9" xlink:to="loc_us-gaap_ShareBasedCompensation_7a4f7792-1511-453a-a87a-29359a41535e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_34d61968-251c-4ad8-9136-8f0b514cba31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f1bdde-5b14-4641-8dc7-03fa986419d9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_34d61968-251c-4ad8-9136-8f0b514cba31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_113b8220-467c-466c-85b6-92b9fce08587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f1bdde-5b14-4641-8dc7-03fa986419d9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_113b8220-467c-466c-85b6-92b9fce08587" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_9293431f-e874-498f-a979-8ac0b822b989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f1bdde-5b14-4641-8dc7-03fa986419d9" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_9293431f-e874-498f-a979-8ac0b822b989" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4f1be9be-0132-41a8-8eb6-dcb8c246b7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1ec988d5-26ee-4212-9de9-367616cdb828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4f1be9be-0132-41a8-8eb6-dcb8c246b7b0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1ec988d5-26ee-4212-9de9-367616cdb828" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9c2a2b4b-713e-4836-9bff-3402d05e6ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4f1be9be-0132-41a8-8eb6-dcb8c246b7b0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9c2a2b4b-713e-4836-9bff-3402d05e6ecf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#BalanceSheetAccountDetailOtherAssetsDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a3d3c52d-5d2d-46f5-96ad-ad5bd52ac0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantRights_1352514d-19c9-4764-bcc8-e30dab637ae1" xlink:href="tars-20210630.xsd#tars_EquityWarrantRights"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_a3d3c52d-5d2d-46f5-96ad-ad5bd52ac0b5" xlink:to="loc_tars_EquityWarrantRights_1352514d-19c9-4764-bcc8-e30dab637ae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_28971c23-e700-4175-967a-0591d643502b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_a3d3c52d-5d2d-46f5-96ad-ad5bd52ac0b5" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_28971c23-e700-4175-967a-0591d643502b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositAssets_b052fe5b-03e8-47aa-9c1e-c460c068e8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_a3d3c52d-5d2d-46f5-96ad-ad5bd52ac0b5" xlink:to="loc_us-gaap_DepositAssets_b052fe5b-03e8-47aa-9c1e-c460c068e8a4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_cf117ea4-9248-4dd7-92de-f117f42ee215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_bb1e0b29-5ecd-4cde-aedc-6c27877703c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_cf117ea4-9248-4dd7-92de-f117f42ee215" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_bb1e0b29-5ecd-4cde-aedc-6c27877703c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_61f9cb48-7431-4136-969e-cb5463a1d9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_cf117ea4-9248-4dd7-92de-f117f42ee215" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_61f9cb48-7431-4136-969e-cb5463a1d9f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_f32c94d1-b63f-47c2-8af4-88af8e7917be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_cf117ea4-9248-4dd7-92de-f117f42ee215" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_f32c94d1-b63f-47c2-8af4-88af8e7917be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_3481f8e5-2cbd-422e-b5c8-6736b9e0d94b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_cf117ea4-9248-4dd7-92de-f117f42ee215" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_3481f8e5-2cbd-422e-b5c8-6736b9e0d94b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AccruedClinicalStudiesCurrent_0e7b6204-f8af-4047-8532-c60f3eacd20b" xlink:href="tars-20210630.xsd#tars_AccruedClinicalStudiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_cf117ea4-9248-4dd7-92de-f117f42ee215" xlink:to="loc_tars_AccruedClinicalStudiesCurrent_0e7b6204-f8af-4047-8532-c60f3eacd20b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5fcdeed4-79b0-409c-8f02-3e1a00425ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_cf117ea4-9248-4dd7-92de-f117f42ee215" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5fcdeed4-79b0-409c-8f02-3e1a00425ebf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0cbc811e-14d4-42e7-ad36-acee7edaa69c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_124b97a4-d768-4414-a808-186e5e89423c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_0cbc811e-14d4-42e7-ad36-acee7edaa69c" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_124b97a4-d768-4414-a808-186e5e89423c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_199eb87a-d620-4fc2-84f7-9e26cdcf0fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_0cbc811e-14d4-42e7-ad36-acee7edaa69c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_199eb87a-d620-4fc2-84f7-9e26cdcf0fe6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_11ecce11-9c7f-4cfd-b0b7-6552a117f418" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_0cbc811e-14d4-42e7-ad36-acee7edaa69c" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_11ecce11-9c7f-4cfd-b0b7-6552a117f418" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#StockholdersEquitySharesReservedforIssuanceDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_60b7a5e8-084d-4a8d-af78-7aee8c02de0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_137536e9-01c5-4711-9804-4f29a75ac1b1" xlink:href="tars-20210630.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_60b7a5e8-084d-4a8d-af78-7aee8c02de0e" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_137536e9-01c5-4711-9804-4f29a75ac1b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_40ebe899-404c-41ad-8878-d9aedff5308c" xlink:href="tars-20210630.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_60b7a5e8-084d-4a8d-af78-7aee8c02de0e" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_40ebe899-404c-41ad-8878-d9aedff5308c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant_a8d01106-b5e9-4f96-b6a6-1946d3e45dfa" xlink:href="tars-20210630.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_60b7a5e8-084d-4a8d-af78-7aee8c02de0e" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant_a8d01106-b5e9-4f96-b6a6-1946d3e45dfa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#NetIncomeLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/NetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_03ee2a74-6fc7-4c11-b900-a2e7702b00d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_cb0242ea-bd31-40c9-94c2-c4800ae1425e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_03ee2a74-6fc7-4c11-b900-a2e7702b00d9" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_cb0242ea-bd31-40c9-94c2-c4800ae1425e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_df88c40c-ef10-4948-83e1-a9f86ac7c054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_03ee2a74-6fc7-4c11-b900-a2e7702b00d9" xlink:to="loc_us-gaap_NetIncomeLoss_df88c40c-ef10-4948-83e1-a9f86ac7c054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5ef992f0-d22d-40b2-b926-7ac359c7768b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9f8c3ea2-0658-4b6f-a32d-1cffd901e480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5ef992f0-d22d-40b2-b926-7ac359c7768b" xlink:to="loc_us-gaap_NetIncomeLoss_9f8c3ea2-0658-4b6f-a32d-1cffd901e480" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_916617d0-b0f4-4ecf-88e8-5fdec17ee317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5ef992f0-d22d-40b2-b926-7ac359c7768b" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_916617d0-b0f4-4ecf-88e8-5fdec17ee317" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_13c78ad0-a225-4a5b-aa87-92e58de9ab3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ea6a0113-d75b-4037-985b-dcd8940022ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_13c78ad0-a225-4a5b-aa87-92e58de9ab3a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ea6a0113-d75b-4037-985b-dcd8940022ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantsFairValueDisclosure_e62a7ad5-8f52-419e-b997-e99412232233" xlink:href="tars-20210630.xsd#tars_EquityWarrantsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_13c78ad0-a225-4a5b-aa87-92e58de9ab3a" xlink:to="loc_tars_EquityWarrantsFairValueDisclosure_e62a7ad5-8f52-419e-b997-e99412232233" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#CommitmentContingenciesFacilityLeasesDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f879dc1e-bb1d-49fd-a9a9-fc77825bb97d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_37aed2f9-8300-4bdd-aa30-f94c62bf16be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f879dc1e-bb1d-49fd-a9a9-fc77825bb97d" xlink:to="loc_us-gaap_OperatingLeaseLiability_37aed2f9-8300-4bdd-aa30-f94c62bf16be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_133f5146-20c6-4076-a87d-14527584dcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f879dc1e-bb1d-49fd-a9a9-fc77825bb97d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_133f5146-20c6-4076-a87d-14527584dcdc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails_1" xlink:type="simple" xlink:href="tars-20210630.xsd#CommitmentContingenciesFacilityLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dd713d24-3cae-4058-b606-ee3a301e2dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_853ca7ef-baf3-4c00-8cad-caf7ee7289c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dd713d24-3cae-4058-b606-ee3a301e2dd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_853ca7ef-baf3-4c00-8cad-caf7ee7289c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7d969a06-f78e-4597-9986-986fed8ad9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dd713d24-3cae-4058-b606-ee3a301e2dd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7d969a06-f78e-4597-9986-986fed8ad9dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_49d3d1a3-a90e-4dd9-af8e-5c49f1d48902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dd713d24-3cae-4058-b606-ee3a301e2dd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_49d3d1a3-a90e-4dd9-af8e-5c49f1d48902" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_60ec8f0c-6419-4277-b289-4062a9d07a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dd713d24-3cae-4058-b606-ee3a301e2dd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_60ec8f0c-6419-4277-b289-4062a9d07a5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b2e9866c-e6bd-4304-a8ea-86b20edc436d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dd713d24-3cae-4058-b606-ee3a301e2dd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b2e9866c-e6bd-4304-a8ea-86b20edc436d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#CommitmentContingenciesLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_29df9aa4-b0f4-408a-a2be-e471fdb0ddce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_5488ff77-4054-4105-9d6a-656a8acebac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_29df9aa4-b0f4-408a-a2be-e471fdb0ddce" xlink:to="loc_us-gaap_ShortTermLeaseCost_5488ff77-4054-4105-9d6a-656a8acebac2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_ab5e84e6-d327-45f0-b6d8-782ec5600d53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_29df9aa4-b0f4-408a-a2be-e471fdb0ddce" xlink:to="loc_us-gaap_VariableLeaseCost_ab5e84e6-d327-45f0-b6d8-782ec5600d53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_b7c6f7af-850e-466f-8b8e-5244f83f62c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_29df9aa4-b0f4-408a-a2be-e471fdb0ddce" xlink:to="loc_us-gaap_OperatingLeaseCost_b7c6f7af-850e-466f-8b8e-5244f83f62c2" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>tars-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1b782ba2-cb83-443a-9650-7dcdabbf6aa7,g:fefcf97f-7929-4215-bb38-a69760b7d0fa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="tars-20210630.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="id9c4d77a8f864557aeeee1aa35462878_CondensedStatementsofOperationsandComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_b2505c60-1605-458e-9c01-83305cda7b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:to="loc_us-gaap_RevenuesAbstract_b2505c60-1605-458e-9c01-83305cda7b2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_45e9086d-9c43-4fe2-9999-91a16b4bba2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_b2505c60-1605-458e-9c01-83305cda7b2f" xlink:to="loc_us-gaap_Revenues_45e9086d-9c43-4fe2-9999-91a16b4bba2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_a8092059-37ae-439d-8d71-e9c26ee72829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:to="loc_us-gaap_OperatingExpensesAbstract_a8092059-37ae-439d-8d71-e9c26ee72829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_4878df80-be21-4b0c-8597-a26afff1adcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a8092059-37ae-439d-8d71-e9c26ee72829" xlink:to="loc_us-gaap_CostOfRevenue_4878df80-be21-4b0c-8597-a26afff1adcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a2152e78-6bbc-4df6-b7cf-de8a3bf4b78d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a8092059-37ae-439d-8d71-e9c26ee72829" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a2152e78-6bbc-4df6-b7cf-de8a3bf4b78d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_15a7b82b-45e8-4be6-8c74-c88744119038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a8092059-37ae-439d-8d71-e9c26ee72829" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_15a7b82b-45e8-4be6-8c74-c88744119038" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_09316575-4f3d-4a52-ac23-0055d6900563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a8092059-37ae-439d-8d71-e9c26ee72829" xlink:to="loc_us-gaap_OperatingExpenses_09316575-4f3d-4a52-ac23-0055d6900563" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_152ec468-b289-4ed6-9d35-ba7905a9b748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:to="loc_us-gaap_OperatingIncomeLoss_152ec468-b289-4ed6-9d35-ba7905a9b748" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8e31e232-0c41-4e97-8d58-f2ab910324a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8e31e232-0c41-4e97-8d58-f2ab910324a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_47ccf772-cef1-4686-a8fc-ed824e43c0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8e31e232-0c41-4e97-8d58-f2ab910324a5" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_47ccf772-cef1-4686-a8fc-ed824e43c0e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c1299e6b-547f-43dc-8600-3dfbaf42247f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8e31e232-0c41-4e97-8d58-f2ab910324a5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c1299e6b-547f-43dc-8600-3dfbaf42247f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_bf2633e5-a275-40a5-9429-525f47a6d82f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8e31e232-0c41-4e97-8d58-f2ab910324a5" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_bf2633e5-a275-40a5-9429-525f47a6d82f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_29f85cec-d604-4018-beb0-6ea934fb8f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8e31e232-0c41-4e97-8d58-f2ab910324a5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_29f85cec-d604-4018-beb0-6ea934fb8f49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4ce0cf0f-ac4f-4147-b597-aba50f550253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4ce0cf0f-ac4f-4147-b597-aba50f550253" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c2ca0f21-701d-411a-ac66-0538f5413d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:to="loc_us-gaap_NetIncomeLoss_c2ca0f21-701d-411a-ac66-0538f5413d32" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_12ff07ac-f6ea-475f-bbb1-0753c0006a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_12ff07ac-f6ea-475f-bbb1-0753c0006a14" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_51177a92-3b9c-4e62-a7ba-e345e0cc700b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:to="loc_us-gaap_EarningsPerShareAbstract_51177a92-3b9c-4e62-a7ba-e345e0cc700b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7d6e03f6-8057-43b5-9268-d8940305f24d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_51177a92-3b9c-4e62-a7ba-e345e0cc700b" xlink:to="loc_us-gaap_EarningsPerShareBasic_7d6e03f6-8057-43b5-9268-d8940305f24d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b3a2a0a5-05fd-443e-bad6-780d7f67defc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_51177a92-3b9c-4e62-a7ba-e345e0cc700b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b3a2a0a5-05fd-443e-bad6-780d7f67defc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_79cd3c2e-f889-4ebd-b9b2-89d6f8c5137d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_79cd3c2e-f889-4ebd-b9b2-89d6f8c5137d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f55a2c8d-bb7c-4507-a29c-9f19c8280dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_79cd3c2e-f889-4ebd-b9b2-89d6f8c5137d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f55a2c8d-bb7c-4507-a29c-9f19c8280dc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5bda01dd-bdb0-4317-a492-76bae10e3139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_79cd3c2e-f889-4ebd-b9b2-89d6f8c5137d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5bda01dd-bdb0-4317-a492-76bae10e3139" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3fc8ddb6-efe5-4b87-a951-9ec4d8dd9d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:to="loc_us-gaap_StatementTable_3fc8ddb6-efe5-4b87-a951-9ec4d8dd9d0b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_eef3d82b-f9e4-4a1e-92bd-84d87140cfce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3fc8ddb6-efe5-4b87-a951-9ec4d8dd9d0b" xlink:to="loc_srt_ProductOrServiceAxis_eef3d82b-f9e4-4a1e-92bd-84d87140cfce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eef3d82b-f9e4-4a1e-92bd-84d87140cfce_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_eef3d82b-f9e4-4a1e-92bd-84d87140cfce" xlink:to="loc_srt_ProductsAndServicesDomain_eef3d82b-f9e4-4a1e-92bd-84d87140cfce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7c6ed483-2768-4b77-9025-b4033212aeb5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_eef3d82b-f9e4-4a1e-92bd-84d87140cfce" xlink:to="loc_srt_ProductsAndServicesDomain_7c6ed483-2768-4b77-9025-b4033212aeb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LicenseAndCollaborationMember_0677e377-fdaa-4e1a-837e-b56b190a2733" xlink:href="tars-20210630.xsd#tars_LicenseAndCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7c6ed483-2768-4b77-9025-b4033212aeb5" xlink:to="loc_tars_LicenseAndCollaborationMember_0677e377-fdaa-4e1a-837e-b56b190a2733" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_f4cf0152-9ad8-48bb-b894-65affa647e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tars_LicenseAndCollaborationMember_0677e377-fdaa-4e1a-837e-b56b190a2733" xlink:to="loc_us-gaap_LicenseAndServiceMember_f4cf0152-9ad8-48bb-b894-65affa647e1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborationMember_e3728de5-524f-4bab-91e6-2e17c2f2f7ab" xlink:href="tars-20210630.xsd#tars_CollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tars_LicenseAndCollaborationMember_0677e377-fdaa-4e1a-837e-b56b190a2733" xlink:to="loc_tars_CollaborationMember_e3728de5-524f-4bab-91e6-2e17c2f2f7ab" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="tars-20210630.xsd#CondensedStatementsofPreferredStockandStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit" xlink:type="extended" id="icec9555b278a4f0f9be756b71cfbec0e_CondensedStatementsofPreferredStockandStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2a6bda4c-e6f0-477e-979a-50b6c8db6765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2a6bda4c-e6f0-477e-979a-50b6c8db6765" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8c9f0734-cda5-42a9-88ab-5d5b437c0124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8c9f0734-cda5-42a9-88ab-5d5b437c0124" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_52c86e26-b5fb-4adf-b634-38524628a308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_StockholdersEquity_52c86e26-b5fb-4adf-b634-38524628a308" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f16585e6-e19b-4aa9-839a-feb770406de5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f16585e6-e19b-4aa9-839a-feb770406de5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b3001dd1-a965-44ea-bcb7-f1fc83d74077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_NetIncomeLoss_b3001dd1-a965-44ea-bcb7-f1fc83d74077" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7a74f223-22f7-4dc7-a1dd-fbc7fde37658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7a74f223-22f7-4dc7-a1dd-fbc7fde37658" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_849c48f6-f259-4686-bf95-ceb08630b880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_849c48f6-f259-4686-bf95-ceb08630b880" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_93fc0d15-dc7c-4909-a119-fc96fdefc75c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_93fc0d15-dc7c-4909-a119-fc96fdefc75c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_435eac27-2dc7-465f-9b28-72ac81c5f42c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_435eac27-2dc7-465f-9b28-72ac81c5f42c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_71e49bff-dbec-4150-999f-540546e3393d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_71e49bff-dbec-4150-999f-540546e3393d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_8fc510f2-252f-46f2-bd47-7ccdfebc20a5" xlink:href="tars-20210630.xsd#tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_8fc510f2-252f-46f2-bd47-7ccdfebc20a5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_0ebe4665-7cad-4fb0-bc19-20304806e4af" xlink:href="tars-20210630.xsd#tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_0ebe4665-7cad-4fb0-bc19-20304806e4af" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f87bbd88-f587-4e62-9166-5e87585d86f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8ce43440-5b05-491f-a672-62984cf0c350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c55cb698-4a79-47c5-a446-6ed0215932e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_266ddcde-bea8-461d-9738-0012fc72ffb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2a6bda4c-e6f0-477e-979a-50b6c8db6765" xlink:to="loc_us-gaap_StatementTable_266ddcde-bea8-461d-9738-0012fc72ffb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0f94bd4f-ef96-4f57-a4be-83cf44845afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_266ddcde-bea8-461d-9738-0012fc72ffb3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0f94bd4f-ef96-4f57-a4be-83cf44845afa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0f94bd4f-ef96-4f57-a4be-83cf44845afa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0f94bd4f-ef96-4f57-a4be-83cf44845afa" xlink:to="loc_us-gaap_EquityComponentDomain_0f94bd4f-ef96-4f57-a4be-83cf44845afa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d8e56a6c-b082-4882-bd2a-1f6f21e8e6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0f94bd4f-ef96-4f57-a4be-83cf44845afa" xlink:to="loc_us-gaap_EquityComponentDomain_d8e56a6c-b082-4882-bd2a-1f6f21e8e6d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_0a7fff29-5f4f-4f50-b090-6692569428fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d8e56a6c-b082-4882-bd2a-1f6f21e8e6d1" xlink:to="loc_us-gaap_PreferredStockMember_0a7fff29-5f4f-4f50-b090-6692569428fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e38a4238-a443-4601-ad45-2c4c43fae133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d8e56a6c-b082-4882-bd2a-1f6f21e8e6d1" xlink:to="loc_us-gaap_CommonStockMember_e38a4238-a443-4601-ad45-2c4c43fae133" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_72e99511-29dd-4734-8750-12e4ae59af63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d8e56a6c-b082-4882-bd2a-1f6f21e8e6d1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_72e99511-29dd-4734-8750-12e4ae59af63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7e6c4da2-7547-4691-a405-239605251a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d8e56a6c-b082-4882-bd2a-1f6f21e8e6d1" xlink:to="loc_us-gaap_RetainedEarningsMember_7e6c4da2-7547-4691-a405-239605251a91" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#DescriptionofBusinessandPresentationofFinancialStatementsDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" xlink:type="extended" id="i309e24041e4543439bc8ab2dd4aead84_DescriptionofBusinessandPresentationofFinancialStatementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_38be201f-6823-43e5-a9a4-ccd21e6a3a21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2c75c185-9b8e-4303-b500-1c390e6f317d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_38be201f-6823-43e5-a9a4-ccd21e6a3a21" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2c75c185-9b8e-4303-b500-1c390e6f317d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_aa6a7dfc-6862-4d0e-b28c-52d6306c4575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_38be201f-6823-43e5-a9a4-ccd21e6a3a21" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_aa6a7dfc-6862-4d0e-b28c-52d6306c4575" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_407b649d-ab47-47af-8d24-652202b229dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_38be201f-6823-43e5-a9a4-ccd21e6a3a21" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_407b649d-ab47-47af-8d24-652202b229dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_c5f66f25-1e41-44e6-9d93-580375057da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_38be201f-6823-43e5-a9a4-ccd21e6a3a21" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_c5f66f25-1e41-44e6-9d93-580375057da7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a4c7d564-3338-4749-8f90-ec1e637d6445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_38be201f-6823-43e5-a9a4-ccd21e6a3a21" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a4c7d564-3338-4749-8f90-ec1e637d6445" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_c69edd3f-230a-4314-a67d-04e1dd4c85c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_38be201f-6823-43e5-a9a4-ccd21e6a3a21" xlink:to="loc_us-gaap_SubsequentEventTable_c69edd3f-230a-4314-a67d-04e1dd4c85c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a8a9f4e4-4bcb-4a03-a384-415d0faf1e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_c69edd3f-230a-4314-a67d-04e1dd4c85c0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a8a9f4e4-4bcb-4a03-a384-415d0faf1e9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a8a9f4e4-4bcb-4a03-a384-415d0faf1e9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a8a9f4e4-4bcb-4a03-a384-415d0faf1e9d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a8a9f4e4-4bcb-4a03-a384-415d0faf1e9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12e441c1-7588-4ce8-a19a-23b1a77ef1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a8a9f4e4-4bcb-4a03-a384-415d0faf1e9d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12e441c1-7588-4ce8-a19a-23b1a77ef1b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_59432963-417a-4377-bd2f-138fd5255249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12e441c1-7588-4ce8-a19a-23b1a77ef1b8" xlink:to="loc_us-gaap_IPOMember_59432963-417a-4377-bd2f-138fd5255249" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_54bbcc58-3a41-4a1a-8f55-29b64e2e7853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12e441c1-7588-4ce8-a19a-23b1a77ef1b8" xlink:to="loc_us-gaap_OverAllotmentOptionMember_54bbcc58-3a41-4a1a-8f55-29b64e2e7853" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="extended" id="i8f3f3c1db880459b9efd09879e2d91d5_BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_728957aa-6596-4990-b105-33635c978975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_384e1df5-4054-4798-8a18-fd75d95adff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_728957aa-6596-4990-b105-33635c978975" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_384e1df5-4054-4798-8a18-fd75d95adff0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1fa99a49-bb19-4b6a-b32e-6e3d135744f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_728957aa-6596-4990-b105-33635c978975" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1fa99a49-bb19-4b6a-b32e-6e3d135744f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_520e6575-c755-4136-8f45-1f1e7e7d0095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_728957aa-6596-4990-b105-33635c978975" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_520e6575-c755-4136-8f45-1f1e7e7d0095" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ea84f569-9f5d-41bc-afbc-5601b11fe659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_728957aa-6596-4990-b105-33635c978975" xlink:to="loc_us-gaap_Depreciation_ea84f569-9f5d-41bc-afbc-5601b11fe659" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6313f02e-dcce-47f1-8448-a9fb5a6eb77f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_728957aa-6596-4990-b105-33635c978975" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6313f02e-dcce-47f1-8448-a9fb5a6eb77f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_397f50be-380f-4d82-bdcd-32cbb72aa0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6313f02e-dcce-47f1-8448-a9fb5a6eb77f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_397f50be-380f-4d82-bdcd-32cbb72aa0fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_397f50be-380f-4d82-bdcd-32cbb72aa0fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_397f50be-380f-4d82-bdcd-32cbb72aa0fc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_397f50be-380f-4d82-bdcd-32cbb72aa0fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b4379095-a7f0-4ecb-9cf6-a4e6f62f1ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_397f50be-380f-4d82-bdcd-32cbb72aa0fc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b4379095-a7f0-4ecb-9cf6-a4e6f62f1ece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2601b0c2-85d0-42a7-b6c8-3287d636a443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b4379095-a7f0-4ecb-9cf6-a4e6f62f1ece" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2601b0c2-85d0-42a7-b6c8-3287d636a443" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_e33dd16d-a67f-4468-945b-1d423ac680ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b4379095-a7f0-4ecb-9cf6-a4e6f62f1ece" xlink:to="loc_us-gaap_OfficeEquipmentMember_e33dd16d-a67f-4468-945b-1d423ac680ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_ec27ef21-9e59-4286-9b33-624b5589d797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b4379095-a7f0-4ecb-9cf6-a4e6f62f1ece" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_ec27ef21-9e59-4286-9b33-624b5589d797" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5f8ce8d7-4f6a-4726-9bbf-a2e0b8e057ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b4379095-a7f0-4ecb-9cf6-a4e6f62f1ece" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5f8ce8d7-4f6a-4726-9bbf-a2e0b8e057ea" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended" id="i7f96c6058a07440ea910fad28615b96f_StockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_231dfe03-93a6-400c-9299-5f26b728587c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4d3f2b6c-93db-4c7d-b327-e3231f1a0d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_231dfe03-93a6-400c-9299-5f26b728587c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4d3f2b6c-93db-4c7d-b327-e3231f1a0d7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_4fe68822-9c2a-4388-a94c-8afd3d23fb65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_231dfe03-93a6-400c-9299-5f26b728587c" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_4fe68822-9c2a-4388-a94c-8afd3d23fb65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockNumberOfVotes_598cab13-d52d-4498-ba8b-0f79fac3f6f9" xlink:href="tars-20210630.xsd#tars_CommonStockNumberOfVotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_231dfe03-93a6-400c-9299-5f26b728587c" xlink:to="loc_tars_CommonStockNumberOfVotes_598cab13-d52d-4498-ba8b-0f79fac3f6f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_28a5d070-ea6f-4db4-a43a-63c441380e63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_231dfe03-93a6-400c-9299-5f26b728587c" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_28a5d070-ea6f-4db4-a43a-63c441380e63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b490dae2-0f91-4d9d-8a9d-c3f500ee420f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_231dfe03-93a6-400c-9299-5f26b728587c" xlink:to="loc_us-gaap_CommonStockSharesIssued_b490dae2-0f91-4d9d-8a9d-c3f500ee420f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_11d4fd96-96cf-4d1f-b5c0-3d372992a704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_231dfe03-93a6-400c-9299-5f26b728587c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_11d4fd96-96cf-4d1f-b5c0-3d372992a704" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9af2bb46-9904-4d5b-bf0b-db260caaf9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_231dfe03-93a6-400c-9299-5f26b728587c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9af2bb46-9904-4d5b-bf0b-db260caaf9f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5aa2cbb9-2cfe-40e4-ada5-90e7ebe19b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9af2bb46-9904-4d5b-bf0b-db260caaf9f3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5aa2cbb9-2cfe-40e4-ada5-90e7ebe19b95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5aa2cbb9-2cfe-40e4-ada5-90e7ebe19b95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5aa2cbb9-2cfe-40e4-ada5-90e7ebe19b95" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5aa2cbb9-2cfe-40e4-ada5-90e7ebe19b95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6c7d1a96-6ac4-4a12-b878-8ed33becafa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5aa2cbb9-2cfe-40e4-ada5-90e7ebe19b95" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6c7d1a96-6ac4-4a12-b878-8ed33becafa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_4c5b2aa2-d33a-4e9b-8dd6-c0e741691c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6c7d1a96-6ac4-4a12-b878-8ed33becafa3" xlink:to="loc_us-gaap_IPOMember_4c5b2aa2-d33a-4e9b-8dd6-c0e741691c2e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="ib232da35f1b94dd0af81d27dda2186da_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_70a14dee-0201-4185-a23a-4fd9a2a0ba62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_70a14dee-0201-4185-a23a-4fd9a2a0ba62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease_42d88617-ee02-4ed3-9e95-1bfc4204d7d0" xlink:href="tars-20210630.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease_42d88617-ee02-4ed3-9e95-1bfc4204d7d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue_900b94de-945a-427b-9340-2565c963a326" xlink:href="tars-20210630.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue_900b94de-945a-427b-9340-2565c963a326" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_fc3b707f-9ed8-40c2-8318-12797277277f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_fc3b707f-9ed8-40c2-8318-12797277277f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_87bca381-c512-4d99-ae38-270e2143239b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_87bca381-c512-4d99-ae38-270e2143239b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath_edd63f4f-71db-4d33-870b-b0ff0890149f" xlink:href="tars-20210630.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath_edd63f4f-71db-4d33-870b-b0ff0890149f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability_f31eed67-5206-4da1-908b-c13c1e8c35f4" xlink:href="tars-20210630.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability_f31eed67-5206-4da1-908b-c13c1e8c35f4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations_7f6a731f-dca6-4764-9d0f-6052507af97b" xlink:href="tars-20210630.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations_7f6a731f-dca6-4764-9d0f-6052507af97b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_4c2338dd-c55a-4d2d-be36-d427f4734493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_4c2338dd-c55a-4d2d-be36-d427f4734493" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a46c7771-045e-4f6a-9026-6d732a3f078c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a46c7771-045e-4f6a-9026-6d732a3f078c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_becf3b4f-d69f-4b44-a5b5-4cbc1fd5a678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a46c7771-045e-4f6a-9026-6d732a3f078c" xlink:to="loc_us-gaap_PlanNameAxis_becf3b4f-d69f-4b44-a5b5-4cbc1fd5a678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_becf3b4f-d69f-4b44-a5b5-4cbc1fd5a678_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_becf3b4f-d69f-4b44-a5b5-4cbc1fd5a678" xlink:to="loc_us-gaap_PlanNameDomain_becf3b4f-d69f-4b44-a5b5-4cbc1fd5a678_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0bde030d-5d05-4c47-b20c-dc2a4f8e097a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_becf3b4f-d69f-4b44-a5b5-4cbc1fd5a678" xlink:to="loc_us-gaap_PlanNameDomain_0bde030d-5d05-4c47-b20c-dc2a4f8e097a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityIncentivePlan2020Member_98cf8072-7110-45b0-ab95-b1e16582698b" xlink:href="tars-20210630.xsd#tars_EquityIncentivePlan2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0bde030d-5d05-4c47-b20c-dc2a4f8e097a" xlink:to="loc_tars_EquityIncentivePlan2020Member_98cf8072-7110-45b0-ab95-b1e16582698b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityIncentivePlan2016Member_3c2c19da-b809-4aa8-a3d4-fe96a53b2881" xlink:href="tars-20210630.xsd#tars_EquityIncentivePlan2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0bde030d-5d05-4c47-b20c-dc2a4f8e097a" xlink:to="loc_tars_EquityIncentivePlan2016Member_3c2c19da-b809-4aa8-a3d4-fe96a53b2881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a8aa75d4-7a91-4f80-9660-534e0553f376" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a46c7771-045e-4f6a-9026-6d732a3f078c" xlink:to="loc_srt_RangeAxis_a8aa75d4-7a91-4f80-9660-534e0553f376" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a8aa75d4-7a91-4f80-9660-534e0553f376_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a8aa75d4-7a91-4f80-9660-534e0553f376" xlink:to="loc_srt_RangeMember_a8aa75d4-7a91-4f80-9660-534e0553f376_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_19a7544d-96e6-46e6-a007-b0d09c91f769" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a8aa75d4-7a91-4f80-9660-534e0553f376" xlink:to="loc_srt_RangeMember_19a7544d-96e6-46e6-a007-b0d09c91f769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d504cafd-567b-48c5-a175-89a8506d066f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_19a7544d-96e6-46e6-a007-b0d09c91f769" xlink:to="loc_srt_MinimumMember_d504cafd-567b-48c5-a175-89a8506d066f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_50e62025-621b-41dc-9925-f9e266119b01" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_19a7544d-96e6-46e6-a007-b0d09c91f769" xlink:to="loc_srt_MaximumMember_50e62025-621b-41dc-9925-f9e266119b01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ce1a072e-3e54-47b7-8b2b-ca3b192be33d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a46c7771-045e-4f6a-9026-6d732a3f078c" xlink:to="loc_us-gaap_AwardTypeAxis_ce1a072e-3e54-47b7-8b2b-ca3b192be33d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce1a072e-3e54-47b7-8b2b-ca3b192be33d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ce1a072e-3e54-47b7-8b2b-ca3b192be33d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce1a072e-3e54-47b7-8b2b-ca3b192be33d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32e01d21-d8f0-4ec4-8b7e-39936c27e075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ce1a072e-3e54-47b7-8b2b-ca3b192be33d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32e01d21-d8f0-4ec4-8b7e-39936c27e075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2c9c1e8f-851f-48a4-8213-1a2bd199e6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32e01d21-d8f0-4ec4-8b7e-39936c27e075" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2c9c1e8f-851f-48a4-8213-1a2bd199e6ca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#StockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" xlink:type="extended" id="ib7b56984b8b149b69423817e24b3abb0_StockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_57bffcf3-6235-404d-b3b2-e92c2b17c906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_33d24807-3ee5-4362-84f4-1becf968a48b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_57bffcf3-6235-404d-b3b2-e92c2b17c906" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_33d24807-3ee5-4362-84f4-1becf968a48b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cc0960bd-02ae-41d6-929e-91acbbbbe7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_57bffcf3-6235-404d-b3b2-e92c2b17c906" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cc0960bd-02ae-41d6-929e-91acbbbbe7e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a6a345f9-5b0e-4fd7-b429-664b7ab35974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cc0960bd-02ae-41d6-929e-91acbbbbe7e4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a6a345f9-5b0e-4fd7-b429-664b7ab35974" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a6a345f9-5b0e-4fd7-b429-664b7ab35974_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a6a345f9-5b0e-4fd7-b429-664b7ab35974" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a6a345f9-5b0e-4fd7-b429-664b7ab35974_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_391833a6-0a78-41fb-a020-c6625430d8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a6a345f9-5b0e-4fd7-b429-664b7ab35974" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_391833a6-0a78-41fb-a020-c6625430d8ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f329e388-273d-4e3f-b93e-5bdd8e290532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_391833a6-0a78-41fb-a020-c6625430d8ed" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f329e388-273d-4e3f-b93e-5bdd8e290532" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_60221953-2610-4ca0-a26f-6a4e302c3644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_391833a6-0a78-41fb-a020-c6625430d8ed" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_60221953-2610-4ca0-a26f-6a4e302c3644" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#NetIncomeLossPerShareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended" id="ibe18e03ca31d438a8a5e4939ed79fc3f_NetIncomeLossPerShareAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_148deceb-b427-437e-9ebc-a72b72c30ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_73579ca4-5f55-4a45-a212-04e469f7dd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_148deceb-b427-437e-9ebc-a72b72c30ec9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_73579ca4-5f55-4a45-a212-04e469f7dd6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f1216655-2be2-4bda-8330-a10ba8e96c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_148deceb-b427-437e-9ebc-a72b72c30ec9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f1216655-2be2-4bda-8330-a10ba8e96c15" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_566e78a6-2cea-4a32-a71f-14ede99ab6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f1216655-2be2-4bda-8330-a10ba8e96c15" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_566e78a6-2cea-4a32-a71f-14ede99ab6cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_566e78a6-2cea-4a32-a71f-14ede99ab6cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_566e78a6-2cea-4a32-a71f-14ede99ab6cf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_566e78a6-2cea-4a32-a71f-14ede99ab6cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72a9baf8-2afb-4a08-9da9-a93cd64001ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_566e78a6-2cea-4a32-a71f-14ede99ab6cf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72a9baf8-2afb-4a08-9da9-a93cd64001ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_18b831b2-12e0-4423-a4ef-fe26bcfc39b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72a9baf8-2afb-4a08-9da9-a93cd64001ef" xlink:to="loc_us-gaap_EmployeeStockOptionMember_18b831b2-12e0-4423-a4ef-fe26bcfc39b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_379c95b7-2267-4a13-947b-9912e9963e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72a9baf8-2afb-4a08-9da9-a93cd64001ef" xlink:to="loc_us-gaap_PreferredStockMember_379c95b7-2267-4a13-947b-9912e9963e41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_e9d9fe9f-d76f-4d61-8cf7-e80c0de1191d" xlink:href="tars-20210630.xsd#tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72a9baf8-2afb-4a08-9da9-a93cd64001ef" xlink:to="loc_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_e9d9fe9f-d76f-4d61-8cf7-e80c0de1191d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="extended" id="i6f2ad6c3820c46d99430e212eee5a218_FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f5c137da-a233-43c5-a6e4-7f080a3942bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4bd7bea3-9f07-4d4c-b5ab-16d33c02e799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f5c137da-a233-43c5-a6e4-7f080a3942bb" xlink:to="loc_us-gaap_AssetsAbstract_4bd7bea3-9f07-4d4c-b5ab-16d33c02e799" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0f4d8126-2009-41a7-8fd5-4ff2d3b5ae74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4bd7bea3-9f07-4d4c-b5ab-16d33c02e799" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0f4d8126-2009-41a7-8fd5-4ff2d3b5ae74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantsFairValueDisclosure_a413c10e-5659-4132-9d23-47ab96bff1ff" xlink:href="tars-20210630.xsd#tars_EquityWarrantsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4bd7bea3-9f07-4d4c-b5ab-16d33c02e799" xlink:to="loc_tars_EquityWarrantsFairValueDisclosure_a413c10e-5659-4132-9d23-47ab96bff1ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6e753bb2-037d-4ac7-a584-4fa606cbd63f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4bd7bea3-9f07-4d4c-b5ab-16d33c02e799" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6e753bb2-037d-4ac7-a584-4fa606cbd63f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3d8ce36a-2870-40b4-869a-12c341563a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f5c137da-a233-43c5-a6e4-7f080a3942bb" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3d8ce36a-2870-40b4-869a-12c341563a39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2cd8eb67-f9cd-4758-86ef-5fe4eee68a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3d8ce36a-2870-40b4-869a-12c341563a39" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2cd8eb67-f9cd-4758-86ef-5fe4eee68a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2cd8eb67-f9cd-4758-86ef-5fe4eee68a1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2cd8eb67-f9cd-4758-86ef-5fe4eee68a1a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2cd8eb67-f9cd-4758-86ef-5fe4eee68a1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_43932c6f-7f17-4ce5-878c-6c642c21ff16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2cd8eb67-f9cd-4758-86ef-5fe4eee68a1a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_43932c6f-7f17-4ce5-878c-6c642c21ff16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ce6639dd-a479-476b-ace8-84ef1f21a0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_43932c6f-7f17-4ce5-878c-6c642c21ff16" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ce6639dd-a479-476b-ace8-84ef1f21a0a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9032972d-9ece-46bf-8f17-a8cbd0ab5aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_43932c6f-7f17-4ce5-878c-6c642c21ff16" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9032972d-9ece-46bf-8f17-a8cbd0ab5aca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_232b57bc-ea51-4f5b-87b6-1b963362ec8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_43932c6f-7f17-4ce5-878c-6c642c21ff16" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_232b57bc-ea51-4f5b-87b6-1b963362ec8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_737dafd3-91c3-49ba-bbc6-afa656bf134e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3d8ce36a-2870-40b4-869a-12c341563a39" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_737dafd3-91c3-49ba-bbc6-afa656bf134e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_737dafd3-91c3-49ba-bbc6-afa656bf134e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_737dafd3-91c3-49ba-bbc6-afa656bf134e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_737dafd3-91c3-49ba-bbc6-afa656bf134e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e9746c52-026f-4050-816f-ff0e136b8787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_737dafd3-91c3-49ba-bbc6-afa656bf134e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e9746c52-026f-4050-816f-ff0e136b8787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2a357e71-c0a1-46a6-89c3-b55a138fb787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e9746c52-026f-4050-816f-ff0e136b8787" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2a357e71-c0a1-46a6-89c3-b55a138fb787" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails" xlink:type="extended" id="i5b0afae3e6c74071b37c1d5486c835fc_FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2364e8ae-3d3a-4217-a06e-2d54a9a3a06f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6dbbbdb2-d09e-4cc8-ba1d-7344b971978d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2364e8ae-3d3a-4217-a06e-2d54a9a3a06f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6dbbbdb2-d09e-4cc8-ba1d-7344b971978d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_414d2d0a-f901-43c0-829f-df0d403b1183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6dbbbdb2-d09e-4cc8-ba1d-7344b971978d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_414d2d0a-f901-43c0-829f-df0d403b1183" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_8801e27d-e5f4-485f-a5ac-02370e8df3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6dbbbdb2-d09e-4cc8-ba1d-7344b971978d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_8801e27d-e5f4-485f-a5ac-02370e8df3f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5ccdd4c8-52f3-49f5-a4ee-800dc4cf9cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6dbbbdb2-d09e-4cc8-ba1d-7344b971978d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5ccdd4c8-52f3-49f5-a4ee-800dc4cf9cb8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ab9925aa-b891-48b7-9f7c-67558b733c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4df4c9a2-fc54-4bb4-b21f-a71a52616183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2364e8ae-3d3a-4217-a06e-2d54a9a3a06f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4df4c9a2-fc54-4bb4-b21f-a71a52616183" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1a0d8393-7b03-4bd4-be04-42acf9d0da7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4df4c9a2-fc54-4bb4-b21f-a71a52616183" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1a0d8393-7b03-4bd4-be04-42acf9d0da7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1a0d8393-7b03-4bd4-be04-42acf9d0da7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1a0d8393-7b03-4bd4-be04-42acf9d0da7e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1a0d8393-7b03-4bd4-be04-42acf9d0da7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_07f651b7-c652-4bb5-8ec3-8bfb3730d345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1a0d8393-7b03-4bd4-be04-42acf9d0da7e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_07f651b7-c652-4bb5-8ec3-8bfb3730d345" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_1de88bfa-f003-4d47-a7f9-b5d79b93127f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07f651b7-c652-4bb5-8ec3-8bfb3730d345" xlink:to="loc_us-gaap_SalesMember_1de88bfa-f003-4d47-a7f9-b5d79b93127f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseMember_7348d45e-9fc7-4f07-b0f5-2c5a8e90adf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07f651b7-c652-4bb5-8ec3-8bfb3730d345" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseMember_7348d45e-9fc7-4f07-b0f5-2c5a8e90adf1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#CommitmentContingenciesFacilityLeasesDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails" xlink:type="extended" id="id9d90aec856d49dab77486b04ba7ac18_CommitmentContingenciesFacilityLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LesseeOperatingLeaseNumberOfLeaseContracts_b43766a2-a482-4028-9916-c9cb874a8e0c" xlink:href="tars-20210630.xsd#tars_LesseeOperatingLeaseNumberOfLeaseContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:to="loc_tars_LesseeOperatingLeaseNumberOfLeaseContracts_b43766a2-a482-4028-9916-c9cb874a8e0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_8d182423-3da9-43d6-b2b8-a7f5f1753d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_8d182423-3da9-43d6-b2b8-a7f5f1753d7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_34354c06-501d-4f99-9020-f8c5f63fbf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_34354c06-501d-4f99-9020-f8c5f63fbf7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LesseeOperatingLeaseNumberOfContractsNotImpaired_d39c14de-e317-4b6c-ac6d-06fc30b9864a" xlink:href="tars-20210630.xsd#tars_LesseeOperatingLeaseNumberOfContractsNotImpaired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:to="loc_tars_LesseeOperatingLeaseNumberOfContractsNotImpaired_d39c14de-e317-4b6c-ac6d-06fc30b9864a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6e353261-2198-439b-a425-2bef5a0bb241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6e353261-2198-439b-a425-2bef5a0bb241" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_94cc798b-b958-43cc-9aaf-30f720818e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_94cc798b-b958-43cc-9aaf-30f720818e0b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5492a5db-952e-45b9-9f53-c5d30feec50b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5492a5db-952e-45b9-9f53-c5d30feec50b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c98165db-c068-4dfb-be4e-9d3eff218b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c98165db-c068-4dfb-be4e-9d3eff218b7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3e39ed9e-594b-4970-b5ee-944a137c34bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3e39ed9e-594b-4970-b5ee-944a137c34bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4093a844-277f-415f-8e2f-3c930acfe137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4093a844-277f-415f-8e2f-3c930acfe137" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9249f879-f983-48dc-ba36-95c41cf624e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9249f879-f983-48dc-ba36-95c41cf624e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_16f7f55e-af5d-483e-a1af-fb8dbd475d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_16f7f55e-af5d-483e-a1af-fb8dbd475d05" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e3706e23-de06-46e9-9d92-5544def0c16a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e3706e23-de06-46e9-9d92-5544def0c16a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_964b90b5-799b-407d-9606-eb0e8eae560d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_964b90b5-799b-407d-9606-eb0e8eae560d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_38427fcd-654d-43e3-a9f3-5c0d5b16e9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:to="loc_us-gaap_OperatingLeaseLiability_38427fcd-654d-43e3-a9f3-5c0d5b16e9ee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_c79221e0-14d3-417a-89e2-2c5032f97e59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_c79221e0-14d3-417a-89e2-2c5032f97e59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_9f5fcdd6-bfe2-4984-bd7d-5c86202906c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c79221e0-14d3-417a-89e2-2c5032f97e59" xlink:to="loc_us-gaap_LeaseContractualTermAxis_9f5fcdd6-bfe2-4984-bd7d-5c86202906c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_9f5fcdd6-bfe2-4984-bd7d-5c86202906c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_9f5fcdd6-bfe2-4984-bd7d-5c86202906c3" xlink:to="loc_us-gaap_LeaseContractualTermDomain_9f5fcdd6-bfe2-4984-bd7d-5c86202906c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_32921e5b-78d3-41b3-83d3-f4a2f6f66818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_9f5fcdd6-bfe2-4984-bd7d-5c86202906c3" xlink:to="loc_us-gaap_LeaseContractualTermDomain_32921e5b-78d3-41b3-83d3-f4a2f6f66818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_IrvineOfficeAndFacilitiesLeaseMember_ceea4836-d226-449d-aff9-3f759c96bfbe" xlink:href="tars-20210630.xsd#tars_IrvineOfficeAndFacilitiesLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_32921e5b-78d3-41b3-83d3-f4a2f6f66818" xlink:to="loc_tars_IrvineOfficeAndFacilitiesLeaseMember_ceea4836-d226-449d-aff9-3f759c96bfbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_OtherFacilityLeasesMember_6c9d331d-5cae-4c19-b368-870b5785577d" xlink:href="tars-20210630.xsd#tars_OtherFacilityLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_32921e5b-78d3-41b3-83d3-f4a2f6f66818" xlink:to="loc_tars_OtherFacilityLeasesMember_6c9d331d-5cae-4c19-b368-870b5785577d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#CommitmentContingenciesInLicenseAgreementforLotilanerDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" xlink:type="extended" id="i297e12eb91f6463c85e3348fecd2971d_CommitmentContingenciesInLicenseAgreementforLotilanerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4cc489bb-c337-4009-acb8-a5fa8a46184e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4cc489bb-c337-4009-acb8-a5fa8a46184e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment_88fc0606-e314-4d5d-8fd1-5047a40b9b07" xlink:href="tars-20210630.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:to="loc_tars_CollaborativeArrangementMaximumMilestonePayment_88fc0606-e314-4d5d-8fd1-5047a40b9b07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_UpfrontPayment_1432254a-36c4-4dac-b49e-2f2e92146692" xlink:href="tars-20210630.xsd#tars_UpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:to="loc_tars_UpfrontPayment_1432254a-36c4-4dac-b49e-2f2e92146692" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_737cbbcf-a13d-4003-9291-4e0b9fed542a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_737cbbcf-a13d-4003-9291-4e0b9fed542a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_3b0d9f9c-6495-4c54-9650-1c9c5c798003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_3b0d9f9c-6495-4c54-9650-1c9c5c798003" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_f99999b9-3ce7-4c9c-8651-b58e8039ea4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:to="loc_us-gaap_SharePrice_f99999b9-3ce7-4c9c-8651-b58e8039ea4b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_1af6af89-93ec-475b-89a9-57c8be3568b9" xlink:href="tars-20210630.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:to="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_1af6af89-93ec-475b-89a9-57c8be3568b9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_3c69b062-cfd8-4ccd-b399-8e86ca6ad3dd" xlink:href="tars-20210630.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:to="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_3c69b062-cfd8-4ccd-b399-8e86ca6ad3dd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_1b697ee9-3a93-46a6-b498-4b56c5aa872b" xlink:href="tars-20210630.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:to="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_1b697ee9-3a93-46a6-b498-4b56c5aa872b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9251039-4b63-464c-848d-755c08ba7df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9251039-4b63-464c-848d-755c08ba7df8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4f95e526-a684-4ba5-adde-e6cff083f106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9251039-4b63-464c-848d-755c08ba7df8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4f95e526-a684-4ba5-adde-e6cff083f106" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f95e526-a684-4ba5-adde-e6cff083f106_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f95e526-a684-4ba5-adde-e6cff083f106" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f95e526-a684-4ba5-adde-e6cff083f106_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6127a0e-a516-4bb6-b193-f96a7d8219f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f95e526-a684-4ba5-adde-e6cff083f106" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6127a0e-a516-4bb6-b193-f96a7d8219f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_f6be7b42-0bc5-4043-b7b1-c7dc102e7bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6127a0e-a516-4bb6-b193-f96a7d8219f5" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_f6be7b42-0bc5-4043-b7b1-c7dc102e7bed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1c72b2e5-7da9-44f2-a84d-8199b8d8da50" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9251039-4b63-464c-848d-755c08ba7df8" xlink:to="loc_srt_ProductOrServiceAxis_1c72b2e5-7da9-44f2-a84d-8199b8d8da50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1c72b2e5-7da9-44f2-a84d-8199b8d8da50_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1c72b2e5-7da9-44f2-a84d-8199b8d8da50" xlink:to="loc_srt_ProductsAndServicesDomain_1c72b2e5-7da9-44f2-a84d-8199b8d8da50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bf07c0dd-00f5-4815-aa9f-5a7ba878f5c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1c72b2e5-7da9-44f2-a84d-8199b8d8da50" xlink:to="loc_srt_ProductsAndServicesDomain_bf07c0dd-00f5-4815-aa9f-5a7ba878f5c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClinicalMilestonesMember_9249d066-1649-48c7-a73d-de17d779e641" xlink:href="tars-20210630.xsd#tars_ClinicalMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bf07c0dd-00f5-4815-aa9f-5a7ba878f5c2" xlink:to="loc_tars_ClinicalMilestonesMember_9249d066-1649-48c7-a73d-de17d779e641" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommercialAndSalesMilestonesMember_e0911d7d-d41f-49d8-b7d4-e14d2736b697" xlink:href="tars-20210630.xsd#tars_CommercialAndSalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bf07c0dd-00f5-4815-aa9f-5a7ba878f5c2" xlink:to="loc_tars_CommercialAndSalesMilestonesMember_e0911d7d-d41f-49d8-b7d4-e14d2736b697" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b780dcbc-eb08-4f0b-a2f8-730b8ef58e43" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9251039-4b63-464c-848d-755c08ba7df8" xlink:to="loc_srt_CounterpartyNameAxis_b780dcbc-eb08-4f0b-a2f8-730b8ef58e43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b780dcbc-eb08-4f0b-a2f8-730b8ef58e43_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b780dcbc-eb08-4f0b-a2f8-730b8ef58e43" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b780dcbc-eb08-4f0b-a2f8-730b8ef58e43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc019594-60a7-468c-821b-462980c890e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b780dcbc-eb08-4f0b-a2f8-730b8ef58e43" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc019594-60a7-468c-821b-462980c890e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember_1a76a1ee-3f7e-48ca-ad49-75a2dbfc5dd2" xlink:href="tars-20210630.xsd#tars_LianBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc019594-60a7-468c-821b-462980c890e8" xlink:to="loc_tars_LianBioMember_1a76a1ee-3f7e-48ca-ad49-75a2dbfc5dd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ElancoMember_f4c7134f-9a92-43b7-a609-8f846d569f96" xlink:href="tars-20210630.xsd#tars_ElancoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc019594-60a7-468c-821b-462980c890e8" xlink:to="loc_tars_ElancoMember_f4c7134f-9a92-43b7-a609-8f846d569f96" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/OutLicenseAgreementDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#OutLicenseAgreementDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/OutLicenseAgreementDetails" xlink:type="extended" id="i50524b3844ab4f4f9a5cab4499b05bfb_OutLicenseAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_403c4696-91fb-42d2-b834-8b8d3669c9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_UpfrontPayment_1e210490-d36e-4e52-801d-35cec39667b9" xlink:href="tars-20210630.xsd#tars_UpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_403c4696-91fb-42d2-b834-8b8d3669c9d2" xlink:to="loc_tars_UpfrontPayment_1e210490-d36e-4e52-801d-35cec39667b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment_2b1ecc1b-0b6e-4466-8334-22d2a388f8f7" xlink:href="tars-20210630.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_403c4696-91fb-42d2-b834-8b8d3669c9d2" xlink:to="loc_tars_CollaborativeArrangementMaximumMilestonePayment_2b1ecc1b-0b6e-4466-8334-22d2a388f8f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMilestonePayment_a247c1c5-729b-47f7-8adf-cb1416f0de04" xlink:href="tars-20210630.xsd#tars_CollaborativeArrangementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_403c4696-91fb-42d2-b834-8b8d3669c9d2" xlink:to="loc_tars_CollaborativeArrangementMilestonePayment_a247c1c5-729b-47f7-8adf-cb1416f0de04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_aabb91f5-0f90-4094-acc4-2ca8f45b504a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_403c4696-91fb-42d2-b834-8b8d3669c9d2" xlink:to="loc_us-gaap_Revenues_aabb91f5-0f90-4094-acc4-2ca8f45b504a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c04f4e1c-9e3b-4840-8bdc-4cfa1602772b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_403c4696-91fb-42d2-b834-8b8d3669c9d2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c04f4e1c-9e3b-4840-8bdc-4cfa1602772b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1062e27e-2cad-4bb7-bb12-567b8910c2cb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c04f4e1c-9e3b-4840-8bdc-4cfa1602772b" xlink:to="loc_srt_CounterpartyNameAxis_1062e27e-2cad-4bb7-bb12-567b8910c2cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1062e27e-2cad-4bb7-bb12-567b8910c2cb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1062e27e-2cad-4bb7-bb12-567b8910c2cb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1062e27e-2cad-4bb7-bb12-567b8910c2cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ccf828fc-e641-4ee1-ae24-7f72f0a02ce0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1062e27e-2cad-4bb7-bb12-567b8910c2cb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ccf828fc-e641-4ee1-ae24-7f72f0a02ce0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember_6ab6bdff-1e9d-486a-95e2-bc9a0cec6cbd" xlink:href="tars-20210630.xsd#tars_LianBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ccf828fc-e641-4ee1-ae24-7f72f0a02ce0" xlink:to="loc_tars_LianBioMember_6ab6bdff-1e9d-486a-95e2-bc9a0cec6cbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3cd0f7e8-0516-4641-b5f5-9fd906d7628b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c04f4e1c-9e3b-4840-8bdc-4cfa1602772b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3cd0f7e8-0516-4641-b5f5-9fd906d7628b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3cd0f7e8-0516-4641-b5f5-9fd906d7628b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3cd0f7e8-0516-4641-b5f5-9fd906d7628b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3cd0f7e8-0516-4641-b5f5-9fd906d7628b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f6dc20d-b4e9-4ea6-a694-b3354c60c532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3cd0f7e8-0516-4641-b5f5-9fd906d7628b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f6dc20d-b4e9-4ea6-a694-b3354c60c532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_014c1d86-6f62-4016-9325-4687c166eb72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f6dc20d-b4e9-4ea6-a694-b3354c60c532" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_014c1d86-6f62-4016-9325-4687c166eb72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_67691bd6-995f-4ef8-ae79-a157040445bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c04f4e1c-9e3b-4840-8bdc-4cfa1602772b" xlink:to="loc_srt_ProductOrServiceAxis_67691bd6-995f-4ef8-ae79-a157040445bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_67691bd6-995f-4ef8-ae79-a157040445bb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_67691bd6-995f-4ef8-ae79-a157040445bb" xlink:to="loc_srt_ProductsAndServicesDomain_67691bd6-995f-4ef8-ae79-a157040445bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_269bc122-e319-46fa-bba9-a4d54cb2cda8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_67691bd6-995f-4ef8-ae79-a157040445bb" xlink:to="loc_srt_ProductsAndServicesDomain_269bc122-e319-46fa-bba9-a4d54cb2cda8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DevelopmentAndRegulatoryMilestoneMember_eb137e9b-293a-4798-a575-648e75a63c36" xlink:href="tars-20210630.xsd#tars_DevelopmentAndRegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_269bc122-e319-46fa-bba9-a4d54cb2cda8" xlink:to="loc_tars_DevelopmentAndRegulatoryMilestoneMember_eb137e9b-293a-4798-a575-648e75a63c36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_SalesMilestoneMember_57f0cfae-c3e7-45c8-a971-0d288cfe7b5e" xlink:href="tars-20210630.xsd#tars_SalesMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_269bc122-e319-46fa-bba9-a4d54cb2cda8" xlink:to="loc_tars_SalesMilestoneMember_57f0cfae-c3e7-45c8-a971-0d288cfe7b5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_c688a273-300f-4724-bde0-422378ff1332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_269bc122-e319-46fa-bba9-a4d54cb2cda8" xlink:to="loc_us-gaap_LicenseAndServiceMember_c688a273-300f-4724-bde0-422378ff1332" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborationMember_6334de7e-41b1-41d1-93bd-53f285d15ede" xlink:href="tars-20210630.xsd#tars_CollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_269bc122-e319-46fa-bba9-a4d54cb2cda8" xlink:to="loc_tars_CollaborationMember_6334de7e-41b1-41d1-93bd-53f285d15ede" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>tars-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1b782ba2-cb83-443a-9650-7dcdabbf6aa7,g:fefcf97f-7929-4215-bb38-a69760b7d0fa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_tars_LesseeOperatingLeaseNumberOfContractsNotImpaired_4231424c-e43e-473a-9472-65ecaf167050_terseLabel_en-US" xlink:label="lab_tars_LesseeOperatingLeaseNumberOfContractsNotImpaired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of leases not impaired</link:label>
    <link:label id="lab_tars_LesseeOperatingLeaseNumberOfContractsNotImpaired_label_en-US" xlink:label="lab_tars_LesseeOperatingLeaseNumberOfContractsNotImpaired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Contracts Not Impaired</link:label>
    <link:label id="lab_tars_LesseeOperatingLeaseNumberOfContractsNotImpaired_documentation_en-US" xlink:label="lab_tars_LesseeOperatingLeaseNumberOfContractsNotImpaired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Contracts Not Impaired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LesseeOperatingLeaseNumberOfContractsNotImpaired" xlink:href="tars-20210630.xsd#tars_LesseeOperatingLeaseNumberOfContractsNotImpaired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LesseeOperatingLeaseNumberOfContractsNotImpaired" xlink:to="lab_tars_LesseeOperatingLeaseNumberOfContractsNotImpaired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9995e409-b41f-4fd2-9f68-17a56734f320_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_1b215b74-473d-4d50-9502-d77c627aaf39_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4144560c-e5b4-4a80-9462-a219d29312e9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, non-current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_f26f9bf0-73c6-4ed7-825e-0e40b8e901bf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ae947ed5-a53b-4fc3-8caf-3b0b836932e6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98308d01-cf7a-48b8-9233-ef29ffa28ec3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockNumberOfVotes_94e61ed2-8131-43e5-9b1e-c75d677a0b27_terseLabel_en-US" xlink:label="lab_tars_CommonStockNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock voting rights, number of votes</link:label>
    <link:label id="lab_tars_CommonStockNumberOfVotes_label_en-US" xlink:label="lab_tars_CommonStockNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number Of Votes</link:label>
    <link:label id="lab_tars_CommonStockNumberOfVotes_documentation_en-US" xlink:label="lab_tars_CommonStockNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number Of Votes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockNumberOfVotes" xlink:href="tars-20210630.xsd#tars_CommonStockNumberOfVotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockNumberOfVotes" xlink:to="lab_tars_CommonStockNumberOfVotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_02a03a44-650a-4d99-8d54-127f28e3ab96_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_bab01ca9-cfdb-4471-a81f-906d48e379ca_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c5527ac5-1452-45fe-b40f-0c89354f974b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b9643a13-5245-4e1d-b8b0-acda2a84ab9c_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f519d14b-dabe-48f1-b8c3-61a56e01b287_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_62a2caa4-02e8-467e-88db-476c68426878_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock pursuant to in-license agreement</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_58d30210-6609-42b8-974b-6ed0b858428a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_193cf52b-31c0-46e1-bbe0-96fbb5bc7a00_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_84f015a9-20ed-4cc0-a268-27b8fd1ed9d1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_f6375127-d706-4d9d-8664-0b3fd3db6e70_periodStartLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_43d65175-0d01-45c4-9bb9-c7eb5536f91c_periodEndLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_028c0e73-5cd2-473f-b95e-38b1cb944729_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_85c31327-a216-49aa-9dde-fe42b644be71_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_afdb2088-0024-4058-92c3-3a6746975807_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_097a5a62-80c4-4283-bade-462f598d5ab5_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for license agreement, share price (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_c1731645-c2d0-4c69-af29-81cedd6386c1_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_13a529ee-e580-4a2b-aa5c-5c61d9d876a0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ed4e0556-4ef3-4f73-8637-8f9c74d69200_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_50d0d964-0f75-4d1d-bd85-e916bccc55b4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_4d467b55-3081-4436-b3ba-31f97d2a07f0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_756b53ca-17f9-41f4-a691-94fb08aad619_terseLabel_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options issued and outstanding (shares)</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_label_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_documentation_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:href="tars-20210630.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:to="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_63453877-d382-4934-b510-040175d98274_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CollaborativeArrangementMaximumMilestonePayment_6a87c876-61dc-42ef-a426-4982d01f9acc_terseLabel_en-US" xlink:label="lab_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum milestone payments</link:label>
    <link:label id="lab_tars_CollaborativeArrangementMaximumMilestonePayment_label_en-US" xlink:label="lab_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment</link:label>
    <link:label id="lab_tars_CollaborativeArrangementMaximumMilestonePayment_documentation_en-US" xlink:label="lab_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:href="tars-20210630.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:to="lab_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_b6c42064-5a2c-414f-92fc-ef3a7560c9a1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segment</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_OtherFacilityLeasesMember_aa3df79f-1934-42d9-be2e-717888dfacec_terseLabel_en-US" xlink:label="lab_tars_OtherFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other facility leases</link:label>
    <link:label id="lab_tars_OtherFacilityLeasesMember_label_en-US" xlink:label="lab_tars_OtherFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Facility Leases [Member]</link:label>
    <link:label id="lab_tars_OtherFacilityLeasesMember_documentation_en-US" xlink:label="lab_tars_OtherFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Facility Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_OtherFacilityLeasesMember" xlink:href="tars-20210630.xsd#tars_OtherFacilityLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_OtherFacilityLeasesMember" xlink:to="lab_tars_OtherFacilityLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_28bc9c25-8060-4911-86f4-8b4a2d78678d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_14c309da-7265-415f-aad5-98ad673ff672_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant_9c7d60d3-25a1-4c34-abca-ecdf5d751d41_terseLabel_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options reserved for future grant (shares)</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant_label_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Available For Future Grant</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant_documentation_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Available For Future Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant" xlink:href="tars-20210630.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant" xlink:to="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_eaf50de6-e4c9-4673-8250-192881f3bcd2_terseLabel_en-US" xlink:label="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of repurchase rights related to common stock issued pursuant to early exercises (shares)</link:label>
    <link:label id="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_label_en-US" xlink:label="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Lapse Of Repurchase Rights</link:label>
    <link:label id="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_documentation_en-US" xlink:label="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Lapse Of Repurchase Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" xlink:href="tars-20210630.xsd#tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" xlink:to="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f82532ed-157a-4fc2-ab50-7712c37591ee_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_9ea28a5a-3398-4628-8f90-641e613e74a1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_95deec20-cdaa-485b-a545-e5f4c5a4cc6b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_7d9159d8-61ed-4875-94e4-34d1a9f42a73_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0c2aa451-37e8-49b5-9012-e260320011e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_dfbe44ec-86af-4c0f-8637-2091563752d0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of vested stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_90ba84e6-ca16-44b4-bc20-94bebc560055_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_29856e0e-ddbe-476e-bc21-8df7dd577f1d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c0f37a1f-d955-498a-ab97-e516409340e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4a6a5323-e618-4f54-bde9-ca2f8e064b76_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_b6499e4c-c40c-49db-af4d-1f1b6bb4666b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_aeddf1e7-f30f-4ef6-8d59-d961234542a7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of equity warrant rights</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a40ab268-83df-4b8d-8444-b15558849e53_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_57971eb3-91c6-462e-a8a7-d19e3570f337_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_EquityIncentivePlan2016Member_8672482b-1242-466d-b42d-f3225c25b677_terseLabel_en-US" xlink:label="lab_tars_EquityIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Plan</link:label>
    <link:label id="lab_tars_EquityIncentivePlan2016Member_label_en-US" xlink:label="lab_tars_EquityIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2016 [Member]</link:label>
    <link:label id="lab_tars_EquityIncentivePlan2016Member_documentation_en-US" xlink:label="lab_tars_EquityIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2016</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityIncentivePlan2016Member" xlink:href="tars-20210630.xsd#tars_EquityIncentivePlan2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_EquityIncentivePlan2016Member" xlink:to="lab_tars_EquityIncentivePlan2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f4b8333a-8548-4d78-a76a-0de21ddeaaf5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_21a011ce-65f3-4db3-bb42-b6f94225bb97_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_db263b91-b364-4536-8216-2dabcf063ed9_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future lease payments, undiscounted</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1cb2b8c9-10be-4436-9bad-728502a2c150_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_52c9049a-969d-4210-986d-49bb684bed1c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_17f908c4-e75c-4ac9-9b41-2d9e44a62586_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ef1fda9a-96f0-4c39-a68f-8067a3dd45dd_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_bb6815e8-e01d-4411-ba2c-71bd765d8c15_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_AccruedClinicalStudiesCurrent_50e01fcc-e3fd-47ab-bf41-d480416a4060_terseLabel_en-US" xlink:label="lab_tars_AccruedClinicalStudiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical studies</link:label>
    <link:label id="lab_tars_AccruedClinicalStudiesCurrent_label_en-US" xlink:label="lab_tars_AccruedClinicalStudiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Studies, Current</link:label>
    <link:label id="lab_tars_AccruedClinicalStudiesCurrent_documentation_en-US" xlink:label="lab_tars_AccruedClinicalStudiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Studies, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AccruedClinicalStudiesCurrent" xlink:href="tars-20210630.xsd#tars_AccruedClinicalStudiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_AccruedClinicalStudiesCurrent" xlink:to="lab_tars_AccruedClinicalStudiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_bfef2a44-2ee7-41d2-9244-e1ed51390464_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_04ee8adf-1987-48ca-b5b9-5d1fa060862b_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: undistributed income allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5098d6c9-d89f-4d6b-a33d-107703d8e5c0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cb9bee4c-d38d-49a9-9377-07c72d9230fb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1886e394-f9d3-4e70-bbac-aad0562d5e40_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_38e67e9d-d501-4b7b-9297-5e37c1fa301f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ProceedsFromEarlyExerciseOfStockOptions_59244117-725c-4eda-bb8b-c9ec18a010f9_terseLabel_en-US" xlink:label="lab_tars_ProceedsFromEarlyExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options prior to vesting</link:label>
    <link:label id="lab_tars_ProceedsFromEarlyExerciseOfStockOptions_label_en-US" xlink:label="lab_tars_ProceedsFromEarlyExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Early Exercise Of Stock Options</link:label>
    <link:label id="lab_tars_ProceedsFromEarlyExerciseOfStockOptions_documentation_en-US" xlink:label="lab_tars_ProceedsFromEarlyExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Early Exercise Of Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ProceedsFromEarlyExerciseOfStockOptions" xlink:href="tars-20210630.xsd#tars_ProceedsFromEarlyExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ProceedsFromEarlyExerciseOfStockOptions" xlink:to="lab_tars_ProceedsFromEarlyExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_b28b9003-a3eb-4e95-88b0-28a55d38ae51_terseLabel_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares to be issued upon 18-month anniversary of contract execution, value</link:label>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_label_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services</link:label>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_documentation_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" xlink:href="tars-20210630.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" xlink:to="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_7da0ba18-921f-47eb-af86-4e0d6991665d_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_188d7121-4ad7-453d-9da0-90b299858cd8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_7f2ef5e7-eeda-49ec-81bf-3166ea03e61d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_92f2b107-c5f8-4f7a-9f98-955680907aa6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0e232dbe-e872-4eee-9f98-2e3fdf823ed8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_6b21158a-4922-4ab4-a680-e303e5b97abc_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Smaller Reporting Company</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_20afc559-4e3c-4fae-abc7-14c6becfe76d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_60bcd77d-7808-4814-9300-1e487f4a7e8e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_5919d812-1d08-4b9a-892e-515887ae3f43_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split, conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_563c2553-fe26-45d8-a766-ba2034b5159a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_9ca2d0d1-25da-4807-9a0f-432ea5d7af81_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_703d4d15-9831-4718-82e1-367fdf7d50e3_terseLabel_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares to be issued upon 18-month anniversary of contract execution, share price (usd per share)</link:label>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_label_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services</link:label>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_documentation_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" xlink:href="tars-20210630.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" xlink:to="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_69aa2787-6ef5-4dd4-9472-05bddd1b0ba0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CollaborationMember_65323937-06ab-44e8-b20a-ca1d31c0ae4b_terseLabel_en-US" xlink:label="lab_tars_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration</link:label>
    <link:label id="lab_tars_CollaborationMember_label_en-US" xlink:label="lab_tars_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_tars_CollaborationMember_documentation_en-US" xlink:label="lab_tars_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborationMember" xlink:href="tars-20210630.xsd#tars_CollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CollaborationMember" xlink:to="lab_tars_CollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0702a3c-a0bc-4521-8a16-6c644838c203_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_3e910db7-c658-4c9e-a55b-1a12be39e63c_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of equity warrant rights</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_ddb75217-2cd1-4a5a-8358-e69156a83b84_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative assets</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_590eece5-4e26-425d-9e75-9e51a6b07de4_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_78206127-c404-4e69-8b89-4dbdfdab6d75_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_d4eaa880-1bef-4f69-bd7c-bfa3b84235c3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_3adcf85c-de34-43a4-ab33-a6117940ccb8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ff3c7f0d-2ad6-456d-99ab-23e5ab4f2f6d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_1dfc338e-eacf-45a5-b864-b1a0d832ce6c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations_bce1be2e-3570-4b6c-b115-0b0cf064e598_terseLabel_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise period from termination upon all other separations</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations_label_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon All Other Separations</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations_documentation_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon All Other Separations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations" xlink:href="tars-20210630.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations" xlink:to="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_4a50c937-f697-4a20-a840-b3cdcd937aca_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 authorized at June&#160;30, 2021 and December&#160;31, 2020; no shares issued and outstanding at June&#160;30, 2021 and December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_07a3f51d-88dd-41f5-a9f4-0155cae177ca_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_4224a215-eaa8-4284-bd3c-5539336b78b0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial fair value estimate of equity warrant rights upon issuance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a19237c9-4c17-442d-9747-1607a85fd0fa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_856c76aa-285b-470b-9aae-8757ed274e4d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_dbbcd155-0dbb-4a44-8630-318685d7d7d2_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_45ec1e83-8d2c-4bd3-9b3d-8db1c8228ca5_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d3f77e79-6250-4551-9195-77b2287ac4ef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5cc71c1c-3d52-4b83-bcff-bb3bdc8c25a9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4224dbd3-3560-40c7-bf11-bda635095297_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2ae4b5b6-f4b0-4d2b-b2b4-2c7b813475f6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment &amp; Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_37c75d17-cb20-4093-a0dd-856c91d47443_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_64b66f04-2fe8-4f71-8951-882b958b36be_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6b4cbc0c-5297-4033-86f3-2a2e6984f7de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_eb066834-66de-454d-94c2-ea4838a12595_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_a9e0d5a6-1336-4c50-a181-611aa832fc19_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_642875d1-fa79-4375-a86b-5c0fa5da4390_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions of property and equipment in accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_cba9b934-5284-417b-9a91-6d5cf15fb28c_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset obtained in exchange for operating lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f72ed1a2-090a-4dcb-9f67-607694758bed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basis and diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_023ec129-1667-4fbf-926f-f2f510a39379_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_15d4a7ac-56bb-46f7-92f8-88273b672121_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_7e28e726-36c3-4283-9b52-6ad59261ccec_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7ed9fa62-eb99-4df9-b9c8-047649aafdf6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_59542dba-a33e-4aa4-8d25-246a15eceb65_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_47162680-0d8f-4859-9466-8e987945ddf7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e541598c-2f5b-46fc-80ee-bb2145913e0b_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_c68a7a91-40f5-4759-bc2b-9e3e2fd9093d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_358ed1f4-f27d-425c-9993-62fd42ec2a22_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_22362a8f-79a5-4b5b-ba18-ed2750b6a62c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2d6b0e33-4c3f-48a4-9fea-6e9b9f3f278c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_5a5daa37-1a5b-400f-a103-838502e92dbe_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share attributable to common stockholders - basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_6ad6b5c2-fcc8-4150-9df1-6ab97b186123_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2481a0ac-931b-44ec-a169-f1f36dbd01d9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income available to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e40e93d6-305a-4671-9040-24c13a5006d3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_91e763a2-ada2-4ea0-b99e-517b67fa85fe_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income available to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts_37aba32a-e42c-4109-b5a8-a9503e374e60_terseLabel_en-US" xlink:label="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of leases</link:label>
    <link:label id="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts_label_en-US" xlink:label="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Lease Contracts</link:label>
    <link:label id="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts_documentation_en-US" xlink:label="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Lease Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LesseeOperatingLeaseNumberOfLeaseContracts" xlink:href="tars-20210630.xsd#tars_LesseeOperatingLeaseNumberOfLeaseContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LesseeOperatingLeaseNumberOfLeaseContracts" xlink:to="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_39dbafa3-ca3d-40f6-a34a-0d36a7baf1e3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_3a6e87f2-b63f-494b-9c5d-54f73db01124_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_7d655771-a74d-4f03-bf37-2d591c0970d1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for early exercise of stock options</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_8db7db55-95db-4806-a42d-f835e38de6c6_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Account Detail</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_696f04f6-14d6-4651-b321-7e4e7b84ac0e_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_76e5cd3f-1316-4226-ad77-877bde8fb6e5_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_767f06c8-7de0-41ea-8287-9207dcf0d153_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_SalesMilestoneMember_9867e381-46c4-401e-85b3-af589baca09d_terseLabel_en-US" xlink:label="lab_tars_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone</link:label>
    <link:label id="lab_tars_SalesMilestoneMember_label_en-US" xlink:label="lab_tars_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone [Member]</link:label>
    <link:label id="lab_tars_SalesMilestoneMember_documentation_en-US" xlink:label="lab_tars_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_SalesMilestoneMember" xlink:href="tars-20210630.xsd#tars_SalesMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_SalesMilestoneMember" xlink:to="lab_tars_SalesMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LicenseAndCollaborationMember_d0bfad42-04ce-4795-a9b4-fc2c486c3a91_terseLabel_en-US" xlink:label="lab_tars_LicenseAndCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fees and Collaboration</link:label>
    <link:label id="lab_tars_LicenseAndCollaborationMember_label_en-US" xlink:label="lab_tars_LicenseAndCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration [Member]</link:label>
    <link:label id="lab_tars_LicenseAndCollaborationMember_documentation_en-US" xlink:label="lab_tars_LicenseAndCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LicenseAndCollaborationMember" xlink:href="tars-20210630.xsd#tars_LicenseAndCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LicenseAndCollaborationMember" xlink:to="lab_tars_LicenseAndCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_b0cc12b8-5eed-46f8-9ed3-ecf76be8b964_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on lease termination</link:label>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_label_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Termination of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnTerminationOfLease" xlink:to="lab_us-gaap_GainLossOnTerminationOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_404ecf44-b636-49a1-9107-f1f60edfdd4a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_968413d8-1e93-4b78-bba3-39bdb1155708_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted EPS</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_d89732cc-5815-4cb1-b30b-cb038f4c5f3a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies and Use of Estimates</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_cade6c2a-624d-4a89-8f51-ad8f7cc80d13_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_35a7d6ca-3cdc-493e-b013-6457d19620b5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:to="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_51b9c7c7-175d-4c08-95f3-7206311584b5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_2aa8355c-f641-45cc-b673-39777e80fed2_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ClinicalMilestonesMember_c46185e9-3fb0-4144-a3f5-5f6b04ebffd1_terseLabel_en-US" xlink:label="lab_tars_ClinicalMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical milestones</link:label>
    <link:label id="lab_tars_ClinicalMilestonesMember_label_en-US" xlink:label="lab_tars_ClinicalMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Milestones [Member]</link:label>
    <link:label id="lab_tars_ClinicalMilestonesMember_documentation_en-US" xlink:label="lab_tars_ClinicalMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClinicalMilestonesMember" xlink:href="tars-20210630.xsd#tars_ClinicalMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ClinicalMilestonesMember" xlink:to="lab_tars_ClinicalMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_264a39d4-fd5e-4d7c-ab5f-e158268ca616_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d1c525bf-941d-4005-91c8-42869ffaf82e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_ae253049-5b56-4a52-9504-7bed4c895480_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic EPS</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_62c21318-1c1e-48a3-85d4-bd4976ff7116_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_5e0bf246-ac5e-4c1f-a192-9fabef3456cb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_86b7bd6e-90ad-4427-8f2f-9149e58201c1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_b4b6714d-7b60-41f8-89a7-77c1d7bd048d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_6759855b-8ee9-442e-97c5-cc36f526dee4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_704400a4-0a2b-4c1f-8e60-c4002b819a8e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_26bfb262-1fc3-4b01-aa6f-972889de82b6_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2d51401a-46de-40b2-9686-8b52060420d2_netLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_cb40fb32-855e-4ff1-978b-9a64604acc41_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_d85f4131-a2c7-4a82-bda0-a035128383cb_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share attributable to common stockholders - diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_86633033-7348-4d49-a6c6-1ceaf59a461f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_92383fb1-ce0b-4ac9-bfd4-636bbe3c7749_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fees</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_010365e4-7866-454c-87e3-9751db7d359a_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_744fa0c4-25d2-46ae-8328-5897c4fa8932_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_2d37febe-74ea-4438-8682-b1231a240fed_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDepreciationAndAmortization" xlink:to="lab_us-gaap_OtherDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_e25cde61-34da-4df4-95f5-283e76f49d1f_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_0bdc781d-d5d7-4020-8a4d-374de0274c22_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_a314bf66-54fa-4ca0-85a6-b930826bc739_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_632a4704-1b89-44c4-9a05-e086e7e45bea_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_8be9f9e6-9b99-47f4-8aa7-e3bde552667b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock option early exercise liability, current portion</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_0a1b927e-110a-4177-9225-b1ec5fd211e1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of license fees and collaboration revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_fa838871-dbff-43b5-821c-57bed289d859_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d934134d-416e-4c22-b6f6-9dce1c42fca7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9b2e2f07-7af4-49c9-9977-f6ec4408ce25_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_771baa39-1d59-4b00-8e42-ab97837ed994_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain from transactions denominated in a foreign currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_c3545458-0f1b-4d92-8d25-05faf9cb0d46_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b94ad248-7ef8-43d4-86bd-b018e6200e85_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_731a0574-68b3-4634-9666-7f1a96e993c6_terseLabel_en-US" xlink:label="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early-exercised and unvested stock options</link:label>
    <link:label id="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_label_en-US" xlink:label="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Early-Exercised Option [Member]</link:label>
    <link:label id="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_documentation_en-US" xlink:label="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Early-Exercised Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" xlink:href="tars-20210630.xsd#tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" xlink:to="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_47ec006f-6810-4b42-b684-94488acc23d8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2f8fdd2c-d1e3-4de9-8eb5-febc1e22967c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_20aa6c6e-6648-4b85-a327-b14d6db85deb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b2e88e6c-22c9-4f10-929b-f0c72ae8392c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, preferred stock and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_fc3eea4e-35fa-4c46-b031-ca7a310e7c05_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_ba2fdaed-7e6d-4921-b556-43042f6581bb_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_48e991d8-890e-4e39-bb0c-472f41c1fba3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_eb5259f4-93b2-4cac-849d-5eaf90ab0085_terseLabel_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares to be issued upon 18-month anniversary of contract execution (shares)</link:label>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_label_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services</link:label>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_documentation_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" xlink:href="tars-20210630.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" xlink:to="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_3d1ded2b-2b40-4267-a7b4-3495a9d8cc4f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fd7cfd60-487a-4fa0-afe9-9f9b35292003_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES, PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue_2e14edaa-2d52-4e07-a1e9-61aacee482ce_terseLabel_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum exercise price, percent of fair market value of common stock on grant date</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue_label_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Minimum Exercise Price, Percent Of Fair Market Value</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue_documentation_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Minimum Exercise Price, Percent Of Fair Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue" xlink:href="tars-20210630.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue" xlink:to="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_83b1c05e-90f9-40cb-a007-5ec77952ef6d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business and Presentation of Financial Statements</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f81a1614-1a67-4b7a-bdfe-fe5cee337264_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_bd036b38-6aa7-43b2-b86d-7030991c60b5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_fcf22e2b-8402-4a23-9278-89e8b5279424_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_408dd386-7af1-4e58-a610-33d60af0f644_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d5590bda-4c6b-493f-8d18-9d85f7245ce0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_bc007be2-40a9-42ce-9fbf-5ec088614465_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_586b8db6-d624-4c99-b763-73c644dfa7d1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8a9bbd63-dc38-415a-8d14-96d4b6f04a41_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_648e1814-54be-478c-8a32-4528d95b3cbe_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of vested stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ElancoMember_fdb2c296-faab-42ce-8828-b18a3161f4db_terseLabel_en-US" xlink:label="lab_tars_ElancoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elanco</link:label>
    <link:label id="lab_tars_ElancoMember_label_en-US" xlink:label="lab_tars_ElancoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elanco [Member]</link:label>
    <link:label id="lab_tars_ElancoMember_documentation_en-US" xlink:label="lab_tars_ElancoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elanco</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ElancoMember" xlink:href="tars-20210630.xsd#tars_ElancoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ElancoMember" xlink:to="lab_tars_ElancoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_da70f930-048b-4c37-8e7f-294a3b572b65_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_7f5ecefe-2ace-422d-8df5-cb0f11f6cfc8_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_095bb0b2-f15f-4942-bc0d-fba29bfe22bf_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_EquityIncentivePlan2020Member_9f98bc42-3572-49a3-973f-9969948e9db4_terseLabel_en-US" xlink:label="lab_tars_EquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Plan</link:label>
    <link:label id="lab_tars_EquityIncentivePlan2020Member_label_en-US" xlink:label="lab_tars_EquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2020 [Member]</link:label>
    <link:label id="lab_tars_EquityIncentivePlan2020Member_documentation_en-US" xlink:label="lab_tars_EquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityIncentivePlan2020Member" xlink:href="tars-20210630.xsd#tars_EquityIncentivePlan2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_EquityIncentivePlan2020Member" xlink:to="lab_tars_EquityIncentivePlan2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7cc4cdd3-1721-4cef-a2b3-73bf2dcc38fd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_8e81ec7c-0e56-400a-a733-102d7552ad71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock details</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_da117dc3-72cf-45a7-ad0e-656d6c370da8_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_4ca65b24-f2df-426e-a421-78e2faa3b021_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_0b3bddc2-9abf-4a01-921b-e4ab8b3b18c5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_98eeb988-b1c7-4d75-821a-350acc0f0d88_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath_6208deb0-18c8-46f0-9571-373fda6eac7a_terseLabel_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise period from termination upon death</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath_label_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Death</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath_documentation_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Death</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath" xlink:href="tars-20210630.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath" xlink:to="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_72e6faf5-e153-4e2c-8aac-4328ad2c6be1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock option early exercise liability, non-current portion</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_bd3814cb-2b21-49c4-b27e-046dfeb34459_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: undistributed income reallocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_6e974510-4232-4e0c-b6ab-8269767f94ca_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ba05cc29-2252-4a5f-9107-6ef4cb681f71_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_866a3d8b-28a5-4bea-ab49-6c6a9344846e_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_de2f5985-f69d-4eee-85ee-6ed3906845e6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ec5bedff-bd10-4965-9b43-40b65e78c6c8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_79be39a5-a7cd-4c89-9362-9bbe470e1086_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_f860105f-3362-4e7c-9343-44f16b40734b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_UpfrontPayment_479c35db-15fe-4e48-a8d3-69cf50bd8a88_terseLabel_en-US" xlink:label="lab_tars_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_tars_UpfrontPayment_label_en-US" xlink:label="lab_tars_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment</link:label>
    <link:label id="lab_tars_UpfrontPayment_documentation_en-US" xlink:label="lab_tars_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_UpfrontPayment" xlink:href="tars-20210630.xsd#tars_UpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_UpfrontPayment" xlink:to="lab_tars_UpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_477f0929-85c8-4565-be84-f373aae0e14c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockSharesSubjectToRepurchase_bef451a5-9df1-46e4-b552-35985abe7cf7_terseLabel_en-US" xlink:label="lab_tars_CommonStockSharesSubjectToRepurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, subject to repurchase (shares)</link:label>
    <link:label id="lab_tars_CommonStockSharesSubjectToRepurchase_label_en-US" xlink:label="lab_tars_CommonStockSharesSubjectToRepurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Subject To Repurchase</link:label>
    <link:label id="lab_tars_CommonStockSharesSubjectToRepurchase_documentation_en-US" xlink:label="lab_tars_CommonStockSharesSubjectToRepurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Subject To Repurchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockSharesSubjectToRepurchase" xlink:href="tars-20210630.xsd#tars_CommonStockSharesSubjectToRepurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockSharesSubjectToRepurchase" xlink:to="lab_tars_CommonStockSharesSubjectToRepurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8f347824-ba45-4e6b-a153-45656a97ce38_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2041a277-d329-462c-b852-1f357e2baf91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a4a9b8bf-801e-4600-9c55-565d3cd03a78_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability_bbef0901-c068-470a-b51f-eb387dbab0c6_terseLabel_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise period from termination upon disability</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability_label_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Disability</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability_documentation_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Disability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability" xlink:href="tars-20210630.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability" xlink:to="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7a1d8cc2-1888-41ca-9e7b-491d3d1cce23_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_b54a1d1e-5392-4610-a33e-702c56b9c25e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_4d83e346-ec2a-4a6f-8abc-d58a4ed5e40d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_2025a6f2-1edd-4a3c-90f2-c19fdc7082da_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_d653f3c5-8c95-4456-a3d8-ce1a331e9131_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_38786541-73e6-4c3e-a9cf-3e3c99a7f176_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_60299a83-4300-4ce0-92c3-9d7853cce71e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_cbbe0f7b-5fa6-426a-b773-a1d8168556da_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of operating lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_aba4225f-572a-4477-94f6-548150333141_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 200,000,000 shares authorized; 20,704,104 shares issued and 20,573,951 outstanding, which excludes 130,153 shares subject to repurchase at June&#160;30, 2021 (unaudited); 20,502,576 shares issued and 20,323,301 outstanding, which excludes 179,375 shares subject to repurchase at December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_065b8835-b0d0-4cdf-ad0f-1c8dc414b8be_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_02164370-65c4-4e33-84e8-28c23e0cb5f9_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (expense) income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5d55ebd0-6766-423f-a2e9-d05617f07bd6_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_54ca6d74-f317-481d-8746-a68d65982722_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3ed109d2-3dfa-461e-ba7e-844dd8caba24_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_34036d2d-3030-4ae2-bbeb-d06f8c073731_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_de99a4f5-8c10-4b65-8058-66f0c7f6582f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments measured at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositAssets_705c1b3d-ccf5-426c-ab1a-3b9cce8ce232_terseLabel_en-US" xlink:label="lab_us-gaap_DepositAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits</link:label>
    <link:label id="lab_us-gaap_DepositAssets_label_en-US" xlink:label="lab_us-gaap_DepositAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposit Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositAssets" xlink:to="lab_us-gaap_DepositAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_789ebc9a-bf4d-4738-9726-584db1166cf9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3ec9765c-ba28-4d24-82c8-683c3c132383_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (remaining six months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_06764d3f-9935-435c-8a8c-0d551d8ed199_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_a0409b92-d6df-4b24-a09b-9ac936deae8b_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon conversion of preferred stock (shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease_393ed5fe-e2d9-4864-a36b-701ba20931e6_terseLabel_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance, increase percentage on first business day of each of next ten fiscal years</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease_label_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved For Future Issuance, Annual Percentage Increase</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease_documentation_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved For Future Issuance, Annual Percentage Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease" xlink:href="tars-20210630.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease" xlink:to="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LianBioMember_7238e02e-e32a-4fc7-a912-3cae6c363ed0_terseLabel_en-US" xlink:label="lab_tars_LianBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LianBio</link:label>
    <link:label id="lab_tars_LianBioMember_label_en-US" xlink:label="lab_tars_LianBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LianBio [Member]</link:label>
    <link:label id="lab_tars_LianBioMember_documentation_en-US" xlink:label="lab_tars_LianBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LianBio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember" xlink:href="tars-20210630.xsd#tars_LianBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LianBioMember" xlink:to="lab_tars_LianBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_7384a727-da5a-43fa-97e5-c1d895bf505a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_353494c6-aef8-4901-bf3c-aeb9e1e68015_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_df9e6878-8409-4cd1-877c-149105305b63_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2082ebcc-190a-4584-a341-285ae4929afc_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_369d1d81-4092-408e-ba5a-fe1830f22d76_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cf54f8b2-f9be-4f3e-9a99-bc9967d2c53f_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5404a8e9-fc0f-4400-9e8e-aa085005d71c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash &#8212; beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_828427ff-f589-4089-aca7-9c8b91c24bc3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash &#8212; end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a607fc6f-943a-45e2-abdb-0a3db8dd6eda_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_5a19d857-b664-41d2-a6c1-4b7eb2aec1f4_terseLabel_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units outstanding</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_label_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_documentation_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:href="tars-20210630.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:to="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_22af0b76-905f-4f20-a2d6-85038fca63ee_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_f6286312-99bf-4c87-a838-e5d4854421d3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_fcee0f8a-0192-40e3-b6c5-dd02b4eda029_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_EquityWarrantRights_78c46754-2063-4d24-8745-c2ddf852a23f_terseLabel_en-US" xlink:label="lab_tars_EquityWarrantRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity warrant rights*</link:label>
    <link:label id="lab_tars_EquityWarrantRights_label_en-US" xlink:label="lab_tars_EquityWarrantRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrant Rights</link:label>
    <link:label id="lab_tars_EquityWarrantRights_documentation_en-US" xlink:label="lab_tars_EquityWarrantRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrant Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantRights" xlink:href="tars-20210630.xsd#tars_EquityWarrantRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_EquityWarrantRights" xlink:to="lab_tars_EquityWarrantRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_81de23b7-e72a-4f15-8a0a-c91e67063bf7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c4919ddf-e73d-48c1-9d1d-6ac5d6933522_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_18431f82-603d-4156-a8f6-cadfe8616ce3_terseLabel_en-US" xlink:label="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of repurchase rights related to common stock issued pursuant to early exercises</link:label>
    <link:label id="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_label_en-US" xlink:label="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Lapse Of Repurchase Rights</link:label>
    <link:label id="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_documentation_en-US" xlink:label="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Lapse Of Repurchase Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" xlink:href="tars-20210630.xsd#tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" xlink:to="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_80b9fe9f-0b22-4c00-aa3a-365d3c25b09d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Less): Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b8c9c2d0-973d-49d2-a458-c0fee9d4bc10_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares of common stock reserved (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_eb1f6990-13d3-4369-a0ed-c026f10b60b7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares of common stock reserved (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_c7304a22-65ae-48b0-81cd-625fe8d12043_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income (expense), net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_01c25436-5b0f-418a-904c-1f1e3df17be1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_4bd52791-f145-4ac8-a553-6faad7d03eba_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b876d26e-27c1-415c-b05a-d373cadbee0d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued, net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_61ce0924-fa80-47d2-82f2-3422fe2b3d88_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3fe1bece-d88c-44c2-87e7-dbd41e9b035f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_4806d6d5-45cf-4297-97fa-e551800aada6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bb29c79d-d2c4-462f-8bba-4148a0aeb161_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of vested stock options (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1e75bc91-70a0-4f95-9fd4-2d42365f73aa_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesTableTextBlock_43b911e9-9580-4976-b334-e238ec791981_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ed66528a-61e2-4ef4-9b2f-f3903217da74_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6b9dc2df-838b-4aaa-a0bd-8884431dc35f_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_1ca0a512-3ff1-4707-a411-d8dd6330538b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock dividends declared (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_654f3a8a-3eab-475c-94b0-4ffd00b87ac7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service condition period for full vesting</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_5d95d0f5-1c5d-420e-b57b-3539ef22fe9f_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters' option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d47100d4-43ce-4537-9e55-6b80b86d7a8d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_58e598f8-ebfb-4982-b7c9-d97c6d42e401_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CollaborativeArrangementMilestonePayment_67d4e527-7cb3-4dff-b3b9-e03be1f019b9_terseLabel_en-US" xlink:label="lab_tars_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment achieved</link:label>
    <link:label id="lab_tars_CollaborativeArrangementMilestonePayment_label_en-US" xlink:label="lab_tars_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment</link:label>
    <link:label id="lab_tars_CollaborativeArrangementMilestonePayment_documentation_en-US" xlink:label="lab_tars_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMilestonePayment" xlink:href="tars-20210630.xsd#tars_CollaborativeArrangementMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CollaborativeArrangementMilestonePayment" xlink:to="lab_tars_CollaborativeArrangementMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0829f184-15fa-4bde-a412-ccb8b5864a7f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_140315b7-eaa6-474b-85af-bd72572dfe54_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2c5cb630-52e6-4d44-b14f-46e67fa1b6e9_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unexercised stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d916a79b-9a7a-483a-a9e8-e590528af781_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_bfc315c3-957a-4d33-bc45-dd0ad4f5061e_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_29225f64-ecfc-46d1-baae-643210a05a5f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued as consideration for in-license rights</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_9d78f11a-3aa0-4412-af0f-5b52034f16ff_netLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued to licensor pursuant to execution of out-license agreement</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_317afeae-3537-458c-81ef-d62633d9b8fa_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for license agreement, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_07926421-e110-4b3f-a091-58a66739cfaa_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_IrvineOfficeAndFacilitiesLeaseMember_c1f0ced3-e05c-4871-ad11-0aa68fbbf932_terseLabel_en-US" xlink:label="lab_tars_IrvineOfficeAndFacilitiesLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Irvine office and laboratory facility</link:label>
    <link:label id="lab_tars_IrvineOfficeAndFacilitiesLeaseMember_label_en-US" xlink:label="lab_tars_IrvineOfficeAndFacilitiesLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Irvine Office And Facilities Lease [Member]</link:label>
    <link:label id="lab_tars_IrvineOfficeAndFacilitiesLeaseMember_documentation_en-US" xlink:label="lab_tars_IrvineOfficeAndFacilitiesLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Irvine Office And Facilities Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_IrvineOfficeAndFacilitiesLeaseMember" xlink:href="tars-20210630.xsd#tars_IrvineOfficeAndFacilitiesLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_IrvineOfficeAndFacilitiesLeaseMember" xlink:to="lab_tars_IrvineOfficeAndFacilitiesLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_716f1ac8-6c19-42d0-9183-79ef05353d96_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ee232d7b-29d2-4263-aba6-903e742fdc94_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c4d287e-09fe-4150-9017-5d6ca32e2ff7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4b39281b-07df-4337-9da6-fbbe4bb5d920_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b78493d-1656-454e-80a8-f83cb5e28819_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Less): Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_aeee1fc5-6e65-46e3-bd9f-45b25ee152eb_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations before other (expense) income and income taxes</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_20fe1ff8-1d4b-47f6-9091-251c2a934176_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ade482f4-4998-4e1c-a275-459eff787a7f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f9807c95-42dc-4762-8ade-70438150dd47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_789aa462-70f5-4509-964a-dd239542cb5f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a3c13d6d-7c27-4e87-8ccc-dc84a8beb647_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination_2efed124-9607-437a-bd0a-4f1a805aa993_negatedLabel_en-US" xlink:label="lab_tars_DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derecognition of right-of-use asset upon lease termination</link:label>
    <link:label id="lab_tars_DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination_label_en-US" xlink:label="lab_tars_DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decapitalization Of Operating Lease, Right Of Use Asset, Lease Termination</link:label>
    <link:label id="lab_tars_DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination_documentation_en-US" xlink:label="lab_tars_DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decapitalization Of Operating Lease, Right Of Use Asset, Lease Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination" xlink:href="tars-20210630.xsd#tars_DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination" xlink:to="lab_tars_DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_ea48232a-7fb0-4508-bc5c-e6e94e0691c9_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out-License Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_de4a7c6c-e96e-43cb-9bf5-ddbce222a956_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfba70d3-6e69-4e28-b467-465c9560b52f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseMember_d0a5f0aa-349e-4aea-9a86-3537687cdfc0_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3f8f04eb-9063-41d9-9ea9-395046bb6d7a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_99452d57-91bd-4718-9212-373abb13fc3a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5bebe9e6-23db-4b55-bb67-a96666d9371b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_cea3d3c5-1ec0-446d-92c1-c555cd79163d_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_1ad6c168-6aa8-4d7e-9c24-601293d96cb0_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_b0e9ad8c-8f15-469f-ba36-81e1f2201c81_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable and other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_213d1167-e9ee-4489-8028-730c8ed5f37f_terseLabel_en-US" xlink:label="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employment arrangements with executive officers</link:label>
    <link:label id="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_label_en-US" xlink:label="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Employment Arrangements With Executive Officers</link:label>
    <link:label id="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_documentation_en-US" xlink:label="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Employment Arrangements With Executive Officers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:href="tars-20210630.xsd#tars_NumberOfEmploymentArrangementsWithExecutiveOfficers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:to="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ba9346e2-f8cf-46d9-b1d7-aa6059800d47_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aae79691-c029-48d4-9582-41ebf45f7130_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_cdcf3f8b-6f56-46c5-8295-1dbb5e4fee2d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_3dd07984-1407-401e-b3af-b1cc6db08409_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_66e83c46-703a-4ca5-89db-aed88580a20d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_148d7b03-fbc7-4d8f-814d-ae4458372f23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_12a5ef47-b81d-4c3a-aae7-5bb2d6d3d204_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued or Effective Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8265a63b-c436-42d8-9b3f-6d6f2a8251b3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_fbcddc13-19ec-4514-87d0-bf5118024139_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_1094f843-0caf-4fc9-809b-2120fbe4f0a6_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ca989aef-9201-49cf-93db-aa3fc2310412_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_c861b2a3-f9d0-4b68-9426-cf03c77b92cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0b199e08-9792-4aa8-ad8e-e8bab9fb6ad7_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_DevelopmentAndRegulatoryMilestoneMember_e4508ba6-9623-467b-b1b0-51f069a2a744_terseLabel_en-US" xlink:label="lab_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Regulatory Milestone</link:label>
    <link:label id="lab_tars_DevelopmentAndRegulatoryMilestoneMember_label_en-US" xlink:label="lab_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone [Member]</link:label>
    <link:label id="lab_tars_DevelopmentAndRegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:href="tars-20210630.xsd#tars_DevelopmentAndRegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:to="lab_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_2e135693-76c2-4b9c-827a-594dd5935316_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_419d2994-11b3-4522-8e56-b4243edee3a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_ea0f3786-465b-40f5-a25e-948dcf925f0f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_0b4efb72-ee10-4873-b0f9-84eb0768f957_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7aa412b4-f443-493f-b584-2ab20b36ab94_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_931b7838-cfe4-4f41-8e56-f036c5b4d337_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future contractual lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3f9a2246-b015-4583-b85d-15c445a00c71_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_727b652e-f7cc-44d9-8c25-0d4f61e76d0c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_27cd1282-1274-4604-a406-9422be95f60a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_bf177bec-1b44-497a-b6ea-27e2c7d393e2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued as consideration for in-license rights (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_8465f5e3-986c-49be-8e69-1d9a8239bc63_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for license agreement (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_37d18df5-e426-4e04-ae5e-49e8292d6a31_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommercialAndSalesMilestonesMember_1a938aa0-7755-4877-acee-b13e7868e775_terseLabel_en-US" xlink:label="lab_tars_CommercialAndSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and sales milestones</link:label>
    <link:label id="lab_tars_CommercialAndSalesMilestonesMember_label_en-US" xlink:label="lab_tars_CommercialAndSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Sales Milestones [Member]</link:label>
    <link:label id="lab_tars_CommercialAndSalesMilestonesMember_documentation_en-US" xlink:label="lab_tars_CommercialAndSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Sales Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommercialAndSalesMilestonesMember" xlink:href="tars-20210630.xsd#tars_CommercialAndSalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommercialAndSalesMilestonesMember" xlink:to="lab_tars_CommercialAndSalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_efb5cfaa-b2d0-4f5c-bb55-b93ea56fba37_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_4d08125f-7ab9-4ce4-8cd2-5caf6990dda5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e4c1555-c2a7-4ff2-b2b9-5b25d0ffb104_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_8b4f37b9-60f5-48a7-bc30-f7b299c30a87_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_EquityWarrantsFairValueDisclosure_78d22e65-8ae5-4930-a6ff-a2cb4c36b367_terseLabel_en-US" xlink:label="lab_tars_EquityWarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity warrant rights</link:label>
    <link:label id="lab_tars_EquityWarrantsFairValueDisclosure_label_en-US" xlink:label="lab_tars_EquityWarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants, Fair Value Disclosure</link:label>
    <link:label id="lab_tars_EquityWarrantsFairValueDisclosure_documentation_en-US" xlink:label="lab_tars_EquityWarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantsFairValueDisclosure" xlink:href="tars-20210630.xsd#tars_EquityWarrantsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_EquityWarrantsFairValueDisclosure" xlink:to="lab_tars_EquityWarrantsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_c04338d6-a172-4b4c-a918-e4bdf5afccfd_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_f8d8424f-ede6-4b86-9f5c-5373479ec854_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_41078a64-8f37-42bc-838d-4549dfe8ddb7_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_14dfe98b-ac41-44d3-bce4-1d9d2aead7b0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Miscellaneous, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_310e742c-d4f6-4e27-b20e-6b0ca86db0bd_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931fc50f-6099-4064-ac00-7432ab02eef2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_bf558de7-f583-455f-9fa1-22c954b730d4_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures Noncash Investing and Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>tars-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1b782ba2-cb83-443a-9650-7dcdabbf6aa7,g:fefcf97f-7929-4215-bb38-a69760b7d0fa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://tarsusrx.com/role/Cover" xlink:type="simple" xlink:href="tars-20210630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_39f3436f-08dd-4b2a-aa27-28d4f0104378" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_DocumentType_39f3436f-08dd-4b2a-aa27-28d4f0104378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_6e2a616a-49cb-45f9-92f6-74e3a35d571a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_DocumentQuarterlyReport_6e2a616a-49cb-45f9-92f6-74e3a35d571a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f2a0def9-49ed-4b5f-9aea-82f8ebb6b2ce" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_DocumentPeriodEndDate_f2a0def9-49ed-4b5f-9aea-82f8ebb6b2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_48df610f-9357-4181-acce-be3ae41eb6c4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_DocumentTransitionReport_48df610f-9357-4181-acce-be3ae41eb6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2a3d8af6-7449-4bfc-b9cc-9cd1f0204d1a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_EntityFileNumber_2a3d8af6-7449-4bfc-b9cc-9cd1f0204d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f480d2c8-8d2b-4299-beda-0f2d848fff74" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_EntityRegistrantName_f480d2c8-8d2b-4299-beda-0f2d848fff74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_57ff9d18-0cc3-4acb-9d35-4b7d31c9d05b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_57ff9d18-0cc3-4acb-9d35-4b7d31c9d05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4c8abd2d-f387-410e-a059-752a2bbf3dfb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_EntityTaxIdentificationNumber_4c8abd2d-f387-410e-a059-752a2bbf3dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e35b1331-2244-4d13-ae0b-e46c24b1d698" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_EntityAddressAddressLine1_e35b1331-2244-4d13-ae0b-e46c24b1d698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6dada589-16b8-40c7-a627-1dc3384e5050" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_EntityAddressCityOrTown_6dada589-16b8-40c7-a627-1dc3384e5050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_36401d45-461f-478f-87a4-268cb197f899" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_EntityAddressStateOrProvince_36401d45-461f-478f-87a4-268cb197f899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3bd9d473-5c28-418b-a217-befc73c7f614" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_EntityAddressPostalZipCode_3bd9d473-5c28-418b-a217-befc73c7f614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1429da91-4c32-4501-86de-063311ff562f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_CityAreaCode_1429da91-4c32-4501-86de-063311ff562f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_98b662f0-62db-4321-9f22-d40484036c12" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_LocalPhoneNumber_98b662f0-62db-4321-9f22-d40484036c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_46f6bcc1-0030-44aa-bc40-0bd93e1b9759" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_Security12bTitle_46f6bcc1-0030-44aa-bc40-0bd93e1b9759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7da09f9e-8b2f-4c62-ba90-69476bb7de55" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_TradingSymbol_7da09f9e-8b2f-4c62-ba90-69476bb7de55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6801993a-45dd-40c3-ab50-51a9f39e274b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_SecurityExchangeName_6801993a-45dd-40c3-ab50-51a9f39e274b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_4cdccf43-51ca-4471-ba53-ed8b4f8565a7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_EntityCurrentReportingStatus_4cdccf43-51ca-4471-ba53-ed8b4f8565a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_1e7e09e0-12e9-499b-9f96-fb96a166ee6b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_EntityInteractiveDataCurrent_1e7e09e0-12e9-499b-9f96-fb96a166ee6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_22a64f1b-5f39-4b83-b818-0257d3e68e48" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_EntityFilerCategory_22a64f1b-5f39-4b83-b818-0257d3e68e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2937c624-ed5f-4cef-a834-a2b5dd9fb3e0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_EntitySmallBusiness_2937c624-ed5f-4cef-a834-a2b5dd9fb3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2e557627-b044-4aba-a268-31c4f499adb1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_EntityEmergingGrowthCompany_2e557627-b044-4aba-a268-31c4f499adb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_814a389d-7411-4ce7-b269-eb9bab89c003" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_EntityExTransitionPeriod_814a389d-7411-4ce7-b269-eb9bab89c003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_25e5d88f-11e7-4b76-8c54-1558daea06c0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_EntityShellCompany_25e5d88f-11e7-4b76-8c54-1558daea06c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_98529df5-d0bd-4aa7-8d8f-89ea88d3a08f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_98529df5-d0bd-4aa7-8d8f-89ea88d3a08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8b3a1be9-276a-41b2-ab60-585eb4a1d980" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_AmendmentFlag_8b3a1be9-276a-41b2-ab60-585eb4a1d980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_48ce58d3-44c7-4c11-97f6-6bc40007b07f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_EntityCentralIndexKey_48ce58d3-44c7-4c11-97f6-6bc40007b07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_46963bf8-b689-4f51-b4c7-df34a42a628d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_CurrentFiscalYearEndDate_46963bf8-b689-4f51-b4c7-df34a42a628d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d273b182-c7a3-4895-95ae-b927e4cc25b7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_DocumentFiscalYearFocus_d273b182-c7a3-4895-95ae-b927e4cc25b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3d015bad-93fb-4155-b71a-e492d9daf881" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d751e87-15d6-4fae-aaa2-08d7f055533c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_3d015bad-93fb-4155-b71a-e492d9daf881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="tars-20210630.xsd#CondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_eff7b2e0-d578-4652-a1c8-6b4ba7a3b56c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3dd63d67-39b5-4161-ab29-7b7c035d6183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eff7b2e0-d578-4652-a1c8-6b4ba7a3b56c" xlink:to="loc_us-gaap_AssetsAbstract_3dd63d67-39b5-4161-ab29-7b7c035d6183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3bf280c9-7015-44e6-9965-f3ba84800c83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3dd63d67-39b5-4161-ab29-7b7c035d6183" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3bf280c9-7015-44e6-9965-f3ba84800c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1cdbc80-104e-4c2d-9e94-55656706daf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3bf280c9-7015-44e6-9965-f3ba84800c83" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1cdbc80-104e-4c2d-9e94-55656706daf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_4b722bbe-51ac-4467-9c79-51bd63036cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3bf280c9-7015-44e6-9965-f3ba84800c83" xlink:to="loc_us-gaap_RestrictedCashCurrent_4b722bbe-51ac-4467-9c79-51bd63036cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7a442fea-0d2a-4d4c-86c0-7beeaadc8b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3bf280c9-7015-44e6-9965-f3ba84800c83" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7a442fea-0d2a-4d4c-86c0-7beeaadc8b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_c10d8d03-5726-4fa0-9a1d-c54b687cde43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3bf280c9-7015-44e6-9965-f3ba84800c83" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_c10d8d03-5726-4fa0-9a1d-c54b687cde43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_140414c9-94c7-4298-8a4c-69db7e85cd57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3bf280c9-7015-44e6-9965-f3ba84800c83" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_140414c9-94c7-4298-8a4c-69db7e85cd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a035c36f-2eb8-43f2-ab1d-8f4d5b72501d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3bf280c9-7015-44e6-9965-f3ba84800c83" xlink:to="loc_us-gaap_AssetsCurrent_a035c36f-2eb8-43f2-ab1d-8f4d5b72501d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_53d38221-ad24-477d-bbb2-262a0ff0ebb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3dd63d67-39b5-4161-ab29-7b7c035d6183" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_53d38221-ad24-477d-bbb2-262a0ff0ebb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f855d774-4971-4ba3-9269-ae057ea7089a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3dd63d67-39b5-4161-ab29-7b7c035d6183" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f855d774-4971-4ba3-9269-ae057ea7089a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_347bfb43-5df8-4a80-9308-084967dc43c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3dd63d67-39b5-4161-ab29-7b7c035d6183" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_347bfb43-5df8-4a80-9308-084967dc43c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4c6550c6-b969-412c-a356-5066c5119af3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3dd63d67-39b5-4161-ab29-7b7c035d6183" xlink:to="loc_us-gaap_Assets_4c6550c6-b969-412c-a356-5066c5119af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f1ce08a-a0c3-43b9-9744-f4683ae1adc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eff7b2e0-d578-4652-a1c8-6b4ba7a3b56c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f1ce08a-a0c3-43b9-9744-f4683ae1adc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_00ddc395-b9d9-4d7f-95f7-658ecc8336c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f1ce08a-a0c3-43b9-9744-f4683ae1adc6" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_00ddc395-b9d9-4d7f-95f7-658ecc8336c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1766e101-9d9f-42fe-87fa-049d96e01d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_00ddc395-b9d9-4d7f-95f7-658ecc8336c7" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1766e101-9d9f-42fe-87fa-049d96e01d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c756ebfc-6485-4cf1-bfc7-6d5492647828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_00ddc395-b9d9-4d7f-95f7-658ecc8336c7" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c756ebfc-6485-4cf1-bfc7-6d5492647828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_560e43a4-3ceb-47e3-b928-2af0386b9299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_00ddc395-b9d9-4d7f-95f7-658ecc8336c7" xlink:to="loc_us-gaap_LiabilitiesCurrent_560e43a4-3ceb-47e3-b928-2af0386b9299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6040699f-c469-47c1-acdc-86741624053d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f1ce08a-a0c3-43b9-9744-f4683ae1adc6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6040699f-c469-47c1-acdc-86741624053d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2698eec7-cff8-441c-a850-740f7e63ec49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f1ce08a-a0c3-43b9-9744-f4683ae1adc6" xlink:to="loc_us-gaap_Liabilities_2698eec7-cff8-441c-a850-740f7e63ec49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_dd54d99c-cf36-4bf4-b567-31aba8f1a04a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f1ce08a-a0c3-43b9-9744-f4683ae1adc6" xlink:to="loc_us-gaap_CommitmentsAndContingencies_dd54d99c-cf36-4bf4-b567-31aba8f1a04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ba432de3-6570-4881-8cf9-5a5ddb3b236b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f1ce08a-a0c3-43b9-9744-f4683ae1adc6" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ba432de3-6570-4881-8cf9-5a5ddb3b236b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7305bd87-cf30-45d8-87bc-6d758bceaf1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ba432de3-6570-4881-8cf9-5a5ddb3b236b" xlink:to="loc_us-gaap_PreferredStockValue_7305bd87-cf30-45d8-87bc-6d758bceaf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_67f67465-fa4a-42b0-b22d-f941ed57ecbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ba432de3-6570-4881-8cf9-5a5ddb3b236b" xlink:to="loc_us-gaap_CommonStockValue_67f67465-fa4a-42b0-b22d-f941ed57ecbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_904e9ab6-a0fa-45c8-b0a4-90b7ce68e0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ba432de3-6570-4881-8cf9-5a5ddb3b236b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_904e9ab6-a0fa-45c8-b0a4-90b7ce68e0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3bc1d81f-47ca-4cee-8a82-d376638a4438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ba432de3-6570-4881-8cf9-5a5ddb3b236b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3bc1d81f-47ca-4cee-8a82-d376638a4438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_61682708-0714-4225-8283-4e616c7a3e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ba432de3-6570-4881-8cf9-5a5ddb3b236b" xlink:to="loc_us-gaap_StockholdersEquity_61682708-0714-4225-8283-4e616c7a3e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_88b0b7a1-8b94-4ee0-8054-958c783008b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f1ce08a-a0c3-43b9-9744-f4683ae1adc6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_88b0b7a1-8b94-4ee0-8054-958c783008b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="tars-20210630.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_84a8348d-32d4-4b36-9354-d5e69d9e21f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_49902001-83a2-43a8-9a38-0dfc75afd105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84a8348d-32d4-4b36-9354-d5e69d9e21f6" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_49902001-83a2-43a8-9a38-0dfc75afd105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3f8f3c9f-b9db-417a-b4e3-abc38a755335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84a8348d-32d4-4b36-9354-d5e69d9e21f6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3f8f3c9f-b9db-417a-b4e3-abc38a755335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_382ae6f3-4d6e-44f3-9076-871158210932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84a8348d-32d4-4b36-9354-d5e69d9e21f6" xlink:to="loc_us-gaap_PreferredStockSharesIssued_382ae6f3-4d6e-44f3-9076-871158210932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e26d82a9-6d6a-4fd8-afd9-d2693ae454ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84a8348d-32d4-4b36-9354-d5e69d9e21f6" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_e26d82a9-6d6a-4fd8-afd9-d2693ae454ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f95f2aae-cd39-4834-8cd6-8e1668c4dc64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84a8348d-32d4-4b36-9354-d5e69d9e21f6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f95f2aae-cd39-4834-8cd6-8e1668c4dc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ae2168c7-fae8-4910-86b1-e3d0a5f3dfe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84a8348d-32d4-4b36-9354-d5e69d9e21f6" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ae2168c7-fae8-4910-86b1-e3d0a5f3dfe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a68571ae-b387-4011-af0f-210d01d62eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84a8348d-32d4-4b36-9354-d5e69d9e21f6" xlink:to="loc_us-gaap_CommonStockSharesIssued_a68571ae-b387-4011-af0f-210d01d62eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9f23ba2e-a473-41c0-a716-74801f28eb15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84a8348d-32d4-4b36-9354-d5e69d9e21f6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9f23ba2e-a473-41c0-a716-74801f28eb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockSharesSubjectToRepurchase_436b8ca2-9667-4bc3-8a88-c212d9b6a186" xlink:href="tars-20210630.xsd#tars_CommonStockSharesSubjectToRepurchase"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84a8348d-32d4-4b36-9354-d5e69d9e21f6" xlink:to="loc_tars_CommonStockSharesSubjectToRepurchase_436b8ca2-9667-4bc3-8a88-c212d9b6a186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="tars-20210630.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a00364c9-d664-4548-bfe8-90f7b7759242" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3fc8ddb6-efe5-4b87-a951-9ec4d8dd9d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a00364c9-d664-4548-bfe8-90f7b7759242" xlink:to="loc_us-gaap_StatementTable_3fc8ddb6-efe5-4b87-a951-9ec4d8dd9d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_eef3d82b-f9e4-4a1e-92bd-84d87140cfce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3fc8ddb6-efe5-4b87-a951-9ec4d8dd9d0b" xlink:to="loc_srt_ProductOrServiceAxis_eef3d82b-f9e4-4a1e-92bd-84d87140cfce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7c6ed483-2768-4b77-9025-b4033212aeb5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_eef3d82b-f9e4-4a1e-92bd-84d87140cfce" xlink:to="loc_srt_ProductsAndServicesDomain_7c6ed483-2768-4b77-9025-b4033212aeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LicenseAndCollaborationMember_0677e377-fdaa-4e1a-837e-b56b190a2733" xlink:href="tars-20210630.xsd#tars_LicenseAndCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7c6ed483-2768-4b77-9025-b4033212aeb5" xlink:to="loc_tars_LicenseAndCollaborationMember_0677e377-fdaa-4e1a-837e-b56b190a2733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_f4cf0152-9ad8-48bb-b894-65affa647e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_LicenseAndCollaborationMember_0677e377-fdaa-4e1a-837e-b56b190a2733" xlink:to="loc_us-gaap_LicenseAndServiceMember_f4cf0152-9ad8-48bb-b894-65affa647e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborationMember_e3728de5-524f-4bab-91e6-2e17c2f2f7ab" xlink:href="tars-20210630.xsd#tars_CollaborationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_LicenseAndCollaborationMember_0677e377-fdaa-4e1a-837e-b56b190a2733" xlink:to="loc_tars_CollaborationMember_e3728de5-524f-4bab-91e6-2e17c2f2f7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3fc8ddb6-efe5-4b87-a951-9ec4d8dd9d0b" xlink:to="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_b2505c60-1605-458e-9c01-83305cda7b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:to="loc_us-gaap_RevenuesAbstract_b2505c60-1605-458e-9c01-83305cda7b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_45e9086d-9c43-4fe2-9999-91a16b4bba2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b2505c60-1605-458e-9c01-83305cda7b2f" xlink:to="loc_us-gaap_Revenues_45e9086d-9c43-4fe2-9999-91a16b4bba2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_a8092059-37ae-439d-8d71-e9c26ee72829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:to="loc_us-gaap_OperatingExpensesAbstract_a8092059-37ae-439d-8d71-e9c26ee72829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_4878df80-be21-4b0c-8597-a26afff1adcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a8092059-37ae-439d-8d71-e9c26ee72829" xlink:to="loc_us-gaap_CostOfRevenue_4878df80-be21-4b0c-8597-a26afff1adcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a2152e78-6bbc-4df6-b7cf-de8a3bf4b78d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a8092059-37ae-439d-8d71-e9c26ee72829" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a2152e78-6bbc-4df6-b7cf-de8a3bf4b78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_15a7b82b-45e8-4be6-8c74-c88744119038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a8092059-37ae-439d-8d71-e9c26ee72829" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_15a7b82b-45e8-4be6-8c74-c88744119038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_09316575-4f3d-4a52-ac23-0055d6900563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a8092059-37ae-439d-8d71-e9c26ee72829" xlink:to="loc_us-gaap_OperatingExpenses_09316575-4f3d-4a52-ac23-0055d6900563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_152ec468-b289-4ed6-9d35-ba7905a9b748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:to="loc_us-gaap_OperatingIncomeLoss_152ec468-b289-4ed6-9d35-ba7905a9b748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8e31e232-0c41-4e97-8d58-f2ab910324a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8e31e232-0c41-4e97-8d58-f2ab910324a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_47ccf772-cef1-4686-a8fc-ed824e43c0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8e31e232-0c41-4e97-8d58-f2ab910324a5" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_47ccf772-cef1-4686-a8fc-ed824e43c0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c1299e6b-547f-43dc-8600-3dfbaf42247f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8e31e232-0c41-4e97-8d58-f2ab910324a5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c1299e6b-547f-43dc-8600-3dfbaf42247f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_bf2633e5-a275-40a5-9429-525f47a6d82f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8e31e232-0c41-4e97-8d58-f2ab910324a5" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_bf2633e5-a275-40a5-9429-525f47a6d82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_29f85cec-d604-4018-beb0-6ea934fb8f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8e31e232-0c41-4e97-8d58-f2ab910324a5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_29f85cec-d604-4018-beb0-6ea934fb8f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4ce0cf0f-ac4f-4147-b597-aba50f550253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4ce0cf0f-ac4f-4147-b597-aba50f550253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c2ca0f21-701d-411a-ac66-0538f5413d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:to="loc_us-gaap_NetIncomeLoss_c2ca0f21-701d-411a-ac66-0538f5413d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_12ff07ac-f6ea-475f-bbb1-0753c0006a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_12ff07ac-f6ea-475f-bbb1-0753c0006a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_51177a92-3b9c-4e62-a7ba-e345e0cc700b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:to="loc_us-gaap_EarningsPerShareAbstract_51177a92-3b9c-4e62-a7ba-e345e0cc700b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7d6e03f6-8057-43b5-9268-d8940305f24d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_51177a92-3b9c-4e62-a7ba-e345e0cc700b" xlink:to="loc_us-gaap_EarningsPerShareBasic_7d6e03f6-8057-43b5-9268-d8940305f24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b3a2a0a5-05fd-443e-bad6-780d7f67defc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_51177a92-3b9c-4e62-a7ba-e345e0cc700b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b3a2a0a5-05fd-443e-bad6-780d7f67defc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_79cd3c2e-f889-4ebd-b9b2-89d6f8c5137d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bee71258-76bb-4bde-a5ac-1143d50c29ee" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_79cd3c2e-f889-4ebd-b9b2-89d6f8c5137d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f55a2c8d-bb7c-4507-a29c-9f19c8280dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_79cd3c2e-f889-4ebd-b9b2-89d6f8c5137d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f55a2c8d-bb7c-4507-a29c-9f19c8280dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5bda01dd-bdb0-4317-a492-76bae10e3139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_79cd3c2e-f889-4ebd-b9b2-89d6f8c5137d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5bda01dd-bdb0-4317-a492-76bae10e3139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="tars-20210630.xsd#CondensedStatementsofPreferredStockandStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_01d5d842-a56b-4f61-914f-615813e7aac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_266ddcde-bea8-461d-9738-0012fc72ffb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_01d5d842-a56b-4f61-914f-615813e7aac7" xlink:to="loc_us-gaap_StatementTable_266ddcde-bea8-461d-9738-0012fc72ffb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0f94bd4f-ef96-4f57-a4be-83cf44845afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_266ddcde-bea8-461d-9738-0012fc72ffb3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0f94bd4f-ef96-4f57-a4be-83cf44845afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d8e56a6c-b082-4882-bd2a-1f6f21e8e6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0f94bd4f-ef96-4f57-a4be-83cf44845afa" xlink:to="loc_us-gaap_EquityComponentDomain_d8e56a6c-b082-4882-bd2a-1f6f21e8e6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_0a7fff29-5f4f-4f50-b090-6692569428fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d8e56a6c-b082-4882-bd2a-1f6f21e8e6d1" xlink:to="loc_us-gaap_PreferredStockMember_0a7fff29-5f4f-4f50-b090-6692569428fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e38a4238-a443-4601-ad45-2c4c43fae133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d8e56a6c-b082-4882-bd2a-1f6f21e8e6d1" xlink:to="loc_us-gaap_CommonStockMember_e38a4238-a443-4601-ad45-2c4c43fae133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_72e99511-29dd-4734-8750-12e4ae59af63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d8e56a6c-b082-4882-bd2a-1f6f21e8e6d1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_72e99511-29dd-4734-8750-12e4ae59af63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7e6c4da2-7547-4691-a405-239605251a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d8e56a6c-b082-4882-bd2a-1f6f21e8e6d1" xlink:to="loc_us-gaap_RetainedEarningsMember_7e6c4da2-7547-4691-a405-239605251a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2a6bda4c-e6f0-477e-979a-50b6c8db6765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_266ddcde-bea8-461d-9738-0012fc72ffb3" xlink:to="loc_us-gaap_StatementLineItems_2a6bda4c-e6f0-477e-979a-50b6c8db6765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2a6bda4c-e6f0-477e-979a-50b6c8db6765" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8c9f0734-cda5-42a9-88ab-5d5b437c0124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8c9f0734-cda5-42a9-88ab-5d5b437c0124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_52c86e26-b5fb-4adf-b634-38524628a308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_StockholdersEquity_52c86e26-b5fb-4adf-b634-38524628a308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f16585e6-e19b-4aa9-839a-feb770406de5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f16585e6-e19b-4aa9-839a-feb770406de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b3001dd1-a965-44ea-bcb7-f1fc83d74077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_NetIncomeLoss_b3001dd1-a965-44ea-bcb7-f1fc83d74077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7a74f223-22f7-4dc7-a1dd-fbc7fde37658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7a74f223-22f7-4dc7-a1dd-fbc7fde37658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_849c48f6-f259-4686-bf95-ceb08630b880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_849c48f6-f259-4686-bf95-ceb08630b880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_93fc0d15-dc7c-4909-a119-fc96fdefc75c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_93fc0d15-dc7c-4909-a119-fc96fdefc75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_435eac27-2dc7-465f-9b28-72ac81c5f42c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_435eac27-2dc7-465f-9b28-72ac81c5f42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_71e49bff-dbec-4150-999f-540546e3393d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_71e49bff-dbec-4150-999f-540546e3393d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_8fc510f2-252f-46f2-bd47-7ccdfebc20a5" xlink:href="tars-20210630.xsd#tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_8fc510f2-252f-46f2-bd47-7ccdfebc20a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_0ebe4665-7cad-4fb0-bc19-20304806e4af" xlink:href="tars-20210630.xsd#tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_0ebe4665-7cad-4fb0-bc19-20304806e4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f87bbd88-f587-4e62-9166-5e87585d86f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f87bbd88-f587-4e62-9166-5e87585d86f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8ce43440-5b05-491f-a672-62984cf0c350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_StockholdersEquity_8ce43440-5b05-491f-a672-62984cf0c350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c55cb698-4a79-47c5-a446-6ed0215932e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638d7854-709d-4c97-a7db-fdd781c4debe" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c55cb698-4a79-47c5-a446-6ed0215932e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="tars-20210630.xsd#CondensedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_5a7d9fd7-2129-4ce8-862d-e227483c030f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9d8704c9-ecb5-493c-9264-3d241a85ec90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5a7d9fd7-2129-4ce8-862d-e227483c030f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9d8704c9-ecb5-493c-9264-3d241a85ec90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f886ce5b-bf10-49b1-b0da-3554e48db80c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9d8704c9-ecb5-493c-9264-3d241a85ec90" xlink:to="loc_us-gaap_NetIncomeLoss_f886ce5b-bf10-49b1-b0da-3554e48db80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2391b7b0-958a-4343-914f-1f0b248a4592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9d8704c9-ecb5-493c-9264-3d241a85ec90" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2391b7b0-958a-4343-914f-1f0b248a4592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_75aa2d6a-854f-4edf-93fb-6abb6e236147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2391b7b0-958a-4343-914f-1f0b248a4592" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_75aa2d6a-854f-4edf-93fb-6abb6e236147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8748e569-291c-42a0-a318-6f70bed304bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2391b7b0-958a-4343-914f-1f0b248a4592" xlink:to="loc_us-gaap_ShareBasedCompensation_8748e569-291c-42a0-a318-6f70bed304bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d25ee51b-4546-4c91-aeb2-74bd1b6ec996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2391b7b0-958a-4343-914f-1f0b248a4592" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d25ee51b-4546-4c91-aeb2-74bd1b6ec996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_e42618c8-d598-45ee-88a7-b71b169cc7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2391b7b0-958a-4343-914f-1f0b248a4592" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_e42618c8-d598-45ee-88a7-b71b169cc7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_6d6b5e30-c635-4849-ac96-38e5d2f43bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2391b7b0-958a-4343-914f-1f0b248a4592" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_6d6b5e30-c635-4849-ac96-38e5d2f43bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_e2bac073-bd5b-488c-890e-e75b01049817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2391b7b0-958a-4343-914f-1f0b248a4592" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_e2bac073-bd5b-488c-890e-e75b01049817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_737b2711-faee-422c-8ee7-3d7782a46a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2391b7b0-958a-4343-914f-1f0b248a4592" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_737b2711-faee-422c-8ee7-3d7782a46a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_00273266-5e32-4c8b-bea2-eca821eeb078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2391b7b0-958a-4343-914f-1f0b248a4592" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_00273266-5e32-4c8b-bea2-eca821eeb078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d6e8154-3aac-4d76-81dc-28fdc5a6416d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2391b7b0-958a-4343-914f-1f0b248a4592" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d6e8154-3aac-4d76-81dc-28fdc5a6416d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_34af0b6a-8a2f-42bd-8ca1-8f553c8c277e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d6e8154-3aac-4d76-81dc-28fdc5a6416d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_34af0b6a-8a2f-42bd-8ca1-8f553c8c277e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_b61f935a-671e-4285-a640-068c43325492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d6e8154-3aac-4d76-81dc-28fdc5a6416d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_b61f935a-671e-4285-a640-068c43325492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3701403b-1de1-4e9a-b488-5da3106d219f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d6e8154-3aac-4d76-81dc-28fdc5a6416d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3701403b-1de1-4e9a-b488-5da3106d219f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e7a32837-2ae8-479d-95bf-c3b8abcbd7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d6e8154-3aac-4d76-81dc-28fdc5a6416d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e7a32837-2ae8-479d-95bf-c3b8abcbd7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_3b53f24b-a3ce-4521-87b1-9732368c5e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d6e8154-3aac-4d76-81dc-28fdc5a6416d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_3b53f24b-a3ce-4521-87b1-9732368c5e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8301be7a-8ae1-4b6f-a76e-1c6d257a2c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d6e8154-3aac-4d76-81dc-28fdc5a6416d" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8301be7a-8ae1-4b6f-a76e-1c6d257a2c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_cc991c4f-8534-4cdf-ab25-936255ffffaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d6e8154-3aac-4d76-81dc-28fdc5a6416d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_cc991c4f-8534-4cdf-ab25-936255ffffaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c068f8ba-d26c-44f0-b14d-60ba812afffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9d8704c9-ecb5-493c-9264-3d241a85ec90" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c068f8ba-d26c-44f0-b14d-60ba812afffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e0ad7e26-89a6-4eb3-8caa-7c2b9e3587c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5a7d9fd7-2129-4ce8-862d-e227483c030f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e0ad7e26-89a6-4eb3-8caa-7c2b9e3587c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0481c89c-166f-4bad-ac63-d4c65427248e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e0ad7e26-89a6-4eb3-8caa-7c2b9e3587c6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0481c89c-166f-4bad-ac63-d4c65427248e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81c503e5-bb95-4740-991e-2a842c98e09d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e0ad7e26-89a6-4eb3-8caa-7c2b9e3587c6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81c503e5-bb95-4740-991e-2a842c98e09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d25a4389-840d-4eb1-84ee-cc4c1710c24b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5a7d9fd7-2129-4ce8-862d-e227483c030f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d25a4389-840d-4eb1-84ee-cc4c1710c24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_4af704cd-e434-4ea7-817b-650a78272b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d25a4389-840d-4eb1-84ee-cc4c1710c24b" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_4af704cd-e434-4ea7-817b-650a78272b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_fc45f267-1b6a-4283-bebe-bac28a76379e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d25a4389-840d-4eb1-84ee-cc4c1710c24b" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_fc45f267-1b6a-4283-bebe-bac28a76379e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ProceedsFromEarlyExerciseOfStockOptions_37284f54-214d-4be4-88ea-3665986f68b1" xlink:href="tars-20210630.xsd#tars_ProceedsFromEarlyExerciseOfStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d25a4389-840d-4eb1-84ee-cc4c1710c24b" xlink:to="loc_tars_ProceedsFromEarlyExerciseOfStockOptions_37284f54-214d-4be4-88ea-3665986f68b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7a2f6054-2b23-4e3c-8a9a-88a1aed68fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d25a4389-840d-4eb1-84ee-cc4c1710c24b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7a2f6054-2b23-4e3c-8a9a-88a1aed68fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4fab8620-df8d-4f77-bdb0-beb5fc79d6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5a7d9fd7-2129-4ce8-862d-e227483c030f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4fab8620-df8d-4f77-bdb0-beb5fc79d6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_00496408-657f-4f20-926e-0e3fe65ff439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5a7d9fd7-2129-4ce8-862d-e227483c030f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_00496408-657f-4f20-926e-0e3fe65ff439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_25cc7858-fe86-4e2a-ab24-a871a49aa8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5a7d9fd7-2129-4ce8-862d-e227483c030f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_25cc7858-fe86-4e2a-ab24-a871a49aa8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_27f278f4-96e3-42dc-a954-907f9a9d5c63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5a7d9fd7-2129-4ce8-862d-e227483c030f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_27f278f4-96e3-42dc-a954-907f9a9d5c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a59a033e-ccfd-4bdc-ba3e-3898fe4201e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_27f278f4-96e3-42dc-a954-907f9a9d5c63" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a59a033e-ccfd-4bdc-ba3e-3898fe4201e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_e8556319-adcd-4a3b-a903-7c11212ce3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_27f278f4-96e3-42dc-a954-907f9a9d5c63" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_e8556319-adcd-4a3b-a903-7c11212ce3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cbbb5c70-6893-4703-890d-c1593441eb52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_27f278f4-96e3-42dc-a954-907f9a9d5c63" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cbbb5c70-6893-4703-890d-c1593441eb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6af9891b-aa0a-4f5e-8e9b-0c972d6c046b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5a7d9fd7-2129-4ce8-862d-e227483c030f" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6af9891b-aa0a-4f5e-8e9b-0c972d6c046b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e9647e2d-6a94-4dcf-a879-fd362a463749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6af9891b-aa0a-4f5e-8e9b-0c972d6c046b" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e9647e2d-6a94-4dcf-a879-fd362a463749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8441fde1-b56b-4a18-9710-69189ad743e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6af9891b-aa0a-4f5e-8e9b-0c972d6c046b" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8441fde1-b56b-4a18-9710-69189ad743e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination_08ce7da7-5bc5-4b30-96fd-87e29eda2df4" xlink:href="tars-20210630.xsd#tars_DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6af9891b-aa0a-4f5e-8e9b-0c972d6c046b" xlink:to="loc_tars_DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination_08ce7da7-5bc5-4b30-96fd-87e29eda2df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_0b8cec68-9c39-4c0c-8885-dcbdd28f2f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6af9891b-aa0a-4f5e-8e9b-0c972d6c046b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_0b8cec68-9c39-4c0c-8885-dcbdd28f2f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements" xlink:type="simple" xlink:href="tars-20210630.xsd#DescriptionofBusinessandPresentationofFinancialStatements"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5777b184-4b42-4208-801b-b7c35a1733de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_2ef08485-6215-46d5-ab83-1c38c47e6813" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5777b184-4b42-4208-801b-b7c35a1733de" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_2ef08485-6215-46d5-ab83-1c38c47e6813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#DescriptionofBusinessandPresentationofFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7db737ff-47da-449e-862e-12e6b9ef8cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_c69edd3f-230a-4314-a67d-04e1dd4c85c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7db737ff-47da-449e-862e-12e6b9ef8cfc" xlink:to="loc_us-gaap_SubsequentEventTable_c69edd3f-230a-4314-a67d-04e1dd4c85c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a8a9f4e4-4bcb-4a03-a384-415d0faf1e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c69edd3f-230a-4314-a67d-04e1dd4c85c0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a8a9f4e4-4bcb-4a03-a384-415d0faf1e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12e441c1-7588-4ce8-a19a-23b1a77ef1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a8a9f4e4-4bcb-4a03-a384-415d0faf1e9d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12e441c1-7588-4ce8-a19a-23b1a77ef1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_59432963-417a-4377-bd2f-138fd5255249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12e441c1-7588-4ce8-a19a-23b1a77ef1b8" xlink:to="loc_us-gaap_IPOMember_59432963-417a-4377-bd2f-138fd5255249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_54bbcc58-3a41-4a1a-8f55-29b64e2e7853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12e441c1-7588-4ce8-a19a-23b1a77ef1b8" xlink:to="loc_us-gaap_OverAllotmentOptionMember_54bbcc58-3a41-4a1a-8f55-29b64e2e7853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_38be201f-6823-43e5-a9a4-ccd21e6a3a21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c69edd3f-230a-4314-a67d-04e1dd4c85c0" xlink:to="loc_us-gaap_SubsequentEventLineItems_38be201f-6823-43e5-a9a4-ccd21e6a3a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2c75c185-9b8e-4303-b500-1c390e6f317d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_38be201f-6823-43e5-a9a4-ccd21e6a3a21" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2c75c185-9b8e-4303-b500-1c390e6f317d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_aa6a7dfc-6862-4d0e-b28c-52d6306c4575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_38be201f-6823-43e5-a9a4-ccd21e6a3a21" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_aa6a7dfc-6862-4d0e-b28c-52d6306c4575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_407b649d-ab47-47af-8d24-652202b229dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_38be201f-6823-43e5-a9a4-ccd21e6a3a21" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_407b649d-ab47-47af-8d24-652202b229dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_c5f66f25-1e41-44e6-9d93-580375057da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_38be201f-6823-43e5-a9a4-ccd21e6a3a21" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_c5f66f25-1e41-44e6-9d93-580375057da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a4c7d564-3338-4749-8f90-ec1e637d6445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_38be201f-6823-43e5-a9a4-ccd21e6a3a21" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a4c7d564-3338-4749-8f90-ec1e637d6445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e54a5756-010d-40bb-85ab-cbd9220a0a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7db737ff-47da-449e-862e-12e6b9ef8cfc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e54a5756-010d-40bb-85ab-cbd9220a0a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_53af695a-787b-47f7-a679-383fb3208668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7db737ff-47da-449e-862e-12e6b9ef8cfc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_53af695a-787b-47f7-a679-383fb3208668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_3fc213b1-d42a-4f4c-9c88-864c1500762d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7db737ff-47da-449e-862e-12e6b9ef8cfc" xlink:to="loc_us-gaap_NumberOfReportableSegments_3fc213b1-d42a-4f4c-9c88-864c1500762d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates" xlink:type="simple" xlink:href="tars-20210630.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimates"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ebffd60a-02cf-4c41-89f9-3507452c721b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_f9821138-266e-4bfa-9829-3c45bac52c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ebffd60a-02cf-4c41-89f9-3507452c721b" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_f9821138-266e-4bfa-9829-3c45bac52c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" xlink:type="simple" xlink:href="tars-20210630.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_057c1a79-ec02-465f-bc82-52538b10519c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_7af3d96d-9745-43f8-a66c-247c7f39d92b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_057c1a79-ec02-465f-bc82-52538b10519c" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_7af3d96d-9745-43f8-a66c-247c7f39d92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_dbb6ff16-2626-4c7d-817c-c447e57017a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_057c1a79-ec02-465f-bc82-52538b10519c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_dbb6ff16-2626-4c7d-817c-c447e57017a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_feabeed1-8f22-4d62-bff0-cb6e8101ca05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_057c1a79-ec02-465f-bc82-52538b10519c" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_feabeed1-8f22-4d62-bff0-cb6e8101ca05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_45dfc779-ab93-4b87-b0a9-062268db91cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_057c1a79-ec02-465f-bc82-52538b10519c" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_45dfc779-ab93-4b87-b0a9-062268db91cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_40cb29b5-5cdd-4395-8d05-3fd6596ef507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_057c1a79-ec02-465f-bc82-52538b10519c" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_40cb29b5-5cdd-4395-8d05-3fd6596ef507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_518b4bd8-cc4b-4bfc-87f2-8237921ee86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_057c1a79-ec02-465f-bc82-52538b10519c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_518b4bd8-cc4b-4bfc-87f2-8237921ee86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_6eadbd2b-e792-42e3-b5c8-98288770dc84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_057c1a79-ec02-465f-bc82-52538b10519c" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_6eadbd2b-e792-42e3-b5c8-98288770dc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_42661854-4fe0-465b-b011-169936f5c802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_057c1a79-ec02-465f-bc82-52538b10519c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_42661854-4fe0-465b-b011-169936f5c802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_08c41a05-6e4b-4cc2-a905-9cd2a891b5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_057c1a79-ec02-465f-bc82-52538b10519c" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_08c41a05-6e4b-4cc2-a905-9cd2a891b5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_f0d4e01e-751c-433c-9a1d-52788a1094ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_057c1a79-ec02-465f-bc82-52538b10519c" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_f0d4e01e-751c-433c-9a1d-52788a1094ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_f1098877-50c5-4bb1-a95d-8e273596ccb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_057c1a79-ec02-465f-bc82-52538b10519c" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_f1098877-50c5-4bb1-a95d-8e273596ccb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a1370d88-84a9-4d9f-999e-bd10fb2358a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_057c1a79-ec02-465f-bc82-52538b10519c" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a1370d88-84a9-4d9f-999e-bd10fb2358a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_ee6c31e6-ddba-45f6-811c-52dccccb8051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_057c1a79-ec02-465f-bc82-52538b10519c" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_ee6c31e6-ddba-45f6-811c-52dccccb8051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c8689ca6-411f-454c-a3f2-1fd7208ec5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_057c1a79-ec02-465f-bc82-52538b10519c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c8689ca6-411f-454c-a3f2-1fd7208ec5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetail" xlink:type="simple" xlink:href="tars-20210630.xsd#BalanceSheetAccountDetail"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ba2eb7a4-ec88-47fc-bfd3-792999f86941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_e7954f8e-5d15-4f68-8ccf-c8ca3eea672b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ba2eb7a4-ec88-47fc-bfd3-792999f86941" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_e7954f8e-5d15-4f68-8ccf-c8ca3eea672b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailTables" xlink:type="simple" xlink:href="tars-20210630.xsd#BalanceSheetAccountDetailTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_66039522-1b3d-474d-a56c-d8e3b2f4a2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6abe3762-f2cf-47d6-b972-153108835ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_66039522-1b3d-474d-a56c-d8e3b2f4a2e5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6abe3762-f2cf-47d6-b972-153108835ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_c35c006a-0ff3-4df5-8b92-e4adb0201022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_66039522-1b3d-474d-a56c-d8e3b2f4a2e5" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_c35c006a-0ff3-4df5-8b92-e4adb0201022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_ba4b662f-0450-4bfd-a267-1a5f6a22c56e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_66039522-1b3d-474d-a56c-d8e3b2f4a2e5" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_ba4b662f-0450-4bfd-a267-1a5f6a22c56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesTableTextBlock_29b72d34-d0ac-4567-b79a-63f4d48e1ead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_66039522-1b3d-474d-a56c-d8e3b2f4a2e5" xlink:to="loc_us-gaap_OtherLiabilitiesTableTextBlock_29b72d34-d0ac-4567-b79a-63f4d48e1ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_10e07079-9843-45ce-9cfc-2a2b9218668e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6313f02e-dcce-47f1-8448-a9fb5a6eb77f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_10e07079-9843-45ce-9cfc-2a2b9218668e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6313f02e-dcce-47f1-8448-a9fb5a6eb77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_397f50be-380f-4d82-bdcd-32cbb72aa0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6313f02e-dcce-47f1-8448-a9fb5a6eb77f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_397f50be-380f-4d82-bdcd-32cbb72aa0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b4379095-a7f0-4ecb-9cf6-a4e6f62f1ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_397f50be-380f-4d82-bdcd-32cbb72aa0fc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b4379095-a7f0-4ecb-9cf6-a4e6f62f1ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2601b0c2-85d0-42a7-b6c8-3287d636a443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b4379095-a7f0-4ecb-9cf6-a4e6f62f1ece" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2601b0c2-85d0-42a7-b6c8-3287d636a443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_e33dd16d-a67f-4468-945b-1d423ac680ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b4379095-a7f0-4ecb-9cf6-a4e6f62f1ece" xlink:to="loc_us-gaap_OfficeEquipmentMember_e33dd16d-a67f-4468-945b-1d423ac680ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_ec27ef21-9e59-4286-9b33-624b5589d797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b4379095-a7f0-4ecb-9cf6-a4e6f62f1ece" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_ec27ef21-9e59-4286-9b33-624b5589d797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5f8ce8d7-4f6a-4726-9bbf-a2e0b8e057ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b4379095-a7f0-4ecb-9cf6-a4e6f62f1ece" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5f8ce8d7-4f6a-4726-9bbf-a2e0b8e057ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_728957aa-6596-4990-b105-33635c978975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6313f02e-dcce-47f1-8448-a9fb5a6eb77f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_728957aa-6596-4990-b105-33635c978975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_384e1df5-4054-4798-8a18-fd75d95adff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_728957aa-6596-4990-b105-33635c978975" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_384e1df5-4054-4798-8a18-fd75d95adff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1fa99a49-bb19-4b6a-b32e-6e3d135744f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_728957aa-6596-4990-b105-33635c978975" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1fa99a49-bb19-4b6a-b32e-6e3d135744f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_520e6575-c755-4136-8f45-1f1e7e7d0095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_728957aa-6596-4990-b105-33635c978975" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_520e6575-c755-4136-8f45-1f1e7e7d0095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ea84f569-9f5d-41bc-afbc-5601b11fe659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_728957aa-6596-4990-b105-33635c978975" xlink:to="loc_us-gaap_Depreciation_ea84f569-9f5d-41bc-afbc-5601b11fe659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#BalanceSheetAccountDetailOtherAssetsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_879fec0d-4b39-42c5-9415-fc0af09af78f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositAssets_67dd2c21-53d1-4d30-9058-18ffda948cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_879fec0d-4b39-42c5-9415-fc0af09af78f" xlink:to="loc_us-gaap_DepositAssets_67dd2c21-53d1-4d30-9058-18ffda948cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantRights_0eac1871-afa6-4d22-8a1f-81e5511b1d3c" xlink:href="tars-20210630.xsd#tars_EquityWarrantRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_879fec0d-4b39-42c5-9415-fc0af09af78f" xlink:to="loc_tars_EquityWarrantRights_0eac1871-afa6-4d22-8a1f-81e5511b1d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_d41cccc5-b2e3-4b3a-8c59-edbdb80e264f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_879fec0d-4b39-42c5-9415-fc0af09af78f" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_d41cccc5-b2e3-4b3a-8c59-edbdb80e264f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_aece06f8-2800-406d-b1d8-6d64fcd0daaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_879fec0d-4b39-42c5-9415-fc0af09af78f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_aece06f8-2800-406d-b1d8-6d64fcd0daaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_561c389b-fbab-4d42-b99e-97f36f9a7658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_dbddfdc0-bb76-4e45-9a7e-e9023a6f827f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_561c389b-fbab-4d42-b99e-97f36f9a7658" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_dbddfdc0-bb76-4e45-9a7e-e9023a6f827f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b9f49db1-915d-401d-b7e6-1af502a45437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_561c389b-fbab-4d42-b99e-97f36f9a7658" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b9f49db1-915d-401d-b7e6-1af502a45437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AccruedClinicalStudiesCurrent_874d9f38-0367-4a29-963a-c2c2b9182fcb" xlink:href="tars-20210630.xsd#tars_AccruedClinicalStudiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_561c389b-fbab-4d42-b99e-97f36f9a7658" xlink:to="loc_tars_AccruedClinicalStudiesCurrent_874d9f38-0367-4a29-963a-c2c2b9182fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cae70c6e-63fa-40cd-ad9a-c0c4d236a4da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_561c389b-fbab-4d42-b99e-97f36f9a7658" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cae70c6e-63fa-40cd-ad9a-c0c4d236a4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_da21a881-de8b-4c30-bf15-24b4e17d9d56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_561c389b-fbab-4d42-b99e-97f36f9a7658" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_da21a881-de8b-4c30-bf15-24b4e17d9d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_2dbcffe5-f7e4-47a6-80cf-92d0a0cc874f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_561c389b-fbab-4d42-b99e-97f36f9a7658" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_2dbcffe5-f7e4-47a6-80cf-92d0a0cc874f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_9792dc36-be40-4e26-9420-be49ad420d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_561c389b-fbab-4d42-b99e-97f36f9a7658" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_9792dc36-be40-4e26-9420-be49ad420d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89d941d4-b3c8-48c3-92bb-ca7ed931484e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d6785518-126d-4e32-a511-b706ec174d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89d941d4-b3c8-48c3-92bb-ca7ed931484e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d6785518-126d-4e32-a511-b706ec174d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_b8239768-ddde-452b-841e-25d4a3246aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89d941d4-b3c8-48c3-92bb-ca7ed931484e" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_b8239768-ddde-452b-841e-25d4a3246aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_bb4c0c08-c6f4-4f9b-91f7-98b6bf38a112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89d941d4-b3c8-48c3-92bb-ca7ed931484e" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_bb4c0c08-c6f4-4f9b-91f7-98b6bf38a112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1ead1376-48be-425b-952c-df5d51f1a1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89d941d4-b3c8-48c3-92bb-ca7ed931484e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1ead1376-48be-425b-952c-df5d51f1a1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockholdersEquity" xlink:type="simple" xlink:href="tars-20210630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_58d28ef1-b67b-42da-851a-e2153eba6dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a3e6a4d0-9a73-418c-a866-a0f652dc8bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_58d28ef1-b67b-42da-851a-e2153eba6dfc" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a3e6a4d0-9a73-418c-a866-a0f652dc8bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="tars-20210630.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a8bb8081-7034-41f5-a9a4-c24156d60ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_dd8a2f5b-3c2a-4c32-a6ae-abe7757d894b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a8bb8081-7034-41f5-a9a4-c24156d60ba3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_dd8a2f5b-3c2a-4c32-a6ae-abe7757d894b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8f42bbaa-2b49-4f57-a7c3-fbf5759c1c77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9af2bb46-9904-4d5b-bf0b-db260caaf9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8f42bbaa-2b49-4f57-a7c3-fbf5759c1c77" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9af2bb46-9904-4d5b-bf0b-db260caaf9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5aa2cbb9-2cfe-40e4-ada5-90e7ebe19b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9af2bb46-9904-4d5b-bf0b-db260caaf9f3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5aa2cbb9-2cfe-40e4-ada5-90e7ebe19b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6c7d1a96-6ac4-4a12-b878-8ed33becafa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5aa2cbb9-2cfe-40e4-ada5-90e7ebe19b95" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6c7d1a96-6ac4-4a12-b878-8ed33becafa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_4c5b2aa2-d33a-4e9b-8dd6-c0e741691c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6c7d1a96-6ac4-4a12-b878-8ed33becafa3" xlink:to="loc_us-gaap_IPOMember_4c5b2aa2-d33a-4e9b-8dd6-c0e741691c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_231dfe03-93a6-400c-9299-5f26b728587c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9af2bb46-9904-4d5b-bf0b-db260caaf9f3" xlink:to="loc_us-gaap_ClassOfStockLineItems_231dfe03-93a6-400c-9299-5f26b728587c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4d3f2b6c-93db-4c7d-b327-e3231f1a0d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_231dfe03-93a6-400c-9299-5f26b728587c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4d3f2b6c-93db-4c7d-b327-e3231f1a0d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_4fe68822-9c2a-4388-a94c-8afd3d23fb65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_231dfe03-93a6-400c-9299-5f26b728587c" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_4fe68822-9c2a-4388-a94c-8afd3d23fb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockNumberOfVotes_598cab13-d52d-4498-ba8b-0f79fac3f6f9" xlink:href="tars-20210630.xsd#tars_CommonStockNumberOfVotes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_231dfe03-93a6-400c-9299-5f26b728587c" xlink:to="loc_tars_CommonStockNumberOfVotes_598cab13-d52d-4498-ba8b-0f79fac3f6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_28a5d070-ea6f-4db4-a43a-63c441380e63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_231dfe03-93a6-400c-9299-5f26b728587c" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_28a5d070-ea6f-4db4-a43a-63c441380e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b490dae2-0f91-4d9d-8a9d-c3f500ee420f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_231dfe03-93a6-400c-9299-5f26b728587c" xlink:to="loc_us-gaap_CommonStockSharesIssued_b490dae2-0f91-4d9d-8a9d-c3f500ee420f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_11d4fd96-96cf-4d1f-b5c0-3d372992a704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_231dfe03-93a6-400c-9299-5f26b728587c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_11d4fd96-96cf-4d1f-b5c0-3d372992a704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#StockholdersEquitySharesReservedforIssuanceDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_320441cc-a8d2-42a3-a779-2c58eccda53a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_cb3c5300-a4f4-4b98-9f3c-49d5f1592757" xlink:href="tars-20210630.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_320441cc-a8d2-42a3-a779-2c58eccda53a" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_cb3c5300-a4f4-4b98-9f3c-49d5f1592757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant_95942cb8-cb63-40bb-9040-208b362ba408" xlink:href="tars-20210630.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_320441cc-a8d2-42a3-a779-2c58eccda53a" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant_95942cb8-cb63-40bb-9040-208b362ba408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_64f31417-4c67-45c0-9470-9ff6f11a1152" xlink:href="tars-20210630.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_320441cc-a8d2-42a3-a779-2c58eccda53a" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_64f31417-4c67-45c0-9470-9ff6f11a1152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_51b4f6af-0202-4862-8554-a5ef5d31221a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_320441cc-a8d2-42a3-a779-2c58eccda53a" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_51b4f6af-0202-4862-8554-a5ef5d31221a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="tars-20210630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7efa858c-92b0-4db4-8cf8-a65567c93abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c0fa7cfd-f299-4c67-895e-030a580675db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7efa858c-92b0-4db4-8cf8-a65567c93abe" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c0fa7cfd-f299-4c67-895e-030a580675db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="tars-20210630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3d9cad5b-9e78-4382-9444-fbd85518ae63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30cf7783-d4df-4d2c-bb91-ac853ab63482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3d9cad5b-9e78-4382-9444-fbd85518ae63" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30cf7783-d4df-4d2c-bb91-ac853ab63482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6f85ad2-4c24-420b-bb6a-96c090609b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a46c7771-045e-4f6a-9026-6d732a3f078c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6f85ad2-4c24-420b-bb6a-96c090609b90" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a46c7771-045e-4f6a-9026-6d732a3f078c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_becf3b4f-d69f-4b44-a5b5-4cbc1fd5a678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a46c7771-045e-4f6a-9026-6d732a3f078c" xlink:to="loc_us-gaap_PlanNameAxis_becf3b4f-d69f-4b44-a5b5-4cbc1fd5a678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0bde030d-5d05-4c47-b20c-dc2a4f8e097a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_becf3b4f-d69f-4b44-a5b5-4cbc1fd5a678" xlink:to="loc_us-gaap_PlanNameDomain_0bde030d-5d05-4c47-b20c-dc2a4f8e097a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityIncentivePlan2020Member_98cf8072-7110-45b0-ab95-b1e16582698b" xlink:href="tars-20210630.xsd#tars_EquityIncentivePlan2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0bde030d-5d05-4c47-b20c-dc2a4f8e097a" xlink:to="loc_tars_EquityIncentivePlan2020Member_98cf8072-7110-45b0-ab95-b1e16582698b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityIncentivePlan2016Member_3c2c19da-b809-4aa8-a3d4-fe96a53b2881" xlink:href="tars-20210630.xsd#tars_EquityIncentivePlan2016Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0bde030d-5d05-4c47-b20c-dc2a4f8e097a" xlink:to="loc_tars_EquityIncentivePlan2016Member_3c2c19da-b809-4aa8-a3d4-fe96a53b2881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a8aa75d4-7a91-4f80-9660-534e0553f376" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a46c7771-045e-4f6a-9026-6d732a3f078c" xlink:to="loc_srt_RangeAxis_a8aa75d4-7a91-4f80-9660-534e0553f376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_19a7544d-96e6-46e6-a007-b0d09c91f769" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a8aa75d4-7a91-4f80-9660-534e0553f376" xlink:to="loc_srt_RangeMember_19a7544d-96e6-46e6-a007-b0d09c91f769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d504cafd-567b-48c5-a175-89a8506d066f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_19a7544d-96e6-46e6-a007-b0d09c91f769" xlink:to="loc_srt_MinimumMember_d504cafd-567b-48c5-a175-89a8506d066f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_50e62025-621b-41dc-9925-f9e266119b01" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_19a7544d-96e6-46e6-a007-b0d09c91f769" xlink:to="loc_srt_MaximumMember_50e62025-621b-41dc-9925-f9e266119b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ce1a072e-3e54-47b7-8b2b-ca3b192be33d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a46c7771-045e-4f6a-9026-6d732a3f078c" xlink:to="loc_us-gaap_AwardTypeAxis_ce1a072e-3e54-47b7-8b2b-ca3b192be33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32e01d21-d8f0-4ec4-8b7e-39936c27e075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ce1a072e-3e54-47b7-8b2b-ca3b192be33d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32e01d21-d8f0-4ec4-8b7e-39936c27e075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2c9c1e8f-851f-48a4-8213-1a2bd199e6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32e01d21-d8f0-4ec4-8b7e-39936c27e075" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2c9c1e8f-851f-48a4-8213-1a2bd199e6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a46c7771-045e-4f6a-9026-6d732a3f078c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_70a14dee-0201-4185-a23a-4fd9a2a0ba62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_70a14dee-0201-4185-a23a-4fd9a2a0ba62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease_42d88617-ee02-4ed3-9e95-1bfc4204d7d0" xlink:href="tars-20210630.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease_42d88617-ee02-4ed3-9e95-1bfc4204d7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue_900b94de-945a-427b-9340-2565c963a326" xlink:href="tars-20210630.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue_900b94de-945a-427b-9340-2565c963a326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_fc3b707f-9ed8-40c2-8318-12797277277f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_fc3b707f-9ed8-40c2-8318-12797277277f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_87bca381-c512-4d99-ae38-270e2143239b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_87bca381-c512-4d99-ae38-270e2143239b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath_edd63f4f-71db-4d33-870b-b0ff0890149f" xlink:href="tars-20210630.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath_edd63f4f-71db-4d33-870b-b0ff0890149f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability_f31eed67-5206-4da1-908b-c13c1e8c35f4" xlink:href="tars-20210630.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability_f31eed67-5206-4da1-908b-c13c1e8c35f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations_7f6a731f-dca6-4764-9d0f-6052507af97b" xlink:href="tars-20210630.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations_7f6a731f-dca6-4764-9d0f-6052507af97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_4c2338dd-c55a-4d2d-be36-d427f4734493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc6beb9f-c0ac-4caa-a2fe-e92f909c3243" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_4c2338dd-c55a-4d2d-be36-d427f4734493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#StockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_829942d6-da1c-40b1-bc0e-26d1114a91d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cc0960bd-02ae-41d6-929e-91acbbbbe7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_829942d6-da1c-40b1-bc0e-26d1114a91d4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cc0960bd-02ae-41d6-929e-91acbbbbe7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a6a345f9-5b0e-4fd7-b429-664b7ab35974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cc0960bd-02ae-41d6-929e-91acbbbbe7e4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a6a345f9-5b0e-4fd7-b429-664b7ab35974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_391833a6-0a78-41fb-a020-c6625430d8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a6a345f9-5b0e-4fd7-b429-664b7ab35974" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_391833a6-0a78-41fb-a020-c6625430d8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f329e388-273d-4e3f-b93e-5bdd8e290532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_391833a6-0a78-41fb-a020-c6625430d8ed" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f329e388-273d-4e3f-b93e-5bdd8e290532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_60221953-2610-4ca0-a26f-6a4e302c3644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_391833a6-0a78-41fb-a020-c6625430d8ed" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_60221953-2610-4ca0-a26f-6a4e302c3644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_57bffcf3-6235-404d-b3b2-e92c2b17c906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cc0960bd-02ae-41d6-929e-91acbbbbe7e4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_57bffcf3-6235-404d-b3b2-e92c2b17c906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_33d24807-3ee5-4362-84f4-1becf968a48b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_57bffcf3-6235-404d-b3b2-e92c2b17c906" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_33d24807-3ee5-4362-84f4-1becf968a48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetIncomeLossPerShare" xlink:type="simple" xlink:href="tars-20210630.xsd#NetIncomeLossPerShare"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/NetIncomeLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9d24f94c-6b3f-49fd-bccc-de89bf669f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_e9f3ea8c-51ee-4389-890d-5755e61c9483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9d24f94c-6b3f-49fd-bccc-de89bf669f58" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_e9f3ea8c-51ee-4389-890d-5755e61c9483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetIncomeLossPerShareTables" xlink:type="simple" xlink:href="tars-20210630.xsd#NetIncomeLossPerShareTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/NetIncomeLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_01d4d1f3-3ac4-4a36-87ee-65f7491e6d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5c85b0cf-5068-4265-87dc-2523b4adca20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_01d4d1f3-3ac4-4a36-87ee-65f7491e6d45" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5c85b0cf-5068-4265-87dc-2523b4adca20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#NetIncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/NetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_03572a2a-210e-4803-8108-36d9088e15d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_8b87f797-4326-4889-9360-5f69a12ce870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_03572a2a-210e-4803-8108-36d9088e15d0" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_8b87f797-4326-4889-9360-5f69a12ce870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5ea511f1-d2e3-4caf-9d69-6695c6260b65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_8b87f797-4326-4889-9360-5f69a12ce870" xlink:to="loc_us-gaap_NetIncomeLoss_5ea511f1-d2e3-4caf-9d69-6695c6260b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_a5640905-0b73-4a13-aa5f-e379f4903fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_8b87f797-4326-4889-9360-5f69a12ce870" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_a5640905-0b73-4a13-aa5f-e379f4903fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5cca87b6-4f23-4768-bc86-1425bcbd5463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_8b87f797-4326-4889-9360-5f69a12ce870" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5cca87b6-4f23-4768-bc86-1425bcbd5463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_115ff731-4d2d-4e5c-90fe-cef9fdd2d1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_8b87f797-4326-4889-9360-5f69a12ce870" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_115ff731-4d2d-4e5c-90fe-cef9fdd2d1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_37cc1b17-b384-486e-a8bb-8f484142955c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_8b87f797-4326-4889-9360-5f69a12ce870" xlink:to="loc_us-gaap_EarningsPerShareBasic_37cc1b17-b384-486e-a8bb-8f484142955c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_87c3599a-0b4d-4dec-9101-ae8dd6948e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_03572a2a-210e-4803-8108-36d9088e15d0" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_87c3599a-0b4d-4dec-9101-ae8dd6948e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_efeb742f-6e65-4603-a27f-aa911c61bc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_87c3599a-0b4d-4dec-9101-ae8dd6948e89" xlink:to="loc_us-gaap_NetIncomeLoss_efeb742f-6e65-4603-a27f-aa911c61bc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_340d9c85-64c0-4f4c-950b-b96c53e1e1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_87c3599a-0b4d-4dec-9101-ae8dd6948e89" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_340d9c85-64c0-4f4c-950b-b96c53e1e1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_525ecf0b-3665-4a2e-a542-1b07c116d635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_87c3599a-0b4d-4dec-9101-ae8dd6948e89" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_525ecf0b-3665-4a2e-a542-1b07c116d635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9a72489c-5c34-4113-a73d-675226f8b58c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_87c3599a-0b4d-4dec-9101-ae8dd6948e89" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9a72489c-5c34-4113-a73d-675226f8b58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_e83a5138-d7b2-4ee1-8ed5-ab2a8afd11e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_87c3599a-0b4d-4dec-9101-ae8dd6948e89" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_e83a5138-d7b2-4ee1-8ed5-ab2a8afd11e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ea82fc44-9f13-4a83-bebc-949d5c9e3234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_e83a5138-d7b2-4ee1-8ed5-ab2a8afd11e9" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ea82fc44-9f13-4a83-bebc-949d5c9e3234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_98c6f90c-1ecf-41eb-acc9-c7117ec2034b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_87c3599a-0b4d-4dec-9101-ae8dd6948e89" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_98c6f90c-1ecf-41eb-acc9-c7117ec2034b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_169971d7-a0e3-40cc-93d4-5499dc690b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_87c3599a-0b4d-4dec-9101-ae8dd6948e89" xlink:to="loc_us-gaap_EarningsPerShareDiluted_169971d7-a0e3-40cc-93d4-5499dc690b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#NetIncomeLossPerShareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_49f49d77-5b71-4021-9304-882c48b582a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f1216655-2be2-4bda-8330-a10ba8e96c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_49f49d77-5b71-4021-9304-882c48b582a5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f1216655-2be2-4bda-8330-a10ba8e96c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_566e78a6-2cea-4a32-a71f-14ede99ab6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f1216655-2be2-4bda-8330-a10ba8e96c15" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_566e78a6-2cea-4a32-a71f-14ede99ab6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72a9baf8-2afb-4a08-9da9-a93cd64001ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_566e78a6-2cea-4a32-a71f-14ede99ab6cf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72a9baf8-2afb-4a08-9da9-a93cd64001ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_18b831b2-12e0-4423-a4ef-fe26bcfc39b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72a9baf8-2afb-4a08-9da9-a93cd64001ef" xlink:to="loc_us-gaap_EmployeeStockOptionMember_18b831b2-12e0-4423-a4ef-fe26bcfc39b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_379c95b7-2267-4a13-947b-9912e9963e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72a9baf8-2afb-4a08-9da9-a93cd64001ef" xlink:to="loc_us-gaap_PreferredStockMember_379c95b7-2267-4a13-947b-9912e9963e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_e9d9fe9f-d76f-4d61-8cf7-e80c0de1191d" xlink:href="tars-20210630.xsd#tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72a9baf8-2afb-4a08-9da9-a93cd64001ef" xlink:to="loc_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_e9d9fe9f-d76f-4d61-8cf7-e80c0de1191d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_148deceb-b427-437e-9ebc-a72b72c30ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f1216655-2be2-4bda-8330-a10ba8e96c15" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_148deceb-b427-437e-9ebc-a72b72c30ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_73579ca4-5f55-4a45-a212-04e469f7dd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_148deceb-b427-437e-9ebc-a72b72c30ec9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_73579ca4-5f55-4a45-a212-04e469f7dd6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="tars-20210630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_615d4fb0-4f31-4656-8bf3-9a05136ff536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_7d83e44e-92b7-42a7-ac27-d8b4d1c2ff96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_615d4fb0-4f31-4656-8bf3-9a05136ff536" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_7d83e44e-92b7-42a7-ac27-d8b4d1c2ff96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="tars-20210630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_65caff33-24e9-481a-bd38-4606c20ccd86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_74569182-30e4-4181-b852-ba17b6c3f8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_65caff33-24e9-481a-bd38-4606c20ccd86" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_74569182-30e4-4181-b852-ba17b6c3f8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_5462368d-456a-429b-9908-57ca78df5833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_65caff33-24e9-481a-bd38-4606c20ccd86" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_5462368d-456a-429b-9908-57ca78df5833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_53bad39c-994f-4205-ac8c-d70274cfec7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3d8ce36a-2870-40b4-869a-12c341563a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_53bad39c-994f-4205-ac8c-d70274cfec7c" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3d8ce36a-2870-40b4-869a-12c341563a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2cd8eb67-f9cd-4758-86ef-5fe4eee68a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3d8ce36a-2870-40b4-869a-12c341563a39" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2cd8eb67-f9cd-4758-86ef-5fe4eee68a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_43932c6f-7f17-4ce5-878c-6c642c21ff16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2cd8eb67-f9cd-4758-86ef-5fe4eee68a1a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_43932c6f-7f17-4ce5-878c-6c642c21ff16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ce6639dd-a479-476b-ace8-84ef1f21a0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_43932c6f-7f17-4ce5-878c-6c642c21ff16" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ce6639dd-a479-476b-ace8-84ef1f21a0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9032972d-9ece-46bf-8f17-a8cbd0ab5aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_43932c6f-7f17-4ce5-878c-6c642c21ff16" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9032972d-9ece-46bf-8f17-a8cbd0ab5aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_232b57bc-ea51-4f5b-87b6-1b963362ec8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_43932c6f-7f17-4ce5-878c-6c642c21ff16" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_232b57bc-ea51-4f5b-87b6-1b963362ec8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_737dafd3-91c3-49ba-bbc6-afa656bf134e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3d8ce36a-2870-40b4-869a-12c341563a39" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_737dafd3-91c3-49ba-bbc6-afa656bf134e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e9746c52-026f-4050-816f-ff0e136b8787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_737dafd3-91c3-49ba-bbc6-afa656bf134e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e9746c52-026f-4050-816f-ff0e136b8787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2a357e71-c0a1-46a6-89c3-b55a138fb787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e9746c52-026f-4050-816f-ff0e136b8787" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2a357e71-c0a1-46a6-89c3-b55a138fb787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f5c137da-a233-43c5-a6e4-7f080a3942bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3d8ce36a-2870-40b4-869a-12c341563a39" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f5c137da-a233-43c5-a6e4-7f080a3942bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4bd7bea3-9f07-4d4c-b5ab-16d33c02e799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f5c137da-a233-43c5-a6e4-7f080a3942bb" xlink:to="loc_us-gaap_AssetsAbstract_4bd7bea3-9f07-4d4c-b5ab-16d33c02e799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0f4d8126-2009-41a7-8fd5-4ff2d3b5ae74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4bd7bea3-9f07-4d4c-b5ab-16d33c02e799" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0f4d8126-2009-41a7-8fd5-4ff2d3b5ae74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantsFairValueDisclosure_a413c10e-5659-4132-9d23-47ab96bff1ff" xlink:href="tars-20210630.xsd#tars_EquityWarrantsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4bd7bea3-9f07-4d4c-b5ab-16d33c02e799" xlink:to="loc_tars_EquityWarrantsFairValueDisclosure_a413c10e-5659-4132-9d23-47ab96bff1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6e753bb2-037d-4ac7-a584-4fa606cbd63f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4bd7bea3-9f07-4d4c-b5ab-16d33c02e799" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6e753bb2-037d-4ac7-a584-4fa606cbd63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ded4cca0-915e-4667-a263-327072f79e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4df4c9a2-fc54-4bb4-b21f-a71a52616183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ded4cca0-915e-4667-a263-327072f79e88" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4df4c9a2-fc54-4bb4-b21f-a71a52616183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1a0d8393-7b03-4bd4-be04-42acf9d0da7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4df4c9a2-fc54-4bb4-b21f-a71a52616183" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1a0d8393-7b03-4bd4-be04-42acf9d0da7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_07f651b7-c652-4bb5-8ec3-8bfb3730d345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1a0d8393-7b03-4bd4-be04-42acf9d0da7e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_07f651b7-c652-4bb5-8ec3-8bfb3730d345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_1de88bfa-f003-4d47-a7f9-b5d79b93127f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07f651b7-c652-4bb5-8ec3-8bfb3730d345" xlink:to="loc_us-gaap_SalesMember_1de88bfa-f003-4d47-a7f9-b5d79b93127f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseMember_7348d45e-9fc7-4f07-b0f5-2c5a8e90adf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07f651b7-c652-4bb5-8ec3-8bfb3730d345" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseMember_7348d45e-9fc7-4f07-b0f5-2c5a8e90adf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2364e8ae-3d3a-4217-a06e-2d54a9a3a06f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4df4c9a2-fc54-4bb4-b21f-a71a52616183" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2364e8ae-3d3a-4217-a06e-2d54a9a3a06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6dbbbdb2-d09e-4cc8-ba1d-7344b971978d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2364e8ae-3d3a-4217-a06e-2d54a9a3a06f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6dbbbdb2-d09e-4cc8-ba1d-7344b971978d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_414d2d0a-f901-43c0-829f-df0d403b1183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6dbbbdb2-d09e-4cc8-ba1d-7344b971978d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_414d2d0a-f901-43c0-829f-df0d403b1183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_8801e27d-e5f4-485f-a5ac-02370e8df3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6dbbbdb2-d09e-4cc8-ba1d-7344b971978d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_8801e27d-e5f4-485f-a5ac-02370e8df3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5ccdd4c8-52f3-49f5-a4ee-800dc4cf9cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6dbbbdb2-d09e-4cc8-ba1d-7344b971978d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5ccdd4c8-52f3-49f5-a4ee-800dc4cf9cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ab9925aa-b891-48b7-9f7c-67558b733c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6dbbbdb2-d09e-4cc8-ba1d-7344b971978d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ab9925aa-b891-48b7-9f7c-67558b733c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingencies" xlink:type="simple" xlink:href="tars-20210630.xsd#CommitmentContingencies"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_20b70408-385b-45c0-9a4f-5372956a855d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e3649b4c-7a0a-41b4-ae53-cc0b0b226e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_20b70408-385b-45c0-9a4f-5372956a855d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e3649b4c-7a0a-41b4-ae53-cc0b0b226e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesTables" xlink:type="simple" xlink:href="tars-20210630.xsd#CommitmentContingenciesTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_47adca27-a489-4520-9d71-2b9b86772863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_12f47645-debc-4304-b287-bb72795f0299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_47adca27-a489-4520-9d71-2b9b86772863" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_12f47645-debc-4304-b287-bb72795f0299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_dc4032ff-71ee-449f-8926-4a774213c8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_47adca27-a489-4520-9d71-2b9b86772863" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_dc4032ff-71ee-449f-8926-4a774213c8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#CommitmentContingenciesFacilityLeasesDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_daf281fd-a5d3-48b9-831b-045fdd82fd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_c79221e0-14d3-417a-89e2-2c5032f97e59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_daf281fd-a5d3-48b9-831b-045fdd82fd2a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_c79221e0-14d3-417a-89e2-2c5032f97e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_9f5fcdd6-bfe2-4984-bd7d-5c86202906c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c79221e0-14d3-417a-89e2-2c5032f97e59" xlink:to="loc_us-gaap_LeaseContractualTermAxis_9f5fcdd6-bfe2-4984-bd7d-5c86202906c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_32921e5b-78d3-41b3-83d3-f4a2f6f66818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_9f5fcdd6-bfe2-4984-bd7d-5c86202906c3" xlink:to="loc_us-gaap_LeaseContractualTermDomain_32921e5b-78d3-41b3-83d3-f4a2f6f66818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_IrvineOfficeAndFacilitiesLeaseMember_ceea4836-d226-449d-aff9-3f759c96bfbe" xlink:href="tars-20210630.xsd#tars_IrvineOfficeAndFacilitiesLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_32921e5b-78d3-41b3-83d3-f4a2f6f66818" xlink:to="loc_tars_IrvineOfficeAndFacilitiesLeaseMember_ceea4836-d226-449d-aff9-3f759c96bfbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_OtherFacilityLeasesMember_6c9d331d-5cae-4c19-b368-870b5785577d" xlink:href="tars-20210630.xsd#tars_OtherFacilityLeasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_32921e5b-78d3-41b3-83d3-f4a2f6f66818" xlink:to="loc_tars_OtherFacilityLeasesMember_6c9d331d-5cae-4c19-b368-870b5785577d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c79221e0-14d3-417a-89e2-2c5032f97e59" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LesseeOperatingLeaseNumberOfLeaseContracts_b43766a2-a482-4028-9916-c9cb874a8e0c" xlink:href="tars-20210630.xsd#tars_LesseeOperatingLeaseNumberOfLeaseContracts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:to="loc_tars_LesseeOperatingLeaseNumberOfLeaseContracts_b43766a2-a482-4028-9916-c9cb874a8e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_8d182423-3da9-43d6-b2b8-a7f5f1753d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_8d182423-3da9-43d6-b2b8-a7f5f1753d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_34354c06-501d-4f99-9020-f8c5f63fbf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_34354c06-501d-4f99-9020-f8c5f63fbf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LesseeOperatingLeaseNumberOfContractsNotImpaired_d39c14de-e317-4b6c-ac6d-06fc30b9864a" xlink:href="tars-20210630.xsd#tars_LesseeOperatingLeaseNumberOfContractsNotImpaired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:to="loc_tars_LesseeOperatingLeaseNumberOfContractsNotImpaired_d39c14de-e317-4b6c-ac6d-06fc30b9864a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6e353261-2198-439b-a425-2bef5a0bb241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6e353261-2198-439b-a425-2bef5a0bb241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_94cc798b-b958-43cc-9aaf-30f720818e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_94cc798b-b958-43cc-9aaf-30f720818e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5492a5db-952e-45b9-9f53-c5d30feec50b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5492a5db-952e-45b9-9f53-c5d30feec50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d81e6fd4-46e3-40e1-8966-cbe9fabd31a7" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c98165db-c068-4dfb-be4e-9d3eff218b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c98165db-c068-4dfb-be4e-9d3eff218b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3e39ed9e-594b-4970-b5ee-944a137c34bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3e39ed9e-594b-4970-b5ee-944a137c34bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4093a844-277f-415f-8e2f-3c930acfe137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4093a844-277f-415f-8e2f-3c930acfe137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9249f879-f983-48dc-ba36-95c41cf624e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9249f879-f983-48dc-ba36-95c41cf624e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_16f7f55e-af5d-483e-a1af-fb8dbd475d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_16f7f55e-af5d-483e-a1af-fb8dbd475d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e3706e23-de06-46e9-9d92-5544def0c16a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e3706e23-de06-46e9-9d92-5544def0c16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_964b90b5-799b-407d-9606-eb0e8eae560d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_964b90b5-799b-407d-9606-eb0e8eae560d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_38427fcd-654d-43e3-a9f3-5c0d5b16e9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b9ae708b-b5b2-478a-bb08-6ca961adb483" xlink:to="loc_us-gaap_OperatingLeaseLiability_38427fcd-654d-43e3-a9f3-5c0d5b16e9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails_1" xlink:type="simple" xlink:href="tars-20210630.xsd#CommitmentContingenciesFacilityLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#CommitmentContingenciesLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d07b93df-5206-4b51-8759-71917f1833fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_966e1b73-a890-4040-ab98-e75946ce27fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d07b93df-5206-4b51-8759-71917f1833fe" xlink:to="loc_us-gaap_OperatingLeaseCost_966e1b73-a890-4040-ab98-e75946ce27fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_9e8a782c-da5c-41ad-9011-583213b27909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d07b93df-5206-4b51-8759-71917f1833fe" xlink:to="loc_us-gaap_VariableLeaseCost_9e8a782c-da5c-41ad-9011-583213b27909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_c56c09e1-61f1-4f48-a839-676029d43e28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d07b93df-5206-4b51-8759-71917f1833fe" xlink:to="loc_us-gaap_ShortTermLeaseCost_c56c09e1-61f1-4f48-a839-676029d43e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_fdebaa1b-b8b9-45dd-a07e-1b8210f7d51c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d07b93df-5206-4b51-8759-71917f1833fe" xlink:to="loc_us-gaap_LeaseCost_fdebaa1b-b8b9-45dd-a07e-1b8210f7d51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#CommitmentContingenciesInLicenseAgreementforLotilanerDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9254c021-5673-4482-9b7c-fa2f547b9a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9251039-4b63-464c-848d-755c08ba7df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9254c021-5673-4482-9b7c-fa2f547b9a7d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9251039-4b63-464c-848d-755c08ba7df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4f95e526-a684-4ba5-adde-e6cff083f106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9251039-4b63-464c-848d-755c08ba7df8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4f95e526-a684-4ba5-adde-e6cff083f106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6127a0e-a516-4bb6-b193-f96a7d8219f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f95e526-a684-4ba5-adde-e6cff083f106" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6127a0e-a516-4bb6-b193-f96a7d8219f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_f6be7b42-0bc5-4043-b7b1-c7dc102e7bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6127a0e-a516-4bb6-b193-f96a7d8219f5" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_f6be7b42-0bc5-4043-b7b1-c7dc102e7bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1c72b2e5-7da9-44f2-a84d-8199b8d8da50" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9251039-4b63-464c-848d-755c08ba7df8" xlink:to="loc_srt_ProductOrServiceAxis_1c72b2e5-7da9-44f2-a84d-8199b8d8da50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bf07c0dd-00f5-4815-aa9f-5a7ba878f5c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1c72b2e5-7da9-44f2-a84d-8199b8d8da50" xlink:to="loc_srt_ProductsAndServicesDomain_bf07c0dd-00f5-4815-aa9f-5a7ba878f5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClinicalMilestonesMember_9249d066-1649-48c7-a73d-de17d779e641" xlink:href="tars-20210630.xsd#tars_ClinicalMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bf07c0dd-00f5-4815-aa9f-5a7ba878f5c2" xlink:to="loc_tars_ClinicalMilestonesMember_9249d066-1649-48c7-a73d-de17d779e641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommercialAndSalesMilestonesMember_e0911d7d-d41f-49d8-b7d4-e14d2736b697" xlink:href="tars-20210630.xsd#tars_CommercialAndSalesMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bf07c0dd-00f5-4815-aa9f-5a7ba878f5c2" xlink:to="loc_tars_CommercialAndSalesMilestonesMember_e0911d7d-d41f-49d8-b7d4-e14d2736b697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b780dcbc-eb08-4f0b-a2f8-730b8ef58e43" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9251039-4b63-464c-848d-755c08ba7df8" xlink:to="loc_srt_CounterpartyNameAxis_b780dcbc-eb08-4f0b-a2f8-730b8ef58e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc019594-60a7-468c-821b-462980c890e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b780dcbc-eb08-4f0b-a2f8-730b8ef58e43" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc019594-60a7-468c-821b-462980c890e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember_1a76a1ee-3f7e-48ca-ad49-75a2dbfc5dd2" xlink:href="tars-20210630.xsd#tars_LianBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc019594-60a7-468c-821b-462980c890e8" xlink:to="loc_tars_LianBioMember_1a76a1ee-3f7e-48ca-ad49-75a2dbfc5dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ElancoMember_f4c7134f-9a92-43b7-a609-8f846d569f96" xlink:href="tars-20210630.xsd#tars_ElancoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc019594-60a7-468c-821b-462980c890e8" xlink:to="loc_tars_ElancoMember_f4c7134f-9a92-43b7-a609-8f846d569f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9251039-4b63-464c-848d-755c08ba7df8" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4cc489bb-c337-4009-acb8-a5fa8a46184e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4cc489bb-c337-4009-acb8-a5fa8a46184e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment_88fc0606-e314-4d5d-8fd1-5047a40b9b07" xlink:href="tars-20210630.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:to="loc_tars_CollaborativeArrangementMaximumMilestonePayment_88fc0606-e314-4d5d-8fd1-5047a40b9b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_UpfrontPayment_1432254a-36c4-4dac-b49e-2f2e92146692" xlink:href="tars-20210630.xsd#tars_UpfrontPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:to="loc_tars_UpfrontPayment_1432254a-36c4-4dac-b49e-2f2e92146692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_737cbbcf-a13d-4003-9291-4e0b9fed542a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_737cbbcf-a13d-4003-9291-4e0b9fed542a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_3b0d9f9c-6495-4c54-9650-1c9c5c798003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_3b0d9f9c-6495-4c54-9650-1c9c5c798003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_f99999b9-3ce7-4c9c-8651-b58e8039ea4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:to="loc_us-gaap_SharePrice_f99999b9-3ce7-4c9c-8651-b58e8039ea4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_1af6af89-93ec-475b-89a9-57c8be3568b9" xlink:href="tars-20210630.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:to="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_1af6af89-93ec-475b-89a9-57c8be3568b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_3c69b062-cfd8-4ccd-b399-8e86ca6ad3dd" xlink:href="tars-20210630.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:to="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_3c69b062-cfd8-4ccd-b399-8e86ca6ad3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_1b697ee9-3a93-46a6-b498-4b56c5aa872b" xlink:href="tars-20210630.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7d27d85-958e-4ad9-b1a0-4eb6de93d8b0" xlink:to="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_1b697ee9-3a93-46a6-b498-4b56c5aa872b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#CommitmentContingenciesEmploymentArrangementsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_550ff366-319f-4608-a40c-29bbde66b82d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_2f58d877-38f6-43e7-9ce5-cd73ef8f809d" xlink:href="tars-20210630.xsd#tars_NumberOfEmploymentArrangementsWithExecutiveOfficers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_550ff366-319f-4608-a40c-29bbde66b82d" xlink:to="loc_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_2f58d877-38f6-43e7-9ce5-cd73ef8f809d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/OutLicenseAgreement" xlink:type="simple" xlink:href="tars-20210630.xsd#OutLicenseAgreement"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/OutLicenseAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88905bb1-6c00-4b1c-90d8-27f7d24b5d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e9621a32-68e4-4139-b2a8-0605e5b955a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88905bb1-6c00-4b1c-90d8-27f7d24b5d4e" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e9621a32-68e4-4139-b2a8-0605e5b955a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/OutLicenseAgreementDetails" xlink:type="simple" xlink:href="tars-20210630.xsd#OutLicenseAgreementDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/OutLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4387afdd-01fa-4259-beff-e2f3d664838d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c04f4e1c-9e3b-4840-8bdc-4cfa1602772b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4387afdd-01fa-4259-beff-e2f3d664838d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c04f4e1c-9e3b-4840-8bdc-4cfa1602772b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1062e27e-2cad-4bb7-bb12-567b8910c2cb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c04f4e1c-9e3b-4840-8bdc-4cfa1602772b" xlink:to="loc_srt_CounterpartyNameAxis_1062e27e-2cad-4bb7-bb12-567b8910c2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ccf828fc-e641-4ee1-ae24-7f72f0a02ce0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1062e27e-2cad-4bb7-bb12-567b8910c2cb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ccf828fc-e641-4ee1-ae24-7f72f0a02ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember_6ab6bdff-1e9d-486a-95e2-bc9a0cec6cbd" xlink:href="tars-20210630.xsd#tars_LianBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ccf828fc-e641-4ee1-ae24-7f72f0a02ce0" xlink:to="loc_tars_LianBioMember_6ab6bdff-1e9d-486a-95e2-bc9a0cec6cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3cd0f7e8-0516-4641-b5f5-9fd906d7628b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c04f4e1c-9e3b-4840-8bdc-4cfa1602772b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3cd0f7e8-0516-4641-b5f5-9fd906d7628b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f6dc20d-b4e9-4ea6-a694-b3354c60c532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3cd0f7e8-0516-4641-b5f5-9fd906d7628b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f6dc20d-b4e9-4ea6-a694-b3354c60c532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_014c1d86-6f62-4016-9325-4687c166eb72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f6dc20d-b4e9-4ea6-a694-b3354c60c532" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_014c1d86-6f62-4016-9325-4687c166eb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_67691bd6-995f-4ef8-ae79-a157040445bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c04f4e1c-9e3b-4840-8bdc-4cfa1602772b" xlink:to="loc_srt_ProductOrServiceAxis_67691bd6-995f-4ef8-ae79-a157040445bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_269bc122-e319-46fa-bba9-a4d54cb2cda8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_67691bd6-995f-4ef8-ae79-a157040445bb" xlink:to="loc_srt_ProductsAndServicesDomain_269bc122-e319-46fa-bba9-a4d54cb2cda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DevelopmentAndRegulatoryMilestoneMember_eb137e9b-293a-4798-a575-648e75a63c36" xlink:href="tars-20210630.xsd#tars_DevelopmentAndRegulatoryMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_269bc122-e319-46fa-bba9-a4d54cb2cda8" xlink:to="loc_tars_DevelopmentAndRegulatoryMilestoneMember_eb137e9b-293a-4798-a575-648e75a63c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_SalesMilestoneMember_57f0cfae-c3e7-45c8-a971-0d288cfe7b5e" xlink:href="tars-20210630.xsd#tars_SalesMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_269bc122-e319-46fa-bba9-a4d54cb2cda8" xlink:to="loc_tars_SalesMilestoneMember_57f0cfae-c3e7-45c8-a971-0d288cfe7b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_c688a273-300f-4724-bde0-422378ff1332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_269bc122-e319-46fa-bba9-a4d54cb2cda8" xlink:to="loc_us-gaap_LicenseAndServiceMember_c688a273-300f-4724-bde0-422378ff1332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborationMember_6334de7e-41b1-41d1-93bd-53f285d15ede" xlink:href="tars-20210630.xsd#tars_CollaborationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_269bc122-e319-46fa-bba9-a4d54cb2cda8" xlink:to="loc_tars_CollaborationMember_6334de7e-41b1-41d1-93bd-53f285d15ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_403c4696-91fb-42d2-b834-8b8d3669c9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c04f4e1c-9e3b-4840-8bdc-4cfa1602772b" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_403c4696-91fb-42d2-b834-8b8d3669c9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_UpfrontPayment_1e210490-d36e-4e52-801d-35cec39667b9" xlink:href="tars-20210630.xsd#tars_UpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_403c4696-91fb-42d2-b834-8b8d3669c9d2" xlink:to="loc_tars_UpfrontPayment_1e210490-d36e-4e52-801d-35cec39667b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment_2b1ecc1b-0b6e-4466-8334-22d2a388f8f7" xlink:href="tars-20210630.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_403c4696-91fb-42d2-b834-8b8d3669c9d2" xlink:to="loc_tars_CollaborativeArrangementMaximumMilestonePayment_2b1ecc1b-0b6e-4466-8334-22d2a388f8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMilestonePayment_a247c1c5-729b-47f7-8adf-cb1416f0de04" xlink:href="tars-20210630.xsd#tars_CollaborativeArrangementMilestonePayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_403c4696-91fb-42d2-b834-8b8d3669c9d2" xlink:to="loc_tars_CollaborativeArrangementMilestonePayment_a247c1c5-729b-47f7-8adf-cb1416f0de04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_aabb91f5-0f90-4094-acc4-2ca8f45b504a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_403c4696-91fb-42d2-b834-8b8d3669c9d2" xlink:to="loc_us-gaap_Revenues_aabb91f5-0f90-4094-acc4-2ca8f45b504a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>tars-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:tars="http://tarsusrx.com/20210630"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tars-20210630.xsd" xlink:type="simple"/>
    <context id="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id418552000374cee91d2f152ebbeefbf_I20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2021-08-01</instant>
        </period>
    </context>
    <context id="id5386c319aba4c61a7bf6efd8331dd95_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6a6d638fd8024fb489c508a2ffc1d40a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia569047a0bf44c6a9285af3f2ca01975_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia277d64b3cf54f299bea0e672deb68c6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7b407322af7f46eca61e30b4fecffe2b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i844a21cea71e4d1bae8b39773824d43d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i631be233d7544546b6561e0e68e759a9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idaa5350dda6d437da5ff9a746dca6f3b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i47131aae4502439b84e481d0cd4795aa_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib1e17b2b90194854a0c1f35b7f7a220c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6cfb8f7666f5404697abaf42468b411d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4f0a7226965f407bb1332105daf637d9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i883f70c143b9443d8fd6e696331febda_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ieb7ee0d743be4e14b1401f1d0a96ec6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i52e734a7761645e48b189cb6e2b8421e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac09cf4a066646c188469b8b5c55183e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad26ed4c0a904b1db84e266a4d16a1b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i23ecbbc22f4540cd8bcea0e396ba673e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7a28ec4e85d84692b4ca6a32628fa4be_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibc512caba35a452c8e9461069e750305_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if4ab6ac8e8814105820d3a3d650f85f6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i739e66a8b2094324ad392839b69d2eec_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i33759a7e324e4a7d9618b0aaa5838ece_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8fb433c2724c4c6e91eb08e2465af045_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i47b0c69c412247c68a44124006cf6612_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i17e969dac4d6411dbb826ee3db9998d9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6a8d4c6166724c9dba7245924538fd86_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i345e2829049d4416bf301cc23ac6a406_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id0634e483f0f4516a460bacff8b51bcc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4426dbfe40cc497ab87fc456c68f513e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5291f4b8a4e24019929680d04b243c5f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia1f9f9fed4d646e2b0a01016693eec81_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iaeccdc12ddfa46af872eef01caec5973_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i582e67cbd8fa41379c4ab2acf8ad6e1c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i94907dbf7f4947419d7e95e4a21fe043_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i18065d30bf104e29b2ef78dd078ba467_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5fb6e623368041f9a2fada37f7f956b8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib35a7e25ebbe4fc381478dbc1dc8dbd3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i54f251974ca94b0e9b65707daf81e0f4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2d8683a7d9e14fe9abbd3f6a5c86c6f6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4f0da49422cc4c05b2cba9c4406d801a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ice41973b875c464a83d520944c39c4eb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i58d0bbc40e024b4bab78c783704a7261_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1195e7340d234c54a47b573024044888_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i940347dc2e60436481e72725ac419fe5_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i211c6caec1a14d17bb9a07d1b78206cc_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i760234fe991c4dce8f6fcb5f097fe516_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if1b6177ab72f41b8a0277863efcf4f48_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic6dea8e6a4a44ea8b8d16ccb73c60507_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iff82cd871b884faca9901b82ef49823f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icc3a3e1730b5474fb6d19a4e8ace2be6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib5b15cc9e2f848be9dcc3c45f2dcb249_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id44cd453c94c48e99a7b9568be7f73e7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i37397987845b4ff0830e35dfd25588e8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id299c065b2574582a3d3a576ee8241d8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iefff22de6102436b99e849ce51fd5afa_D20201020-20201020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-20</startDate>
            <endDate>2020-10-20</endDate>
        </period>
    </context>
    <context id="i92fe8dadc41449e49b3e9e72a278675a_I20201020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-20</instant>
        </period>
    </context>
    <context id="ia81ce0ad42d6478f8526933a9dce6e9d_D20201020-20201020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-20</startDate>
            <endDate>2020-10-20</endDate>
        </period>
    </context>
    <context id="i63a91755fb3d4006a2cc404a6ded9de0_D20201008-20201008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2020-10-08</startDate>
            <endDate>2020-10-08</endDate>
        </period>
    </context>
    <context id="i366691130c6c4705a075c2827729e560_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0c14c67cea444f0bb19eaae7c5445028_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i652b87a7987044cca7f42704ba156268_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic9b8f6a5a48541248c73d37edf6dcbae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ad7dbb20ff542cab6548bbf1e554538_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifac36b8ba5a54e45b43ad3707581ea5e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia344278fd11e4e599d06a16dbef3dac0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id9254bbc4390429eadabae632a1ee8ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4fa02c7ace144c81a2fd09a81a1d827c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i160de614ede245e3b4a8318dd5566a1f_I20201020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-20</instant>
        </period>
    </context>
    <context id="i4417090679e84025a7090d9e6076ba21_I20201020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-20</instant>
        </period>
    </context>
    <context id="ide340ac61efb43b08434911f4db98e68_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i70a7676a97b848b1a1f7a3665d148983_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iae02a45997884de49225d614d0b8bfcf_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia1441e738b9045918e9a7e31197dd133_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id52f2032269a4f819d15bd4d1e161a3b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia382e48d34b4428fafebec87724739c8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i09be892cb78f4a5492f5791c5d513c0a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i54c21ad7a9fe43c996fb0628c1fd4ac4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie004d19f0fd443d5b88f07a7468ee270_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idaa289cd736c437987015fee0950c75c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i42649f1122f8480785c73d82be5bd8dc_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i52aedec7a8084e91bca615af7ebec95a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icea321863db444169b622b85850d6e55_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i00691ca440da494bb30506de043894c3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib790f0e6092341f4a52bec6af062bad6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4bb4eaa3ec8e4dea84b9f3711947b2e3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i41b874cb3c6a4ec08fed9386a1952c2d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i09d03f0a6dbb451781fd862327cdf06f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i676991ec719542d787676a12566ca054_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia30cf1b452db4f2ab51f825c5ca653f5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEarlyExercisedOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i219f4b1f55974121826108795989b54f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEarlyExercisedOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iddbd54b520554e4eba813e5be9dfdf7d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i09a13b7525134e7abe18f464f8248af4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i53e1600dba1b4b808a42c009c3b3eaa9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1923bd29bb5b417abd997b0aed3bc467_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia46c6f317af64f7caba90357c4e57a2d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i62e01287e81647ce9087b8b1ff3d25cf_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i220d03846323467db8c56663c9a2e8df_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i229e0511be204ad18d91926584e23767_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6a8425d752d4893941d5870ecfeb307_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8de5698c138449598b8e67a58294917_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if7356e8595ea47819751082d1cbcd009_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i739167d612a94c119439e7d8a3bb2b98_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id7653af8a6494075bf51541661c26fca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3dd90741d4ee44c0912e3f9f2224b6b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i531e6f9904f341b0bf1f8a0e802a62ba_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iabd2ce550eaa434ea84c33a084eae37b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:NonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icb3da3b8c1a44b60becc387206f9893f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tars:IrvineOfficeAndFacilitiesLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie05ece3c0fcc4ccaa63406a8de30a51b_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="ie13dc8d045254f7482573f832793430f_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1452c0961726458e8ba94815bf62b628_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tars:OtherFacilityLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if2b5fae2eaf5463c9ec06e5004104176_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i4f5e022e1a4a4c389fd70f2fdd2953e1_D20190101-20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="i120ab40354ce4e18abe9a05184afca4c_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i93cd1b65dc5e40239017d30da180b216_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0d2fb7b171a54a6d88b68e421934e6d8_I20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="iad5ec97fc35d4af183d9972de8c93b10_I20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CommercialAndSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="i70b499fd960e46b6927230aed1207cbd_D20210401-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="ie07d05df956f4d13b7387802ceea7fc8_D20210401-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="id78fdaf99d664fb88506c79ba98fab86_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i984e3a65060c4cfeb572fc37ad5c4a4b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1af047204199476fbf9fa4a0c7a282ea_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CommercialAndSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i82afa114a25e4157b2a2b9dd666cfc9c_D20200903-20200903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-03</startDate>
            <endDate>2020-09-03</endDate>
        </period>
    </context>
    <context id="i0574c418228c4e3ab5c608032507de3f_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i99377563ab2d44c1b8761203fb868e37_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="ib7f0a54579764e34bd42dd790ba99ef4_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i16f2fabfc6b747e5837e0174609fcc2b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iaa0fee81cd004ce9a21528b56b335914_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie2e854be994f41e6972a64d241a91f47_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:SalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib4ad4f4b71ae44b283fcc4fb9a913a39_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id305f2fec3554db090e0b6fe23e91f04_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i597fcedd8e7a4ac5ad1d8f9599d89d31_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6cb967d1c1e54bef8b85105752dc7964_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>tars:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="vote">
        <measure>tars:vote</measure>
    </unit>
    <unit id="contract">
        <measure>tars:contract</measure>
    </unit>
    <unit id="arrangement">
        <measure>tars:arrangement</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80L2ZyYWc6Mjc4ZjIwYjU4ZDJhNDZiZmIwNjE5MDRmYTJkZmI0MzYvdGFibGU6YWVkOWUyMzg3OTUyNDQwNjg0ZTcwNGI3MTRiYTk4NTQvdGFibGVyYW5nZTphZWQ5ZTIzODc5NTI0NDA2ODRlNzA0YjcxNGJhOTg1NF8yLTEtMS0xLTA_84d11653-d924-4d1a-ac32-795f6a5d946c">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80L2ZyYWc6Mjc4ZjIwYjU4ZDJhNDZiZmIwNjE5MDRmYTJkZmI0MzYvdGFibGU6YWVkOWUyMzg3OTUyNDQwNjg0ZTcwNGI3MTRiYTk4NTQvdGFibGVyYW5nZTphZWQ5ZTIzODc5NTI0NDA2ODRlNzA0YjcxNGJhOTg1NF8zLTEtMS0xLTA_37178177-d779-4341-833c-42969a8dadb5">0001819790</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80L2ZyYWc6Mjc4ZjIwYjU4ZDJhNDZiZmIwNjE5MDRmYTJkZmI0MzYvdGFibGU6YWVkOWUyMzg3OTUyNDQwNjg0ZTcwNGI3MTRiYTk4NTQvdGFibGVyYW5nZTphZWQ5ZTIzODc5NTI0NDA2ODRlNzA0YjcxNGJhOTg1NF80LTEtMS0xLTA_f48c5241-710b-436e-8fae-f2359b47ee2f">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80L2ZyYWc6Mjc4ZjIwYjU4ZDJhNDZiZmIwNjE5MDRmYTJkZmI0MzYvdGFibGU6YWVkOWUyMzg3OTUyNDQwNjg0ZTcwNGI3MTRiYTk4NTQvdGFibGVyYW5nZTphZWQ5ZTIzODc5NTI0NDA2ODRlNzA0YjcxNGJhOTg1NF81LTEtMS0xLTA_cf28cb98-f47c-4753-b0c4-7c0a56cfef1e">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80L2ZyYWc6Mjc4ZjIwYjU4ZDJhNDZiZmIwNjE5MDRmYTJkZmI0MzYvdGFibGU6YWVkOWUyMzg3OTUyNDQwNjg0ZTcwNGI3MTRiYTk4NTQvdGFibGVyYW5nZTphZWQ5ZTIzODc5NTI0NDA2ODRlNzA0YjcxNGJhOTg1NF82LTEtMS0xLTA_5f241fdf-4a2a-4b26-b073-97d454a42923">Q2</dei:DocumentFiscalPeriodFocus>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i63a91755fb3d4006a2cc404a6ded9de0_D20201008-20201008"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNy9mcmFnOmMzZDRmYzhjNDYxNjRmZGY5NGFkZjZhN2M2NTEwMmZlL3RhYmxlOjE0YjRiZTM2OWUzMDRjNDBhNjc3NmZlYTU2OGNmZGIxL3RhYmxlcmFuZ2U6MTRiNGJlMzY5ZTMwNGM0MGE2Nzc2ZmVhNTY4Y2ZkYjFfMi0xLTEtMS0w_66f369b2-bdaf-4da0-bdfd-b2a996bef3d2"
      unitRef="number">0.1346</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="iae02a45997884de49225d614d0b8bfcf_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfMjM4Ng_487f5d4f-2795-4d06-a86b-a0f73cdced0d">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <dei:DocumentType
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTU2_06a445eb-0151-4cb2-803d-81790ec23f47">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6ZTNlMmE2MDMzZTgyNDUyNGE3OTY0NGRjMDM1OTkzZWQvdGFibGVyYW5nZTplM2UyYTYwMzNlODI0NTI0YTc5NjQ0ZGMwMzU5OTNlZF8wLTAtMS0xLTA_51ab11d3-401f-478c-87f5-73d27504c368">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xMjk_17c0ba77-177e-41d8-9d82-f9a3afc25bb7">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6OWM2OWUwZWUwN2VlNGZkOWFiZDQxZTcyNDVkNTk5ZGYvdGFibGVyYW5nZTo5YzY5ZTBlZTA3ZWU0ZmQ5YWJkNDFlNzI0NWQ1OTlkZl8wLTAtMS0xLTA_e4af4ebb-2bc2-4b1c-98b2-56ddfe6e0289">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTU3_ffd9a4e2-bec4-47a0-8e07-42f464b9a81c">001-39614</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTU4_46b849f2-c212-473d-b9ca-c2858a202ea6">TARSUS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6ODlmMDhmNzJhYWNlNDBlNDk1NGE0MzQ2ZGI5OWZhYTAvdGFibGVyYW5nZTo4OWYwOGY3MmFhY2U0MGU0OTU0YTQzNDZkYjk5ZmFhMF8wLTAtMS0xLTA_8b5f7623-0be6-4aae-9aaa-6e22ff64d79e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6ODlmMDhmNzJhYWNlNDBlNDk1NGE0MzQ2ZGI5OWZhYTAvdGFibGVyYW5nZTo4OWYwOGY3MmFhY2U0MGU0OTU0YTQzNDZkYjk5ZmFhMF8wLTItMS0xLTA_e55fd141-cb54-426b-a6fd-79cefd21c1ca">81-4717861</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6OGFlM2M0MGU1NmQ5NDkwNGJmMmNjYWI3NzdmYWUwMDQvdGFibGVyYW5nZTo4YWUzYzQwZTU2ZDk0OTA0YmYyY2NhYjc3N2ZhZTAwNF8wLTAtMS0xLTA_1e9b37ea-35c5-4f45-a2d3-3583777e8d63">15440 Laguna Canyon Road, Suite 160</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6OGFlM2M0MGU1NmQ5NDkwNGJmMmNjYWI3NzdmYWUwMDQvdGFibGVyYW5nZTo4YWUzYzQwZTU2ZDk0OTA0YmYyY2NhYjc3N2ZhZTAwNF8xLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGNhN2Q2NjliNGU0M2JhOGZmYzdkY2VkMGNmMGI3OV80_a50560a9-95ca-4f0f-a6e0-154acc5c3b46">Irvine</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6OGFlM2M0MGU1NmQ5NDkwNGJmMmNjYWI3NzdmYWUwMDQvdGFibGVyYW5nZTo4YWUzYzQwZTU2ZDk0OTA0YmYyY2NhYjc3N2ZhZTAwNF8xLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGNhN2Q2NjliNGU0M2JhOGZmYzdkY2VkMGNmMGI3OV84_093fef0c-de7e-4d18-a022-01285d9ba5ba">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6OGFlM2M0MGU1NmQ5NDkwNGJmMmNjYWI3NzdmYWUwMDQvdGFibGVyYW5nZTo4YWUzYzQwZTU2ZDk0OTA0YmYyY2NhYjc3N2ZhZTAwNF8xLTItMS0xLTA_9fcec914-6836-4be4-86af-5c48652ce73f">92618</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTQ5_10fa9e51-c992-4ab4-be18-c4b103281dd5">(949)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTU5_9affb116-d6ef-4aeb-ae8e-d0e5b06a4eb2">409-9820</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6MTAxMDc0NDFiMmJlNDFjOTkyNzhkOTY0MjJhYzMyZTgvdGFibGVyYW5nZToxMDEwNzQ0MWIyYmU0MWM5OTI3OGQ5NjQyMmFjMzJlOF8xLTAtMS0xLTA_2b1fdb65-9e12-4fe3-a32b-c1652962d18c">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6MTAxMDc0NDFiMmJlNDFjOTkyNzhkOTY0MjJhYzMyZTgvdGFibGVyYW5nZToxMDEwNzQ0MWIyYmU0MWM5OTI3OGQ5NjQyMmFjMzJlOF8xLTEtMS0xLTA_67db0491-b88f-4bc2-9741-2d29fa0a6bdf">TARS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6MTAxMDc0NDFiMmJlNDFjOTkyNzhkOTY0MjJhYzMyZTgvdGFibGVyYW5nZToxMDEwNzQ0MWIyYmU0MWM5OTI3OGQ5NjQyMmFjMzJlOF8xLTItMS0xLTAvdGV4dHJlZ2lvbjowY2JjMjFmMTZiYWM0MzM3YmM2OWMyZmVkMzNkZmNkNF8zNA_c0a1e3a1-669f-4e27-80bd-1347600a10ea">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTYw_df7fce16-bd60-4a52-b6d8-1f60bd6f3bf3">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTUw_587e28da-ba00-48c1-b9ad-552f23d4ef97">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6YjVjZGM1YjFkODZlNDUxOWE1MDI4ZmJkNjAxN2QwMWMvdGFibGVyYW5nZTpiNWNkYzViMWQ4NmU0NTE5YTUwMjhmYmQ2MDE3ZDAxY18xLTAtMS0xLTA_16ada236-9cd2-4703-b303-6400f42cd18b">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6YjVjZGM1YjFkODZlNDUxOWE1MDI4ZmJkNjAxN2QwMWMvdGFibGVyYW5nZTpiNWNkYzViMWQ4NmU0NTE5YTUwMjhmYmQ2MDE3ZDAxY18xLTQtMS0xLTA_6ec54770-cfc3-4feb-9f53-4275c79071e0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGFibGU6YjVjZGM1YjFkODZlNDUxOWE1MDI4ZmJkNjAxN2QwMWMvdGFibGVyYW5nZTpiNWNkYzViMWQ4NmU0NTE5YTUwMjhmYmQ2MDE3ZDAxY18yLTQtMS0xLTA_ff6455fe-07a1-4011-91be-023d4d360a47">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTUx_a364930c-8300-4599-a74a-a24477f7b9de">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTUy_c37e4d73-e501-4247-b8d5-962190dfff99">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="id418552000374cee91d2f152ebbeefbf_I20210801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xL2ZyYWc6ZTA4NjgxYjQwYTU0NDAwNGFmYWFjOTc1Y2E2NzFhYWMvdGV4dHJlZ2lvbjplMDg2ODFiNDBhNTQ0MDA0YWZhYWM5NzVjYTY3MWFhY18xOTUz_2270f95c-66e5-4ea7-a5ee-d910aada5f23"
      unitRef="shares">20574104</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfNS0xLTEtMS0w_b93f53b6-1b66-4145-87e6-503f1391cfa7"
      unitRef="usd">176735000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfNS0zLTEtMS0w_05b8c81b-a1eb-46a0-ade3-57b32b51ba6f"
      unitRef="usd">168129000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfNi0xLTEtMS0w_a71daa03-67e0-4546-a101-72a8a3e5acc4"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfNi0zLTEtMS0w_b061e4fe-5fef-4278-92a7-79f3572f0f57"
      unitRef="usd">20000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfNy0xLTEtMS0w_11b146db-a55f-40cd-bf22-6c59f4c32c8e"
      unitRef="usd">20000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfNy0zLTEtMS0w_e881c4c1-9f00-460c-b268-89c9dafea2c1"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfOS0xLTEtMS0w_095fefac-479b-4d02-ba9f-488bdfa7f221"
      unitRef="usd">157000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfOS0zLTEtMS0w_a0eab939-2329-43ab-b9fc-402643d8fd13"
      unitRef="usd">20000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTAtMS0xLTEtMA_36c9faaf-dfc9-460a-bf17-c5c75b375eb9"
      unitRef="usd">4012000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTAtMy0xLTEtMA_0065d50a-0f4c-4b56-8c13-0ce007294864"
      unitRef="usd">2486000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTEtMS0xLTEtMA_696d4a8b-a027-460c-a3cf-fd7c9254faf8"
      unitRef="usd">200904000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTEtMy0xLTEtMA_4796ac8e-debf-4621-83da-e3d4ff509058"
      unitRef="usd">170655000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTItMS0xLTEtMA_85d55cd3-6136-4041-bea2-6ada956ed7a6"
      unitRef="usd">481000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTItMy0xLTEtMA_3e7b0add-3341-44bd-b83c-a76d248e7454"
      unitRef="usd">548000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTMtMS0xLTEtMA_105b67c2-9e10-4a90-b948-4f986852054e"
      unitRef="usd">540000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTMtMy0xLTEtMA_e5c00147-73d0-4911-ad1c-5129681eb7c0"
      unitRef="usd">688000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTQtMS0xLTEtMA_a23d1f65-bae0-4a60-a85c-dc4d10828846"
      unitRef="usd">1525000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTQtMy0xLTEtMA_c9b13836-4a65-4aff-afed-7df3288d9875"
      unitRef="usd">81000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTUtMS0xLTEtMA_487703e6-373b-4824-80b5-756e32d3237f"
      unitRef="usd">203450000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTUtMy0xLTEtMA_37dd3429-606e-45d2-97b5-0563d688abc6"
      unitRef="usd">171972000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTgtMS0xLTEtMA_9c0cafdb-5994-42f1-b9b5-0fa5345d9e38"
      unitRef="usd">8985000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTgtMy0xLTEtMA_b5e8fe1b-b91a-445f-94a2-8fd753f696d1"
      unitRef="usd">4347000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTktMS0xLTEtMA_6dbe1670-220b-48eb-b68c-120d3a97a065"
      unitRef="usd">1470000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMTktMy0xLTEtMA_32174082-8ae7-4047-8330-67ce381df99b"
      unitRef="usd">1040000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjAtMS0xLTEtMA_f09f7202-c914-40e9-b9cf-9ac695f74505"
      unitRef="usd">10455000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjAtMy0xLTEtMA_c1379362-9260-4f82-b3d1-313196ab3bfc"
      unitRef="usd">5387000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjEtMS0xLTEtMA_f6d2730b-a8d0-4229-aab5-0573a6e12d13"
      unitRef="usd">524000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjEtMy0xLTEtMA_2d5f92f3-4020-433d-87cd-3afca012a586"
      unitRef="usd">605000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjItMS0xLTEtMA_bdbcfb72-d620-4029-a1ae-3e72925addd7"
      unitRef="usd">10979000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjItMy0xLTEtMA_d872d732-3c6d-4b74-a547-6ef0d8d47913"
      unitRef="usd">5992000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjMtMS0xLTEtMA_ff8e9991-c46e-4997-abfb-6c3978440e2a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjMtMy0xLTEtMA_ab547e5e-b5ce-4089-8fb9-0eee6dbb009e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjc0N2Y0NjA5YzY0ZDRkOTJhN2RmNjViOTJiYjRlMzk1XzIx_1c33b3da-2bed-47ed-803a-596e18e69167"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjc0N2Y0NjA5YzY0ZDRkOTJhN2RmNjViOTJiYjRlMzk1XzIx_ad73728f-6f51-4d21-bb74-49ed143a5fe5"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjc0N2Y0NjA5YzY0ZDRkOTJhN2RmNjViOTJiYjRlMzk1XzM1_142c8167-7280-4acd-96b0-20459b42a9fb"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjc0N2Y0NjA5YzY0ZDRkOTJhN2RmNjViOTJiYjRlMzk1XzM1_3d4074ca-10a7-4982-bc49-9476853c6292"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjc0N2Y0NjA5YzY0ZDRkOTJhN2RmNjViOTJiYjRlMzk1XzYz_3109f0cd-0a8d-439e-a752-12aa1b6a3094"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjc0N2Y0NjA5YzY0ZDRkOTJhN2RmNjViOTJiYjRlMzk1XzYz_dc7f3be3-0fc0-4af9-9cc3-85212e86fe2c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjc0N2Y0NjA5YzY0ZDRkOTJhN2RmNjViOTJiYjRlMzk1XzYz_ed0a2b68-9132-4128-95ef-5e8a96eff919"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjc0N2Y0NjA5YzY0ZDRkOTJhN2RmNjViOTJiYjRlMzk1XzYz_fcc716db-3377-4aa3-a926-b5ba678c8770"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMS0xLTEtMA_686aaed6-31cf-462d-921e-e19060027ce7"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjUtMy0xLTEtMA_cda21b4f-4a62-4af5-8700-fbab6af604d9"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzE4_10b1a972-207f-49ea-b81a-e327899e2548"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzE4_bcdce746-b25f-4487-828c-0f2ae9f1f50c"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzMy_6647eb2b-cf56-4445-abf2-6947dd9f2c6f"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzMy_6eafa6d2-c149-4573-9493-63c32f499c25"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzU0_3fdaf6af-2418-46b1-b960-fe24e85fc202"
      unitRef="shares">20704104</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzc1_a914b6f9-2e67-4d76-9fe3-69ae22fc1dfb"
      unitRef="shares">20573951</us-gaap:CommonStockSharesOutstanding>
    <tars:CommonStockSharesSubjectToRepurchase
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzEwNg_081b566f-3519-43c7-8702-6162b61cdca4"
      unitRef="shares">130153</tars:CommonStockSharesSubjectToRepurchase>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzE1Nw_c67bffe7-91a9-4790-9562-4bfebe158574"
      unitRef="shares">20502576</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzE3OA_2bc01189-9494-4c98-b2ea-07bccf9d4b3b"
      unitRef="shares">20323301</us-gaap:CommonStockSharesOutstanding>
    <tars:CommonStockSharesSubjectToRepurchase
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmYxNjdhYTM0MDE4MzRkYWZhMjc1Njg2NWFjZWUxOTRkXzIwOQ_5e725829-2849-4bcf-8524-ca0775d7da88"
      unitRef="shares">179375</tars:CommonStockSharesSubjectToRepurchase>
    <us-gaap:CommonStockValue
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMS0xLTEtMA_b2594554-ced0-48f0-b4ab-cb63435af61e"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjYtMy0xLTEtMA_a9906ce6-b223-455a-b6ac-3df7e2e6fb70"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjctMS0xLTEtMA_a6ab4622-a6db-4807-a912-1fc3e8a398fa"
      unitRef="usd">208591000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjctMy0xLTEtMA_10d70464-ed35-4378-8853-9188e9db4571"
      unitRef="usd">198821000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjgtMS0xLTEtMA_51b22389-7ee9-4264-bd25-027edda1e42f"
      unitRef="usd">-16124000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjgtMy0xLTEtMA_badf3259-3e32-4bb7-b351-34d4bf1c00fe"
      unitRef="usd">-32845000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjktMS0xLTEtMA_6aa902f5-f972-4d4f-b2dd-e44bd8d963f0"
      unitRef="usd">192471000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMjktMy0xLTEtMA_22e2b0bd-fec2-4ff1-aa68-6df4a83e6b55"
      unitRef="usd">165980000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMzAtMS0xLTEtMA_d3387889-ecc6-4d41-9095-656d58dbb127"
      unitRef="usd">203450000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8xOS9mcmFnOjQwYWMwZWNhMDQ4YjQzMjI4ODViODIxMTkzN2VkYzQwL3RhYmxlOmY5MTg4ZmVhMDc5OTRkNDdhNWQxYjJkZWZlMTFkN2YyL3RhYmxlcmFuZ2U6ZjkxODhmZWEwNzk5NGQ0N2E1ZDFiMmRlZmUxMWQ3ZjJfMzAtMy0xLTEtMA_849269d1-bb4f-49a1-bb0e-cf52a82b14f0"
      unitRef="usd">171972000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i6a6d638fd8024fb489c508a2ffc1d40a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMy0xLTEtMS0w_9b8514fd-de00-4594-8d3c-74162d07560c"
      unitRef="usd">19048000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia569047a0bf44c6a9285af3f2ca01975_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMy0zLTEtMS0w_570dbb04-2e11-457e-a26e-16f3f726d290"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia277d64b3cf54f299bea0e672deb68c6_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMy01LTEtMS05Ng_e8d2ffc8-8501-4b28-aeaa-8f0b1b149cf7"
      unitRef="usd">52359000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b407322af7f46eca61e30b4fecffe2b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMy03LTEtMS05Ng_d5093507-857d-4905-bba2-d7494f51d4b2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i844a21cea71e4d1bae8b39773824d43d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNC0xLTEtMS0w_aecdde0e-7795-4268-b200-358be11a4e16"
      unitRef="usd">2969000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i631be233d7544546b6561e0e68e759a9_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNC0zLTEtMS0w_beb9ac29-ea38-435b-9717-a68c5890de88"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idaa5350dda6d437da5ff9a746dca6f3b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNC01LTEtMS05Ng_ad9179fe-75a8-4e84-a5bb-61ac9e6ef343"
      unitRef="usd">3090000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i47131aae4502439b84e481d0cd4795aa_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNC03LTEtMS05Ng_0d8f974e-4f97-435f-8833-d9e799fd3747"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNS0xLTEtMS0w_aae40a09-a1b8-46a4-b4ba-4a439bc6b501"
      unitRef="usd">22017000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNS0zLTEtMS0w_b64067d2-b8c4-4744-8d1d-f9e6b34e2152"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNS01LTEtMS05Ng_71eb3ace-8374-4aea-a3cd-28b677201c2b"
      unitRef="usd">55449000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNS03LTEtMS05Ng_b8f108dd-54a8-480c-89d2-1e0e8aa5cbee"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="ib1e17b2b90194854a0c1f35b7f7a220c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNy0xLTEtMS0w_cca63b31-caa7-4d8b-98d5-19db1790c454"
      unitRef="usd">737000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i6cfb8f7666f5404697abaf42468b411d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNy0zLTEtMS0w_df61b935-36bc-4e94-b9e6-14b371b0c034"
      unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i4f0a7226965f407bb1332105daf637d9_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNy01LTEtMS05Ng_10e74731-41d3-4e02-9439-1b84c2960c5b"
      unitRef="usd">2034000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i883f70c143b9443d8fd6e696331febda_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfNy03LTEtMS05Ng_7e459764-83ce-4dd5-ad70-df963c084d86"
      unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfOC0xLTEtMS0w_804b7db7-173f-4fd7-9294-242b2c554051"
      unitRef="usd">7204000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfOC0zLTEtMS0w_a2534c24-6f5f-409c-b99e-9bc8dfc4fc8f"
      unitRef="usd">1737000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfOC01LTEtMS0w_002392f4-3a06-47f5-8ae7-46eb8682fa69"
      unitRef="usd">23465000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfOC03LTEtMS0w_24ba5bda-28c1-4b23-bdaf-9ef45d125a44"
      unitRef="usd">3249000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfOS0xLTEtMS0w_4796e55a-e748-4a4c-aa3e-5b373b31572d"
      unitRef="usd">6794000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfOS0zLTEtMS0w_09d0717b-161c-4e4e-a907-43c6e21109a0"
      unitRef="usd">1526000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfOS01LTEtMS0w_13072813-8c6b-476c-9026-3b174085d9a3"
      unitRef="usd">11954000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfOS03LTEtMS0w_44db3898-8bd8-45f5-9b8d-c0cea98c9ebe"
      unitRef="usd">2132000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTAtMS0xLTEtMA_f195776e-16dc-4efc-911c-bc96fd1f8d4e"
      unitRef="usd">14735000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTAtMy0xLTEtMA_91c63b2e-e570-4841-a720-702f8400f99a"
      unitRef="usd">3263000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTAtNS0xLTEtMA_d3f0ca83-b1fd-4627-84e3-b512fd43d66b"
      unitRef="usd">37453000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTAtNy0xLTEtMA_c19054c2-6c9e-4f4f-884a-af5e873c7f5b"
      unitRef="usd">5381000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTEtMS0xLTEtMA_64a6c741-07de-4062-86cc-b72f2d24e7be"
      unitRef="usd">7282000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTEtMy0xLTEtMA_7434e458-bdec-42df-a45c-16c1c98d6e54"
      unitRef="usd">-3263000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTEtNS0xLTEtMA_34869f7b-b1f0-462b-8183-7341a0cf47c8"
      unitRef="usd">17996000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTEtNy0xLTEtMA_48eedfe3-983e-4871-9667-6feda8817d1e"
      unitRef="usd">-5381000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTMtMS0xLTEtMA_142bb2f1-1d3f-458f-b3e4-2a1e4cb8f317"
      unitRef="usd">7000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTMtMy0xLTEtMA_9d627109-ac5a-44b4-b5c1-0f6888904954"
      unitRef="usd">13000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTMtNS0xLTEtMA_2c226a93-7092-4d12-aa0e-6876e8e29402"
      unitRef="usd">16000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTMtNy0xLTEtMA_f7d3ba37-f16f-4496-aedf-4f81d3faecd8"
      unitRef="usd">174000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTQtMS0xLTEtMA_6478fc64-905e-4ef8-ba0c-9c735310948b"
      unitRef="usd">-39000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTQtMy0xLTEtMA_8626dc28-61f4-4078-8eb9-7ab50991cfc8"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTQtNS0xLTEtOTY_ec3cd70f-c2aa-4906-bcc1-1879ecae56c4"
      unitRef="usd">-73000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTQtNy0xLTEtOTY_1a9b8414-0fcc-4deb-ac5d-cf5592b6ee3a"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTYtMS0xLTEtMA_9ce4d0f6-c461-4a20-87cf-2bc5254650ae"
      unitRef="usd">-876000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTYtMy0xLTEtMA_21a549e4-7dae-4c25-8d0f-30beeccf1b4c"
      unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTYtNS0xLTEtMA_cb615e21-ad54-466c-9dbb-daef133eabcd"
      unitRef="usd">-876000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTYtNy0xLTEtMA_01356b32-2c25-411d-91d0-d4bfda60d00b"
      unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTctMS0xLTEtMA_71890427-d9d9-44d6-a780-da637bf8511c"
      unitRef="usd">-908000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTctMy0xLTEtMA_1a3a3d67-98c1-488e-ae73-05083398acd1"
      unitRef="usd">13000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTctNS0xLTEtMA_8b49e7ca-c9f1-43e1-a238-58633c92f7c3"
      unitRef="usd">-933000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTctNy0xLTEtMA_fe763f07-4a8e-4049-a6eb-dcd2c88b3395"
      unitRef="usd">174000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTgtMS0xLTEtMA_627e9853-0623-47c3-ad7e-0ab4b70e81e8"
      unitRef="usd">29000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTgtMy0xLTEtMA_980b116d-6f9c-42d4-8dc5-8a5078f368c2"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTgtNS0xLTEtMA_b2404bce-88ea-42c8-99ff-e7041ce270a6"
      unitRef="usd">342000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTgtNy0xLTEtMA_4b9db744-546f-47db-b6d5-3655f93af453"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTktMS0xLTEtMA_2275d7ae-1e40-4e3f-81c4-f6c3ec09f21d"
      unitRef="usd">6345000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTktMS0xLTEtMA_6f265270-5938-475d-a5b8-9e985315fcbb"
      unitRef="usd">6345000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTktMy0xLTEtMA_618bdf6b-e049-4661-828d-7a3fc70e9588"
      unitRef="usd">-3250000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTktMy0xLTEtMA_7b277b4e-a332-4a91-a14a-13fbc900bda0"
      unitRef="usd">-3250000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTktNS0xLTEtMA_175cd416-6007-4df2-81ee-08a6315f7343"
      unitRef="usd">16721000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTktNS0xLTEtMA_9beee3be-798b-4a2d-a774-87458c85b95b"
      unitRef="usd">16721000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTktNy0xLTEtMA_79619b0d-452e-4be5-bcf3-24a002ba63fc"
      unitRef="usd">-5207000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMTktNy0xLTEtMA_a24b4c98-6472-44c6-82ed-ba6caa96cf51"
      unitRef="usd">-5207000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjEtMS0xLTEtMA_21f2cda2-4417-4f1d-8e97-2c1e61b3f3b1"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjEtMy0xLTEtMA_3022bbc2-170e-4e14-9272-74bfed0a75b9"
      unitRef="usdPerShare">-1.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjEtNS0xLTEtMA_12e50fed-15bc-4123-9bec-138b1b8ad6cc"
      unitRef="usdPerShare">0.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjEtNy0xLTEtMA_0b4db2a8-d3b2-4369-8fec-66e9e6c0243c"
      unitRef="usdPerShare">-1.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjItMS0xLTEtMA_173ce298-3a1a-431f-9cad-f903ae41a483"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjItMy0xLTEtMA_ee7a3611-a44d-4701-896f-2816428d6c43"
      unitRef="usdPerShare">-1.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjItNS0xLTEtOTY_afe7b8b4-eb67-40e2-b971-fbb13b9e1746"
      unitRef="usdPerShare">0.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjItNy0xLTEtOTY_e998afb3-d468-4e31-bfbc-a73ff1f61190"
      unitRef="usdPerShare">-1.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjQtMS0xLTEtMA_fcfdeb60-ad1d-44bc-99ca-7b6c50502649"
      unitRef="shares">20555258</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjQtMy0xLTEtMA_1c1d762c-fd50-481c-93aa-6311a8f90f9a"
      unitRef="shares">2651321</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjQtNS0xLTEtMA_6f3cd9f7-10cf-4a60-9dfd-7fc7df5d4379"
      unitRef="shares">20446246</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjQtNy0xLTEtMA_0f9edd7a-23fd-41b0-9edf-50aff9cd7728"
      unitRef="shares">2650843</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjUtMS0xLTEtMA_fb2e1a59-5dd5-42ec-9fe5-7aa36dc5c8aa"
      unitRef="shares">21966599</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjUtMy0xLTEtMA_05f417be-5bb4-41cb-9c5e-a18dbbb89d6f"
      unitRef="shares">2651321</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjUtNS0xLTEtOTY_e5d419e4-2a7a-4407-bae9-325ed51deeb8"
      unitRef="shares">21895304</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yMi9mcmFnOjg3NThjMTZhZGQ5MDRjNmJhZmNiZmUzZTI1ZTU1ZDEzL3RhYmxlOjQyYzA4ZmYwNjMyZTQxYjQ4ZTc1NjM3NzExODE0NjYzL3RhYmxlcmFuZ2U6NDJjMDhmZjA2MzJlNDFiNDhlNzU2Mzc3MTE4MTQ2NjNfMjUtNy0xLTEtOTY_ab2535c3-b959-498e-980b-ef552e224e9a"
      unitRef="shares">2650843</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ieb7ee0d743be4e14b1401f1d0a96ec6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMi0xLTEtMS0w_6c8e0c6b-7f8b-4e5a-9380-aee6b8ccd93c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ieb7ee0d743be4e14b1401f1d0a96ec6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMi0zLTEtMS0w_b0ffb336-03b8-4163-80da-3dadf3e3033e"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i52e734a7761645e48b189cb6e2b8421e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMi01LTEtMS0w_9a1d42e0-85f5-40e4-a2ad-9fc548a5a1b6"
      unitRef="shares">20323201</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i52e734a7761645e48b189cb6e2b8421e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMi03LTEtMS0w_582c8c87-ab4d-4136-a51a-4e5a99194387"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac09cf4a066646c188469b8b5c55183e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMi05LTEtMS0w_48c9d725-c819-4e77-85b4-cc3fb526354e"
      unitRef="usd">198821000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iad26ed4c0a904b1db84e266a4d16a1b4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMi0xMS0xLTEtMA_1ddc4c45-7965-4aed-8538-7a61b4834604"
      unitRef="usd">-32845000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMi0xMy0xLTEtMA_81f8066b-aba1-4ec5-8768-bb2858b96627"
      unitRef="usd">165980000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i23ecbbc22f4540cd8bcea0e396ba673e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMy0xMS0xLTEtMA_68043025-3979-468e-94eb-8fdd6ae6bf79"
      unitRef="usd">10376000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7a28ec4e85d84692b4ca6a32628fa4be_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMy0xMy0xLTEtMA_014d250c-ac7b-42a3-883d-d802cb89207f"
      unitRef="usd">10376000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibc512caba35a452c8e9461069e750305_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNC05LTEtMS0w_d07e32f4-f20b-46b5-a98b-478b7622eec6"
      unitRef="usd">1363000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7a28ec4e85d84692b4ca6a32628fa4be_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNC0xMy0xLTEtMA_6b40b18d-1158-4b9a-87f1-2c3fe39a7cd1"
      unitRef="usd">1363000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if4ab6ac8e8814105820d3a3d650f85f6_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNS01LTEtMS0w_6c68f9e0-344d-49dc-8232-75ef9c233ab0"
      unitRef="shares">13773</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibc512caba35a452c8e9461069e750305_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNS05LTEtMS0w_31f537db-3a6e-487c-a199-6299f612cf24"
      unitRef="usd">19000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7a28ec4e85d84692b4ca6a32628fa4be_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNS0xMy0xLTEtMA_7b865052-dbaf-4a74-abc5-3ed368f84057"
      unitRef="usd">19000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="if4ab6ac8e8814105820d3a3d650f85f6_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNi01LTEtMS0w_fb68a2e1-0be4-4617-b499-38f233a92109"
      unitRef="shares">187500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="ibc512caba35a452c8e9461069e750305_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNi05LTEtMS0w_b85123b6-36bd-4af7-87ba-34250621af9d"
      unitRef="usd">5494000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i7a28ec4e85d84692b4ca6a32628fa4be_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNi0xMy0xLTEtMA_7647b6ba-59e0-44c3-86f7-de89f296052f"
      unitRef="usd">5494000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i739e66a8b2094324ad392839b69d2eec_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNy0xLTEtMS0w_cfe28d5c-5b27-4c46-8e90-93280909a59d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i739e66a8b2094324ad392839b69d2eec_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNy0zLTEtMS0w_d06a3acb-846c-4321-9b0f-33436181a835"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i33759a7e324e4a7d9618b0aaa5838ece_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNy01LTEtMS0w_4ee06dd8-6ec5-4b36-bd3d-1f71acd900ec"
      unitRef="shares">20524474</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i33759a7e324e4a7d9618b0aaa5838ece_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNy03LTEtMS0w_84d74651-29d1-49e5-92cf-59febc95cac0"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8fb433c2724c4c6e91eb08e2465af045_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNy05LTEtMS0w_3d632238-5f7b-4946-bf66-530502ad98fc"
      unitRef="usd">205697000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i47b0c69c412247c68a44124006cf6612_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNy0xMS0xLTEtMA_de6a1e15-7277-48fd-8e79-ace4b1b7312f"
      unitRef="usd">-22469000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i17e969dac4d6411dbb826ee3db9998d9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfNy0xMy0xLTEtMA_f3dd8648-894b-4ed1-94e5-bb50355da195"
      unitRef="usd">183232000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i6a8d4c6166724c9dba7245924538fd86_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfOC0xMS0xLTEtMA_24d476ae-f166-4d70-9e1b-ca911e98ba75"
      unitRef="usd">6345000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfOC0xMy0xLTEtMA_5377d3a8-aa42-4ed1-ba56-eef096f8c38b"
      unitRef="usd">6345000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i345e2829049d4416bf301cc23ac6a406_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfOS05LTEtMS0w_d7e0841b-34a0-4306-b004-5e6637d47891"
      unitRef="usd">2794000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfOS0xMy0xLTEtMA_f75eba29-6255-45b3-a26b-bb0821405e8e"
      unitRef="usd">2794000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <tars:StockIssuedDuringPeriodSharesLapseOfRepurchaseRights
      contextRef="id0634e483f0f4516a460bacff8b51bcc_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTAtNS0xLTEtNTA4_8e943125-5c33-4e7f-9f11-6bc8f0f811e7"
      unitRef="shares">49222</tars:StockIssuedDuringPeriodSharesLapseOfRepurchaseRights>
    <tars:StockIssuedDuringPeriodValueLapseOfRepurchaseRights
      contextRef="i345e2829049d4416bf301cc23ac6a406_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTAtOS0xLTEtNTA4_cc020d5e-4515-40d1-8fc6-0ea15b6ec137"
      unitRef="usd">99000</tars:StockIssuedDuringPeriodValueLapseOfRepurchaseRights>
    <tars:StockIssuedDuringPeriodValueLapseOfRepurchaseRights
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTAtMTMtMS0xLTUwOA_ac3c56ae-070b-4c44-8e6e-b1864c4bbdfe"
      unitRef="usd">99000</tars:StockIssuedDuringPeriodValueLapseOfRepurchaseRights>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id0634e483f0f4516a460bacff8b51bcc_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTAtNS0xLTEtMA_dc50171b-6c0f-495b-b727-5daf2fbbe045"
      unitRef="shares">255</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i345e2829049d4416bf301cc23ac6a406_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTAtOS0xLTEtMA_68df2839-466f-448f-9636-e2f9e821a5a0"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTAtMTMtMS0xLTA_1cac080b-e4e2-466e-a01a-2b0d6b78db76"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i4426dbfe40cc497ab87fc456c68f513e_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTEtMS0xLTEtMA_6f716cb1-40bf-4454-8174-b32ce78cba5d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4426dbfe40cc497ab87fc456c68f513e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTEtMy0xLTEtMA_874bc423-c438-4a05-b952-b877a81b9dfc"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5291f4b8a4e24019929680d04b243c5f_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTEtNS0xLTEtMA_e4604830-c128-4656-8104-a95c8dd27cb0"
      unitRef="shares">20573951</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5291f4b8a4e24019929680d04b243c5f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTEtNy0xLTEtMA_c46ca175-714d-47d2-8d7f-491c45656a2e"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia1f9f9fed4d646e2b0a01016693eec81_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTEtOS0xLTEtMA_98701c1e-fe1d-4d2e-9b1a-ae4626d1ae32"
      unitRef="usd">208591000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaeccdc12ddfa46af872eef01caec5973_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTEtMTEtMS0xLTA_96a76ad7-2c22-4a04-8c4c-4f6b6b96585a"
      unitRef="usd">-16124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOmVkZWU0NmMzZWE2MjRkYjVhOGRmMTg5N2JhYzkzOWJlL3RhYmxlcmFuZ2U6ZWRlZTQ2YzNlYTYyNGRiNWE4ZGYxODk3YmFjOTM5YmVfMTEtMTMtMS0xLTA_79ef90bf-60ec-4689-bb44-7ba15c99cddd"
      unitRef="usd">192471000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i582e67cbd8fa41379c4ab2acf8ad6e1c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMi0xLTEtMS0w_e09e1a56-54cf-4625-9c0c-210193d92770"
      unitRef="shares">8249939</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i582e67cbd8fa41379c4ab2acf8ad6e1c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMi0zLTEtMS0w_e65fc16e-f7b0-4863-a388-980d2ab70b92"
      unitRef="usd">63402000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i94907dbf7f4947419d7e95e4a21fe043_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMi01LTEtMS0w_221ec691-26eb-4611-9241-bb3c8d459090"
      unitRef="shares">2646619</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i94907dbf7f4947419d7e95e4a21fe043_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMi03LTEtMS0w_85ee3678-74d4-458f-b107-45846e624185"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i18065d30bf104e29b2ef78dd078ba467_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMi05LTEtMS0w_a32453e0-1f5a-4cdf-a6b9-d9944ee4bd35"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5fb6e623368041f9a2fada37f7f956b8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMi0xMS0xLTEtMA_f9aa4739-3e36-40a2-8623-fe2fa859a00b"
      unitRef="usd">-6034000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib35a7e25ebbe4fc381478dbc1dc8dbd3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMi0xMy0xLTEtMA_96d8a7e0-a708-47eb-8e23-0a9c35061035"
      unitRef="usd">-6005000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i54f251974ca94b0e9b65707daf81e0f4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMy0xMS0xLTEtMA_b0bc399e-80b7-4510-a69c-34e541fa3e96"
      unitRef="usd">-1957000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2d8683a7d9e14fe9abbd3f6a5c86c6f6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMy0xMy0xLTEtMA_a1a4dee3-4516-4b28-84ca-e9addd65f468"
      unitRef="usd">-1957000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4f0da49422cc4c05b2cba9c4406d801a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNC05LTEtMS0w_f5af8887-d51e-496e-9457-c1906a99bd22"
      unitRef="usd">4000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2d8683a7d9e14fe9abbd3f6a5c86c6f6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNC0xMy0xLTEtMA_dbe2c13c-adff-43eb-895b-c3d5f6c9995f"
      unitRef="usd">4000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <tars:StockIssuedDuringPeriodSharesLapseOfRepurchaseRights
      contextRef="ice41973b875c464a83d520944c39c4eb_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNS01LTEtMS0w_f18c92c5-6225-4ab9-9106-25927914b777"
      unitRef="shares">4300</tars:StockIssuedDuringPeriodSharesLapseOfRepurchaseRights>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i58d0bbc40e024b4bab78c783704a7261_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNi0xLTEtMS0w_56bd92b7-3dab-41da-b6a3-df9d73107c1c"
      unitRef="shares">8249939</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i58d0bbc40e024b4bab78c783704a7261_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNi0zLTEtMS0w_131856f0-139b-4d7f-b099-df5bb4268eab"
      unitRef="usd">63402000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1195e7340d234c54a47b573024044888_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNi01LTEtMS0w_ac56d540-3cb8-4718-ae23-fcd8c91c33a9"
      unitRef="shares">2650919</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1195e7340d234c54a47b573024044888_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNi03LTEtMS0w_50d50729-7e36-462d-b27e-4759c068375b"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i940347dc2e60436481e72725ac419fe5_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNi05LTEtMS0w_4868b42b-a796-4d85-a7cf-95136fb4258d"
      unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i211c6caec1a14d17bb9a07d1b78206cc_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNi0xMS0xLTEtMA_e8cd9824-0fd2-43b5-bd33-45a5beee8de7"
      unitRef="usd">-7991000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i760234fe991c4dce8f6fcb5f097fe516_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNi0xMy0xLTEtMA_4c0bb48b-1ec7-4829-97e3-edda471f928d"
      unitRef="usd">-7958000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="if1b6177ab72f41b8a0277863efcf4f48_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNy0xMS0xLTEtMA_1ac828a7-ef17-4685-b5d6-ec1495ea4ac4"
      unitRef="usd">-3250000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfNy0xMy0xLTEtMA_6a1d3aa9-7416-439c-b05c-2f387b417769"
      unitRef="usd">-3250000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic6dea8e6a4a44ea8b8d16ccb73c60507_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfOC05LTEtMS0w_ecab0105-5942-43f1-bbe3-7ba1f52080df"
      unitRef="usd">173000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfOC0xMy0xLTEtMA_017c6968-d348-4e5e-817b-9682266a9f31"
      unitRef="usd">173000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iff82cd871b884faca9901b82ef49823f_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfOS01LTEtMS0w_085f6184-5ecd-4511-81e0-c52c088c10af"
      unitRef="shares">1000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="icc3a3e1730b5474fb6d19a4e8ace2be6_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMTAtMS0xLTEtMA_7e9af184-63ae-479e-b9b5-2c2264116c58"
      unitRef="shares">8249939</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icc3a3e1730b5474fb6d19a4e8ace2be6_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMTAtMy0xLTEtMA_21c96ef4-99cc-4f02-9cb3-0381c87e18f1"
      unitRef="usd">63402000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib5b15cc9e2f848be9dcc3c45f2dcb249_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMTAtNS0xLTEtMA_36ce95ee-b7d1-4b36-b114-0465ed9962c5"
      unitRef="shares">2651996</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib5b15cc9e2f848be9dcc3c45f2dcb249_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMTAtNy0xLTEtMA_0ce6dc7c-9e16-4522-9165-0f223d6ad1d8"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id44cd453c94c48e99a7b9568be7f73e7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMTAtOS0xLTEtMA_f7a1061e-3d0f-4cad-a075-4d348b81a75b"
      unitRef="usd">204000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i37397987845b4ff0830e35dfd25588e8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMTAtMTEtMS0xLTA_bb87001c-5287-42f5-aeb4-14ed70892506"
      unitRef="usd">-11241000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id299c065b2574582a3d3a576ee8241d8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yNS9mcmFnOmYwYTg4YWQwOTgzNzQwMGI4MjVjM2I4MGRhNmE5NjBkL3RhYmxlOjFhOTMxN2ViOGNlNjRkZjNiNzUzNDEyZGNmNmNiNzVmL3RhYmxlcmFuZ2U6MWE5MzE3ZWI4Y2U2NGRmM2I3NTM0MTJkY2Y2Y2I3NWZfMTAtMTMtMS0xLTA_e03e0675-7d4e-43bf-b9a2-340aa084cd0f"
      unitRef="usd">-11035000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMy0xLTEtMS0w_96e60902-94fb-45b2-b7e5-964082eaa404"
      unitRef="usd">16721000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMy0zLTEtMS0w_cc527f07-4092-4fe0-847c-5939477bca40"
      unitRef="usd">-5207000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNS0xLTEtMS0w_77b3fd66-02ae-4599-ad82-35c775af9e58"
      unitRef="usd">189000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNS0zLTEtMS0w_12365984-3755-4787-9066-8508e830d7c1"
      unitRef="usd">32000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNi0xLTEtMS0w_1292826a-60b3-4add-81be-76eff7282a41"
      unitRef="usd">4157000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNi0zLTEtMS0w_e18aa851-0402-4d8b-8893-9e89e0fbe9a9"
      unitRef="usd">177000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNy0xLTEtMS0w_e0cba69d-14ae-495c-b9e9-4deab0d0a8b7"
      unitRef="usd">87000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNy0zLTEtMS0w_25c69677-a7ec-4ccc-9896-57eec79c3a2e"
      unitRef="usd">38000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfOC0xLTEtMS0w_857c77f3-b247-448a-8354-51647352393e"
      unitRef="usd">-70000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfOC0zLTEtMS0w_b2dcc368-5895-4d8d-8eb0-2e17b7d4393f"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfOS0xLTEtMS0w_f95b7368-3739-4f9c-937c-2d384f14e047"
      unitRef="usd">-2000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfOS0zLTEtMS0w_9701b101-0aca-46c9-b623-a69f598f55fc"
      unitRef="usd">0</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTAtMS0xLTEtMA_239cfdde-5458-47d7-8058-8fdf4fa3a9ee"
      unitRef="usd">-876000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTAtMy0xLTEtMA_b6d0b118-13bd-47f2-bc98-baa62f393719"
      unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTMtMS0xLTEtMA_5d5cc9cd-b5c5-46ab-9ec4-1d6e1369eeb2"
      unitRef="usd">8000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTMtMy0xLTEtMA_e918b626-5755-42ab-bb57-4321c1ac98c1"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTQtMS0xLTEtMA_3a594081-aca9-4cbb-b9e1-2116f57a1555"
      unitRef="usd">5494000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTQtMy0xLTEtMA_686e16f6-da07-4ea9-91fd-cf25e3d4b3a5"
      unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTYtMS0xLTEtMA_bc426e57-503f-4270-bc00-c6e6b2daf6d7"
      unitRef="usd">20000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTYtMy0xLTEtMA_f2d6e759-56dd-4980-b6be-eeb815b44a9c"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTgtMS0xLTEtMA_9399b8e9-30a5-47a9-a550-c71f9e4e4cc9"
      unitRef="usd">137000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTgtMy0xLTEtMA_926058ab-a47a-4222-a1bb-d7876bf50277"
      unitRef="usd">-34000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTktMS0xLTEtMA_b944cba1-8696-4b14-bd15-5098629fec8f"
      unitRef="usd">1527000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMTktMy0xLTEtMA_6e6529a8-2830-4616-9a1c-bcd5116d5702"
      unitRef="usd">1526000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjAtMS0xLTEtMA_58a28c9d-54dd-4ad2-a09e-931c5abfe791"
      unitRef="usd">2326000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjAtMy0xLTEtMA_1f3d2979-6965-42f5-9a37-acebf5280445"
      unitRef="usd">27000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjEtMS0xLTEtMA_57141a4b-0f3e-481e-b2fc-3a9efbf868d2"
      unitRef="usd">4622000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjEtMy0xLTEtMA_9db995ce-8a80-4a81-bef1-2643444a974f"
      unitRef="usd">1953000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjItMS0xLTEtMA_4acf8bce-c836-4a79-912c-76c82588bf20"
      unitRef="usd">430000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjItMy0xLTEtMA_1f4c9de5-3b5b-4d04-8a33-335ecf11583f"
      unitRef="usd">-27000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjMtMS0xLTEtMA_dc093c5f-46a6-4725-873d-a9684cf6e09a"
      unitRef="usd">107000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjMtMy0xLTEtMA_d2bab856-5ca3-4816-91c5-99fb0c69b8be"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjQtMS0xLTEtMA_d3bbb145-d71a-4aa4-ba27-8b0f30225e30"
      unitRef="usd">8757000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjQtMy0xLTEtMA_880e19fb-9e12-4627-b2e0-2c4026f1f549"
      unitRef="usd">-4553000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjYtMS0xLTEtMA_9581ee92-d2e8-430f-8942-a6cb0c3054d4"
      unitRef="usd">191000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjYtMy0xLTEtMA_ca364933-f2dd-433b-ba5a-536db7a6d4ee"
      unitRef="usd">371000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjctMS0xLTEtMA_bb49da71-34a2-44a5-9d82-7a2a2120ed98"
      unitRef="usd">-191000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMjctMy0xLTEtMA_3a50655e-498f-484f-8e09-5ca7a2cf25f7"
      unitRef="usd">-371000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzAtMS0xLTEtMA_8968fb7e-dbb3-4c30-8632-b586f42fe83e"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzAtMy0xLTEtMA_e1730463-fe6a-4ea1-9b0b-5f9d3bba020a"
      unitRef="usd">28000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzQtMS0xLTEtMA_fb3d3261-3182-49b9-8c6e-c74795371a4e"
      unitRef="usd">20000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzQtMy0xLTEtMA_f9405d35-999b-4f66-aa28-04652af0069c"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <tars:ProceedsFromEarlyExerciseOfStockOptions
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzUtMS0xLTEtMA_f58d23ef-1116-4314-90c1-67f01ba4e0c3"
      unitRef="usd">0</tars:ProceedsFromEarlyExerciseOfStockOptions>
    <tars:ProceedsFromEarlyExerciseOfStockOptions
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzUtMy0xLTEtMA_f4566b7f-d588-4355-b39e-25c983192514"
      unitRef="usd">135000</tars:ProceedsFromEarlyExerciseOfStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzYtMS0xLTEtMA_95262383-935d-49a2-ad7c-5068f8580795"
      unitRef="usd">20000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzYtMy0xLTEtMA_a1b8ba66-b048-421f-827f-2ca7321cdcb5"
      unitRef="usd">107000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzctMS0xLTEtMA_77906b0d-60c3-4daf-a343-cc6f77be3ef1"
      unitRef="usd">8586000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzctMy0xLTEtMA_f18329e1-d921-4073-83cb-e6070801a0ec"
      unitRef="usd">-4817000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzgtMS0xLTEtMA_1cbe9e44-a9fd-4bc3-97d5-55a699bad419"
      unitRef="usd">168149000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib35a7e25ebbe4fc381478dbc1dc8dbd3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzgtMy0xLTEtMA_1825bcf4-9369-468e-95b8-e121fc20c108"
      unitRef="usd">57972000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzktMS0xLTEtMA_96d13c3e-d8fc-41b4-99b4-e822ed1979ec"
      unitRef="usd">176735000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id299c065b2574582a3d3a576ee8241d8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfMzktMy0xLTEtMA_cd78796a-28c7-49da-980e-2f6fc0b0d3bd"
      unitRef="usd">53155000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDEtMS0xLTEtMA_0b25b5db-e79a-4f4b-8b6c-c9e73ade8558"
      unitRef="usd">176735000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id299c065b2574582a3d3a576ee8241d8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDEtMy0xLTEtMA_ed0fe2b4-d976-4a13-b00c-76612c42c39e"
      unitRef="usd">53135000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDItMS0xLTEtMA_c304a508-329e-48db-bd1a-330797f2eca2"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="id299c065b2574582a3d3a576ee8241d8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDItMy0xLTEtMA_d3f79c1c-68af-464f-802f-8bdfbe8cd873"
      unitRef="usd">20000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDMtMS0xLTEtMA_fa4cf1ac-e3a8-416b-b3ad-37b43c46f204"
      unitRef="usd">176735000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id299c065b2574582a3d3a576ee8241d8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDMtMy0xLTEtMA_b3ccb8bb-6289-43d8-89e6-04652cdac634"
      unitRef="usd">53155000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDUtMS0xLTEtMA_3c093b03-8f97-4726-8e63-1c6e77eab02f"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDUtMy0xLTEtMA_955163a5-602e-42f9-8253-62489ba45d01"
      unitRef="usd">767000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDctMS0xLTEtMA_0635d8ee-8b4c-4cd4-9b8e-8574c038152b"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDctMy0xLTEtMA_63c96b1b-d94d-4dd1-ba99-8d1c1d0f741c"
      unitRef="usd">47000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <tars:DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDgtMS0xLTEtMA_23c92bb1-c209-41ce-966e-d0cb53bf0ade"
      unitRef="usd">38000</tars:DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination>
    <tars:DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDgtMy0xLTEtMA_028d3f26-0fcc-4029-a486-cf6b9cd01986"
      unitRef="usd">0</tars:DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDktMS0xLTEtMA_513fa855-e253-494e-99e7-daec9d5a3963"
      unitRef="usd">5494000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8yOC9mcmFnOmFjYzEzZDBkM2M3NTQyOTZiZDE3ZmZjNDc1NzE4ZjkwL3RhYmxlOjZmNTZjNDAzMTJhZTQyZDc4OGU2Yjc4N2ZjZTEyM2FhL3RhYmxlcmFuZ2U6NmY1NmM0MDMxMmFlNDJkNzg4ZTZiNzg3ZmNlMTIzYWFfNDktMy0xLTEtMA_69083b28-d36f-4eac-8b33-bf07cf1976d8"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfNjU1Mg_071ecf7d-490a-4b87-a448-c9b660192a14">DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(a) Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tarsus Pharmaceuticals, Inc. (&#x201c;Tarsus&#x201d; or the &#x201c;Company&#x201d;) is a late clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutic candidates to address large market opportunities initially in ophthalmic conditions where there are limited treatment alternatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(b) Reverse Stock Split and Initial Public Offering &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On October 8, 2020, the Tarsus Board of Directors approved a 1-for-7.4276 reverse stock split and a certificate of amendment was filed to amend the Company's certificate of incorporation to effect this reverse split.  The par value was not adjusted as a result of the reverse stock split.  All share and per share information included in the accompanying financial statements give retroactive effect to this reverse stock split for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On October 20, 2020, the Company completed its initial public offering ("IPO") through an underwritten sale of 6,325,000&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; sh&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ares of its common stock at a price &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;of $16.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; per share, inclusive of an additional 825,000 shares of its common stock sold upon the full exercise of the underwriters&#x2019; purchase option. The aggregate net proceeds by the Company from the offering totaled $91.7 million, after deducting underwriting discounts and commissions and other offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Concurrent with the closing of the Company's IPO, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;all then-outstanding shares of its convertible preferred stock (see &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Note 4&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;) were automatically converted into an aggregate of 11,107,018 issued shares of common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;(c)  Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently has no product sales, and since inception, has accumulated losses and negative cash flows from operations (other than consideration received from an out-licensing agreement, as discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), resulting in an accumulated deficit of $16.1 million as of June&#160;30, 2021 and $32.8 million as of December&#160;31, 2020. The Company&#x2019;s cash and cash equivalents were $176.7 million and $168.1 million as of June&#160;30, 2021 and December&#160;31, 2020, respectively. The Company has funded its inception-to-date operations primarily through equity capital raises and proceeds from its out-license agreement.  The Company believes that its existing capital resources will be sufficient to meet projected operating requirements beyond at least 12 months from the August 5, 2021 filing date of this Form 10-Q.  Accordingly, the accompanying financial statements in this Form 10-Q have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operations currently consist of its corporate organization build-out, intellectual property licensing activities, and conducting preclinical and clinical studies. The Company faces the clinical, business, and liquidity risks that are typically associated with early-stage biotechnology companies; it must complete expensive research and development activities, achieve research and development outcomes that are inherently uncertain, recruit and retain skilled personnel (including executive management), and build and defend its intellectual property rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company&#x2019;s research and development activities and other operating expenses.  The Company will be required to raise additional capital to fund its future operations, however, no assurance can be given as to whether financing will be available on terms acceptable to the Company, if at all.  If the Company raises additional funds by issuing equity securities, its stockholders may experience dilution. Any future debt financing into which the Company enters may impose additional covenants that restrict operations, including limitations on its ability to incur liens or additional debt, pay dividends, repurchase common stock, make certain investments, or engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity raise may contain terms that are not favorable to the Company or its stockholders. The Company&#x2019;s potential inability to raise capital when needed could have a negative impact on its financial condition and ability to pursue planned business strategies. If the Company is unable to raise additional funds as required, it may need to delay, reduce, or terminate some or all &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;its development programs and clinical trials. The Company may also be required to sell or license its rights to product candidates in certain territories or indications that it would otherwise prefer to develop and commercialize on its own. If the Company is required to enter into collaborations and other arrangements to address its liquidity needs, it may have to give up certain rights that limit its ability to develop and commercialize product candidates or may have other terms that are not favorable to the Company or its stockholders, which could materially and adversely affect its business and financial prospects. These factors may adversely impact the Company's ability to achieve its business objectives and would likely have an adverse effect on its future business prospects, or even its ability to remain a going concern. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(d) Operating Segment  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has operated and managed its business and financial information on an aggregate basis for the purposes of evaluating financial performance and the allocation of capital and personnel resources. Accordingly, the Company&#x2019;s management determined that it operates in one reportable operating segment.  This single segment is focused exclusively on developing pharmaceutical products for eventual commercialization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(e) Emerging Growth Company Status&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has irrevocably elected to not take this exemption and, as a result, will adopt new or revised accounting standards on the relevant effective dates on which adoption of such standards is required for other public companies that are not emerging growth companies.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iefff22de6102436b99e849ce51fd5afa_D20201020-20201020"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfNTc1_07f71ba9-9c52-4a03-b66e-ef04aff39930"
      unitRef="shares">6325000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i92fe8dadc41449e49b3e9e72a278675a_I20201020"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfNjE5_68bb533e-beb4-4cdb-974a-ae20c6507e1f"
      unitRef="usdPerShare">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia81ce0ad42d6478f8526933a9dce6e9d_D20201020-20201020"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfNjYw_1542edb3-7b81-4edc-a5a0-6c151ebc5ce6"
      unitRef="shares">825000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iefff22de6102436b99e849ce51fd5afa_D20201020-20201020"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfODEx_a635d44c-73a3-4875-aecc-7437971fb3ba"
      unitRef="usd">91700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i92fe8dadc41449e49b3e9e72a278675a_I20201020"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfMTA3NQ_609c36dd-20d9-49ee-ac15-15eeae8469cf"
      unitRef="shares">11107018</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfMTc0Ng_fae5374f-b6d6-48ff-834a-5e6d0ac9d000"
      unitRef="usd">-16100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfMTc2Mg_d1e8642f-0ece-4a36-bc45-bb78066af103"
      unitRef="usd">-32800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfMTgxOQ_2bbea0db-33c3-453f-8299-8d19d388cd02"
      unitRef="usd">176700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfMTgyNg_bb023032-b322-4d6e-bda7-0b6167516ac9"
      unitRef="usd">168100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfNjU1Mw_6d3f8bf1-7e59-4070-bc14-30c089202573">To date, the Company has operated and managed its business and financial information on an aggregate basis for the purposes of evaluating financial performance and the allocation of capital and personnel resources. Accordingly, the Company&#x2019;s management determined that it operates in one reportable operating segment.  This single segment is focused exclusively on developing pharmaceutical products for eventual commercialization.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF8zNC9mcmFnOjBkMGI2Mzk4NTYxZDQzM2JiYTE3N2QyOWQ0OTZmNGVmL3RleHRyZWdpb246MGQwYjYzOTg1NjFkNDMzYmJhMTc3ZDI5ZDQ5NmY0ZWZfNTc3NA_c1d1f0e8-7bc0-4cea-bd62-bc2303c689dd"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NTE_5d69ce5f-7b32-4674-9ff3-04b452c88d49">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(i) Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information and pursuant to Form 10-Q and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Article 10 of Regulation S-X &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, the accompanying condensed financial statements do not include all of the information and footnotes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim condensed balance sheet as of June&#160;30, 2021, and the interim condensed statements of operations and comprehensive income (loss), changes in preferred stock and stockholders&#x2019; equity and cash flows for the three and six months ended June&#160;30, 2021 and 2020 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial data and other information disclosed in these notes related to the three and six-month periods are also unaudited. The condensed balance sheet as of December 31, 2020 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three and six months ended June&#160;30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021 or any other interim or annual period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited condensed financial statements should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2020 in the Company&#x2019;s Annual Report on Form 10-K (&#x201c;Annual Report&#x201d;) for the fiscal year ended December 31, 2020, as filed with the SEC on March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These amounts may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an on-going basis, management evaluates its most critical estimates and assumptions, including those related to the (i)&#160;fair value of equity-based awards and periodic recognition of stock-based compensation, (ii)&#160;the realization of income tax assets and estimates of tax liabilities, and (iii)&#160;expense accruals related to research and development activities, including clinical trials.  The accounting policies and estimates that most significantly impact the presented amounts within the accompanying condensed financial statements are further described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(ii) Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, with original maturities of three months or less from the purchase date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(iii) Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash represents cash held as collateral for the Company&#x2019;s corporate credit card program. Any cash that is legally or contractually restricted from immediate use is classified as restricted cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(iv) Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents in deposits at financial institutions that exceed federally insured limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the World Health Organization declared a pandemic related to the global novel coronavirus disease 2019 (&#x201c;COVID-19&#x201d;) outbreak. To date, the Company&#x2019;s operations have not been significantly impacted by the COVID-19 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pandemic, though the Company continues to monitor the potential impact COVID-19 may have on its ongoing and planned clinical trials. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak may have on these activities or its financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s results of operations involve numerous risks and uncertainties. Factors that could adversely impact the Company&#x2019;s operating results and business objectives include, but are not limited to, (1) uncertainty of results of clinical trials, (2) uncertainty of regulatory approval of the Company&#x2019;s potential product candidates, including TP-03 for ophthalmic conditions, TP-04 for treatment of skin conditions and TP-05 for prophylaxis of Lyme and community malaria reduction, (3) uncertainty of market acceptance of its product candidates, (4) competition from substitute products and other companies, (5) securing and protecting proprietary technology and strategic relationships, and (6) and dependence on key individuals and sole source suppliers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s product candidates require approvals from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive these necessary approvals. If the Company is denied approval, approval is delayed, or is unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company's business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(v) Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at historical cost and is depreciated on a straight-line basis over an estimated useful life that corresponds with its designated asset category. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of &#x201c;long-lived assets&#x201d; (which includes property and equipment) whenever events or changes in circumstances in the business indicate that the asset&#x2019;s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value. Other than the right-of-use ("ROU") asset impairment discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there were no events or changes in business circumstances during the three and six months ended June 30, 2021 or year ended December&#160;31, 2020 that indicated the carrying amounts of any long-lived assets were not fully recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(vi) Revenue Recognition for Out-License Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently has one out-license arrangement that allows the licensee to market the Company&#x2019;s TP-03 product (representing "functional intellectual property") in certain territories for a certain field of use and for a stated term - see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract, (b) the contract&#x2019;s transaction price for allocation (including variable consideration), (c) the stand-alone selling price for each identified performance obligation, and (d) the timing and amount of  revenue recognition in each period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's out-license arrangement, as described in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, was analyzed under GAAP to determine whether the promised goods or services (which include the license, and know-how, data, and information necessary or reasonably useful for the research, development, manufacture, or commercialization of any license product, and governance committee services) are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is considered to not be distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's out-license arrangement is in exchange for the following forms of consideration: (i) upfront cash payments, (ii) equity-based consideration, (iii) sales royalties, (iv) sales threshold milestones, (v) development milestone fees, and (vi) regulatory milestone fees.  Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied.   The Company evaluates the progress related to each milestone at each reporting &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;period and, if necessary, also adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Terms for Receipt of Payments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual terms that establish the Company&#x2019;s right to collect specified amounts from its customers and the require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Upfront License Fees:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company determines whether non-refundable license consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the out-license.  The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Development Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The Company utilizes the &#x201c;most likely amount&#x201d; method to estimate the amount of consideration to which it will be entitled for achievement of development milestones. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint.  At each reporting period, the Company re-evaluates this associated revenue recognition constraint.  Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, thus reflected in the financial statements in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Regulatory Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company utilizes the &#x201c;most likely amount&#x201d; method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied). Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are constrained for revenue recognition until achievement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under the "sales-or-usage-based royalty exception" the Company recognizes revenue based on the contractual percentage of the licensee&#x2019;s sales to its customers at the later of (i) the occurrence of the related sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from its out-licensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Threshold Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Similar to royalties, applying the "sales-or-usage-based royalty exception", the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from out-licensing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(vii) Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. These expenses also include internal costs directly attributable to in-development programs, including cost of certain salaries, payroll taxes, employee benefits, and stock-based compensation expense, as well as laboratory and clinical supplies, pre-clinical and clinical trial related expenses, and the cost of services provided by outside contractors. The Company recognizes expense for pre-clinical studies and clinical trial activities performed by these third parties. This is typically based upon estimates of the proportion of work completed over the term of the individual study or trial, as well as patient enrollment and dosing events in accordance with agreements established with clinical research organizations ("CROs") and clinical trial or pre-clinical study sites.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered, and may continue to enter into, license agreements to access and utilize intellectual property for drug development. In each case, the Company evaluates if the assets acquired in a transaction represent the acquisition of an as&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;set or a business, as defined under applicable GAAP. The Company&#x2019;s executed in-license agreements (see &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8(b)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) were evaluated and determined to represent asset acquisitions. Because these assets have not yet received regulatory approval&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and have no alternative future uses, the purchase price for each was immediately recognized as research and development expense. In addition, any future milestone payments (whether in the form of cash or stock) made before product regulatory approval (that do not meet the definition of a derivative) will also be immediately recognized as research and development expense when paid or becomes payable, provided there is no alternative future use of the rights in other research and development projects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(viii) Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense is recognized for all equity awards granted to employees, consultants, and members of the Company&#x2019;s Board of Directors and is recognized at fair value. For stock-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date is the date of grant and the related expense is recognized on a straight-line basis over each award&#x2019;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes compensation cost if and when it concludes that it is probable that the performance condition will be achieved and the related expense is recognized on an accelerated attribution method. As applicable, the Company reverses previously recognized expense for forfeitures of unvested awards in the period of occurrence. The Company uses the Black-Scholes pricing model to estimate the fair value of stock option awards as of the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The measurement of the fair value of stock-based awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#x2019;s judgment, including (a)&#160;the fair value of the Company&#x2019;s common stock on the date of the option grant, (b)&#160;the expected term of the stock option until its exercise by the recipient, (c)&#160;stock price volatility over the expected term, (d)&#160;the prevailing risk-free interest rate over the expected term, and (e)&#160;expected dividend payments over the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management estimates the expected term of awarded stock options utilizing the &#x201c;simplified method&#x201d; for awards as the Company does not yet have sufficient exercise history since its November 2016 formation. Further, prior to the IPO, the Company was privately-held and therefore lacked company-specific historical and implied volatility information of its stock.&#160;Accordingly, management estimated this expected volatility based on a designated peer-group of publicly-traded companies for a look-back period, as of the date of grant, that corresponded with the expected term of the awarded stock option. The Company estimates the risk-free interest rate based upon the U.S. Department of the Treasury yield curve in effect at award grant for time periods that correspond with the expected term of the awarded stock option. The Company&#x2019;s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the IPO, given the absence of a public trading market, the Company&#x2019;s Board of Directors, with input from management, considered numerous objective and subjective factors to determine the fair value of its common stock. The factors included: (i)&#160;third-party valuations of the Company&#x2019;s common stock; (ii)&#160;the Company&#x2019;s stage of development; (iii)&#160;the status of research and development efforts; (iv)&#160;the rights, preferences and privileges of the Company&#x2019;s preferred stock relative to common stock; (v)&#160;the Company&#x2019;s operating results and financial condition, including the Company&#x2019;s levels of available capital resources; (vi)&#160;equity market conditions affecting comparable public companies; (vii)&#160;general U.S. market conditions; and (viii)&#160;the lack of current marketability of the Company&#x2019;s common stock. Subsequent to the IPO, the fair value of the Company&#x2019;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All stock-based compensation expense is reported in the Statements of Operations and Comprehensive Income (Loss) within "research and development" expense or "general and administrative" expense, based upon the assigned department of the award recipient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(ix) Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reported in the financial statements, as well as operating losses and tax credit carryforwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain due to the Company&#x2019;s historical operating performance and recorded cumulative net losses in prior fiscal periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is recorded to reduce deferred tax assets, because based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If and when the Company were to determine that deferred tax assets are realizable, an adjustment to the corresponding valuation allowance would increase the net income in the period that such determination was made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event that the Company is assessed interest and/or penalties from taxing authorities that have not been previously accrued, such amounts would be included as a component of &#x201c;income tax expense&#x201d; within the Statements of Operations and Comprehensive Income (Loss) in the period the notice was received. To date there have been no interest or penalties charged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simplifying the Accounting for Income Taxes (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2019-12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; removes certain exceptions for performing intraperiod tax allocations, recognizing deferred taxes for investments, and calculating income taxes in interim periods.  The guidance also simplifies the accounting for franchise taxes, transactions that result in a step-up in the tax basis of goodwill, and the effect of enacted changes in tax laws or rates in interim periods.  The Company adopted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2019-12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the first quarter of 2021, which had no material impact to its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(x) Net Income (Loss) per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per share attributable to common stockholders is calculated by dividing the net income (loss) by the weighted-average number of shares of common stock outstanding for the period, without the consideration for potential dilutive shares of common stock. Diluted net income (loss) per share is computed by dividing the net income (loss) by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method, as applicable. The Company&#x2019;s participating securities include unvested common stock awards issued upon early exercise of certain stock options, as early exercised unvested common stock awards have a non-forfeitable right to dividends. The Company&#x2019;s participating securities do not have a contractual obligation to share in the Company&#x2019;s losses, so in periods of net losses, the two-class method of calculating basic and diluted earnings per share is not required. In periods of net income, basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. In periods of net income, net income is attributed to both common stockholders and participating security holders, and therefore, net income is allocated to shares of common stock and participating securities, as if all of the earnings for the period had been distributed. Diluted earnings per share under the two-class method is calculated using the more dilutive of the treasury stock or the two-class method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to a net loss for the three and six months ended June 30, 2020, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in these periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(xi) Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to their short maturities. Derivative instruments (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) are carried at fair value based on unobservable market inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(xii) Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) represents all changes in stockholders&#x2019; equity (deficit), except those resulting from distributions to stockholders. For all periods presented, comprehensive income (loss) was the same as reported net income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(xiii) Recently Issued or Effective Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#x2019;s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these condensed financial statements have been determined by the Company&#x2019;s management to have no impact, or an immaterial impact, on its current and expected future financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NDc_e0779ffa-d53f-4127-a959-a0f8d408f3a5">Basis of Presentation&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information and pursuant to Form 10-Q and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Article 10 of Regulation S-X &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, the accompanying condensed financial statements do not include all of the information and footnotes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim condensed balance sheet as of June&#160;30, 2021, and the interim condensed statements of operations and comprehensive income (loss), changes in preferred stock and stockholders&#x2019; equity and cash flows for the three and six months ended June&#160;30, 2021 and 2020 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial data and other information disclosed in these notes related to the three and six-month periods are also unaudited. The condensed balance sheet as of December 31, 2020 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three and six months ended June&#160;30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021 or any other interim or annual period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited condensed financial statements should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2020 in the Company&#x2019;s Annual Report on Form 10-K (&#x201c;Annual Report&#x201d;) for the fiscal year ended December 31, 2020, as filed with the SEC on March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These amounts may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an on-going basis, management evaluates its most critical estimates and assumptions, including those related to the (i)&#160;fair value of equity-based awards and periodic recognition of stock-based compensation, (ii)&#160;the realization of income tax assets and estimates of tax liabilities, and (iii)&#160;expense accruals related to research and development activities, including clinical trials.  The accounting policies and estimates that most significantly impact the presented amounts within the accompanying condensed financial statements are further described below:&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NTI_ed4ab0bc-466c-4545-9017-79c1319a3bdd">Cash and Cash EquivalentsCash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, with original maturities of three months or less from the purchase date.</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NTM_d423c302-92e7-4463-b271-62705c227132">Restricted CashRestricted cash represents cash held as collateral for the Company&#x2019;s corporate credit card program. Any cash that is legally or contractually restricted from immediate use is classified as restricted cash.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NDU_6a9dd9ac-b3ee-4554-af91-842b6f0ade08">Concentration of Credit Risk and Other Risks and Uncertainties&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents in deposits at financial institutions that exceed federally insured limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the World Health Organization declared a pandemic related to the global novel coronavirus disease 2019 (&#x201c;COVID-19&#x201d;) outbreak. To date, the Company&#x2019;s operations have not been significantly impacted by the COVID-19 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pandemic, though the Company continues to monitor the potential impact COVID-19 may have on its ongoing and planned clinical trials. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak may have on these activities or its financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s results of operations involve numerous risks and uncertainties. Factors that could adversely impact the Company&#x2019;s operating results and business objectives include, but are not limited to, (1) uncertainty of results of clinical trials, (2) uncertainty of regulatory approval of the Company&#x2019;s potential product candidates, including TP-03 for ophthalmic conditions, TP-04 for treatment of skin conditions and TP-05 for prophylaxis of Lyme and community malaria reduction, (3) uncertainty of market acceptance of its product candidates, (4) competition from substitute products and other companies, (5) securing and protecting proprietary technology and strategic relationships, and (6) and dependence on key individuals and sole source suppliers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s product candidates require approvals from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive these necessary approvals. If the Company is denied approval, approval is delayed, or is unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company's business.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NTQ_db62fcb6-6c52-48db-aeda-73fa06757fbb">Property and EquipmentProperty and equipment is stated at historical cost and is depreciated on a straight-line basis over an estimated useful life that corresponds with its designated asset category. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of &#x201c;long-lived assets&#x201d; (which includes property and equipment) whenever events or changes in circumstances in the business indicate that the asset&#x2019;s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NDY_26419d4a-f46e-4808-8fc4-8e38a7529d8c">Revenue Recognition for Out-License Arrangements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently has one out-license arrangement that allows the licensee to market the Company&#x2019;s TP-03 product (representing "functional intellectual property") in certain territories for a certain field of use and for a stated term - see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract, (b) the contract&#x2019;s transaction price for allocation (including variable consideration), (c) the stand-alone selling price for each identified performance obligation, and (d) the timing and amount of  revenue recognition in each period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's out-license arrangement, as described in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, was analyzed under GAAP to determine whether the promised goods or services (which include the license, and know-how, data, and information necessary or reasonably useful for the research, development, manufacture, or commercialization of any license product, and governance committee services) are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is considered to not be distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's out-license arrangement is in exchange for the following forms of consideration: (i) upfront cash payments, (ii) equity-based consideration, (iii) sales royalties, (iv) sales threshold milestones, (v) development milestone fees, and (vi) regulatory milestone fees.  Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied.   The Company evaluates the progress related to each milestone at each reporting &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;period and, if necessary, also adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Terms for Receipt of Payments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual terms that establish the Company&#x2019;s right to collect specified amounts from its customers and the require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Upfront License Fees:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company determines whether non-refundable license consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the out-license.  The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Development Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The Company utilizes the &#x201c;most likely amount&#x201d; method to estimate the amount of consideration to which it will be entitled for achievement of development milestones. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint.  At each reporting period, the Company re-evaluates this associated revenue recognition constraint.  Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, thus reflected in the financial statements in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Regulatory Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company utilizes the &#x201c;most likely amount&#x201d; method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied). Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are constrained for revenue recognition until achievement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under the "sales-or-usage-based royalty exception" the Company recognizes revenue based on the contractual percentage of the licensee&#x2019;s sales to its customers at the later of (i) the occurrence of the related sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from its out-licensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Threshold Milestones:&lt;/span&gt; Similar to royalties, applying the "sales-or-usage-based royalty exception", the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from out-licensing arrangements.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NDg_6eb49c77-8cb0-490c-ba5d-53a37beb2bc1">Research and Development CostsResearch and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. These expenses also include internal costs directly attributable to in-development programs, including cost of certain salaries, payroll taxes, employee benefits, and stock-based compensation expense, as well as laboratory and clinical supplies, pre-clinical and clinical trial related expenses, and the cost of services provided by outside contractors. The Company recognizes expense for pre-clinical studies and clinical trial activities performed by these third parties. This is typically based upon estimates of the proportion of work completed over the term of the individual study or trial, as well as patient enrollment and dosing events in accordance with agreements established with clinical research organizations ("CROs") and clinical trial or pre-clinical study sites.&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered, and may continue to enter into, license agreements to access and utilize intellectual property for drug development. In each case, the Company evaluates if the assets acquired in a transaction represent the acquisition of an as&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;set or a business, as defined under applicable GAAP. The Company&#x2019;s executed in-license agreements (see &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8(b)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) were evaluated and determined to represent asset acquisitions. Because these assets have not yet received regulatory approval&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and have no alternative future uses, the purchase price for each was immediately recognized as research and development expense. In addition, any future milestone payments (whether in the form of cash or stock) made before product regulatory approval (that do not meet the definition of a derivative) will also be immediately recognized as research and development expense when paid or becomes payable, provided there is no alternative future use of the rights in other research and development projects.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NDM_ab101c56-a7c3-4c2f-b8e1-1a91bf2dce65">Stock-Based Compensation&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense is recognized for all equity awards granted to employees, consultants, and members of the Company&#x2019;s Board of Directors and is recognized at fair value. For stock-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date is the date of grant and the related expense is recognized on a straight-line basis over each award&#x2019;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes compensation cost if and when it concludes that it is probable that the performance condition will be achieved and the related expense is recognized on an accelerated attribution method. As applicable, the Company reverses previously recognized expense for forfeitures of unvested awards in the period of occurrence. The Company uses the Black-Scholes pricing model to estimate the fair value of stock option awards as of the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The measurement of the fair value of stock-based awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#x2019;s judgment, including (a)&#160;the fair value of the Company&#x2019;s common stock on the date of the option grant, (b)&#160;the expected term of the stock option until its exercise by the recipient, (c)&#160;stock price volatility over the expected term, (d)&#160;the prevailing risk-free interest rate over the expected term, and (e)&#160;expected dividend payments over the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management estimates the expected term of awarded stock options utilizing the &#x201c;simplified method&#x201d; for awards as the Company does not yet have sufficient exercise history since its November 2016 formation. Further, prior to the IPO, the Company was privately-held and therefore lacked company-specific historical and implied volatility information of its stock.&#160;Accordingly, management estimated this expected volatility based on a designated peer-group of publicly-traded companies for a look-back period, as of the date of grant, that corresponded with the expected term of the awarded stock option. The Company estimates the risk-free interest rate based upon the U.S. Department of the Treasury yield curve in effect at award grant for time periods that correspond with the expected term of the awarded stock option. The Company&#x2019;s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the IPO, given the absence of a public trading market, the Company&#x2019;s Board of Directors, with input from management, considered numerous objective and subjective factors to determine the fair value of its common stock. The factors included: (i)&#160;third-party valuations of the Company&#x2019;s common stock; (ii)&#160;the Company&#x2019;s stage of development; (iii)&#160;the status of research and development efforts; (iv)&#160;the rights, preferences and privileges of the Company&#x2019;s preferred stock relative to common stock; (v)&#160;the Company&#x2019;s operating results and financial condition, including the Company&#x2019;s levels of available capital resources; (vi)&#160;equity market conditions affecting comparable public companies; (vii)&#160;general U.S. market conditions; and (viii)&#160;the lack of current marketability of the Company&#x2019;s common stock. Subsequent to the IPO, the fair value of the Company&#x2019;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All stock-based compensation expense is reported in the Statements of Operations and Comprehensive Income (Loss) within "research and development" expense or "general and administrative" expense, based upon the assigned department of the award recipient.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NTU_73b2f569-2b26-4a01-9f30-c9bda0ea4487">Income TaxesIncome taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts &lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reported in the financial statements, as well as operating losses and tax credit carryforwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain due to the Company&#x2019;s historical operating performance and recorded cumulative net losses in prior fiscal periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is recorded to reduce deferred tax assets, because based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If and when the Company were to determine that deferred tax assets are realizable, an adjustment to the corresponding valuation allowance would increase the net income in the period that such determination was made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event that the Company is assessed interest and/or penalties from taxing authorities that have not been previously accrued, such amounts would be included as a component of &#x201c;income tax expense&#x201d; within the Statements of Operations and Comprehensive Income (Loss) in the period the notice was received. To date there have been no interest or penalties charged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simplifying the Accounting for Income Taxes (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2019-12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; removes certain exceptions for performing intraperiod tax allocations, recognizing deferred taxes for investments, and calculating income taxes in interim periods.  The guidance also simplifies the accounting for franchise taxes, transactions that result in a step-up in the tax basis of goodwill, and the effect of enacted changes in tax laws or rates in interim periods.  The Company adopted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2019-12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the first quarter of 2021, which had no material impact to its financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NDk_14547057-bae4-465e-8fec-219844c4d25a">Net Income (Loss) per Share Attributable to Common Stockholders&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per share attributable to common stockholders is calculated by dividing the net income (loss) by the weighted-average number of shares of common stock outstanding for the period, without the consideration for potential dilutive shares of common stock. Diluted net income (loss) per share is computed by dividing the net income (loss) by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method, as applicable. The Company&#x2019;s participating securities include unvested common stock awards issued upon early exercise of certain stock options, as early exercised unvested common stock awards have a non-forfeitable right to dividends. The Company&#x2019;s participating securities do not have a contractual obligation to share in the Company&#x2019;s losses, so in periods of net losses, the two-class method of calculating basic and diluted earnings per share is not required. In periods of net income, basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. In periods of net income, net income is attributed to both common stockholders and participating security holders, and therefore, net income is allocated to shares of common stock and participating securities, as if all of the earnings for the period had been distributed. Diluted earnings per share under the two-class method is calculated using the more dilutive of the treasury stock or the two-class method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to a net loss for the three and six months ended June 30, 2020, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in these periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NTA_dc25356d-e96b-48f0-922b-21c93e12fc5a">Fair Value MeasurementsAssets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to their short maturities. Derivative instruments (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) are carried at fair value based on unobservable market inputs.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NTY_3b04349d-9d16-45bf-a797-bcba80846f7c">Comprehensive Income (Loss)Comprehensive income (loss) represents all changes in stockholders&#x2019; equity (deficit), except those resulting from distributions to stockholders. For all periods presented, comprehensive income (loss) was the same as reported net income (loss).</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80MC9mcmFnOjFhMDA5MGZlZDJiNTQ1MjBiYzkwMWFhNjA2ODBkOGJmL3RleHRyZWdpb246MWEwMDkwZmVkMmI1NDUyMGJjOTAxYWE2MDY4MGQ4YmZfMjU0NDQ_c590390f-0e7a-4185-82a0-13b81a0a1b0d">Recently Issued or Effective Accounting StandardsRecently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#x2019;s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these condensed financial statements have been determined by the Company&#x2019;s management to have no impact, or an immaterial impact, on its current and expected future financial position, results of operations, or cash flows.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RleHRyZWdpb246MmU2ZGQ3YTJkNmU0NDBmMzg3M2UyOTVlN2NiOWNhOWFfMjQyNw_f5b58195-50d5-42a1-ba65-7cc03d8d15f8">BALANCE SHEET ACCOUNT DETAIL&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The composition of selected financial statement captions that comprise the accompanying balance sheets are summarized below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(a) Property and Equipment, net of Accumulated Depreciation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Property and equipment, net of accumulated depreciation&#x201d; consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Less): Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net of accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense (included within &#x201c;total operating expenses&#x201d; in the accompanying Statements of Operations and Comprehensive Income (Loss)) for the three months ended June 30, 2021 and 2020 was $125 thousand and $17 thousand, respectively, and for the six months ended June 30, 2021 and 2020 was $189 thousand and $32 thousand, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(b) Other Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;"Other assets" consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity warrant rights*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;              *In January 2020, the FASB issued &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Update No. 2020-01, Investments&#x2014;Equity Securities (Topic 321), &#160;&#160;&#160;&#160;                   Investments&#x2014;Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)&#x2014;Clarifying the Interactions between Topic 321, Topic 323, and Topic 815&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (a consensus of the Emerging Issues Task Force), which clarifies the interaction of the accounting for equity securities, investments accounted for under the equity method, and certain forward contracts and purchased options. This update is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The Company is in the process of determining the impact the adoption will have on its financial statements, beginning as of and for the three months ending March 31, 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(c) Accounts Payable and Other Accrued Liabilities&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Accounts payable and other accrued liabilities&#x201d; consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical studies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock option early exercise liability, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(d) Other Long-Term Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Other long-term liabilities&#x201d; consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock option early exercise liability, non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RleHRyZWdpb246MmU2ZGQ3YTJkNmU0NDBmMzg3M2UyOTVlN2NiOWNhOWFfMjQyOA_2b2442d0-72e9-420f-a3eb-8bbf7a43ecfd">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Property and equipment, net of accumulated depreciation&#x201d; consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Less): Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net of accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i366691130c6c4705a075c2827729e560_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfMS0xLTEtMS0w_ad074135-8986-4ad1-8517-a84b05c79f0f"
      unitRef="usd">365000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0c14c67cea444f0bb19eaae7c5445028_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfMS0zLTEtMS0w_423611db-6fec-48d1-b0b6-7a871ff16d2f"
      unitRef="usd">294000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i652b87a7987044cca7f42704ba156268_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfMi0xLTEtMS0w_1a55f26d-2535-47c7-a113-fd41526a9e9b"
      unitRef="usd">52000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic9b8f6a5a48541248c73d37edf6dcbae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfMi0zLTEtMS0w_5339ff47-55bf-4fe4-9f78-8aa17b7dcb6d"
      unitRef="usd">74000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0ad7dbb20ff542cab6548bbf1e554538_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfMy0xLTEtMS0w_1f3cfe7e-0cb5-4aaf-b7a8-1058d3fc1404"
      unitRef="usd">167000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifac36b8ba5a54e45b43ad3707581ea5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfMy0zLTEtMS0w_60e3ceef-a28c-44e5-885b-f59e04e8b506"
      unitRef="usd">173000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia344278fd11e4e599d06a16dbef3dac0_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfNC0xLTEtMS0w_7d35b09b-3df3-47ab-bf50-1897634cea95"
      unitRef="usd">163000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id9254bbc4390429eadabae632a1ee8ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfNC0zLTEtMS0w_854a0a6e-995d-4de8-bd85-9c8446064600"
      unitRef="usd">141000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfNS0xLTEtMS0w_5f9f303a-fa9c-48b6-880a-89d889734f2e"
      unitRef="usd">747000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfNS0zLTEtMS0w_44a1265a-67c6-4241-ac16-de73766203ae"
      unitRef="usd">682000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfNi0xLTEtMS0w_1f7e0fe8-9ad9-4ed2-8a3f-5186ee92645c"
      unitRef="usd">266000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfNi0zLTEtMS0w_2f1d4e6e-c6ed-4570-b48e-a17ba20b64da"
      unitRef="usd">134000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfNy0xLTEtMS0w_f2969bd5-dcb3-4864-a19c-e8ebbc39df38"
      unitRef="usd">481000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjlmZTBhNGFkMmU4MzQyMjU5ZmU4ODI4YjI0MGExMjZmL3RhYmxlcmFuZ2U6OWZlMGE0YWQyZTgzNDIyNTlmZTg4MjhiMjQwYTEyNmZfNy0zLTEtMS0w_7174105e-5679-47e9-aff7-ab40ce56ebca"
      unitRef="usd">548000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RleHRyZWdpb246MmU2ZGQ3YTJkNmU0NDBmMzg3M2UyOTVlN2NiOWNhOWFfMjE5OTAyMzI1ODAyOA_09bc6c84-feec-4ce3-8be3-a89b8046c2a1"
      unitRef="usd">125000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RleHRyZWdpb246MmU2ZGQ3YTJkNmU0NDBmMzg3M2UyOTVlN2NiOWNhOWFfMzI5ODUzNDg4NTkyNA_d509aae5-9c19-4f0d-bff6-435b83854047"
      unitRef="usd">17000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RleHRyZWdpb246MmU2ZGQ3YTJkNmU0NDBmMzg3M2UyOTVlN2NiOWNhOWFfMzI5ODUzNDg4NTkxOQ_905fd9f6-1f33-4415-a9ac-dcc043feaee9"
      unitRef="usd">189000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RleHRyZWdpb246MmU2ZGQ3YTJkNmU0NDBmMzg3M2UyOTVlN2NiOWNhOWFfNDgz_f0c1c76d-ad0e-4159-9c65-06038d0b563a"
      unitRef="usd">32000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RleHRyZWdpb246MmU2ZGQ3YTJkNmU0NDBmMzg3M2UyOTVlN2NiOWNhOWFfMjQyNA_0bc157f1-36dd-47b1-ad54-257ed6e8685d">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;"Other assets" consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity warrant rights*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;              *In January 2020, the FASB issued &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Update No. 2020-01, Investments&#x2014;Equity Securities (Topic 321), &#160;&#160;&#160;&#160;                   Investments&#x2014;Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)&#x2014;Clarifying the Interactions between Topic 321, Topic 323, and Topic 815&lt;/span&gt; (a consensus of the Emerging Issues Task Force), which clarifies the interaction of the accounting for equity securities, investments accounted for under the equity method, and certain forward contracts and purchased options. This update is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The Company is in the process of determining the impact the adoption will have on its financial statements, beginning as of and for the three months ending March 31, 2022.</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <us-gaap:DepositAssets
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmZiY2Q3Yjc2NDUzODQ0MmQ5ZGFmZTE1MzEzZGMzOTFhL3RhYmxlcmFuZ2U6ZmJjZDdiNzY0NTM4NDQyZDlkYWZlMTUzMTNkYzM5MWFfMS0xLTEtMS0w_50629ea0-968e-4619-89ed-6ec5f5873094"
      unitRef="usd">27000</us-gaap:DepositAssets>
    <us-gaap:DepositAssets
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmZiY2Q3Yjc2NDUzODQ0MmQ5ZGFmZTE1MzEzZGMzOTFhL3RhYmxlcmFuZ2U6ZmJjZDdiNzY0NTM4NDQyZDlkYWZlMTUzMTNkYzM5MWFfMS0zLTEtMS0w_33051b02-45c3-496f-81e7-85dac14ebe3b"
      unitRef="usd">33000</us-gaap:DepositAssets>
    <tars:EquityWarrantRights
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmZiY2Q3Yjc2NDUzODQ0MmQ5ZGFmZTE1MzEzZGMzOTFhL3RhYmxlcmFuZ2U6ZmJjZDdiNzY0NTM4NDQyZDlkYWZlMTUzMTNkYzM5MWFfMi0xLTEtMS0w_5654109f-37f5-4ce9-ab59-28ada0fa532f"
      unitRef="usd">1076000</tars:EquityWarrantRights>
    <tars:EquityWarrantRights
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmZiY2Q3Yjc2NDUzODQ0MmQ5ZGFmZTE1MzEzZGMzOTFhL3RhYmxlcmFuZ2U6ZmJjZDdiNzY0NTM4NDQyZDlkYWZlMTUzMTNkYzM5MWFfMi0zLTEtMS0w_ba50d641-e390-4ffa-b578-0e704564de66"
      unitRef="usd">0</tars:EquityWarrantRights>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmZiY2Q3Yjc2NDUzODQ0MmQ5ZGFmZTE1MzEzZGMzOTFhL3RhYmxlcmFuZ2U6ZmJjZDdiNzY0NTM4NDQyZDlkYWZlMTUzMTNkYzM5MWFfMy0xLTEtMS0w_f87d5839-2d8a-457d-8a1c-3443bec2cf2c"
      unitRef="usd">422000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmZiY2Q3Yjc2NDUzODQ0MmQ5ZGFmZTE1MzEzZGMzOTFhL3RhYmxlcmFuZ2U6ZmJjZDdiNzY0NTM4NDQyZDlkYWZlMTUzMTNkYzM5MWFfMy0zLTEtMS0w_5e099a0b-7d81-4edc-be0e-6365c83131eb"
      unitRef="usd">48000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmZiY2Q3Yjc2NDUzODQ0MmQ5ZGFmZTE1MzEzZGMzOTFhL3RhYmxlcmFuZ2U6ZmJjZDdiNzY0NTM4NDQyZDlkYWZlMTUzMTNkYzM5MWFfNC0xLTEtMS0w_b9d766ec-64a7-42a3-9c6f-368654fb8410"
      unitRef="usd">1525000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmZiY2Q3Yjc2NDUzODQ0MmQ5ZGFmZTE1MzEzZGMzOTFhL3RhYmxlcmFuZ2U6ZmJjZDdiNzY0NTM4NDQyZDlkYWZlMTUzMTNkYzM5MWFfNC0zLTEtMS0w_d65c8cdc-b889-4c4e-b1dc-6166ec24d50f"
      unitRef="usd">81000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RleHRyZWdpb246MmU2ZGQ3YTJkNmU0NDBmMzg3M2UyOTVlN2NiOWNhOWFfMjQyNQ_701698e7-46a4-4f92-98ae-be626f6a433a">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Accounts payable and other accrued liabilities&#x201d; consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical studies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock option early exercise liability, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfMS0xLTEtMS0w_2691d613-c2f4-473b-bbd5-6744820811e4"
      unitRef="usd">3303000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfMS0zLTEtMS0w_8975a806-6aae-4d03-bef5-511641eb0363"
      unitRef="usd">2237000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfMy0xLTEtMS0w_b7e575d8-d280-4293-8789-fed2b272668a"
      unitRef="usd">229000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfMy0zLTEtMS0w_d8825308-a670-4fd9-8b09-8e172bafd1f5"
      unitRef="usd">282000</us-gaap:OperatingLeaseLiabilityCurrent>
    <tars:AccruedClinicalStudiesCurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNC0xLTEtMS0w_1deab10f-8534-462d-96f8-c14865c355bc"
      unitRef="usd">3358000</tars:AccruedClinicalStudiesCurrent>
    <tars:AccruedClinicalStudiesCurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNC0zLTEtMS0w_1e79202c-a47b-43e7-9aa4-285b04b0406d"
      unitRef="usd">1524000</tars:AccruedClinicalStudiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNS0xLTEtMS03NzI_d763681d-6e89-44af-a6d4-1c78aad93858"
      unitRef="usd">1504000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNS0zLTEtMS03NzI_668f1060-60bd-42ce-9bab-0662664748e8"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNS0xLTEtMS0w_10d008ce-fff3-46fe-8572-33195733a66e"
      unitRef="usd">342000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNS0zLTEtMS0w_2b043429-0b7f-4332-9584-f474061978e4"
      unitRef="usd">0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNi0xLTEtMS0w_df58449e-3da6-4d80-977b-f821a4cb9df0"
      unitRef="usd">249000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNi0zLTEtMS0w_1292f6ca-0d79-48e8-a585-6476716e170d"
      unitRef="usd">304000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNy0xLTEtMS0w_a58fe3ec-5d22-471c-95e2-49d377697405"
      unitRef="usd">8985000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOmI0YzBlNDQxODNkZDQwZjI4MjM4ZDlmNzFkN2MxY2JhL3RhYmxlcmFuZ2U6YjRjMGU0NDE4M2RkNDBmMjgyMzhkOWY3MWQ3YzFjYmFfNy0zLTEtMS0w_ff2aef19-acd0-4b22-bc01-03cecfd0c123"
      unitRef="usd">4347000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesTableTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RleHRyZWdpb246MmU2ZGQ3YTJkNmU0NDBmMzg3M2UyOTVlN2NiOWNhOWFfMjQyNg_45483a33-d8e8-40c8-8fe8-04705152a523">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Other long-term liabilities&#x201d; consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock option early exercise liability, non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjExMGMyYzg1Y2Q5NjQ1YjJiZmI0MmQ4MDc2MmI3MTdhL3RhYmxlcmFuZ2U6MTEwYzJjODVjZDk2NDViMmJmYjQyZDgwNzYyYjcxN2FfMS0xLTEtMS0w_7dc22164-bc4b-4590-b9e9-351648b5f429"
      unitRef="usd">405000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjExMGMyYzg1Y2Q5NjQ1YjJiZmI0MmQ4MDc2MmI3MTdhL3RhYmxlcmFuZ2U6MTEwYzJjODVjZDk2NDViMmJmYjQyZDgwNzYyYjcxN2FfMS0zLTEtMS0w_b76ae388-a1e8-445c-b6fe-77e6f3d9eb9b"
      unitRef="usd">549000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjExMGMyYzg1Y2Q5NjQ1YjJiZmI0MmQ4MDc2MmI3MTdhL3RhYmxlcmFuZ2U6MTEwYzJjODVjZDk2NDViMmJmYjQyZDgwNzYyYjcxN2FfMi0xLTEtMS0w_d95f776a-2ecb-4c59-954a-1443545b1c80"
      unitRef="usd">107000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjExMGMyYzg1Y2Q5NjQ1YjJiZmI0MmQ4MDc2MmI3MTdhL3RhYmxlcmFuZ2U6MTEwYzJjODVjZDk2NDViMmJmYjQyZDgwNzYyYjcxN2FfMi0zLTEtMS0w_3c955c6a-4fb3-42f1-ad47-0448dafbd977"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjExMGMyYzg1Y2Q5NjQ1YjJiZmI0MmQ4MDc2MmI3MTdhL3RhYmxlcmFuZ2U6MTEwYzJjODVjZDk2NDViMmJmYjQyZDgwNzYyYjcxN2FfMy0xLTEtMS0w_8df2c36c-1405-4392-b712-4cb189383e2f"
      unitRef="usd">12000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjExMGMyYzg1Y2Q5NjQ1YjJiZmI0MmQ4MDc2MmI3MTdhL3RhYmxlcmFuZ2U6MTEwYzJjODVjZDk2NDViMmJmYjQyZDgwNzYyYjcxN2FfMy0zLTEtMS0w_cccc86ca-5be9-453d-8a2f-138e08077232"
      unitRef="usd">56000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjExMGMyYzg1Y2Q5NjQ1YjJiZmI0MmQ4MDc2MmI3MTdhL3RhYmxlcmFuZ2U6MTEwYzJjODVjZDk2NDViMmJmYjQyZDgwNzYyYjcxN2FfNC0xLTEtMS0w_d427eeea-a81a-4f34-9fa2-6e369932cf1d"
      unitRef="usd">524000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80My9mcmFnOjJlNmRkN2EyZDZlNDQwZjM4NzNlMjk1ZTdjYjljYTlhL3RhYmxlOjExMGMyYzg1Y2Q5NjQ1YjJiZmI0MmQ4MDc2MmI3MTdhL3RhYmxlcmFuZ2U6MTEwYzJjODVjZDk2NDViMmJmYjQyZDgwNzYyYjcxN2FfNC0zLTEtMS0w_c4a4e73a-de26-423c-a3a1-6b1c8eaf9f21"
      unitRef="usd">605000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfOTQ1_79553214-ba04-4e62-a44d-c504c5c4d77b">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Authorized Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the October 2020 Amended and Restated Certificate of Incorporation, the Company is authorized to issue two classes of stock: common and preferred&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The total number of shares authorized for issuance is 200.0 million shares of common stock and 10.0 million shares of preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Overview and Reserve for Future Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stockholders have one vote for each share of common stock held and are entitled to receive any dividends declared by the Company&#x2019;s Board of Directors when legally available for distribution, then-subject to the dividend rights of the holders of preferred stock. For the three and six months ended June 30, 2021 and for the year ended December&#160;31, 2020, no dividends were declared.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021 and December&#160;31, 2020, the Company had 20.7 million and 20.5 million shares of common stock issued, respectively. At June&#160;30, 2021 and December&#160;31, 2020, the Company had 20.6 million, an&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d 20.3 million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares of common stock outstanding, respectively. The following shares of common stock were reserved for issuance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options issued and outstanding &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,598,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,836,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock awards reserved for future grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,451,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,414,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total shares of common stock reserved&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,054,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,250,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfMjUz_e91d157c-a432-47e7-ba55-161de67616bf"
      unitRef="shares">200000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfMjgz_b0c07bcb-d2c3-4f35-ad50-8133c976ad41"
      unitRef="shares">10000000.0</us-gaap:TemporaryEquitySharesAuthorized>
    <tars:CommonStockNumberOfVotes
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfMzky_ea9e56a1-8b06-4705-b601-7cd304f3fd80"
      unitRef="vote">1</tars:CommonStockNumberOfVotes>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfNjcz_65a27fb3-bada-49d3-b392-6316edb168d8"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i4fa02c7ace144c81a2fd09a81a1d827c_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfNjcz_c565af56-f8aa-4992-b41c-a4c1a02f721e"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockSharesIssued
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfNzM0_062ae3ec-888a-41e5-96b6-20e06fd9da3b"
      unitRef="shares">20700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfNzQx_74df4529-d006-4c4e-a40e-16acf193f112"
      unitRef="shares">20500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfODE5_1ff6a610-76f1-42a9-a776-8c736b097da0"
      unitRef="shares">20600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfODI3_c8652c4a-acb6-4bb7-8047-6189c31fe34b"
      unitRef="shares">20300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RleHRyZWdpb246ZTUzYzg4ZjQwMWM3NGUyOWFmZDdlOTQ3OWU2YWEwZWNfOTQ2_c59639bb-fded-4fc2-bf34-665d7a688d27">The following shares of common stock were reserved for issuance:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options issued and outstanding &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,598,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,836,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock awards reserved for future grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,451,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,414,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total shares of common stock reserved&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,054,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,250,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RhYmxlOjYwMTliYzg3MGY5MTQ2Y2JhM2VjNDExYmNlMzQxODM4L3RhYmxlcmFuZ2U6NjAxOWJjODcwZjkxNDZjYmEzZWM0MTFiY2UzNDE4MzhfMi0xLTEtMS0w_01fec5a0-61f8-4195-b037-f8dbeb964981"
      unitRef="shares">2598764</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RhYmxlOjYwMTliYzg3MGY5MTQ2Y2JhM2VjNDExYmNlMzQxODM4L3RhYmxlcmFuZ2U6NjAxOWJjODcwZjkxNDZjYmEzZWM0MTFiY2UzNDE4MzhfMi0zLTEtMS0w_cd92b9ba-2cdd-48f2-8baa-e0494c9e6b52"
      unitRef="shares">1836739</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RhYmxlOjYwMTliYzg3MGY5MTQ2Y2JhM2VjNDExYmNlMzQxODM4L3RhYmxlcmFuZ2U6NjAxOWJjODcwZjkxNDZjYmEzZWM0MTFiY2UzNDE4MzhfMy0xLTEtMS0w_3bc3c577-8a77-4117-90b8-9a362f63706f"
      unitRef="shares">9451191</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RhYmxlOjYwMTliYzg3MGY5MTQ2Y2JhM2VjNDExYmNlMzQxODM4L3RhYmxlcmFuZ2U6NjAxOWJjODcwZjkxNDZjYmEzZWM0MTFiY2UzNDE4MzhfMy0zLTEtMS0w_e9ea2c81-cf25-4692-90a9-3b8c190bebce"
      unitRef="shares">9414091</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RhYmxlOjYwMTliYzg3MGY5MTQ2Y2JhM2VjNDExYmNlMzQxODM4L3RhYmxlcmFuZ2U6NjAxOWJjODcwZjkxNDZjYmEzZWM0MTFiY2UzNDE4MzhfNC0xLTEtMS03NTY_f42ea0d3-67cb-4d21-b0c4-1b7236a22429"
      unitRef="shares">4257</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RhYmxlOjYwMTliYzg3MGY5MTQ2Y2JhM2VjNDExYmNlMzQxODM4L3RhYmxlcmFuZ2U6NjAxOWJjODcwZjkxNDZjYmEzZWM0MTFiY2UzNDE4MzhfNC0zLTEtMS03NTY_6c9317e4-3a10-406f-89c2-bbb6cbe4b9e9"
      unitRef="shares">0</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RhYmxlOjYwMTliYzg3MGY5MTQ2Y2JhM2VjNDExYmNlMzQxODM4L3RhYmxlcmFuZ2U6NjAxOWJjODcwZjkxNDZjYmEzZWM0MTFiY2UzNDE4MzhfNC0xLTEtMS0w_5d90fafa-451d-40ae-b30e-10c5990ed32b"
      unitRef="shares">12054212</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80Ni9mcmFnOmU1M2M4OGY0MDFjNzRlMjlhZmQ3ZTk0NzllNmFhMGVjL3RhYmxlOjYwMTliYzg3MGY5MTQ2Y2JhM2VjNDExYmNlMzQxODM4L3RhYmxlcmFuZ2U6NjAxOWJjODcwZjkxNDZjYmEzZWM0MTFiY2UzNDE4MzhfNC0zLTEtMS0w_a7183d9e-63cb-4695-bbd2-2963b6e31750"
      unitRef="shares">11250830</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfNDM0MA_bcf124fa-ca6a-4a79-989f-3d3f2abf259b">STOCK-BASED COMPENSATION&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 and 2016 Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Board of Directors and stockholders adopted and approved the Company's 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;) on October 8, 2020. The 2020 Plan replaced the Company's 2016 Equity Incentive Plan that was earlier adopted in December 2016 (the &#x201c;2016 Plan&#x201d;).  However, awards outstanding under the 2016 Plan will continue to be governed by its original terms. The number of shares of the Company's common stock that were initially available for issuance under the 2020 Plan equaled the initial sum of 9,000,000 shares &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;plus&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2,432,980 shares that were then available for issuance under the 2016 Plan. The 2020 Plan provides for the following types of awards: incentive and non-statutory stock options, stock appreciation rights, restricted shares, and restricted stock units.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of shares of common stock reserved for issuance under the 2020 Plan are increased automatically on the first business day of each fiscal year, commencing in 2021 and ending in 2030, by a number equal to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;lesser of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: (i) 4% of the shares of common stock outstanding on the last day of the prior fiscal year; or (ii) the number of shares determined by the Company's Board of Directors. In general, to the extent that any awards under the 2020 Plan are forfeited, terminate, expire or lapse without the issuance of shares, or if the Company reacquires the shares subject to awards granted under the 2020 Plan, those shares will again become available for issuance under the 2020 Plan, as will shares applied to pay the exercise or purchase price of an award or to satisfy tax withholding obligations related to any award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based awards are governed by agreements between the Company and the recipients. Incentive stock options and nonqualified stock options may be granted under the 2020 Plan (and previously the 2016 Plan) at an exercise price of not less than 100% of the fair market value of common stock on the respective date of grant.  The grant date is the date the terms of the award are formally approved by the Company&#x2019;s Board of Directors or its designee. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through June&#160;30, 2021, all awards issued under the 2020 Plan and 2016 Plan were in the form of stock options and restricted stock units. These stock award agreements have service and/or performance conditions for vesting, unless immediately vested on the date of grant. Stock awards granted typically have &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfMjM4Ng_487f5d4f-2795-4d06-a86b-a0f73cdced0d"&gt;one&lt;/span&gt; to four-year service conditions for full vesting. The performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options must be exercised, if at all, no later than 10 years from the date of grant. Upon termination of employment, vested stock options may be exercised within 12 months after the date of termination upon death, six months after the date of termination upon disability, and three months after the date of termination for all other separations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Summary&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense is recorded in the accompanying condensed statements of operations and comprehensive income (loss) based on the assigned or designated department of the award recipient. Stock-based compensation expense for the three and six months ended June 30, 2021 and 2020 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pre-Vesting Exercise Feature of Certain Stock Options &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2016 Plan permitted certain option holders to exercise awarded options prior to vesting. Upon this early exercise, the options became subject to a restricted stock agreement and remain subject to the same vesting provisions in the corresponding stock option award. These unvested options are subject to repurchase by the Company upon employee termination at the same price exercised. These unvested shares of common stock are reported as issued (but not outstanding) on the accompanying Balance Sheets while subject to repurchase by the Company. These shares are also excluded from the basic net income (loss) per share until the repurchase right lapses upon vesting, but are included in the diluted net income per share for the three and six months ended June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;The Company initially records a liability for these early exercises that is subsequently reclassified into stockholders&#x2019; equity on a pro rata basis as vesting occurs. As of June&#160;30, 2021 and December&#160;31, 2020, the Company recorded the unvested portion of the exercise proceeds of $0.3 million and $0.4 million, respectively, as a liability from the early exercise in the accompanying Balance Sheets.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i160de614ede245e3b4a8318dd5566a1f_I20201020"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfNTcy_ff74eef3-7928-4b65-968e-47478a2a5d6a"
      unitRef="shares">9000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i4417090679e84025a7090d9e6076ba21_I20201020"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfNTg3_61d4f3d3-7b2e-485a-8716-c7b0945ce471"
      unitRef="shares">2432980</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease
      contextRef="ide340ac61efb43b08434911f4db98e68_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfMTA2NQ_8aaedf96-c9d3-4206-b31a-f84faf634546"
      unitRef="number">0.04</tars:CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease>
    <tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue
      contextRef="i70a7676a97b848b1a1f7a3665d148983_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfMTkxOA_4a498b1a-439a-44d6-90f6-885d29221fae"
      unitRef="number">1</tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ia1441e738b9045918e9a7e31197dd133_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfNDM0MQ_42dd39d3-bd70-4e8c-af3f-9f3617a29a50">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="id52f2032269a4f819d15bd4d1e161a3b_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfMjY3NA_929eda63-9311-4495-8e4c-aa2dbcc391b3">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath
      contextRef="id52f2032269a4f819d15bd4d1e161a3b_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfMjc3OA_1df8e417-a4dc-4144-9b72-5abc3c8bbd34">P12M</tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath>
    <tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability
      contextRef="id52f2032269a4f819d15bd4d1e161a3b_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfMjgyMw_c0d5c0f5-addf-4e48-89de-bf27df09541f">P6M</tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability>
    <tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations
      contextRef="id52f2032269a4f819d15bd4d1e161a3b_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfMjg3Nw_9f5089e1-6e38-4eea-8ba9-2c7486eb680b">P3M</tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfNDM0Mg_b3068d9c-15af-4c66-b6e6-272ce167eef8">Stock-based compensation expense for the three and six months ended June 30, 2021 and 2020 was as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia382e48d34b4428fafebec87724739c8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfMi0xLTEtMS0w_3726f7ed-9381-486c-9487-612663cac5b9"
      unitRef="usd">427000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i09be892cb78f4a5492f5791c5d513c0a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfMi0zLTEtMS0w_44d6b5d7-13a8-401b-9dc6-3895980e9c1b"
      unitRef="usd">14000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i54c21ad7a9fe43c996fb0628c1fd4ac4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfMi01LTEtMS0w_5106e14f-6b9a-4f3d-b2cb-7c5e3baca061"
      unitRef="usd">771000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie004d19f0fd443d5b88f07a7468ee270_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfMi03LTEtMS0w_fb289f83-db6d-46ab-8a10-257100fd0465"
      unitRef="usd">15000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idaa289cd736c437987015fee0950c75c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfMy0xLTEtMS0w_144ed55f-605a-439f-96c8-33b02ba1c38c"
      unitRef="usd">2367000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i42649f1122f8480785c73d82be5bd8dc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfMy0zLTEtMS0w_a39ec3a6-4d9e-4590-8b40-6f75d994e244"
      unitRef="usd">159000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i52aedec7a8084e91bca615af7ebec95a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfMy01LTEtMS0w_d1634125-6554-4a3c-82ed-4395397488d4"
      unitRef="usd">3386000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icea321863db444169b622b85850d6e55_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfMy03LTEtMS0w_96229abc-5dd2-40fa-903a-948c3ec8e49a"
      unitRef="usd">162000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfNC0xLTEtMS0w_09c7fb07-5693-4134-a965-fc81194e6015"
      unitRef="usd">2794000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfNC0zLTEtMS0w_1219d366-cfab-4f00-9161-9e0b3402a035"
      unitRef="usd">173000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfNC01LTEtMS0w_be3d9e83-3aba-4db2-9926-59c99058b419"
      unitRef="usd">4157000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RhYmxlOjhiZTU1MTRjZWNkNTQzOTM4NjFmNTUxZWJmNTJiNGEwL3RhYmxlcmFuZ2U6OGJlNTUxNGNlY2Q1NDM5Mzg2MWY1NTFlYmY1MmI0YTBfNC03LTEtMS0w_8b2e5a69-c01f-47a6-bbc0-2090d4407378"
      unitRef="usd">177000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfNDI2Mw_6486e611-a8d4-4c30-9b0a-3848f7ee2546"
      unitRef="usd">300000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfMzI5ODUzNDg4NzY5OA_944d7725-f495-4329-9d90-4858b078a279"
      unitRef="usd">400000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMTQxMw_a9b1bd36-ca20-435e-961a-4a6c4d1265d9">NET INCOME (LOSS) PER SHARE&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company permits certain option holders to exercise awarded options prior to vesting (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). Upon this early exercise, these options become subject to a restricted stock agreement and remain subject to the same vesting provisions in the corresponding stock option award. These early exercised options are considered to be "participating securities" due to non-forfeitable right to dividends (i.e., even prior to vesting). For the three and six months ended June 30, 2021, the "two-class method" was utilized to calculate diluted net income per share as it was more dilutive than the "treasury stock metho&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d". Due to a net loss for the three months ended March 31, 2020, all otherwise potentially dilutive securities are antidilutive. Accordingly, basic net loss per share equals diluted net loss per share for the three and six months ended June 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; table sets forth the computation of basic and diluted net loss per share attributable to common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: undistributed income allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,555,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,651,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,446,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,650,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share attributable to common stockholders&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: undistributed income reallocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,555,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,651,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,446,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,650,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,449,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,966,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,651,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,895,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,650,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share attributable to common stockholders&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; three and six months ended June&#160;30, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 0.8&#160;million unexercised stock options were excluded from the computation of n&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;et income per share because the effect would have been anti-dilutive. Additionally, during the three and six months ended June 30, 2020, 1.2&#160;million unexercised stock options, 8.2&#160;million shares of preferred stock, and 67&#160;thousand early-exercised and unvested stock options were excluded from the calculation of diluted net loss per share attributable to common stockholders because their impact under the &#x201c;treasury stock method&#x201d; and "if-converted metho&lt;/span&gt;d" would have been anti-dilutive.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMTQxNA_5018d555-827d-4aab-9820-ad15f52b4450">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company permits certain option holders to exercise awarded options prior to vesting (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). Upon this early exercise, these options become subject to a restricted stock agreement and remain subject to the same vesting provisions in the corresponding stock option award. These early exercised options are considered to be "participating securities" due to non-forfeitable right to dividends (i.e., even prior to vesting). For the three and six months ended June 30, 2021, the "two-class method" was utilized to calculate diluted net income per share as it was more dilutive than the "treasury stock metho&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d". Due to a net loss for the three months ended March 31, 2020, all otherwise potentially dilutive securities are antidilutive. Accordingly, basic net loss per share equals diluted net loss per share for the three and six months ended June 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; table sets forth the computation of basic and diluted net loss per share attributable to common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: undistributed income allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,555,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,651,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,446,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,650,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share attributable to common stockholders&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: undistributed income reallocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,555,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,651,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,446,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,650,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,449,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,966,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,651,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,895,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,650,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share attributable to common stockholders&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMy0xLTEtMS0w_ac7ae272-dbd0-4fa4-8497-7cc7946cc346"
      unitRef="usd">6345000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMy0zLTEtMS0w_97e4bab8-8966-41f7-8427-0c018af94d38"
      unitRef="usd">-3250000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMy00LTEtMS0yMzM_1f17aae9-411f-4445-be0e-7ddb4c5b819c"
      unitRef="usd">16721000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMy02LTEtMS0yMzM_9796aa65-7800-41b6-a5b8-b891a19259be"
      unitRef="usd">-5207000</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNC0xLTEtMS0w_2125bdd1-625a-4867-b59f-85b333d949f3"
      unitRef="usd">46000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNC0zLTEtMS0w_370d64b0-3527-4bbb-88dd-94703b0ba7f2"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNC00LTEtMS0yMzM_174faf28-566e-4fed-b8ed-5957f08f20ea"
      unitRef="usd">133000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNC02LTEtMS0yMzM_e4e3c53f-a64f-4132-b124-afaef271d712"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNS0xLTEtMS0w_35536ffb-6540-4e0d-ac16-31b4c9961b82"
      unitRef="usd">6299000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNS0zLTEtMS0w_9d968104-c43c-4ce5-aa67-c41cae620cd7"
      unitRef="usd">-3250000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNS00LTEtMS0yMzM_877e254c-6b11-4a3f-818a-f42db2ccac0f"
      unitRef="usd">16588000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNS02LTEtMS0yMzM_9794bbce-a1ea-4792-b314-1d21c9c32a00"
      unitRef="usd">-5207000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNy0xLTEtMS0w_355fc19c-11eb-4eda-b947-6342e7accd3e"
      unitRef="shares">20555258</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNy0zLTEtMS0w_0e9fdad5-deea-49ca-a617-9eb750676020"
      unitRef="shares">2651321</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNy00LTEtMS0yMzM_1561c451-3bb6-4812-9289-a269c61620f2"
      unitRef="shares">20446246</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfNy02LTEtMS0yMzM_d7650d30-4e5d-4c2e-9bd7-fff9adede115"
      unitRef="shares">2650843</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfOC0xLTEtMS0w_21f2cda2-4417-4f1d-8e97-2c1e61b3f3b1"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfOC0zLTEtMS0w_3022bbc2-170e-4e14-9272-74bfed0a75b9"
      unitRef="usdPerShare">-1.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfOC00LTEtMS0yMzM_12e50fed-15bc-4123-9bec-138b1b8ad6cc"
      unitRef="usdPerShare">0.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfOC02LTEtMS0yMzM_0b4db2a8-d3b2-4369-8fec-66e9e6c0243c"
      unitRef="usdPerShare">-1.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTEtMS0xLTEtMA_1b61195b-ea97-4fcd-9e1e-240bbeb56189"
      unitRef="usd">6345000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTEtMy0xLTEtMA_e9a39d48-6f08-4fc6-a152-6821b60a9810"
      unitRef="usd">-3250000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTEtNC0xLTEtMjMz_c260c080-c7c4-4b12-8bcc-7563cd13fc8a"
      unitRef="usd">16721000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTEtNi0xLTEtMjMz_03aec959-260a-41c2-9c49-3567233bf924"
      unitRef="usd">-5207000</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTItMS0xLTEtMA_3fe5e88b-e4ff-496e-a106-e50761af0924"
      unitRef="usd">43000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTItMy0xLTEtMA_07f54a22-b43a-4d62-9149-cd652dfd206d"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTItNC0xLTEtMjMz_b653c796-535b-4d04-bf93-1abb94ccdca3"
      unitRef="usd">124000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTItNi0xLTEtMjMz_c55bb573-1647-4316-ab3d-0a1455fbb9dd"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTMtMS0xLTEtMA_040b60c3-d7d3-4252-942e-7f6d5b078f1d"
      unitRef="usd">6302000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTMtMy0xLTEtMA_85ed6cf2-e44a-45f6-8c30-543cd6dff3d8"
      unitRef="usd">-3250000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTMtNC0xLTEtMjMz_761e88e1-69e0-4be3-a1b0-6e494ab03d7f"
      unitRef="usd">16597000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTMtNi0xLTEtMjMz_20e55b47-5fa4-4786-9fc6-e9831e94b157"
      unitRef="usd">-5207000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTUtMS0xLTEtMA_a7c172a3-eead-4e22-a017-4a309b6abaff"
      unitRef="shares">20555258</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTUtMy0xLTEtMA_485abf2c-5d68-466d-89cd-f7560335fca3"
      unitRef="shares">2651321</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTUtNC0xLTEtMjMz_5bcb81fa-0f8e-409e-83bb-348e00feb64b"
      unitRef="shares">20446246</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTUtNi0xLTEtMjMz_866010be-4253-45dc-b360-41ac8febae12"
      unitRef="shares">2650843</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTctMS0xLTEtMA_8b1bb7f3-17c4-4dfe-b74a-ae806b7a0514"
      unitRef="shares">1411341</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTctMy0xLTEtMA_73712614-fc32-449f-ac1e-a0ef99a072e2"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTctNC0xLTEtMjMz_48f6a817-487b-46c9-a765-70b9221b3caa"
      unitRef="shares">1449058000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTctNi0xLTEtMjMz_7ff6da4d-7c63-4494-8e21-d02fa7c370fd"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTgtMS0xLTEtMA_51348066-daa5-4823-8c0a-b4d8a8aed62d"
      unitRef="shares">21966599</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTgtMy0xLTEtMA_44ff5838-4ade-419f-b4fb-2e75088afbbb"
      unitRef="shares">2651321</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTgtNC0xLTEtMjMz_64193a56-6b56-4cef-aecc-8f3bcd24cd09"
      unitRef="shares">21895304</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTgtNi0xLTEtMjMz_1b846402-1da9-4439-b84b-a6e153d580d3"
      unitRef="shares">2650843</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTktMS0xLTEtMA_173ce298-3a1a-431f-9cad-f903ae41a483"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTktMy0xLTEtMA_ee7a3611-a44d-4701-896f-2816428d6c43"
      unitRef="usdPerShare">-1.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTktNC0xLTEtMjMz_afe7b8b4-eb67-40e2-b971-fbb13b9e1746"
      unitRef="usdPerShare">0.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RhYmxlOjU5NDJkNDQ2MWM1NzRlOGZhNjUxYjRkM2ZhYTljOTZjL3RhYmxlcmFuZ2U6NTk0MmQ0NDYxYzU3NGU4ZmE2NTFiNGQzZmFhOWM5NmNfMTktNi0xLTEtMjMz_e998afb3-d468-4e31-bfbc-a73ff1f61190"
      unitRef="usdPerShare">-1.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i00691ca440da494bb30506de043894c3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMzI5ODUzNDg4NTIyNw_15fdab91-ac05-4f30-be82-2cafab290482"
      unitRef="shares">800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib790f0e6092341f4a52bec6af062bad6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMzI5ODUzNDg4NTIyNw_92732721-12da-4c82-86f8-55d5b3f44456"
      unitRef="shares">800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4bb4eaa3ec8e4dea84b9f3711947b2e3_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMTEzOA_5bb9db16-3bf1-4595-ae3a-0d6ee6faad1e"
      unitRef="shares">1200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i41b874cb3c6a4ec08fed9386a1952c2d_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMTEzOA_a3074bfa-615d-45cd-8519-64fc9604d2db"
      unitRef="shares">1200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i09d03f0a6dbb451781fd862327cdf06f_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMTE3MQ_21b9509f-0b77-4e64-8e8d-4f5cdaabfd6f"
      unitRef="shares">8200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i676991ec719542d787676a12566ca054_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMTE3MQ_d3bdb04a-6ab1-4c58-9e42-90ca4a49eef6"
      unitRef="shares">8200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia30cf1b452db4f2ab51f825c5ca653f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMTA5OTUxMTYzMDcyNg_1ee9ffd0-5b0d-4091-adca-91ac215fe429"
      unitRef="shares">67000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i219f4b1f55974121826108795989b54f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81Mi9mcmFnOmJiZTYwNTkwMzhjZDQxMzU5MWQxYTlhMmVhMTAxOGNjL3RleHRyZWdpb246YmJlNjA1OTAzOGNkNDEzNTkxZDFhOWEyZWExMDE4Y2NfMTA5OTUxMTYzMDcyNg_d984e477-e88e-4222-a850-a139a492a2ac"
      unitRef="shares">67000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RleHRyZWdpb246NzNiNzMxZjBlYWY0NDNmN2E1Zjc1ZDYzOWM3MmU0NmRfMjE3OA_66e5d7a9-1526-4843-af12-30d7d7c500c2">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes certain financial instruments measured at fair value that are included within the accompanying balance sheets, and their designation among the three fair value measurement categories (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2(xiii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity warrant rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Money Market Funds&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market fund holdings are included in "cash and cash equivalents" on the accompanying Balance Sheets and are classified within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the fair value hierarchy because of their readily-available market prices in active markets that are publicly accessible at the measurement date. These money market funds are invested in U.S. Treasury, bills, notes, and other obligations issued or guaranteed as to principal and interest by the U.S. Government or its agencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Warrant Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, contemporaneous with the China Out-License transaction (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), the Company and LianBio Ophthalmology Limited (&#x201c;LianBio&#x201d;), executed a warrant agreement for the Company to purchase a stated number of equity securities of LianBio, a privately-held China-focused pharmaceutical company, at fair value (on a per share basis at the time of issuance).  The warrants will vest upon the achievement of certain clinical and regulatory events. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These warrants are classified as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the fair value measurement hierarchy. The most significant assumptions  used in the option pricing valuation model to determine fair value include: the estimated current fair value of LianBio common stock, LianBio stock volatility (based on the historical volatility of similar companies), and the probability of achievement of discrete clinical and regulatory milestones for the vesting of each of the three warrants.  As of June&#160;30, 2021, one of these three milestones was met for vesting of the respective warrant.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These warrant agreements allow for "noncash settlement" and therefore met the criteria to be recognized as a "derivative asset" on the accompanying Condensed Balance Sheets and are presented within "other assets" as of June&#160;30, 2021 (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). These warrants will be remeasured with a corresponding amount reported in "other (expense) income, net" on the Statement of Operations and Comprehensive Income (Loss) at each reporting date, until exercised or expired. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in fair value of the equity warrant rights presented in "other assets" on the accompanying Condensed Balance Sheets. The measurement of the equity warrant rights represents a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; financial instrument:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity Warrant Rights, presented in "other assets" within the Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Initial fair value estimate of equity warrant rights upon issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revaluation of equity warrant rights upon achievement of first development milestone, included in "license fees"  within the Condensed Statement of Operations for the three months ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revaluation of equity warrant rights included in "other income (expense), net" within the Condensed Statement of Operations for the three months ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RleHRyZWdpb246NzNiNzMxZjBlYWY0NDNmN2E1Zjc1ZDYzOWM3MmU0NmRfMjE3OQ_1d8017f7-dfb7-48fa-8648-23d653d8c5e0">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes certain financial instruments measured at fair value that are included within the accompanying balance sheets, and their designation among the three fair value measurement categories (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2(xiii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity warrant rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iddbd54b520554e4eba813e5be9dfdf7d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMy0xLTEtMS0w_eb85d47f-16c7-4d1c-be23-325eb7a7517b"
      unitRef="usd">176710000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i09a13b7525134e7abe18f464f8248af4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMy0zLTEtMS0w_cd565e43-c9ea-40be-93ac-3e7e24bb0897"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i53e1600dba1b4b808a42c009c3b3eaa9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMy01LTEtMS0w_600c173c-6392-48b1-982f-7ac512eba50e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1923bd29bb5b417abd997b0aed3bc467_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMy03LTEtMS0w_921d19fe-9a01-4fa3-8e54-9d96e38369d4"
      unitRef="usd">176710000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="iddbd54b520554e4eba813e5be9dfdf7d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfNC0xLTEtMS0w_e85b6da2-2361-4b90-89a1-d7714b3672e2"
      unitRef="usd">0</tars:EquityWarrantsFairValueDisclosure>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="i09a13b7525134e7abe18f464f8248af4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfNC0zLTEtMS0w_da733db8-5911-48f3-a64e-b8f07bfd37b8"
      unitRef="usd">0</tars:EquityWarrantsFairValueDisclosure>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="i53e1600dba1b4b808a42c009c3b3eaa9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfNC01LTEtMS0w_b7d7d382-c33c-45e0-9886-f17c58600647"
      unitRef="usd">1076000</tars:EquityWarrantsFairValueDisclosure>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="i1923bd29bb5b417abd997b0aed3bc467_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfNC03LTEtMS0w_61dac780-f1aa-45e6-97b8-a9cd6300a923"
      unitRef="usd">1076000</tars:EquityWarrantsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia46c6f317af64f7caba90357c4e57a2d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfNS0xLTEtMS0w_908ee0ee-787b-4ff9-8cb7-11bc20f1d36c"
      unitRef="usd">176710000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i62e01287e81647ce9087b8b1ff3d25cf_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfNS0zLTEtMS0w_79f4e01a-a603-4e4a-b7c6-c0190608b49f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i220d03846323467db8c56663c9a2e8df_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfNS01LTEtMS0w_f9aae14d-b31f-48bf-9c90-512122767e39"
      unitRef="usd">1076000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfNS03LTEtMS0w_4f9a3844-388e-4277-a09e-98a703f2ff67"
      unitRef="usd">177786000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i229e0511be204ad18d91926584e23767_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMTAtMS0xLTEtMA_89a22bab-2096-42dd-8558-858c3de16f99"
      unitRef="usd">168129000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic6a8425d752d4893941d5870ecfeb307_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMTAtMy0xLTEtMA_b350f4ea-4f3a-416a-8e7c-2e5c837616fd"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id8de5698c138449598b8e67a58294917_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMTAtNS0xLTEtMA_de9a4b6a-c4cc-4e96-a262-4f7924eb5ed4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if7356e8595ea47819751082d1cbcd009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMTAtNy0xLTEtMA_919ec3e9-2384-48f1-9094-bbd951c0f57b"
      unitRef="usd">168129000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i739167d612a94c119439e7d8a3bb2b98_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMTEtMS0xLTEtMA_9b461914-04a8-4c63-a909-8665423da8f9"
      unitRef="usd">168129000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id7653af8a6494075bf51541661c26fca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMTEtMy0xLTEtMA_fd82b46d-5161-4f27-bf41-41d1b47a4eb3"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3dd90741d4ee44c0912e3f9f2224b6b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMTEtNS0xLTEtMA_1492a209-5dfe-42e6-9bb4-e0392ce28a67"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOmRlYjI2OGJhMWU2NTRiMzViNmE1MGNkZmIwMDY5NDQ0L3RhYmxlcmFuZ2U6ZGViMjY4YmExZTY1NGIzNWI2YTUwY2RmYjAwNjk0NDRfMTEtNy0xLTEtMA_93dd28bb-ef2c-4057-b379-59e5cfb11ae1"
      unitRef="usd">168129000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RleHRyZWdpb246NzNiNzMxZjBlYWY0NDNmN2E1Zjc1ZDYzOWM3MmU0NmRfMTA5OTUxMTYzMTYzNw_c186b359-d699-4183-b25e-038713eb4233">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in fair value of the equity warrant rights presented in "other assets" on the accompanying Condensed Balance Sheets. The measurement of the equity warrant rights represents a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; financial instrument:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity Warrant Rights, presented in "other assets" within the Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Initial fair value estimate of equity warrant rights upon issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revaluation of equity warrant rights upon achievement of first development milestone, included in "license fees"  within the Condensed Statement of Operations for the three months ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revaluation of equity warrant rights included in "other income (expense), net" within the Condensed Statement of Operations for the three months ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOjM2M2VhOTUyZjA0YzQyZmM4NDQyNWU3NzZkNTFmMjE2L3RhYmxlcmFuZ2U6MzYzZWE5NTJmMDRjNDJmYzg0NDI1ZTc3NmQ1MWYyMTZfMS0xLTEtMS0yNjIx_a697765b-c56a-41d9-b986-ce00d06a54cf"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i7a28ec4e85d84692b4ca6a32628fa4be_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOjM2M2VhOTUyZjA0YzQyZmM4NDQyNWU3NzZkNTFmMjE2L3RhYmxlcmFuZ2U6MzYzZWE5NTJmMDRjNDJmYzg0NDI1ZTc3NmQ1MWYyMTZfMi0xLTEtMS0yNjIx_2e5e3e11-ee9f-4b01-8480-6da414a006ed"
      unitRef="usd">1233000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i17e969dac4d6411dbb826ee3db9998d9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOjM2M2VhOTUyZjA0YzQyZmM4NDQyNWU3NzZkNTFmMjE2L3RhYmxlcmFuZ2U6MzYzZWE5NTJmMDRjNDJmYzg0NDI1ZTc3NmQ1MWYyMTZfMy0xLTEtMS0yNjk0_e6be9fca-1c02-465f-b2a8-334ef35ce3f2"
      unitRef="usd">1233000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i531e6f9904f341b0bf1f8a0e802a62ba_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOjM2M2VhOTUyZjA0YzQyZmM4NDQyNWU3NzZkNTFmMjE2L3RhYmxlcmFuZ2U6MzYzZWE5NTJmMDRjNDJmYzg0NDI1ZTc3NmQ1MWYyMTZfMy0xLTEtMS0yNjIx_b33c56ab-67fe-4234-ba55-ed0ddc130ff5"
      unitRef="usd">719000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="iabd2ce550eaa434ea84c33a084eae37b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOjM2M2VhOTUyZjA0YzQyZmM4NDQyNWU3NzZkNTFmMjE2L3RhYmxlcmFuZ2U6MzYzZWE5NTJmMDRjNDJmYzg0NDI1ZTc3NmQ1MWYyMTZfNC0xLTEtMS0yNjIx_63287854-6b17-416e-b1fd-eeff1781d39d"
      unitRef="usd">-876000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF81NS9mcmFnOjczYjczMWYwZWFmNDQzZjdhNWY3NWQ2MzljNzJlNDZkL3RhYmxlOjM2M2VhOTUyZjA0YzQyZmM4NDQyNWU3NzZkNTFmMjE2L3RhYmxlcmFuZ2U6MzYzZWE5NTJmMDRjNDJmYzg0NDI1ZTc3NmQ1MWYyMTZfNS0xLTEtMS0yNjIx_1636279c-f42e-4cd0-b899-4dbe0977b571"
      unitRef="usd">1076000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfODEzMw_5ce997f8-8dd2-4c14-a4ed-03c38ac81bae">COMMITMENTS&#160;&amp;amp; CONTINGENCIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(a) Facility Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, the Company enters lease agreements with unaffiliated parties for the use of office and laboratory facilities and office equipment. As of December&#160;31, 2020, the Company had three active facility leases in Irvine, California.  Separately in January 2021, the Company entered into a six-month lease for an additional adjacent administrative office suite that was not capitalized due to its under 12-month term.  In December 2020, the Company recorded a $15 thousand impairment of its "operating lease right-of-use lease asset" in connection with its decision to early terminate one of the leases, which was completed in January 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's remaining two capitalized facility leases for adjacent administrative and laboratory suites in Irvine, California commenced on June&#160;1, 2020. These leases each expire on January&#160;31, 2024 and one includes a renewal option that was not reasonably certain to be exercised at the time of lease commencement for purposes of its associated accounting for  capitalized "operating lease right-of-use asset" and accompanying lease liability included within "accounts payable and other accrued liabilities" and "other long-term liabilities" on the accompanying Condensed Balance Sheets, amounting to an aggregate $0.6 million.  These operating leases have annual rent that is payable monthly and carry fixed annual increases. Also, under these arrangements, real estate taxes, certain operating expenses, and common area maintenance are paid by the Company; since these costs are variable in nature, they are excluded from the measurement of the reported right-of-use asset and liability and are expensed as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2020 and for the three and six months ended June 30, 2021, the Company had no sublease arrangements with it as lessor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Components of Lease Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The liability associated with each lease is amortized over the respective lease term using the &#x201c;effective interest rate method.&#x201d; The Company&#x2019;s right-of-use asset is amortized over the lease term on a straight-line basis to lease expense, as reported on an allocated basis within &#x201c;research and development&#x201d; and &#x201c;general and administrative&#x201d; expenses on the accompanying Statements of Operations and Comprehensive Income (Loss). The components of lease cost were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:49.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.138%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Weighted-Average Remaining Lease Term and Applied Discount Rate as of June 30, 2021 and December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021 and December&#160;31, 2020, the Company's active facility leases had a weighted average remaining lease term of 2 years, 7 months and 2 years, 10 months, respectively.  The weighted average estimated incremental borrowing rate of 10% was utilized to present value future minimum lease payments since an implicit interest rate was not readily determinable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Future Contractual Lease Payments as of June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The below table summarizes the (i)&#160;minimum lease payments over the next five years and thereafter, (ii)&#160;lease arrangement imputed interest, and (iii)&#160;present value of future lease payments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases - future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future lease payments, undiscounted&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Less): Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(b) In-License Agreements for Lotilaner&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Agreement for Skin and Eye Disease or Conditions in Humans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2019, the Company entered into an in-license agreement with Elanco Tiergesundheit AG (&#x201c;Elanco&#x201d;) for exclusive worldwide rights to certain intellectual property for the development and commercialization of lotilaner in the treatment or cure of any eye or skin disease or condition in humans (the "January 2019 Agreement"). The Company has sole financial responsibility for related development, regulatory, and commercialization activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company made a $1.0 million upfront payment at execution of the January 2019 Agreement. In September 2020, the Company made a required $1.0 million clinical milestone payment associated with the first of two U.S. pivotal trials for the treatment of Demodex blepharitis.  The Company recognized an additional $2.0 million expense for its second pivotal trial milestone in the three and six months ended June 30, 2021, which was paid in April 2021.  These amounts are presented in the applicable period within "research and development" expense in the accompanying Statements of Operations and Comprehensive Income (Loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may make further cash payments to Elanco under this January 2019 Agreement upon the achievement of certain clinical milestones in the treatment of human skin diseases using lotilaner for an aggregate maximum of $3.0 million and various commercial and sales threshold milestones for an aggregate maximum of $79.0 million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its net sales. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;double-digits of such proceeds, except for territories in which the Company achieved applicable regulatory approval prior to sublicense execution.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the China Out-License discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company made a required contractual payment in the amount of $2.5 million to Elanco as part of the receipt of $25 million of initial proceeds from LianBio during the three months ended June 30, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Agreement for All Other Diseases or Conditions in Humans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:56.55pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2020, the Company executed an expanded license agreement with Elanco, granting it a worldwide  license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention, or cure of "all other" diseases and conditions in humans (i.e., beyond that of the eye or skin, the &#x201c;September 2020 Agreement&#x201d;).  The Company issued Elanco 222,460 shares of its common stock at the execution of the September 2020 Agreement. The value of these shares was $3.1 million ($14.0003 per share, approximating the issuance price of the Company's Series C preferred stock in September 2020).  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is required to make further cash payments to Elanco under the September 2020 Agreement upon the achievement of various clinical milestones for an aggregate maximum of $4.5 million and various commercial and sales threshold milestones for an aggregate maximum of $77.0 million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its net sales. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, except for territories in which the Company achieved applicable regulatory approval prior to sublicense execution.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2021, the Company entered into an out-license agreement with LianBio (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;), which  obligated it to grant Elanco an additional fixed 187,500 shares of the Company's common stock that were otherwise required to be granted no later than the 18-month anniversary of the September 2020 Agreement for the Company's continued license exclusivity.  These additional shares were valued at $5.5 million based on the Company's stock closing price of $29.30 per share (on the date the issuance became contractually required) and is reported within "research and development" expense within the accompanying Statements of Operations and Comprehensive Income (Loss) for the three and six months ended June 30, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:56.55pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(c) Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment agreements with six of its named executive officers. These agreements provide for the payment of certain benefits upon separation of employment under specified circumstances, such as termination without cause, or termination in connection with a change in control event.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(d) Litigation Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company is currently not aware of any such matters where there is at least a reasonable probability that a material loss, if any, has been or will be incurred for financial statement recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(e) Indemnities and Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has certain indemnity commitments, under which it may be required to make payments to its officers and directors in relation to certain transactions to the maximum extent permitted under applicable laws. The duration of these indemnities varies, and in certain cases, is indefinite and does not provide for any limitation of maximum payments. The Company has not been obligated to make any such payments to date and no liabilities have been recorded for this contingency in the accompanying Condensed Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <tars:LesseeOperatingLeaseNumberOfLeaseContracts
      contextRef="icb3da3b8c1a44b60becc387206f9893f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMjYw_ea15f790-8022-4e2c-ada0-6b93da7c71d5"
      unitRef="contract">3</tars:LesseeOperatingLeaseNumberOfLeaseContracts>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ie05ece3c0fcc4ccaa63406a8de30a51b_I20210131"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfODEzNA_54989a69-8225-4acb-a0dd-599234e777af">P6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="ie13dc8d045254f7482573f832793430f_D20201201-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNTM1_fd445a49-b74d-403b-b1b5-51d0f2e5e553"
      unitRef="usd">15000</us-gaap:OperatingLeaseImpairmentLoss>
    <tars:LesseeOperatingLeaseNumberOfContractsNotImpaired
      contextRef="i1452c0961726458e8ba94815bf62b628_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNzMw_ea92f822-745d-42ab-9733-50b5d4146e14"
      unitRef="contract">2</tars:LesseeOperatingLeaseNumberOfContractsNotImpaired>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if2b5fae2eaf5463c9ec06e5004104176_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMTMyMQ_823886d0-9076-4688-bfe5-234ead1f3ca7"
      unitRef="usd">600000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfODEzNQ_820f1956-119c-4272-ae62-691576d67b1a">The components of lease cost were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.138%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfMi0xLTEtMS0w_801a107a-0ea5-4d8b-ba63-147681e9f7bc"
      unitRef="usd">60000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfMi0zLTEtMS0w_ae35960c-c05c-454d-adf2-eec3be2cb0b6"
      unitRef="usd">38000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfMi00LTEtMS0yNjg_d94946f0-7854-4057-a640-4c278c085135"
      unitRef="usd">120000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfMi02LTEtMS0yNjg_c8e7e006-3fea-458e-9a55-be65b70b8378"
      unitRef="usd">53000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfMy0xLTEtMS0w_664a8e0b-d1fa-46cb-923b-f3c4dcc046cf"
      unitRef="usd">11000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfMy0zLTEtMS0w_04516645-7a31-4e16-a149-c24f725ff339"
      unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfMy00LTEtMS0yNjg_530e1df1-ecf2-4f06-a333-a7370831aa88"
      unitRef="usd">71000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfMy02LTEtMS0yNjg_1e5c61d8-8977-4559-9067-8d41584a9320"
      unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfNC0xLTEtMS0w_eaa611b4-f24c-4a75-b241-ac9032742825"
      unitRef="usd">63000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfNC0zLTEtMS0w_9d0649ed-8a74-4e68-96ba-4c98cc24bafd"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfNC00LTEtMS0yNjg_29f07f8d-8d0a-4f31-b99e-48d08873319d"
      unitRef="usd">95000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfNC02LTEtMS0yNjg_c711a02f-c447-4099-b451-e73e08551bf2"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfNS0xLTEtMS0w_fab3a2cd-97bd-42b1-9566-ec1ffcd13fee"
      unitRef="usd">134000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="if335be491ecb49528b78ab0c5a9bed8d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfNS0zLTEtMS0w_8ab7078d-def1-4acb-8735-ee91f65627a8"
      unitRef="usd">38000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfNS00LTEtMS0yNjg_4a7c5097-74d9-4bc8-9038-fe24790a970f"
      unitRef="usd">286000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i3603412d98184aa6b0d8a284fe8cb3f5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOmVmZDJkNjExZjQ0MjQ0NTVhMmVhOGMwNjFlZTA3YTY5L3RhYmxlcmFuZ2U6ZWZkMmQ2MTFmNDQyNDQ1NWEyZWE4YzA2MWVlMDdhNjlfNS02LTEtMS0yNjg_b10deac2-7722-41f4-966d-c00d6bd7b8b0"
      unitRef="usd">53000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMjU0MQ_64afe2ed-e0e4-4e1a-be26-b89b43deb093">P2Y7M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5e6394dd3d154e6eb7f0921e8d91a105_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMjU0OA_510984bb-2d6f-4211-b3b9-65ec4540e9a5">P2Y10M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMjYyOA_6020a409-1beb-4ecf-9936-f567cb7c6ae0"
      unitRef="number">0.10</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfODEzMg_b1de9a3c-4cf5-410e-980a-854e956bc8a8">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The below table summarizes the (i)&#160;minimum lease payments over the next five years and thereafter, (ii)&#160;lease arrangement imputed interest, and (iii)&#160;present value of future lease payments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases - future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future lease payments, undiscounted&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Less): Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOjczZDYxNDVmYWM1YjQxNTA4ZjU1NTg4ZTcyZjlkMDg5L3RhYmxlcmFuZ2U6NzNkNjE0NWZhYzViNDE1MDhmNTU1ODhlNzJmOWQwODlfMS0xLTEtMS0w_7e4e8bad-f042-42f4-a4d4-03ded5031d18"
      unitRef="usd">140000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOjczZDYxNDVmYWM1YjQxNTA4ZjU1NTg4ZTcyZjlkMDg5L3RhYmxlcmFuZ2U6NzNkNjE0NWZhYzViNDE1MDhmNTU1ODhlNzJmOWQwODlfMi0xLTEtMS0w_95078064-f26c-4902-802e-176f095a8328"
      unitRef="usd">271000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOjczZDYxNDVmYWM1YjQxNTA4ZjU1NTg4ZTcyZjlkMDg5L3RhYmxlcmFuZ2U6NzNkNjE0NWZhYzViNDE1MDhmNTU1ODhlNzJmOWQwODlfMy0xLTEtMS0w_f586095c-27ab-4fa6-aa96-a3025546da59"
      unitRef="usd">281000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOjczZDYxNDVmYWM1YjQxNTA4ZjU1NTg4ZTcyZjlkMDg5L3RhYmxlcmFuZ2U6NzNkNjE0NWZhYzViNDE1MDhmNTU1ODhlNzJmOWQwODlfNC0xLTEtMS0w_21f89ead-8738-4fae-b418-88bc243f6d3b"
      unitRef="usd">25000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOjczZDYxNDVmYWM1YjQxNTA4ZjU1NTg4ZTcyZjlkMDg5L3RhYmxlcmFuZ2U6NzNkNjE0NWZhYzViNDE1MDhmNTU1ODhlNzJmOWQwODlfNS0xLTEtMS0w_f28ca2a0-9a4b-4e5f-bb94-1ce6d91b38c7"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOjczZDYxNDVmYWM1YjQxNTA4ZjU1NTg4ZTcyZjlkMDg5L3RhYmxlcmFuZ2U6NzNkNjE0NWZhYzViNDE1MDhmNTU1ODhlNzJmOWQwODlfNi0xLTEtMS0w_8d1fb3a8-91ab-42f9-856f-6aee248c4e29"
      unitRef="usd">717000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOjczZDYxNDVmYWM1YjQxNTA4ZjU1NTg4ZTcyZjlkMDg5L3RhYmxlcmFuZ2U6NzNkNjE0NWZhYzViNDE1MDhmNTU1ODhlNzJmOWQwODlfNy0xLTEtMS0w_51f307e6-5e78-41a7-bf3c-0d31f5e6a82c"
      unitRef="usd">83000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RhYmxlOjczZDYxNDVmYWM1YjQxNTA4ZjU1NTg4ZTcyZjlkMDg5L3RhYmxlcmFuZ2U6NzNkNjE0NWZhYzViNDE1MDhmNTU1ODhlNzJmOWQwODlfOC0xLTEtMS0w_298cb424-8bd1-4a52-8a7c-416e7f87bef4"
      unitRef="usd">634000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4f5e022e1a4a4c389fd70f2fdd2953e1_D20190101-20190131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMzU1Nw_be96ac2d-00ff-4ff8-8568-ea60dc4e0311"
      unitRef="usd">1000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i120ab40354ce4e18abe9a05184afca4c_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMzY2Nw_11d69842-ccce-4398-b903-f6d5d5a2888c"
      unitRef="usd">1000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i93cd1b65dc5e40239017d30da180b216_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMzgzMA_3660a3c8-0582-4b2c-9383-9f9a294fc9fd"
      unitRef="usd">2000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <tars:CollaborativeArrangementMaximumMilestonePayment
      contextRef="i0d2fb7b171a54a6d88b68e421934e6d8_I20190131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNDMxOQ_7c27c262-fbf3-4f08-83a9-9326e06669e3"
      unitRef="usd">3000000.0</tars:CollaborativeArrangementMaximumMilestonePayment>
    <tars:CollaborativeArrangementMaximumMilestonePayment
      contextRef="iad5ec97fc35d4af183d9972de8c93b10_I20190131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNDQwNA_7625aa99-d718-406d-8dad-f24fa90828c1"
      unitRef="usd">79000000.0</tars:CollaborativeArrangementMaximumMilestonePayment>
    <tars:UpfrontPayment
      contextRef="i70b499fd960e46b6927230aed1207cbd_D20210401-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMTA5OTUxMTYzNjc5OQ_bbff749b-5fd5-4a18-975b-f37f86808c41"
      unitRef="usd">2500000</tars:UpfrontPayment>
    <tars:UpfrontPayment
      contextRef="ie07d05df956f4d13b7387802ceea7fc8_D20210401-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMTA5OTUxMTYzNjgxMw_4661fc08-cd37-45a8-97e0-9c35dcd76adf"
      unitRef="usd">25000000</tars:UpfrontPayment>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i120ab40354ce4e18abe9a05184afca4c_D20200901-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNTI5MA_857be988-f4a6-4ff4-b88c-8008e95100f6"
      unitRef="shares">222460</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i120ab40354ce4e18abe9a05184afca4c_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNTQwMA_f6c2ba98-8ace-4fd8-94d7-64841b494ee8"
      unitRef="usd">3100000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:SharePrice
      contextRef="id78fdaf99d664fb88506c79ba98fab86_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNTQwNA_0e17868a-15f9-498a-bafa-ca74fb7cf5de"
      unitRef="usdPerShare">14.0003</us-gaap:SharePrice>
    <tars:CollaborativeArrangementMaximumMilestonePayment
      contextRef="i984e3a65060c4cfeb572fc37ad5c4a4b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMzI5ODUzNDg5MjY1OA_6b6c2806-b78f-4230-b00a-e6dded9dbe54"
      unitRef="usd">4500000</tars:CollaborativeArrangementMaximumMilestonePayment>
    <tars:CollaborativeArrangementMaximumMilestonePayment
      contextRef="i1af047204199476fbf9fa4a0c7a282ea_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfMzI5ODUzNDg5Mjc0NA_27f94f9c-d2ce-4a9c-b571-fc5fc7557871"
      unitRef="usd">77000000.0</tars:CollaborativeArrangementMaximumMilestonePayment>
    <tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices
      contextRef="i120ab40354ce4e18abe9a05184afca4c_D20200901-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNTY3MQ_336ff7ed-1841-4ebb-82f3-7f637e38a11b"
      unitRef="shares">187500</tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices>
    <tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices
      contextRef="i82afa114a25e4157b2a2b9dd666cfc9c_D20200903-20200903"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNTkxNA_c08e2184-2c05-439a-a3a1-46784acb3927"
      unitRef="usd">5500000</tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices>
    <tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices
      contextRef="i120ab40354ce4e18abe9a05184afca4c_D20200901-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNTk2Mw_ce380c9a-b3ec-4efd-93b8-669cbc2352f7"
      unitRef="usdPerShare">29.30</tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices>
    <tars:NumberOfEmploymentArrangementsWithExecutiveOfficers
      contextRef="id5386c319aba4c61a7bf6efd8331dd95_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82MS9mcmFnOmMxYjE1MmZkZjY0ZjQ2MGFhMDIzOGIxY2Y4YjljNDQ4L3RleHRyZWdpb246YzFiMTUyZmRmNjRmNDYwYWEwMjM4YjFjZjhiOWM0NDhfNjk1OQ_784070a2-7ea7-4151-8a71-e2d984c8ac58"
      unitRef="arrangement">6</tars:NumberOfEmploymentArrangementsWithExecutiveOfficers>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfMjM1Nw_899b30ba-53cb-46fc-a031-eae274079e9b">OUT-LICENSE AGREEMENT&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Out-License of TP-03 Commercial Rights in Greater China in March 2021&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:56.55pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 26, 2021, the Company entered into an out-license agreement with LianBio for its exclusive development and commercialization rights of TP-03 (lotilaner ophthalmic solution, 0.25%) in the People&#x2019;s Republic of China, Hong Kong, Macau, and Taiwan (the &#x201c;China Territory&#x201d;) for the treatment of Demodex blepharitis and Meibomian Gland Disease (the &#x201c;China Out-License&#x201d;).  LianBio is contractually responsible for all clinical development and commercialization activities and costs within the China Territory.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company received payments from LianBio of $15.0 million in April 2021 and $10.0 million in May 2021 as initial consideration, and $10.0&#160;million in June 2021 for the achievement of a clinical development milestone.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company also is eligible to receive other payments and consideration from LianBio upon achievement of certain additional milestones, including: (i) TP-03 clinical development and regulatory milestones of up to $65.0&#160;million (including $20&#160;million for the achievement of a clinical milestone in June 2021 that is presented within "accounts receivable" on the accompanying Condensed Balance Sheets), (ii) TP-03 sales-based milestones for the China Territory of up to  $100.0 million, (iii) tiered mid-to-high-teen royalties for China Territory TP-03 sales, and (iv) equity warrants issued to the Company in March 2021 for purchase of LianBio equity securities, subject to TP-03 clinical/regulatory achievements for vesting. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:56.55pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized "license fees" and "collaboration revenue" for the three months ended June 30, 2021 of $19.0 million and $3.0 million, respectively, in the accompanying Condensed Statements of Operations and Comprehensive Income (Loss), in accordance with the revenue recognition accounting policy described in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2(vi).  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These amounts represent separately valued "performance obligations" in the China Out-License&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended June 30, 2021, the Company recognized $52.4 million and $3.1 million, respectively, for "license fees" and "collaboration revenue".&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These revenue amounts were each recognized upon (i) the transfer of TP-03 license rights in the China Territory to LianBio and (ii) the actual or partial completion of clinical activities and related data for the Company's pivotal trials of TP-03 in the treatment of Demodex blepharitis (each representing separately valued "performance obligations" in the China Out-License).  As part of this revenue recognition model, the Company was required to value the LianBio equity warrant, applying a discounted cash flow model with highly subjective inputs for this pre-revenue company, and to also consider the probability of achievement of requisite vesting events.&lt;/span&gt;&lt;/div&gt;In future periods, the Company may recognize additional revenue from contractual receipts due from LianBio as (1) performance obligations are satisfied related to the completion of the TP-03 pivotal trial and as associated clinical data and reports are delivered, (2) regulatory approval events are achieved, and (3) LianBio has sales of TP-03 in the China Territory.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <tars:UpfrontPayment
      contextRef="i0574c418228c4e3ab5c608032507de3f_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfNjQz_50e2a13f-815f-449e-ad10-58c041ad1539"
      unitRef="usd">15000000.0</tars:UpfrontPayment>
    <tars:UpfrontPayment
      contextRef="i99377563ab2d44c1b8761203fb868e37_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfNjY1_d51c523a-645c-4b49-9ce8-03de6aa28964"
      unitRef="usd">10000000.0</tars:UpfrontPayment>
    <tars:UpfrontPayment
      contextRef="ib7f0a54579764e34bd42dd790ba99ef4_D20210601-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfMTA5OTUxMTYzMDM3MQ_b1587176-cfbc-4b70-ad4c-f67daeca5a57"
      unitRef="usd">10000000.0</tars:UpfrontPayment>
    <tars:CollaborativeArrangementMaximumMilestonePayment
      contextRef="i16f2fabfc6b747e5837e0174609fcc2b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfMzI5ODUzNDg4NTkxNg_8b6ce761-5352-42ac-8e1c-8a4c5c93c133"
      unitRef="usd">65000000.0</tars:CollaborativeArrangementMaximumMilestonePayment>
    <tars:CollaborativeArrangementMilestonePayment
      contextRef="iaa0fee81cd004ce9a21528b56b335914_D20210601-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfMTA5OTUxMTYzMzU4NA_d740f419-f1aa-49a2-9c3a-ffddc2dd3d2f"
      unitRef="usd">20000000</tars:CollaborativeArrangementMilestonePayment>
    <tars:CollaborativeArrangementMaximumMilestonePayment
      contextRef="ie2e854be994f41e6972a64d241a91f47_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfNzk4_9dd7ebe0-1b95-4be6-b420-86ecfcbab9cd"
      unitRef="usd">100000000.0</tars:CollaborativeArrangementMaximumMilestonePayment>
    <us-gaap:Revenues
      contextRef="ib4ad4f4b71ae44b283fcc4fb9a913a39_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfMTQzMQ_84a4595b-a061-49c2-b04c-03cb7dbe7f5e"
      unitRef="usd">19000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id305f2fec3554db090e0b6fe23e91f04_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfMTQzOA_d0acf4ec-e5c6-4ade-884e-b98b17a1e9d7"
      unitRef="usd">3000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i597fcedd8e7a4ac5ad1d8f9599d89d31_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfMTA5OTUxMTYzNDI3OA_27d7b450-855c-4efc-917f-07043ec6bf77"
      unitRef="usd">52400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6cb967d1c1e54bef8b85105752dc7964_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF82NC9mcmFnOjJmNzE1MmFmYmUxZDRlMDFhYTdkNGUxNDBiNDdjZWRmL3RleHRyZWdpb246MmY3MTUyYWZiZTFkNGUwMWFhN2Q0ZTE0MGI0N2NlZGZfMTA5OTUxMTYzNDI4Mw_40ffaf1d-6812-43a8-8885-17f8c27500ca"
      unitRef="usd">3100000</us-gaap:Revenues>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893640063768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TARSUS PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-4717861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">15440 Laguna Canyon Road, Suite 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irvine<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">409-9820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TARS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Smaller Reporting Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,574,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001819790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893559547576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 176,735<span></span>
</td>
<td class="nump">$ 168,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,012<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">200,904<span></span>
</td>
<td class="nump">170,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,525<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">203,450<span></span>
</td>
<td class="nump">171,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and other accrued liabilities</a></td>
<td class="nump">8,985<span></span>
</td>
<td class="nump">4,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and benefits</a></td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">1,040<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,455<span></span>
</td>
<td class="nump">5,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">524<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,979<span></span>
</td>
<td class="nump">5,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 authorized at June&#160;30, 2021 and December&#160;31, 2020; no shares issued and outstanding at June&#160;30, 2021 and December&#160;31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 200,000,000 shares authorized; 20,704,104 shares issued and 20,573,951 outstanding, which excludes 130,153 shares subject to repurchase at June&#160;30, 2021 (unaudited); 20,502,576 shares issued and 20,323,301 outstanding, which excludes 179,375 shares subject to repurchase at December&#160;31, 2020</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">208,591<span></span>
</td>
<td class="nump">198,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(16,124)<span></span>
</td>
<td class="num">(32,845)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">192,471<span></span>
</td>
<td class="nump">165,980<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, preferred stock and stockholders&#8217; equity</a></td>
<td class="nump">$ 203,450<span></span>
</td>
<td class="nump">$ 171,972<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893560215544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares)</a></td>
<td class="nump">20,704,104<span></span>
</td>
<td class="nump">20,502,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares)</a></td>
<td class="nump">20,573,951<span></span>
</td>
<td class="nump">20,323,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CommonStockSharesSubjectToRepurchase', window );">Common stock, subject to repurchase (shares)</a></td>
<td class="nump">130,153<span></span>
</td>
<td class="nump">179,375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockSharesSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Subject To Repurchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockSharesSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893560547704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 22,017<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 55,449<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,204<span></span>
</td>
<td class="nump">1,737<span></span>
</td>
<td class="nump">23,465<span></span>
</td>
<td class="nump">3,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,794<span></span>
</td>
<td class="nump">1,526<span></span>
</td>
<td class="nump">11,954<span></span>
</td>
<td class="nump">2,132<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">14,735<span></span>
</td>
<td class="nump">3,263<span></span>
</td>
<td class="nump">37,453<span></span>
</td>
<td class="nump">5,381<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations before other (expense) income and income taxes</a></td>
<td class="nump">7,282<span></span>
</td>
<td class="num">(3,263)<span></span>
</td>
<td class="nump">17,996<span></span>
</td>
<td class="num">(5,381)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expense), net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(39)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of equity warrant rights</a></td>
<td class="num">(876)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(876)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income</a></td>
<td class="num">(908)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="num">(933)<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(342)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">6,345<span></span>
</td>
<td class="num">(3,250)<span></span>
</td>
<td class="nump">16,721<span></span>
</td>
<td class="num">(5,207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 6,345<span></span>
</td>
<td class="num">$ (3,250)<span></span>
</td>
<td class="nump">$ 16,721<span></span>
</td>
<td class="num">$ (5,207)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (usd per share)</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="num">$ (1.23)<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="num">$ (1.96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (usd per share)</a></td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="num">$ (1.23)<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="num">$ (1.96)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="nump">20,555,258<span></span>
</td>
<td class="nump">2,651,321<span></span>
</td>
<td class="nump">20,446,246<span></span>
</td>
<td class="nump">2,650,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="nump">21,966,599<span></span>
</td>
<td class="nump">2,651,321<span></span>
</td>
<td class="nump">21,895,304<span></span>
</td>
<td class="nump">2,650,843<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tars_LicenseAndCollaborationMember', window );">License fees and Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of license fees and collaboration revenue</a></td>
<td class="nump">$ 737<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,034<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">19,048<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">52,359<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tars_CollaborationMember', window );">Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 2,969<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,090<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_LicenseAndCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_LicenseAndCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893663476664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,249,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">$ (6,005)<span></span>
</td>
<td class="nump">$ 63,402<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="num">$ (6,034)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,646,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(1,957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,957)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Recognition of stock-based compensation expense</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights', window );">Lapse of repurchase rights related to common stock issued pursuant to early exercises (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,249,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="num">(7,958)<span></span>
</td>
<td class="nump">$ 63,402<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="num">(7,991)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,650,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,249,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">(6,005)<span></span>
</td>
<td class="nump">$ 63,402<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="num">(6,034)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,646,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(5,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued as consideration for in-license rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,249,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="num">(11,035)<span></span>
</td>
<td class="nump">$ 63,402<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="num">(11,241)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,651,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,249,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="num">(7,958)<span></span>
</td>
<td class="nump">$ 63,402<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="num">(7,991)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,650,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(3,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Recognition of stock-based compensation expense</a></td>
<td class="nump">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of vested stock options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,249,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="num">$ (11,035)<span></span>
</td>
<td class="nump">$ 63,402<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="num">(11,241)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,651,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares) at Dec. 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 165,980<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">198,821<span></span>
</td>
<td class="num">(32,845)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2020</a></td>
<td class="nump">20,323,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,323,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 10,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Recognition of stock-based compensation expense</a></td>
<td class="nump">1,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of vested stock options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of vested stock options</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued as consideration for in-license rights (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued as consideration for in-license rights</a></td>
<td class="nump">5,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 183,232<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">205,697<span></span>
</td>
<td class="num">(22,469)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,524,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares) at Dec. 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 165,980<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">198,821<span></span>
</td>
<td class="num">(32,845)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2020</a></td>
<td class="nump">20,323,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,323,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 16,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued as consideration for in-license rights</a></td>
<td class="nump">$ 5,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares) at Jun. 30, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 192,471<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">208,591<span></span>
</td>
<td class="num">(16,124)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (shares) at Jun. 30, 2021</a></td>
<td class="nump">20,573,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,573,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">$ 183,232<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">205,697<span></span>
</td>
<td class="num">(22,469)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,524,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">6,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Recognition of stock-based compensation expense</a></td>
<td class="nump">2,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of vested stock options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of vested stock options</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights', window );">Lapse of repurchase rights related to common stock issued pursuant to early exercises (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights', window );">Lapse of repurchase rights related to common stock issued pursuant to early exercises</a></td>
<td class="nump">$ 99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares) at Jun. 30, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 192,471<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 208,591<span></span>
</td>
<td class="num">$ (16,124)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (shares) at Jun. 30, 2021</a></td>
<td class="nump">20,573,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,573,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Lapse Of Repurchase Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Lapse Of Repurchase Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893560294280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 16,721<span></span>
</td>
<td class="num">$ (5,207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,157<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use asset</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Loss on lease termination</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative assets</a></td>
<td class="nump">876<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized gain from transactions denominated in a foreign currency</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of common stock pursuant to in-license agreement</a></td>
<td class="nump">5,494<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(137)<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,527)<span></span>
</td>
<td class="num">(1,526)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(2,326)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other accrued liabilities</a></td>
<td class="nump">4,622<span></span>
</td>
<td class="nump">1,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued payroll and benefits</a></td>
<td class="nump">430<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">8,757<span></span>
</td>
<td class="num">(4,553)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(191)<span></span>
</td>
<td class="num">(371)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
<td class="num">(191)<span></span>
</td>
<td class="num">(371)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of vested stock options</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_ProceedsFromEarlyExerciseOfStockOptions', window );">Proceeds from exercise of stock options prior to vesting</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">8,586<span></span>
</td>
<td class="num">(4,817)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash &#8212; beginning of year</a></td>
<td class="nump">168,149<span></span>
</td>
<td class="nump">57,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash &#8212; end of period</a></td>
<td class="nump">176,735<span></span>
</td>
<td class="nump">53,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">176,735<span></span>
</td>
<td class="nump">53,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">176,735<span></span>
</td>
<td class="nump">53,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Additions of property and equipment in accounts payable and other accrued liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination', window );">Derecognition of right-of-use asset upon lease termination</a></td>
<td class="num">(38)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to licensor pursuant to execution of out-license agreement</a></td>
<td class="nump">$ 5,494<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decapitalization Of Operating Lease, Right Of Use Asset, Lease Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ProceedsFromEarlyExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Early Exercise Of Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ProceedsFromEarlyExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123386189&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893558660216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Presentation of Financial Statements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Presentation of Financial Statements</a></td>
<td class="text">DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Description of Business</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tarsus Pharmaceuticals, Inc. (&#8220;Tarsus&#8221; or the &#8220;Company&#8221;) is a late clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutic candidates to address large market opportunities initially in ophthalmic conditions where there are limited treatment alternatives.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b) Reverse Stock Split and Initial Public Offering </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 8, 2020, the Tarsus Board of Directors approved a 1-for-7.4276 reverse stock split and a certificate of amendment was filed to amend the Company's certificate of incorporation to effect this reverse split.  The par value was not adjusted as a result of the reverse stock split.  All share and per share information included in the accompanying financial statements give retroactive effect to this reverse stock split for all periods presented.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 20, 2020, the Company completed its initial public offering ("IPO") through an underwritten sale of 6,325,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sh</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ares of its common stock at a price </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of $16.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> per share, inclusive of an additional 825,000 shares of its common stock sold upon the full exercise of the underwriters&#8217; purchase option. The aggregate net proceeds by the Company from the offering totaled $91.7 million, after deducting underwriting discounts and commissions and other offering expenses.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Concurrent with the closing of the Company's IPO, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">all then-outstanding shares of its convertible preferred stock (see </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 4</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) were automatically converted into an aggregate of 11,107,018 issued shares of common stock. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">(c)  Liquidity</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has no product sales, and since inception, has accumulated losses and negative cash flows from operations (other than consideration received from an out-licensing agreement, as discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), resulting in an accumulated deficit of $16.1 million as of June&#160;30, 2021 and $32.8 million as of December&#160;31, 2020. The Company&#8217;s cash and cash equivalents were $176.7 million and $168.1 million as of June&#160;30, 2021 and December&#160;31, 2020, respectively. The Company has funded its inception-to-date operations primarily through equity capital raises and proceeds from its out-license agreement.  The Company believes that its existing capital resources will be sufficient to meet projected operating requirements beyond at least 12 months from the August 5, 2021 filing date of this Form 10-Q.  Accordingly, the accompanying financial statements in this Form 10-Q have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operations currently consist of its corporate organization build-out, intellectual property licensing activities, and conducting preclinical and clinical studies. The Company faces the clinical, business, and liquidity risks that are typically associated with early-stage biotechnology companies; it must complete expensive research and development activities, achieve research and development outcomes that are inherently uncertain, recruit and retain skilled personnel (including executive management), and build and defend its intellectual property rights.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company&#8217;s research and development activities and other operating expenses.  The Company will be required to raise additional capital to fund its future operations, however, no assurance can be given as to whether financing will be available on terms acceptable to the Company, if at all.  If the Company raises additional funds by issuing equity securities, its stockholders may experience dilution. Any future debt financing into which the Company enters may impose additional covenants that restrict operations, including limitations on its ability to incur liens or additional debt, pay dividends, repurchase common stock, make certain investments, or engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity raise may contain terms that are not favorable to the Company or its stockholders. The Company&#8217;s potential inability to raise capital when needed could have a negative impact on its financial condition and ability to pursue planned business strategies. If the Company is unable to raise additional funds as required, it may need to delay, reduce, or terminate some or all </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">its development programs and clinical trials. The Company may also be required to sell or license its rights to product candidates in certain territories or indications that it would otherwise prefer to develop and commercialize on its own. If the Company is required to enter into collaborations and other arrangements to address its liquidity needs, it may have to give up certain rights that limit its ability to develop and commercialize product candidates or may have other terms that are not favorable to the Company or its stockholders, which could materially and adversely affect its business and financial prospects. These factors may adversely impact the Company's ability to achieve its business objectives and would likely have an adverse effect on its future business prospects, or even its ability to remain a going concern. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d) Operating Segment  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has operated and managed its business and financial information on an aggregate basis for the purposes of evaluating financial performance and the allocation of capital and personnel resources. Accordingly, the Company&#8217;s management determined that it operates in one reportable operating segment.  This single segment is focused exclusively on developing pharmaceutical products for eventual commercialization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e) Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has irrevocably elected to not take this exemption and, as a result, will adopt new or revised accounting standards on the relevant effective dates on which adoption of such standards is required for other public companies that are not emerging growth companies.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893554530296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Use of Estimates<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies and Use of Estimates</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i) Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information and pursuant to Form 10-Q and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Article 10 of Regulation S-X </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, the accompanying condensed financial statements do not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim condensed balance sheet as of June&#160;30, 2021, and the interim condensed statements of operations and comprehensive income (loss), changes in preferred stock and stockholders&#8217; equity and cash flows for the three and six months ended June&#160;30, 2021 and 2020 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes related to the three and six-month periods are also unaudited. The condensed balance sheet as of December 31, 2020 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three and six months ended June&#160;30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021 or any other interim or annual period. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed financial statements should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2020 in the Company&#8217;s Annual Report on Form 10-K (&#8220;Annual Report&#8221;) for the fiscal year ended December 31, 2020, as filed with the SEC on March 31, 2021.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These amounts may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an on-going basis, management evaluates its most critical estimates and assumptions, including those related to the (i)&#160;fair value of equity-based awards and periodic recognition of stock-based compensation, (ii)&#160;the realization of income tax assets and estimates of tax liabilities, and (iii)&#160;expense accruals related to research and development activities, including clinical trials.  The accounting policies and estimates that most significantly impact the presented amounts within the accompanying condensed financial statements are further described below:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(ii) Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, with original maturities of three months or less from the purchase date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(iii) Restricted Cash</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash represents cash held as collateral for the Company&#8217;s corporate credit card program. Any cash that is legally or contractually restricted from immediate use is classified as restricted cash.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(iv) Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents in deposits at financial institutions that exceed federally insured limits.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared a pandemic related to the global novel coronavirus disease 2019 (&#8220;COVID-19&#8221;) outbreak. To date, the Company&#8217;s operations have not been significantly impacted by the COVID-19 </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pandemic, though the Company continues to monitor the potential impact COVID-19 may have on its ongoing and planned clinical trials. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak may have on these activities or its financial condition.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results of operations involve numerous risks and uncertainties. Factors that could adversely impact the Company&#8217;s operating results and business objectives include, but are not limited to, (1) uncertainty of results of clinical trials, (2) uncertainty of regulatory approval of the Company&#8217;s potential product candidates, including TP-03 for ophthalmic conditions, TP-04 for treatment of skin conditions and TP-05 for prophylaxis of Lyme and community malaria reduction, (3) uncertainty of market acceptance of its product candidates, (4) competition from substitute products and other companies, (5) securing and protecting proprietary technology and strategic relationships, and (6) and dependence on key individuals and sole source suppliers.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s product candidates require approvals from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive these necessary approvals. If the Company is denied approval, approval is delayed, or is unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company's business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(v) Property and Equipment</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at historical cost and is depreciated on a straight-line basis over an estimated useful life that corresponds with its designated asset category. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of &#8220;long-lived assets&#8221; (which includes property and equipment) whenever events or changes in circumstances in the business indicate that the asset&#8217;s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value. Other than the right-of-use ("ROU") asset impairment discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were no events or changes in business circumstances during the three and six months ended June 30, 2021 or year ended December&#160;31, 2020 that indicated the carrying amounts of any long-lived assets were not fully recoverable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(vi) Revenue Recognition for Out-License Arrangements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview </span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has one out-license arrangement that allows the licensee to market the Company&#8217;s TP-03 product (representing "functional intellectual property") in certain territories for a certain field of use and for a stated term - see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract, (b) the contract&#8217;s transaction price for allocation (including variable consideration), (c) the stand-alone selling price for each identified performance obligation, and (d) the timing and amount of  revenue recognition in each period. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's out-license arrangement, as described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was analyzed under GAAP to determine whether the promised goods or services (which include the license, and know-how, data, and information necessary or reasonably useful for the research, development, manufacture, or commercialization of any license product, and governance committee services) are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is considered to not be distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's out-license arrangement is in exchange for the following forms of consideration: (i) upfront cash payments, (ii) equity-based consideration, (iii) sales royalties, (iv) sales threshold milestones, (v) development milestone fees, and (vi) regulatory milestone fees.  Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied.   The Company evaluates the progress related to each milestone at each reporting </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period and, if necessary, also adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Terms for Receipt of Payments</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual terms that establish the Company&#8217;s right to collect specified amounts from its customers and the require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, as follows:</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Upfront License Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company determines whether non-refundable license consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the out-license.  The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company utilizes the &#8220;most likely amount&#8221; method to estimate the amount of consideration to which it will be entitled for achievement of development milestones. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint.  At each reporting period, the Company re-evaluates this associated revenue recognition constraint.  Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, thus reflected in the financial statements in the period of adjustment. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company utilizes the &#8220;most likely amount&#8221; method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied). Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are constrained for revenue recognition until achievement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the "sales-or-usage-based royalty exception" the Company recognizes revenue based on the contractual percentage of the licensee&#8217;s sales to its customers at the later of (i) the occurrence of the related sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from its out-licensing arrangements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Threshold Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Similar to royalties, applying the "sales-or-usage-based royalty exception", the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from out-licensing arrangements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(vii) Research and Development Costs</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. These expenses also include internal costs directly attributable to in-development programs, including cost of certain salaries, payroll taxes, employee benefits, and stock-based compensation expense, as well as laboratory and clinical supplies, pre-clinical and clinical trial related expenses, and the cost of services provided by outside contractors. The Company recognizes expense for pre-clinical studies and clinical trial activities performed by these third parties. This is typically based upon estimates of the proportion of work completed over the term of the individual study or trial, as well as patient enrollment and dosing events in accordance with agreements established with clinical research organizations ("CROs") and clinical trial or pre-clinical study sites.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered, and may continue to enter into, license agreements to access and utilize intellectual property for drug development. In each case, the Company evaluates if the assets acquired in a transaction represent the acquisition of an as</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">set or a business, as defined under applicable GAAP. The Company&#8217;s executed in-license agreements (see </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8(b)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) were evaluated and determined to represent asset acquisitions. Because these assets have not yet received regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and have no alternative future uses, the purchase price for each was immediately recognized as research and development expense. In addition, any future milestone payments (whether in the form of cash or stock) made before product regulatory approval (that do not meet the definition of a derivative) will also be immediately recognized as research and development expense when paid or becomes payable, provided there is no alternative future use of the rights in other research and development projects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(viii) Stock-Based Compensation</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is recognized for all equity awards granted to employees, consultants, and members of the Company&#8217;s Board of Directors and is recognized at fair value. For stock-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date is the date of grant and the related expense is recognized on a straight-line basis over each award&#8217;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes compensation cost if and when it concludes that it is probable that the performance condition will be achieved and the related expense is recognized on an accelerated attribution method. As applicable, the Company reverses previously recognized expense for forfeitures of unvested awards in the period of occurrence. The Company uses the Black-Scholes pricing model to estimate the fair value of stock option awards as of the date of grant.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement of the fair value of stock-based awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#8217;s judgment, including (a)&#160;the fair value of the Company&#8217;s common stock on the date of the option grant, (b)&#160;the expected term of the stock option until its exercise by the recipient, (c)&#160;stock price volatility over the expected term, (d)&#160;the prevailing risk-free interest rate over the expected term, and (e)&#160;expected dividend payments over the expected term.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management estimates the expected term of awarded stock options utilizing the &#8220;simplified method&#8221; for awards as the Company does not yet have sufficient exercise history since its November 2016 formation. Further, prior to the IPO, the Company was privately-held and therefore lacked company-specific historical and implied volatility information of its stock.&#160;Accordingly, management estimated this expected volatility based on a designated peer-group of publicly-traded companies for a look-back period, as of the date of grant, that corresponded with the expected term of the awarded stock option. The Company estimates the risk-free interest rate based upon the U.S. Department of the Treasury yield curve in effect at award grant for time periods that correspond with the expected term of the awarded stock option. The Company&#8217;s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the IPO, given the absence of a public trading market, the Company&#8217;s Board of Directors, with input from management, considered numerous objective and subjective factors to determine the fair value of its common stock. The factors included: (i)&#160;third-party valuations of the Company&#8217;s common stock; (ii)&#160;the Company&#8217;s stage of development; (iii)&#160;the status of research and development efforts; (iv)&#160;the rights, preferences and privileges of the Company&#8217;s preferred stock relative to common stock; (v)&#160;the Company&#8217;s operating results and financial condition, including the Company&#8217;s levels of available capital resources; (vi)&#160;equity market conditions affecting comparable public companies; (vii)&#160;general U.S. market conditions; and (viii)&#160;the lack of current marketability of the Company&#8217;s common stock. Subsequent to the IPO, the fair value of the Company&#8217;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of grant.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based compensation expense is reported in the Statements of Operations and Comprehensive Income (Loss) within "research and development" expense or "general and administrative" expense, based upon the assigned department of the award recipient.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(ix) Income Taxes</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reported in the financial statements, as well as operating losses and tax credit carryforwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain due to the Company&#8217;s historical operating performance and recorded cumulative net losses in prior fiscal periods.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded to reduce deferred tax assets, because based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If and when the Company were to determine that deferred tax assets are realizable, an adjustment to the corresponding valuation allowance would increase the net income in the period that such determination was made.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that the Company is assessed interest and/or penalties from taxing authorities that have not been previously accrued, such amounts would be included as a component of &#8220;income tax expense&#8221; within the Statements of Operations and Comprehensive Income (Loss) in the period the notice was received. To date there have been no interest or penalties charged.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2019-12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> removes certain exceptions for performing intraperiod tax allocations, recognizing deferred taxes for investments, and calculating income taxes in interim periods.  The guidance also simplifies the accounting for franchise taxes, transactions that result in a step-up in the tax basis of goodwill, and the effect of enacted changes in tax laws or rates in interim periods.  The Company adopted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2019-12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the first quarter of 2021, which had no material impact to its financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(x) Net Income (Loss) per Share Attributable to Common Stockholders</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share attributable to common stockholders is calculated by dividing the net income (loss) by the weighted-average number of shares of common stock outstanding for the period, without the consideration for potential dilutive shares of common stock. Diluted net income (loss) per share is computed by dividing the net income (loss) by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method, as applicable. The Company&#8217;s participating securities include unvested common stock awards issued upon early exercise of certain stock options, as early exercised unvested common stock awards have a non-forfeitable right to dividends. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses, so in periods of net losses, the two-class method of calculating basic and diluted earnings per share is not required. In periods of net income, basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. In periods of net income, net income is attributed to both common stockholders and participating security holders, and therefore, net income is allocated to shares of common stock and participating securities, as if all of the earnings for the period had been distributed. Diluted earnings per share under the two-class method is calculated using the more dilutive of the treasury stock or the two-class method. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to a net loss for the three and six months ended June 30, 2020, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in these periods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(xi) Fair Value Measurements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to their short maturities. Derivative instruments (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) are carried at fair value based on unobservable market inputs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(xii) Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) represents all changes in stockholders&#8217; equity (deficit), except those resulting from distributions to stockholders. For all periods presented, comprehensive income (loss) was the same as reported net income (loss).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(xiii) Recently Issued or Effective Accounting Standards</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#8217;s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these condensed financial statements have been determined by the Company&#8217;s management to have no impact, or an immaterial impact, on its current and expected future financial position, results of operations, or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893558667768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Detail<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Account Detail</a></td>
<td class="text">BALANCE SHEET ACCOUNT DETAIL<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of selected financial statement captions that comprise the accompanying balance sheets are summarized below: </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Property and Equipment, net of Accumulated Depreciation</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Property and equipment, net of accumulated depreciation&#8221; consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:75.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.334%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Less): Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation and amortization</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense (included within &#8220;total operating expenses&#8221; in the accompanying Statements of Operations and Comprehensive Income (Loss)) for the three months ended June 30, 2021 and 2020 was $125 thousand and $17 thousand, respectively, and for the six months ended June 30, 2021 and 2020 was $189 thousand and $32 thousand, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b) Other Assets</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"Other assets" consists of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity warrant rights*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">              *In January 2020, the FASB issued </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Update No. 2020-01, Investments&#8212;Equity Securities (Topic 321), &#160;&#160;&#160;&#160;                   Investments&#8212;Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)&#8212;Clarifying the Interactions between Topic 321, Topic 323, and Topic 815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (a consensus of the Emerging Issues Task Force), which clarifies the interaction of the accounting for equity securities, investments accounted for under the equity method, and certain forward contracts and purchased options. This update is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The Company is in the process of determining the impact the adoption will have on its financial statements, beginning as of and for the three months ending March 31, 2022.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c) Accounts Payable and Other Accrued Liabilities&#160;</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Accounts payable and other accrued liabilities&#8221; consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable and other</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,237&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical studies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock option early exercise liability, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,985&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d) Other Long-Term Liabilities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Other long-term liabilities&#8221; consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, non-current portion</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock option early exercise liability, non-current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893559244552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Authorized Stock</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the October 2020 Amended and Restated Certificate of Incorporation, the Company is authorized to issue two classes of stock: common and preferred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The total number of shares authorized for issuance is 200.0 million shares of common stock and 10.0 million shares of preferred stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Overview and Reserve for Future Issuance</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stockholders have one vote for each share of common stock held and are entitled to receive any dividends declared by the Company&#8217;s Board of Directors when legally available for distribution, then-subject to the dividend rights of the holders of preferred stock. For the three and six months ended June 30, 2021 and for the year ended December&#160;31, 2020, no dividends were declared.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021 and December&#160;31, 2020, the Company had 20.7 million and 20.5 million shares of common stock issued, respectively. At June&#160;30, 2021 and December&#160;31, 2020, the Company had 20.6 million, an</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d 20.3 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock outstanding, respectively. The following shares of common stock were reserved for issuance:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options issued and outstanding </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,598,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,836,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock awards reserved for future grant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,451,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,414,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shares of common stock reserved</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,054,212&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,250,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893555814408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 and 2016 Equity Incentive Plans</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Board of Directors and stockholders adopted and approved the Company's 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) on October 8, 2020. The 2020 Plan replaced the Company's 2016 Equity Incentive Plan that was earlier adopted in December 2016 (the &#8220;2016 Plan&#8221;).  However, awards outstanding under the 2016 Plan will continue to be governed by its original terms. The number of shares of the Company's common stock that were initially available for issuance under the 2020 Plan equaled the initial sum of 9,000,000 shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">plus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2,432,980 shares that were then available for issuance under the 2016 Plan. The 2020 Plan provides for the following types of awards: incentive and non-statutory stock options, stock appreciation rights, restricted shares, and restricted stock units.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of common stock reserved for issuance under the 2020 Plan are increased automatically on the first business day of each fiscal year, commencing in 2021 and ending in 2030, by a number equal to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">lesser of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: (i) 4% of the shares of common stock outstanding on the last day of the prior fiscal year; or (ii) the number of shares determined by the Company's Board of Directors. In general, to the extent that any awards under the 2020 Plan are forfeited, terminate, expire or lapse without the issuance of shares, or if the Company reacquires the shares subject to awards granted under the 2020 Plan, those shares will again become available for issuance under the 2020 Plan, as will shares applied to pay the exercise or purchase price of an award or to satisfy tax withholding obligations related to any award.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards are governed by agreements between the Company and the recipients. Incentive stock options and nonqualified stock options may be granted under the 2020 Plan (and previously the 2016 Plan) at an exercise price of not less than 100% of the fair market value of common stock on the respective date of grant.  The grant date is the date the terms of the award are formally approved by the Company&#8217;s Board of Directors or its designee. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through June&#160;30, 2021, all awards issued under the 2020 Plan and 2016 Plan were in the form of stock options and restricted stock units. These stock award agreements have service and/or performance conditions for vesting, unless immediately vested on the date of grant. Stock awards granted typically have <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhiNjE1NjExMzNlZDRhNmI4NjhkOGQyYjVhMWY5NjQwL3NlYzo4YjYxNTYxMTMzZWQ0YTZiODY4ZDhkMmI1YTFmOTY0MF80OS9mcmFnOjA3ZjlmZDUxYWM4MDRmNTBiYTJkNzA0YmQxMjU5NmMxL3RleHRyZWdpb246MDdmOWZkNTFhYzgwNGY1MGJhMmQ3MDRiZDEyNTk2YzFfMjM4Ng_487f5d4f-2795-4d06-a86b-a0f73cdced0d">one</span> to four-year service conditions for full vesting. The performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options must be exercised, if at all, no later than 10 years from the date of grant. Upon termination of employment, vested stock options may be exercised within 12 months after the date of termination upon death, six months after the date of termination upon disability, and three months after the date of termination for all other separations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Summary</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is recorded in the accompanying condensed statements of operations and comprehensive income (loss) based on the assigned or designated department of the award recipient. Stock-based compensation expense for the three and six months ended June 30, 2021 and 2020 was as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:45.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,794&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,157&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pre-Vesting Exercise Feature of Certain Stock Options </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Plan permitted certain option holders to exercise awarded options prior to vesting. Upon this early exercise, the options became subject to a restricted stock agreement and remain subject to the same vesting provisions in the corresponding stock option award. These unvested options are subject to repurchase by the Company upon employee termination at the same price exercised. These unvested shares of common stock are reported as issued (but not outstanding) on the accompanying Balance Sheets while subject to repurchase by the Company. These shares are also excluded from the basic net income (loss) per share until the repurchase right lapses upon vesting, but are included in the diluted net income per share for the three and six months ended June&#160;30, 2021.</span></div>The Company initially records a liability for these early exercises that is subsequently reclassified into stockholders&#8217; equity on a pro rata basis as vesting occurs. As of June&#160;30, 2021 and December&#160;31, 2020, the Company recorded the unvested portion of the exercise proceeds of $0.3 million and $0.4 million, respectively, as a liability from the early exercise in the accompanying Balance Sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893559244552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text">NET INCOME (LOSS) PER SHARE<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company permits certain option holders to exercise awarded options prior to vesting (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Upon this early exercise, these options become subject to a restricted stock agreement and remain subject to the same vesting provisions in the corresponding stock option award. These early exercised options are considered to be "participating securities" due to non-forfeitable right to dividends (i.e., even prior to vesting). For the three and six months ended June 30, 2021, the "two-class method" was utilized to calculate diluted net income per share as it was more dilutive than the "treasury stock metho</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d". Due to a net loss for the three months ended March 31, 2020, all otherwise potentially dilutive securities are antidilutive. Accordingly, basic net loss per share equals diluted net loss per share for the three and six months ended June 30, 2020. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> table sets forth the computation of basic and diluted net loss per share attributable to common stockholders:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.212%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic EPS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: undistributed income allocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available to common shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,299&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,250)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,588&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,207)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,555,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,651,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,446,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to common stockholders&#8212;basic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.23)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.96)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: undistributed income reallocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available to common shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,302&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,250)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,597&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,207)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,555,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,651,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,446,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,966,599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,651,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,895,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650,843&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to common stockholders&#8212;diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.23)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.96)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> three and six months ended June&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 0.8&#160;million unexercised stock options were excluded from the computation of n</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">et income per share because the effect would have been anti-dilutive. Additionally, during the three and six months ended June 30, 2020, 1.2&#160;million unexercised stock options, 8.2&#160;million shares of preferred stock, and 67&#160;thousand early-exercised and unvested stock options were excluded from the calculation of diluted net loss per share attributable to common stockholders because their impact under the &#8220;treasury stock method&#8221; and "if-converted metho</span>d" would have been anti-dilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893553330104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes certain financial instruments measured at fair value that are included within the accompanying balance sheets, and their designation among the three fair value measurement categories (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2(xiii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity warrant rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,710&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,786&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Money Market Funds</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market fund holdings are included in "cash and cash equivalents" on the accompanying Balance Sheets and are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the fair value hierarchy because of their readily-available market prices in active markets that are publicly accessible at the measurement date. These money market funds are invested in U.S. Treasury, bills, notes, and other obligations issued or guaranteed as to principal and interest by the U.S. Government or its agencies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Warrant Rights</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, contemporaneous with the China Out-License transaction (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Company and LianBio Ophthalmology Limited (&#8220;LianBio&#8221;), executed a warrant agreement for the Company to purchase a stated number of equity securities of LianBio, a privately-held China-focused pharmaceutical company, at fair value (on a per share basis at the time of issuance).  The warrants will vest upon the achievement of certain clinical and regulatory events. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These warrants are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the fair value measurement hierarchy. The most significant assumptions  used in the option pricing valuation model to determine fair value include: the estimated current fair value of LianBio common stock, LianBio stock volatility (based on the historical volatility of similar companies), and the probability of achievement of discrete clinical and regulatory milestones for the vesting of each of the three warrants.  As of June&#160;30, 2021, one of these three milestones was met for vesting of the respective warrant.   </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These warrant agreements allow for "noncash settlement" and therefore met the criteria to be recognized as a "derivative asset" on the accompanying Condensed Balance Sheets and are presented within "other assets" as of June&#160;30, 2021 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). These warrants will be remeasured with a corresponding amount reported in "other (expense) income, net" on the Statement of Operations and Comprehensive Income (Loss) at each reporting date, until exercised or expired. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in fair value of the equity warrant rights presented in "other assets" on the accompanying Condensed Balance Sheets. The measurement of the equity warrant rights represents a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> financial instrument:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"/><td style="width:82.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.595%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Warrant Rights, presented in "other assets" within the Condensed Consolidated Balance Sheets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Initial fair value estimate of equity warrant rights upon issuance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revaluation of equity warrant rights upon achievement of first development milestone, included in "license fees"  within the Condensed Statement of Operations for the three months ended June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revaluation of equity warrant rights included in "other income (expense), net" within the Condensed Statement of Operations for the three months ended June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of June 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893559244552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment &amp; Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitment &amp; Contingencies</a></td>
<td class="text">COMMITMENTS&#160;&amp; CONTINGENCIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Facility Leases </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company enters lease agreements with unaffiliated parties for the use of office and laboratory facilities and office equipment. As of December&#160;31, 2020, the Company had three active facility leases in Irvine, California.  Separately in January 2021, the Company entered into a six-month lease for an additional adjacent administrative office suite that was not capitalized due to its under 12-month term.  In December 2020, the Company recorded a $15 thousand impairment of its "operating lease right-of-use lease asset" in connection with its decision to early terminate one of the leases, which was completed in January 2021.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's remaining two capitalized facility leases for adjacent administrative and laboratory suites in Irvine, California commenced on June&#160;1, 2020. These leases each expire on January&#160;31, 2024 and one includes a renewal option that was not reasonably certain to be exercised at the time of lease commencement for purposes of its associated accounting for  capitalized "operating lease right-of-use asset" and accompanying lease liability included within "accounts payable and other accrued liabilities" and "other long-term liabilities" on the accompanying Condensed Balance Sheets, amounting to an aggregate $0.6 million.  These operating leases have annual rent that is payable monthly and carry fixed annual increases. Also, under these arrangements, real estate taxes, certain operating expenses, and common area maintenance are paid by the Company; since these costs are variable in nature, they are excluded from the measurement of the reported right-of-use asset and liability and are expensed as incurred. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020 and for the three and six months ended June 30, 2021, the Company had no sublease arrangements with it as lessor.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Components of Lease Expense</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liability associated with each lease is amortized over the respective lease term using the &#8220;effective interest rate method.&#8221; The Company&#8217;s right-of-use asset is amortized over the lease term on a straight-line basis to lease expense, as reported on an allocated basis within &#8220;research and development&#8221; and &#8220;general and administrative&#8221; expenses on the accompanying Statements of Operations and Comprehensive Income (Loss). The components of lease cost were as follows:</span></div><div style="margin-top:12pt;text-align:center;text-indent:49.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:40.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.138%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.454%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Weighted-Average Remaining Lease Term and Applied Discount Rate as of June 30, 2021 and December 31, 2020</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021 and December&#160;31, 2020, the Company's active facility leases had a weighted average remaining lease term of 2 years, 7 months and 2 years, 10 months, respectively.  The weighted average estimated incremental borrowing rate of 10% was utilized to present value future minimum lease payments since an implicit interest rate was not readily determinable. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Contractual Lease Payments as of June&#160;30, 2021</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below table summarizes the (i)&#160;minimum lease payments over the next five years and thereafter, (ii)&#160;lease arrangement imputed interest, and (iii)&#160;present value of future lease payments:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases - future payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining six months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future lease payments, undiscounted</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Less): Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease payments</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) In-License Agreements for Lotilaner</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agreement for Skin and Eye Disease or Conditions in Humans</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, the Company entered into an in-license agreement with Elanco Tiergesundheit AG (&#8220;Elanco&#8221;) for exclusive worldwide rights to certain intellectual property for the development and commercialization of lotilaner in the treatment or cure of any eye or skin disease or condition in humans (the "January 2019 Agreement"). The Company has sole financial responsibility for related development, regulatory, and commercialization activities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made a $1.0 million upfront payment at execution of the January 2019 Agreement. In September 2020, the Company made a required $1.0 million clinical milestone payment associated with the first of two U.S. pivotal trials for the treatment of Demodex blepharitis.  The Company recognized an additional $2.0 million expense for its second pivotal trial milestone in the three and six months ended June 30, 2021, which was paid in April 2021.  These amounts are presented in the applicable period within "research and development" expense in the accompanying Statements of Operations and Comprehensive Income (Loss). </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may make further cash payments to Elanco under this January 2019 Agreement upon the achievement of certain clinical milestones in the treatment of human skin diseases using lotilaner for an aggregate maximum of $3.0 million and various commercial and sales threshold milestones for an aggregate maximum of $79.0 million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its net sales. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">double-digits of such proceeds, except for territories in which the Company achieved applicable regulatory approval prior to sublicense execution.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the China Out-License discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company made a required contractual payment in the amount of $2.5 million to Elanco as part of the receipt of $25 million of initial proceeds from LianBio during the three months ended June 30, 2021.  </span></div><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agreement for All Other Diseases or Conditions in Humans</span></div><div style="text-indent:56.55pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2020, the Company executed an expanded license agreement with Elanco, granting it a worldwide  license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention, or cure of "all other" diseases and conditions in humans (i.e., beyond that of the eye or skin, the &#8220;September 2020 Agreement&#8221;).  The Company issued Elanco 222,460 shares of its common stock at the execution of the September 2020 Agreement. The value of these shares was $3.1 million ($14.0003 per share, approximating the issuance price of the Company's Series C preferred stock in September 2020).  </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is required to make further cash payments to Elanco under the September 2020 Agreement upon the achievement of various clinical milestones for an aggregate maximum of $4.5 million and various commercial and sales threshold milestones for an aggregate maximum of $77.0 million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its net sales. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, except for territories in which the Company achieved applicable regulatory approval prior to sublicense execution.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, the Company entered into an out-license agreement with LianBio (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">), which  obligated it to grant Elanco an additional fixed 187,500 shares of the Company's common stock that were otherwise required to be granted no later than the 18-month anniversary of the September 2020 Agreement for the Company's continued license exclusivity.  These additional shares were valued at $5.5 million based on the Company's stock closing price of $29.30 per share (on the date the issuance became contractually required) and is reported within "research and development" expense within the accompanying Statements of Operations and Comprehensive Income (Loss) for the three and six months ended June 30, 2021.  </span></div><div style="text-indent:56.55pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c) Employment Agreements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements with six of its named executive officers. These agreements provide for the payment of certain benefits upon separation of employment under specified circumstances, such as termination without cause, or termination in connection with a change in control event.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Litigation Contingencies</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company is currently not aware of any such matters where there is at least a reasonable probability that a material loss, if any, has been or will be incurred for financial statement recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e) Indemnities and Guarantees</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain indemnity commitments, under which it may be required to make payments to its officers and directors in relation to certain transactions to the maximum extent permitted under applicable laws. The duration of these indemnities varies, and in certain cases, is indefinite and does not provide for any limitation of maximum payments. The Company has not been obligated to make any such payments to date and no liabilities have been recorded for this contingency in the accompanying Condensed Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893555764312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Out-License Agreement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Out-License Agreement</a></td>
<td class="text">OUT-LICENSE AGREEMENT<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License of TP-03 Commercial Rights in Greater China in March 2021</span></div><div><span><br/></span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 26, 2021, the Company entered into an out-license agreement with LianBio for its exclusive development and commercialization rights of TP-03 (lotilaner ophthalmic solution, 0.25%) in the People&#8217;s Republic of China, Hong Kong, Macau, and Taiwan (the &#8220;China Territory&#8221;) for the treatment of Demodex blepharitis and Meibomian Gland Disease (the &#8220;China Out-License&#8221;).  LianBio is contractually responsible for all clinical development and commercialization activities and costs within the China Territory.</span></div><div><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company received payments from LianBio of $15.0 million in April 2021 and $10.0 million in May 2021 as initial consideration, and $10.0&#160;million in June 2021 for the achievement of a clinical development milestone.  </span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also is eligible to receive other payments and consideration from LianBio upon achievement of certain additional milestones, including: (i) TP-03 clinical development and regulatory milestones of up to $65.0&#160;million (including $20&#160;million for the achievement of a clinical milestone in June 2021 that is presented within "accounts receivable" on the accompanying Condensed Balance Sheets), (ii) TP-03 sales-based milestones for the China Territory of up to  $100.0 million, (iii) tiered mid-to-high-teen royalties for China Territory TP-03 sales, and (iv) equity warrants issued to the Company in March 2021 for purchase of LianBio equity securities, subject to TP-03 clinical/regulatory achievements for vesting. </span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized "license fees" and "collaboration revenue" for the three months ended June 30, 2021 of $19.0 million and $3.0 million, respectively, in the accompanying Condensed Statements of Operations and Comprehensive Income (Loss), in accordance with the revenue recognition accounting policy described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2(vi).  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These amounts represent separately valued "performance obligations" in the China Out-License</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, the Company recognized $52.4 million and $3.1 million, respectively, for "license fees" and "collaboration revenue".</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These revenue amounts were each recognized upon (i) the transfer of TP-03 license rights in the China Territory to LianBio and (ii) the actual or partial completion of clinical activities and related data for the Company's pivotal trials of TP-03 in the treatment of Demodex blepharitis (each representing separately valued "performance obligations" in the China Out-License).  As part of this revenue recognition model, the Company was required to value the LianBio equity warrant, applying a discounted cash flow model with highly subjective inputs for this pre-revenue company, and to also consider the probability of achievement of requisite vesting events.</span></div>In future periods, the Company may recognize additional revenue from contractual receipts due from LianBio as (1) performance obligations are satisfied related to the completion of the TP-03 pivotal trial and as associated clinical data and reports are delivered, (2) regulatory approval events are achieved, and (3) LianBio has sales of TP-03 in the China Territory.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893637885784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Use of Estimates (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segment</a></td>
<td class="text">To date, the Company has operated and managed its business and financial information on an aggregate basis for the purposes of evaluating financial performance and the allocation of capital and personnel resources. Accordingly, the Company&#8217;s management determined that it operates in one reportable operating segment.  This single segment is focused exclusively on developing pharmaceutical products for eventual commercialization.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information and pursuant to Form 10-Q and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Article 10 of Regulation S-X </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, the accompanying condensed financial statements do not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim condensed balance sheet as of June&#160;30, 2021, and the interim condensed statements of operations and comprehensive income (loss), changes in preferred stock and stockholders&#8217; equity and cash flows for the three and six months ended June&#160;30, 2021 and 2020 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes related to the three and six-month periods are also unaudited. The condensed balance sheet as of December 31, 2020 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three and six months ended June&#160;30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021 or any other interim or annual period. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed financial statements should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2020 in the Company&#8217;s Annual Report on Form 10-K (&#8220;Annual Report&#8221;) for the fiscal year ended December 31, 2020, as filed with the SEC on March 31, 2021.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These amounts may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an on-going basis, management evaluates its most critical estimates and assumptions, including those related to the (i)&#160;fair value of equity-based awards and periodic recognition of stock-based compensation, (ii)&#160;the realization of income tax assets and estimates of tax liabilities, and (iii)&#160;expense accruals related to research and development activities, including clinical trials.  The accounting policies and estimates that most significantly impact the presented amounts within the accompanying condensed financial statements are further described below:</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsCash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, with original maturities of three months or less from the purchase date.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">Restricted CashRestricted cash represents cash held as collateral for the Company&#8217;s corporate credit card program. Any cash that is legally or contractually restricted from immediate use is classified as restricted cash.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text">Concentration of Credit Risk and Other Risks and Uncertainties<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents in deposits at financial institutions that exceed federally insured limits.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared a pandemic related to the global novel coronavirus disease 2019 (&#8220;COVID-19&#8221;) outbreak. To date, the Company&#8217;s operations have not been significantly impacted by the COVID-19 </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pandemic, though the Company continues to monitor the potential impact COVID-19 may have on its ongoing and planned clinical trials. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak may have on these activities or its financial condition.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results of operations involve numerous risks and uncertainties. Factors that could adversely impact the Company&#8217;s operating results and business objectives include, but are not limited to, (1) uncertainty of results of clinical trials, (2) uncertainty of regulatory approval of the Company&#8217;s potential product candidates, including TP-03 for ophthalmic conditions, TP-04 for treatment of skin conditions and TP-05 for prophylaxis of Lyme and community malaria reduction, (3) uncertainty of market acceptance of its product candidates, (4) competition from substitute products and other companies, (5) securing and protecting proprietary technology and strategic relationships, and (6) and dependence on key individuals and sole source suppliers.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s product candidates require approvals from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive these necessary approvals. If the Company is denied approval, approval is delayed, or is unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company's business.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and EquipmentProperty and equipment is stated at historical cost and is depreciated on a straight-line basis over an estimated useful life that corresponds with its designated asset category. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of &#8220;long-lived assets&#8221; (which includes property and equipment) whenever events or changes in circumstances in the business indicate that the asset&#8217;s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue</a></td>
<td class="text">Revenue Recognition for Out-License Arrangements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview </span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has one out-license arrangement that allows the licensee to market the Company&#8217;s TP-03 product (representing "functional intellectual property") in certain territories for a certain field of use and for a stated term - see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract, (b) the contract&#8217;s transaction price for allocation (including variable consideration), (c) the stand-alone selling price for each identified performance obligation, and (d) the timing and amount of  revenue recognition in each period. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's out-license arrangement, as described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was analyzed under GAAP to determine whether the promised goods or services (which include the license, and know-how, data, and information necessary or reasonably useful for the research, development, manufacture, or commercialization of any license product, and governance committee services) are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is considered to not be distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's out-license arrangement is in exchange for the following forms of consideration: (i) upfront cash payments, (ii) equity-based consideration, (iii) sales royalties, (iv) sales threshold milestones, (v) development milestone fees, and (vi) regulatory milestone fees.  Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied.   The Company evaluates the progress related to each milestone at each reporting </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period and, if necessary, also adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Terms for Receipt of Payments</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual terms that establish the Company&#8217;s right to collect specified amounts from its customers and the require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, as follows:</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Upfront License Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company determines whether non-refundable license consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the out-license.  The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company utilizes the &#8220;most likely amount&#8221; method to estimate the amount of consideration to which it will be entitled for achievement of development milestones. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint.  At each reporting period, the Company re-evaluates this associated revenue recognition constraint.  Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, thus reflected in the financial statements in the period of adjustment. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company utilizes the &#8220;most likely amount&#8221; method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied). Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are constrained for revenue recognition until achievement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the "sales-or-usage-based royalty exception" the Company recognizes revenue based on the contractual percentage of the licensee&#8217;s sales to its customers at the later of (i) the occurrence of the related sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from its out-licensing arrangements.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Threshold Milestones:</span> Similar to royalties, applying the "sales-or-usage-based royalty exception", the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from out-licensing arrangements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">Research and Development CostsResearch and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. These expenses also include internal costs directly attributable to in-development programs, including cost of certain salaries, payroll taxes, employee benefits, and stock-based compensation expense, as well as laboratory and clinical supplies, pre-clinical and clinical trial related expenses, and the cost of services provided by outside contractors. The Company recognizes expense for pre-clinical studies and clinical trial activities performed by these third parties. This is typically based upon estimates of the proportion of work completed over the term of the individual study or trial, as well as patient enrollment and dosing events in accordance with agreements established with clinical research organizations ("CROs") and clinical trial or pre-clinical study sites.<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered, and may continue to enter into, license agreements to access and utilize intellectual property for drug development. In each case, the Company evaluates if the assets acquired in a transaction represent the acquisition of an as</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">set or a business, as defined under applicable GAAP. The Company&#8217;s executed in-license agreements (see </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8(b)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) were evaluated and determined to represent asset acquisitions. Because these assets have not yet received regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and have no alternative future uses, the purchase price for each was immediately recognized as research and development expense. In addition, any future milestone payments (whether in the form of cash or stock) made before product regulatory approval (that do not meet the definition of a derivative) will also be immediately recognized as research and development expense when paid or becomes payable, provided there is no alternative future use of the rights in other research and development projects.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is recognized for all equity awards granted to employees, consultants, and members of the Company&#8217;s Board of Directors and is recognized at fair value. For stock-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date is the date of grant and the related expense is recognized on a straight-line basis over each award&#8217;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes compensation cost if and when it concludes that it is probable that the performance condition will be achieved and the related expense is recognized on an accelerated attribution method. As applicable, the Company reverses previously recognized expense for forfeitures of unvested awards in the period of occurrence. The Company uses the Black-Scholes pricing model to estimate the fair value of stock option awards as of the date of grant.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement of the fair value of stock-based awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#8217;s judgment, including (a)&#160;the fair value of the Company&#8217;s common stock on the date of the option grant, (b)&#160;the expected term of the stock option until its exercise by the recipient, (c)&#160;stock price volatility over the expected term, (d)&#160;the prevailing risk-free interest rate over the expected term, and (e)&#160;expected dividend payments over the expected term.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management estimates the expected term of awarded stock options utilizing the &#8220;simplified method&#8221; for awards as the Company does not yet have sufficient exercise history since its November 2016 formation. Further, prior to the IPO, the Company was privately-held and therefore lacked company-specific historical and implied volatility information of its stock.&#160;Accordingly, management estimated this expected volatility based on a designated peer-group of publicly-traded companies for a look-back period, as of the date of grant, that corresponded with the expected term of the awarded stock option. The Company estimates the risk-free interest rate based upon the U.S. Department of the Treasury yield curve in effect at award grant for time periods that correspond with the expected term of the awarded stock option. The Company&#8217;s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the IPO, given the absence of a public trading market, the Company&#8217;s Board of Directors, with input from management, considered numerous objective and subjective factors to determine the fair value of its common stock. The factors included: (i)&#160;third-party valuations of the Company&#8217;s common stock; (ii)&#160;the Company&#8217;s stage of development; (iii)&#160;the status of research and development efforts; (iv)&#160;the rights, preferences and privileges of the Company&#8217;s preferred stock relative to common stock; (v)&#160;the Company&#8217;s operating results and financial condition, including the Company&#8217;s levels of available capital resources; (vi)&#160;equity market conditions affecting comparable public companies; (vii)&#160;general U.S. market conditions; and (viii)&#160;the lack of current marketability of the Company&#8217;s common stock. Subsequent to the IPO, the fair value of the Company&#8217;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of grant.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based compensation expense is reported in the Statements of Operations and Comprehensive Income (Loss) within "research and development" expense or "general and administrative" expense, based upon the assigned department of the award recipient.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesIncome taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reported in the financial statements, as well as operating losses and tax credit carryforwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain due to the Company&#8217;s historical operating performance and recorded cumulative net losses in prior fiscal periods.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded to reduce deferred tax assets, because based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If and when the Company were to determine that deferred tax assets are realizable, an adjustment to the corresponding valuation allowance would increase the net income in the period that such determination was made.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that the Company is assessed interest and/or penalties from taxing authorities that have not been previously accrued, such amounts would be included as a component of &#8220;income tax expense&#8221; within the Statements of Operations and Comprehensive Income (Loss) in the period the notice was received. To date there have been no interest or penalties charged.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2019-12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> removes certain exceptions for performing intraperiod tax allocations, recognizing deferred taxes for investments, and calculating income taxes in interim periods.  The guidance also simplifies the accounting for franchise taxes, transactions that result in a step-up in the tax basis of goodwill, and the effect of enacted changes in tax laws or rates in interim periods.  The Company adopted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2019-12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the first quarter of 2021, which had no material impact to its financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text">Net Income (Loss) per Share Attributable to Common Stockholders<div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share attributable to common stockholders is calculated by dividing the net income (loss) by the weighted-average number of shares of common stock outstanding for the period, without the consideration for potential dilutive shares of common stock. Diluted net income (loss) per share is computed by dividing the net income (loss) by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method, as applicable. The Company&#8217;s participating securities include unvested common stock awards issued upon early exercise of certain stock options, as early exercised unvested common stock awards have a non-forfeitable right to dividends. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses, so in periods of net losses, the two-class method of calculating basic and diluted earnings per share is not required. In periods of net income, basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. In periods of net income, net income is attributed to both common stockholders and participating security holders, and therefore, net income is allocated to shares of common stock and participating securities, as if all of the earnings for the period had been distributed. Diluted earnings per share under the two-class method is calculated using the more dilutive of the treasury stock or the two-class method. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to a net loss for the three and six months ended June 30, 2020, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in these periods.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value MeasurementsAssets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:<div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to their short maturities. Derivative instruments (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) are carried at fair value based on unobservable market inputs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text">Comprehensive Income (Loss)Comprehensive income (loss) represents all changes in stockholders&#8217; equity (deficit), except those resulting from distributions to stockholders. For all periods presented, comprehensive income (loss) was the same as reported net income (loss).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued or Effective Accounting Standards</a></td>
<td class="text">Recently Issued or Effective Accounting StandardsRecently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#8217;s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these condensed financial statements have been determined by the Company&#8217;s management to have no impact, or an immaterial impact, on its current and expected future financial position, results of operations, or cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893556230248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Property and equipment, net of accumulated depreciation&#8221; consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:75.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.334%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Less): Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation and amortization</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Other assets</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"Other assets" consists of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity warrant rights*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">              *In January 2020, the FASB issued </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Update No. 2020-01, Investments&#8212;Equity Securities (Topic 321), &#160;&#160;&#160;&#160;                   Investments&#8212;Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)&#8212;Clarifying the Interactions between Topic 321, Topic 323, and Topic 815</span> (a consensus of the Emerging Issues Task Force), which clarifies the interaction of the accounting for equity securities, investments accounted for under the equity method, and certain forward contracts and purchased options. This update is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The Company is in the process of determining the impact the adoption will have on its financial statements, beginning as of and for the three months ending March 31, 2022.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Accounts payable and accrued liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Accounts payable and other accrued liabilities&#8221; consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable and other</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,237&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical studies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock option early exercise liability, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,985&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesTableTextBlock', window );">Other long-term liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Other long-term liabilities&#8221; consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, non-current portion</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock option early exercise liability, non-current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893558865112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Stock details</a></td>
<td class="text">The following shares of common stock were reserved for issuance:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options issued and outstanding </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,598,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,836,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock awards reserved for future grant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,451,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,414,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shares of common stock reserved</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,054,212&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,250,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893558783704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-based compensation</a></td>
<td class="text">Stock-based compensation expense for the three and six months ended June 30, 2021 and 2020 was as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:45.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,794&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,157&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893554495848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Net loss per share, basis and diluted</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company permits certain option holders to exercise awarded options prior to vesting (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Upon this early exercise, these options become subject to a restricted stock agreement and remain subject to the same vesting provisions in the corresponding stock option award. These early exercised options are considered to be "participating securities" due to non-forfeitable right to dividends (i.e., even prior to vesting). For the three and six months ended June 30, 2021, the "two-class method" was utilized to calculate diluted net income per share as it was more dilutive than the "treasury stock metho</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d". Due to a net loss for the three months ended March 31, 2020, all otherwise potentially dilutive securities are antidilutive. Accordingly, basic net loss per share equals diluted net loss per share for the three and six months ended June 30, 2020. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> table sets forth the computation of basic and diluted net loss per share attributable to common stockholders:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.212%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic EPS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: undistributed income allocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available to common shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,299&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,250)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,588&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,207)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,555,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,651,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,446,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to common stockholders&#8212;basic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.23)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.96)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted EPS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: undistributed income reallocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available to common shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,302&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,250)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,597&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,207)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,555,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,651,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,446,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,966,599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,651,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,895,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650,843&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to common stockholders&#8212;diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.23)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.96)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893554472904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Financial instruments measured at fair value</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes certain financial instruments measured at fair value that are included within the accompanying balance sheets, and their designation among the three fair value measurement categories (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2(xiii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity warrant rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,710&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,786&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in fair value of derivative liability</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in fair value of the equity warrant rights presented in "other assets" on the accompanying Condensed Balance Sheets. The measurement of the equity warrant rights represents a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> financial instrument:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"/><td style="width:82.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.595%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Warrant Rights, presented in "other assets" within the Condensed Consolidated Balance Sheets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Initial fair value estimate of equity warrant rights upon issuance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revaluation of equity warrant rights upon achievement of first development milestone, included in "license fees"  within the Condensed Statement of Operations for the three months ended June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revaluation of equity warrant rights included in "other income (expense), net" within the Condensed Statement of Operations for the three months ended June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of June 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893555758360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment &amp; Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of lease cost</a></td>
<td class="text">The components of lease cost were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:40.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.138%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.454%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future contractual lease payments</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below table summarizes the (i)&#160;minimum lease payments over the next five years and thereafter, (ii)&#160;lease arrangement imputed interest, and (iii)&#160;present value of future lease payments:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases - future payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining six months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future lease payments, undiscounted</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Less): Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease payments</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893559952056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Presentation of Financial Statements (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 20, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Oct. 08, 2020</div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,124<span></span>
</td>
<td class="nump">$ 32,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,735<span></span>
</td>
<td class="nump">$ 168,129<span></span>
</td>
<td class="nump">$ 53,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Stock issued (shares) | shares</a></td>
<td class="nump">6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (usd per share) | $ / shares</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Stock issued, net proceeds | $</a></td>
<td class="nump">$ 91,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issued upon conversion of preferred stock (shares) | shares</a></td>
<td class="nump">11,107,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters' option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Stock issued (shares) | shares</a></td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893560558168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">(Less): Accumulated depreciation and amortization</a></td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization</a></td>
<td class="nump">481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893554333608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Detail - Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Deposits</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_EquityWarrantRights', window );">Equity warrant rights*</a></td>
<td class="nump">1,076<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other long term assets</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 1,525<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_EquityWarrantRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Warrant Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_EquityWarrantRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893637608936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable and other</a></td>
<td class="nump">$ 3,303<span></span>
</td>
<td class="nump">$ 2,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current portion</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_AccruedClinicalStudiesCurrent', window );">Accrued clinical studies</a></td>
<td class="nump">3,358<span></span>
</td>
<td class="nump">1,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liability</a></td>
<td class="nump">1,504<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Employee stock option early exercise liability, current portion</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and other accrued liabilities</a></td>
<td class="nump">$ 8,985<span></span>
</td>
<td class="nump">$ 4,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_AccruedClinicalStudiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Studies, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_AccruedClinicalStudiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893556243880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Detail - Other Long-Term Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current portion</a></td>
<td class="nump">$ 405<span></span>
</td>
<td class="nump">$ 549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent', window );">Employee stock option early exercise liability, non-current portion</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">$ 524<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893559601896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock, authorized (shares)</a></td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CommonStockNumberOfVotes', window );">Common stock voting rights, number of votes | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock dividends declared (usd per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares)</a></td>
<td class="nump">20,704,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,502,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares)</a></td>
<td class="nump">20,573,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,323,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockNumberOfVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Number Of Votes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockNumberOfVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893554255848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Shares Reserved for Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding', window );">Stock options issued and outstanding (shares)</a></td>
<td class="nump">2,598,764<span></span>
</td>
<td class="nump">1,836,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant', window );">Stock options reserved for future grant (shares)</a></td>
<td class="nump">9,451,191<span></span>
</td>
<td class="nump">9,414,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant', window );">Restricted stock units outstanding</a></td>
<td class="nump">4,257<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved (shares)</a></td>
<td class="nump">12,054,212<span></span>
</td>
<td class="nump">11,250,830<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Available For Future Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893560336504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 20, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved (in shares)</a></td>
<td class="nump">12,054,212<span></span>
</td>
<td class="nump">11,250,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Liability for early exercise of stock options</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Maximum contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath', window );">Exercise period from termination upon death</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability', window );">Exercise period from termination upon disability</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations', window );">Exercise period from termination upon all other separations</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tars_EquityIncentivePlan2020Member', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease', window );">Common stock reserved for issuance, increase percentage on first business day of each of next ten fiscal years</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tars_EquityIncentivePlan2016Member', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,432,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue', window );">Minimum exercise price, percent of fair market value of common stock on grant date</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tars_EquityIncentivePlan2016Member', window );">2016 Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service condition period for full vesting</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tars_EquityIncentivePlan2016Member', window );">2016 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service condition period for full vesting</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved For Future Issuance, Annual Percentage Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon All Other Separations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Death</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Disability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Minimum Exercise Price, Percent Of Fair Market Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tars_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tars_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tars_EquityIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tars_EquityIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893560066680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 2,794<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">$ 4,157<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">771<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 2,367<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">$ 3,386<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893560294792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 6,345<span></span>
</td>
<td class="nump">$ 10,376<span></span>
</td>
<td class="num">$ (3,250)<span></span>
</td>
<td class="num">$ (1,957)<span></span>
</td>
<td class="nump">$ 16,721<span></span>
</td>
<td class="num">$ (5,207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Less: undistributed income allocated to participating securities</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income available to common shareholders</a></td>
<td class="nump">$ 6,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,588<span></span>
</td>
<td class="num">$ (5,207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares outstanding (shares)</a></td>
<td class="nump">20,555,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,651,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,446,246<span></span>
</td>
<td class="nump">2,650,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share attributable to common stockholders - basic (usd per share)</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="num">$ (1.96)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 6,345<span></span>
</td>
<td class="nump">$ 10,376<span></span>
</td>
<td class="num">$ (3,250)<span></span>
</td>
<td class="num">$ (1,957)<span></span>
</td>
<td class="nump">$ 16,721<span></span>
</td>
<td class="num">$ (5,207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Less: undistributed income reallocated to participating securities</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income available to common shareholders</a></td>
<td class="nump">$ 6,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,597<span></span>
</td>
<td class="num">$ (5,207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares outstanding (shares)</a></td>
<td class="nump">20,555,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,651,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,446,246<span></span>
</td>
<td class="nump">2,650,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Common stock options (shares)</a></td>
<td class="nump">1,411,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,449,058,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares outstanding (shares)</a></td>
<td class="nump">21,966,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,651,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,895,304<span></span>
</td>
<td class="nump">2,650,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share attributable to common stockholders - diluted (usd per share)</a></td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="num">$ (1.96)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2740-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2793-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893638208056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Unexercised stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net income (loss) per share</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember', window );">Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net income (loss) per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember', window );">Early-exercised and unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net income (loss) per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893637590152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Instruments Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 177,786<span></span>
</td>
<td class="nump">$ 168,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">176,710<span></span>
</td>
<td class="nump">168,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_EquityWarrantsFairValueDisclosure', window );">Equity warrant rights</a></td>
<td class="nump">1,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">176,710<span></span>
</td>
<td class="nump">168,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">176,710<span></span>
</td>
<td class="nump">168,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_EquityWarrantsFairValueDisclosure', window );">Equity warrant rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_EquityWarrantsFairValueDisclosure', window );">Equity warrant rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">1,076<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_EquityWarrantsFairValueDisclosure', window );">Equity warrant rights</a></td>
<td class="nump">$ 1,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_EquityWarrantsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Warrants, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_EquityWarrantsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893640000728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Changes in Fair Value of Derivative Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of period</a></td>
<td class="nump">$ 1,233<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Initial fair value estimate of equity warrant rights upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, end of period</a></td>
<td class="nump">1,076<span></span>
</td>
<td class="nump">$ 1,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Revaluation of equity warrant rights</a></td>
<td class="nump">719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Revaluation of equity warrant rights</a></td>
<td class="num">$ (876)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893559088600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment &amp; Contingencies - Facility Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>contract</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>contract</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment of operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months<span></span>
</td>
<td class="text">2 years 7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Estimated incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (remaining six months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments, undiscounted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">(Less): Imputed interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=tars_IrvineOfficeAndFacilitiesLeaseMember', window );">Irvine office and laboratory facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_LesseeOperatingLeaseNumberOfLeaseContracts', window );">Number of leases | contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=tars_OtherFacilityLeasesMember', window );">Other facility leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_LesseeOperatingLeaseNumberOfContractsNotImpaired', window );">Number of leases not impaired | contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_LesseeOperatingLeaseNumberOfContractsNotImpaired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Contracts Not Impaired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_LesseeOperatingLeaseNumberOfContractsNotImpaired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_LesseeOperatingLeaseNumberOfLeaseContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Lease Contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_LesseeOperatingLeaseNumberOfLeaseContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=tars_IrvineOfficeAndFacilitiesLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=tars_IrvineOfficeAndFacilitiesLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=tars_OtherFacilityLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=tars_OtherFacilityLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893637688360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment &amp; Contingencies - Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 134<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 286<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893560078360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment &amp; Contingencies - In-License Agreement for Lotilaner (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 03, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,737,000<span></span>
</td>
<td class="nump">$ 23,465,000<span></span>
</td>
<td class="nump">$ 3,249,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for license agreement, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,494,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,494,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">License agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for license agreement (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for license agreement, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock issued for license agreement, share price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.0003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.0003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.0003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices', window );">Additional shares to be issued upon 18-month anniversary of contract execution (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices', window );">Additional shares to be issued upon 18-month anniversary of contract execution, value</a></td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices', window );">Additional shares to be issued upon 18-month anniversary of contract execution, share price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">License agreement | LianBio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_UpfrontPayment', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">License agreement | Elanco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_UpfrontPayment', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">License agreement | Clinical milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">License agreement | Commercial and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CollaborativeArrangementMaximumMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CollaborativeArrangementMaximumMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tars_LianBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tars_LianBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tars_ElancoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tars_ElancoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_ClinicalMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_ClinicalMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_CommercialAndSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_CommercialAndSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893558710360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment &amp; Contingencies - Employment Arrangements (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>arrangement</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers', window );">Number of employment arrangements with executive officers</a></td>
<td class="nump">6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Employment Arrangements With Executive Officers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_NumberOfEmploymentArrangementsWithExecutiveOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893637847224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Out-License Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,017,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 55,449,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,048,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">52,359,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tars_CollaborationMember', window );">Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,969,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,090,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_LianBioMember', window );">LianBio | License agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_UpfrontPayment', window );">Upfront payment received</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_LianBioMember', window );">LianBio | License agreement | Development and Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="nump">65,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CollaborativeArrangementMilestonePayment', window );">Milestone payment achieved</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_LianBioMember', window );">LianBio | License agreement | Sales-Based Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_LianBioMember', window );">LianBio | License agreement | License fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_LianBioMember', window );">LianBio | License agreement | Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CollaborativeArrangementMaximumMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CollaborativeArrangementMaximumMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CollaborativeArrangementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CollaborativeArrangementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tars_LianBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tars_LianBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_DevelopmentAndRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_DevelopmentAndRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_SalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_SalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M*1RJGM.BSL"# &4D\%X#Z'KU#T\-,A(:]$VMTMSV.6Z.W]45JS,!'=O[!DN
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MOF*[3#V)P^^\%114?$N1R?I_=&BQW@@M=U*)O W6(\C3HOG+7ELC3@(T#QQ
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MW08G@B!W@N2@ G86@E;Y@U<?[$"=KL?JN#(A=2P!)6E4G8]2-J3*C>$A=AS
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MMRLPLFAO;]L'Q6MS 7K#E>('\W-/24&%%H#O6\[5XX->H+]#/_\74$L#!!0
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MC3@VQ^W3[3KH@QX3&9U"[,$\,2.('9Q:$$5M2IH!-' CCKRHS89FOR>AB,(
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MMG43NG>2.BL3 -(PVTL'CB&4MCUFCV-X>2!NNC%\IU;<3%\='SMV;Y/HW)9
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MK22*CQ;@_=*!3.4OI*#[^?O]?P!02P,$%     @ "8T$4_32SFQ6(@  TVD
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M:<KM(0<JJ1E$%F2#Q@1?F3?][HQQ\[6S_8Y+W3V%'DO:#OFE*JX]M;0UUL(
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M *.()Q,K(-U7+MRV(-9B8;H[H_8=+RS")57'YF^K8S="3#8$#!*CR63@"J*
MZ6G6=!#<[8E>@O"$:*:5\[EXS,7;%IKR+NL3RH^=+'(/'LO3^9;';VCX]\?I
M'X_5)+8>KC*?@4MSK/CE9S9,>AF#T@TG-#AV#"4GRR>BIM@UL5L]=B$%%EHS
M:E[BW90(W+3SY9U)O[3T'6)A<2<'[:/#U:=@EXD@>=SKX>434_/+F38^6MF)
M&JK<$C5P2$A3D).=?D(HN3TJE%>R<OW8@&98.XE@GH,(82YK5=8 T9*NJJAR
MVRRPD5X-HR"0;&&1=3*BT9!'5**E3INJ7YHI.LPBG,L,4DDJ ]>N)SWX('_
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MT;V-Q)J$#]?7#!Z^1POB/9+1Z9]^KL^*5\B'_97S86]2Q=(7E]-A:XRR!KT
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M$L=!TVR'B565?YA7RM(S[X<%?5>A=@:TOU9TS;03YZ#[4IO_"U!+ P04
M"  )C013A87Y=R8(  #:%   &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6RM6-MRVS@2_164=F;7KE)T=2PGL5UE.YZ9[%3&KL@S^["U#Q )B=B ! .
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M<GTAUXB2%Z P'Q %7:U$@YIV;%.W$4 U1F2H>5TU2@0K%DJL$"U70?EB(W2
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M&L4J.;\,@;U01JU?'&BM!5>.J*L..:CU1?06G.T<23&H@AD<64OS6DMO[%*
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MN9C5#@<Y-^0%8'HEJXT U\HZ41 9(1=6J:"^M?9+45=R/L<YTJM<K*3UI$:
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MX[(6?I:X'9/E!<>LFQ"/], &^OOVV7\!4$L#!!0    (  F-!%/U5S7=O"(
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M>AZ6-B'%V#^3%13X"$4K6[26Y+ EX:M8@<)RQIM;6=O1H[0Z9W[O:]!^L2]
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M>$T0A"7*5 .B> 6KVCL0$I6>;1LG$$1]0YZ2'4X4]5R'XREB@##&6+Y?K7
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M6WP5J1;+;=*A\8.E"W<GA*9P'11]KP';_3Z@$8A 067=E.X(">C/B1H(FY%
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M7#Q WX.WX0],$'^Q[H?_ U!+ P04    "  )C013-K":J-<$   H#0  &0
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MW*;6WSG\XMCI(QML)CLI[^WF>[[V0BL(*\R,96"T/.(%5I4E(AD/ Z<WAK3
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M:H);8]E9@M_*ZU4FVYXC7;,,)Q[UGT:U1^\B/>#!R@C4MV *I%<A A,YZ/(
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MQ\\\?O9*6065$VK"-PX_=.+A!I@LH."BL4_KTI;A==C;$N%<5363#PZYXM9
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MCOB8*8!\OJ54G&Z4@^*?!O/_ %!+ P04    "  )C0135:>IJY "  !U!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6R-E6U/VS 0Q[_**>(%3(P\
M-06A-%)IA[9)$Q4=VXMI+]SDVE@X=K$="OOTLYT0E3:M>-/XX?YWO[M>+NE&
MR$=5(FIXJ1A7(Z_4>GWM^RHOL2+J0JR1FYNED!719BM7OEI+)(435<R/@F#H
M5X1R+TO=V4QFJ:@UHQQG$E1=542^WB 3FY$7>F\']W15:GO@9^F:K'".^F$]
MDV;G=UX*6B%75'"0N!QYX_!Z,K3VSN 7Q8W:6H/-9"'$H]U\*T9>8(&08:ZM
M!V(>SSA!QJPC@_'4^O2ZD%:XO7[S?NMR-[DLB,*)8+]IH<N1=^5!@4M2,WTO
M-E^QS2>Q_G+!E/N%36L;>)#72HNJ%1N"BO+F25[:.FP)PL$!0=0*HH\*XE80
MNT0;,I?6E&B2I5)L0%IKX\TN7&V<VF1#N?T7YUJ:6VIT.KLAC/ <8>Y:9ISG
MHN8:IJ@)9? 9[G2)$L9*H59PVARK,W/Q,)_"Z<D9G #E\+,4M2*\4*FO#9/U
M[.=M_)LF?G0@_O>:7T <G$,41&&/?')</L7<R$,G#][+?5.)KAQ15X[(^8L/
M^+N3*\+I/V);[!PF@BO!:$&:CN,%S"0JY+HY$$NXI=R4CQ(&<W.(IKU-G?Z,
M%TI+TZ!_CQ#%'5'LB 8',UP+175O:1OET"GMZ_J<19>I_[Q=OGV3..Y,W@$-
M.J#!4: O3S75K[ A4A+3*M*^)^I3'U[C)]F*'0:7PQW ?:.@GR_I^)*C?$W+
M,L%7H%%60%SS]O$E>Z$'4;2#UV-SU<\W[/B&'^ [3#7<^\?")$IVL/:-KL(=
M+']K*-B!_(/(%>4*&"Z-*+BX-$G)9L@U&RW6;DXLA#93QRU+\UU :0W,_5((
M_;:QHZ?[TF3_ 5!+ P04    "  )C0132:7Y9BH#  #N"   &0   'AL+W=O
M<FMS:&5E=',O<VAE970R-BYX;6R5EEUOFS 4AO^*A7K12ETA0+ZF)%*;KEJG
M38N6;KN8=N' 26+5V,PV3;-?OV-#:!I(MMTDV)SW\)SCUYC11JI'O08PY#GC
M0H^]M3'Y6]_7R1HRJJ]D#@+O+*7*J,&A6ODZ5T!3)\JX'P9!S\\H$]YDY.9F
M:C*2A>%,P$P176095=L;X'(S]CK>;N(+6ZV-G? GHYRN8 [F:SY3./+K+"G+
M0&@F!5&P''O7G;?3H8UW =\8;/3>-;&5+*1\M(/[=.P%%@@X),9FH/CW!%/@
MW"9"C%]53J]^I!7N7^^RW[G:L98%U3"5_#M+S7KL#3R2PI(6W'R1F_=0U=.U
M^1+)M?LEFRHV\$A2:".S2HP$&1/E/WVN^K GZ,1'!&$E"/]5$%6"R!5:DKFR
M;JFADY&2&Z)L-&:S%ZXW3HW5,&%7<6X4WF6H,Y,;RJE(@,R=9:Z31!;"D%LP
ME''R9C>AR8QNZ8(#H2*UDZJ E'QD=,$X,PPT.2\E^@)%7^>WY/SL@IP1)LC#
M6A8:57KD&^2U3_63BNVF9 N/L'THQ!6)@DL2!F&G13X]+;^%!.4=)P]>RWWL
M4MVJL&Y5Z/)%1_)]5BLJV&]J[7=)IE)HR5E*2S=B6V8*- A33L@EN6,"6\LH
M)W.<!+0^]O'']4(;A>;]>8(HJHDB1Q0?(7I0-,4EV:U1OK=&TJQ!M;6\S-AS
M&>T6?YI$41"-_*?]QC:#PC#JUT&O8.,:-CX)^SD'A;T1*\(!]QWAE7NVE^AS
MI; [))?*-J\-N\S=?44T/*!NB1F$[=#=&KI[$GIG]01OL 274ILB1;^W(78;
MCX^B[N" L1G4Z89Q.V2OANR=A$0K.DN]M+0-K]?RY" ^P&L&!>UL_9JM?Y+M
M7B0R V+H,]0&;:/K-YL7AP=PS9@C<(,:;G 2[EV6<[D%P%65R2.1N=NZ0!7?
M$G@&E;#_]NF@Z<'XT*?-F"@X8H%A7<GP;SX]\@ZPKP=G8?[RMFX#'S:V_& X
MZ!Z0-X/B*#Y\+_A[IY']$OA$U8H)C=M^B;+@JH^5J_)T+0=&YNZ 6DB#QYV[
M7.,'"2@;@/>74IK=P)YY]2?.Y ]02P,$%     @ "8T$4VGAL?+$ @  Y 8
M !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULG97?3]LP$,?_E5/$ TA
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ME66BYAK&J EE< 9WND )MX(OSAY0EG!+R8PRJBDJ.&ZLU(FQ>YR.X?CH!(Z
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M>=Q0HM37 /5]Q;D\O.@.FNO)Z=]02P,$%     @ "8T$4Y=9A1X2 P  )PL
M !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULS59;;]HP%/XK5IXZ:6TN
M7%L!4KE,Z]1.J*S;P[0'-SD0JXZ=V0[0?S_;"2%02-GVT+XDMG.^S]^YV#F]
M%1=/,@90:)U0)OM.K%1ZY;HRC"'!\H*GP/27.1<)5GHJ%JY,!>#(@A+J!I[7
M=A-,F#/HV;6I&/1XIBAA,!5(9DF"Q?,0*%_U'=_9+-R31:S,@COHI7@!,U /
MZ53HF5NR1"0!)@EG2,"\[US[5Q/? JS%=P(K61DCX\HCYT]F<A/U'<\H @JA
M,A18OY8P DH-D];QNR!URCT-L#K>L'^RSFMG'K&$$:<_2*3BOM-U4 1SG%%U
MSU>?H7"H9?A"3J5]HE5AZSDHS*3B20'6"A+"\C=>%X&H #3/84!0 ()]0/,(
MH%$ &J?NT"P S5-W:!4 Z[J;^VX#-\8*#WJ"KY PUIK-#&ST+5K'BS!3*#,E
M]%>B<6KP5=?B#0MY NCLEDOY 4U!H%F,!:!S=,T4B0C-3#+1#,),$$5 HK,Q
M*$RHMCY'TMC*S8LP]"WFF<0LDCU7:85F'S<LU QS-<$1-0UTQYF*)9JP"*(#
M^'$]OEV#=W5DRO $F_ ,@UK"+QF[0 WO(PJ\P#^@9W0ZW#ODSO_M/OGGW7>"
MT2AKI6'YFD?X'ABL081$0H1T889/B*?FM,L:[F;)W;3<C2/<QRIML@YIIG.)
MYH(G:,23-%/87C%\CB98,,(6LE*S/V\U,;I1D,A?-;):I:Q6K<L[LN16%NS(
M"G=E,7VF2'&FJ#U3J=9G#\BA(Y$K:%D%YEY?#KJ>3M>R6F8O;?Q@WVA\ M'D
M%:*=(+7+(+5K@S35=SL(L:F*FK!W2L;.>ZJ&;BFK^];5,.J^3.*+3$]>,=IQ
M[K)T[K+6.1T^^GR^/>'Z!D<96X)4?W'<?6_[W_'>4XK]R@_1?_,D%Q*J"6QW
M]G)<;Y,[YU9^_ F(A>VXI!:7,97?Z^5JV=5=VUYF;WWH7XW\ ^MCTP7:1F-+
MG[>0=U@L").(PEQOY5UTM%"1=V7Y1/'4MAV/7.DFQ@YCW<F", ;Z^YQSM9F8
M#<K>>/ '4$L#!!0    (  F-!%,W^'0/=P,  *\/   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,T+GAM;+67;T_;,!#&OXJ5H8E)&XF=-BFLK01E:$Q#0OS;
M:].ZK45B%]MI0=J'GYV$.*6M"41[0Y/T[O'Y.>[7N+_BXD'."5'@*4V8''AS
MI19'OB_'<Y)B>< 7A.EOIERD6.E;,?/E0A \R9/2Q$=!$/DIILP;]O-GEV+8
MYYE**".7 L@L3;%X/B$)7PT\Z+T\N**SN3(/_&%_@6?DFJC;Q:70=WZE,J$I
M89)R!@29#KQC>#1"/9.01]Q1LI*U:V"V<L_Y@[DYGPR\P%1$$C)61@+KCR49
MD20Q2KJ.QU+4J]8TB?7K%_6S?/-Z,_=8DA%/_M")F@^\G@<F9(JS1%WQU4]2
M;JAK],8\D?E?L"IC P^,,ZEX6B;K"E+*BD_\5!I12X"='0FH3$!-$\(R(<PW
M6E26;^L4*SSL"[X"PD1K-7.1>Y-GZ]U09MIXK83^ENH\-3S#5( [G&0$7! L
M,T%TCY0$W\ 999B-*4[ .9-*9,7S,F@"L *UW/U3HC!-Y!>=>'M]"O;WOH ]
M0!FXF?-,8C:1?5_I<LVB_K@L[:0H#>TH[5?&#D 8? 4H0'!+^LB=?DK&.AWF
MZ<%ZNJ]-JIQ"E5,HUPMWZ!U+290\<BB%E5*8*W5V*-UPI5W%N1Y(:X9.C:%+
M8^@VMPK1*!<UT[D<PCB.>U'?7]9=V1(6]2 ZK,+6:NY4-7><-5]P1I[U/YYX
MT&B99AL-71/M5J+=EI9&E5+4JKS"P4*CN^9@%,/@E8-;PAP.QE6)L;/$'X\9
M5<]@A87 3 %A^+*URGAS^2".MB_>JQ;O.1?_398D^?P)1L%WZ+#[L)([;-DX
M&%@ !?]C&DK5-YNY+<[135@#)VQL*?@+WC4@T$('MJ4.M-B!;NXT&Y)2Y&UC
MM\2YC+6D@6[4-!Z44J=>0;!C<4LDV&W:5>0RW8()1FT;: D"W0CYZ*AL$F6C
MF:Z0]6HM<F!CYJ!W#X@E$6R+(F11A-PH:C8@:),HK^UTAJP79WF#W+QI/!:E
M3I/%:^\^J&DO0Y?5ED4H;-LV"PSD!L8'QP)MXF/MA[9L96/(( L9U!@RX7LG
M UGRH+;D098\R$V>AI/Q-FC*D*B!G18TR V:YI/1VWPWWGRU\FNG*7.4O<!B
M1ID$"9GJM. @UOL3Q>FPN%%\D1^P[KG2Q[7\<JY/U$28 /W]E'/U<F/.;-49
M??@/4$L#!!0    (  F-!%.,E0EF1 ,  !H*   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;-5636_;.!#]*P.AAP1PHZ_$3@K;0.ULL5ELL('3M(?%
M'FAI;!&E2)6D[/3?[Y!2%#EQU+WLH1>;I/@>WWR0,].]TM],@6CAL132S(+"
MVNI#&)JLP)*9,U6AI"\;I4MF::JWH:DTLMR#2A$F430.2\9E,)_ZM3L]GZK:
M"B[Q3H.IRY+I'PL4:C\+XN!I8<6WA74+X7Q:L2W>HWVH[C3-PHXEYR5*PY4$
MC9M9\#'^L(P3!_ [OG#<F]X8G"EKI;ZYR4T^"R*G" 5FUE$P^MOA$H5P3*3C
M>TL:=&<Z8'_\Q/[)&T_&K)G!I1)?>6Z+67 90(X;5@N[4OO?L37HPO%E2AC_
M"_MV;Q1 5ANKRA9,"DHNFW_VV#JB!R">XX"D!20O >=O -(6D'I#&V7>K&MF
MV7RJU1ZTVTUL;N!]X]%D#9<NC/=6TU=..#O_Q+B&+TS4"+?(3*V18F0-O(=E
MP>06#7 )O4UJ ]>H^8XY[\.?G*VYX/8'G%RC95R84T(^W%_#R;M3>.>PGPM5
M&R9S,PTMZ76GAEFK;=%H2][0EL*MDK8P\)O,,3_$AV1G9VSR9.PB&23\HY9G
MD$8C2*(D/J)G.0R_99K@\3'X@9RT\WWJ^=*?^G[4>9*3Q]M Y$!IOL*LUIK+
M+2R8X68$#U*M#>H=6PN$&UG5UNU1,B,T<S=C!$LFLEKX"?R]4D( 9?R>Z?R?
M ='GG>AS+_I\2/2N$;W&+9?2B:.TJ"@M5'XLR@WAV!.Z9V4WCY,TG8:[ONM?
M;XJZ'0="+SJA%X-";R1YDPG8=((!C>5T\WT6X_?:Y2VY13-I0;OK;J"NR&?<
MF)K)#(]E2'/FQ5NV'"@==TK'_]FE*/-A9XY?"X@FXQ?.' ][_$#EI%,Y&52Y
MPAW*&@=2Z+)CNOQU\OZJ$WWU,_-)<4/^5OH<B]?5JWA-XJOCD8BCYT<[&A3S
MERU0T^N:J1+A!!^IJ!L\'8%$.V!JW"L*\:\3H3AYEIW\+S%J:?OWY?UE[U(U
M<L)>E2U1;WWS82!3M;1-#>I6NP;GHR_K+]87KO'QU?N9INF:J,+0BVI X(8H
MH[,)Y8UN&I%F8E7E:_E:6>H,_+"@Y@VUVT#?-TK9IXD[H&L'Y_\"4$L#!!0
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M6[S,_%[F++Y$T8]>8HA!0<^V>)N?P"D*G3=\W-O=Z=X\$=X?\4)%%2'^T3R
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M"^#W1$JS?[&WL.H? =-_ 5!+ P04    "  )C013=HJ17N<"  !4"0  &0
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M[>NL4B6R*N9[^#*.=.B7[9?5A@27NY"X#?'\ALRLC0F#&K*3,:PSAIT9GZ#
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MT<U36-;N H/Q">Z\TAHO@1^J\9>0_P)02P,$%     @ "8T$4_I^7K=G!
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M++N]S!J<ANG5UAOEG/KIHT.P35AB(-[O*.7'1C) <8<\^P]02P,$%     @
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M(? TX@BF #1@2)*X<_#@/(HWYU2\_8UI_!M02P,$%     @ "8T$4Y>*NQS
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M7Y75F9^WNUCB[FZ!K7U.W7 92&Y;TG4EGP\52V"S7-EV+T4F.9#66&K]A4Q
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M&HT!  !/&   &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=E-CH)
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  F-!%./(!<X7 4  !86   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    "  )C01316/Y?ZL%  !2%0  &               @(&?#0  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ "8T$4^,58>?^ @  -0H
M !@              ("!@!,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+
M 0(4 Q0    (  F-!%/Y)22R#@8  &L;   8              " @;06  !X
M;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  )C013T<8OOB0(
M   !-   &               @('X'   >&PO=V]R:W-H965T<R]S:&5E=#4N
M>&UL4$L! A0#%     @ "8T$4T'1]"%R!P  3Q\  !@              ("!
M4B4  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (  F-!%-G
MFS"4C P   H?   8              " @?HL  !X;"]W;W)K<VAE971S+W-H
M965T-RYX;6Q02P$"% ,4    "  )C013]-+.;%8B  #3:0  &
M    @(&\.0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M"8T$4S,D#U-V!@  U0\  !@              ("!2%P  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    (  F-!%-E&#BB*00  +4)   9
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M970Q-"YX;6Q02P$"% ,4    "  )C013'I[DN5 &  ![#P  &0
M    @(%WBP  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M  F-!%/U5S7=O"(  +UN   9              " @?Z1  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ "8T$4S:PFJC7!   * T  !D
M             ("!\;0  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    "  )C013Y:= (*("  ":!0  &0              @('_N0  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (  F-!%,B%4FFF0(
M ,<%   9              " @=B\  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ "8T$4R]UBCWO!   E@P  !D              ("!
MJ+\  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  )C013
M[#&/D3T$  "7"P  &0              @('.Q   >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    (  F-!%.V@_8170,   @(   9
M      " @4+)  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ "8T$4^][Q6'1 P  7PP  !D              ("!ULP  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  )C0130&XT.-T#  ! $
M&0              @('>T   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    (  F-!%-5IZFKD (  '4&   9              " @?+4  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ "8T$4TFE^68J
M P  [@@  !D              ("!N=<  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    "  )C013:>&Q\L0"  #D!@  &0
M@($:VP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (  F-
M!%-<.O3-$0,  "T)   9              " @17>  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ "8T$4RLW7+.: @  N08  !D
M         ("!7>$  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    "  )C013"K9?VG@$  #Y$0  &0              @($NY   >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (  F-!%/GS=ZE(0,  )4*
M   9              " @=WH  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @ "8T$4ZLD F34!   JA0  !D              ("!->P
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  )C013EUF%
M'A(#   G"P  &0              @(% \0  >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    (  F-!%,W^'0/=P,  *\/   9
M  " @8GT  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M"8T$4XR5"69$ P  &@H  !D              ("!-_@  'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    "  )C01378ZL*7$$   4$   &0
M            @(&R^P  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    (  F-!%-VBI%>YP(  %0)   9              " @5H  0!X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ "8T$4YE9H2\"!0
M.1@  !D              ("!> ,! 'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    "  )C013\\ #>@4"   >!   &0              @(&Q
M" $ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (  F-!%/Z
M?EZW9P0  $\6   9              " @>T* 0!X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ "8T$4T_&NF8C P  <!(   T
M     ( !BP\! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  )C013EXJ[',
M   3 @  "P              @ '9$@$ 7W)E;',O+G)E;'-02P$"% ,4
M"  )C013T]+81:L#  !B&P  #P              @ '"$P$ >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ "8T$4SQA]1J- 0  3Q@  !H
M ( !FA<! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M"8T$4YC$(26B 0  IA@  !,              ( !7QD! %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     #  ,  '#0  ,AL!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>139</ContextCount>
  <ElementCount>287</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>38</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Statements of Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit</Role>
      <ShortName>Condensed Statements of Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedStatementsofCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business and Presentation of Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements</Role>
      <ShortName>Description of Business and Presentation of Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates</Role>
      <ShortName>Summary of Significant Accounting Policies and Use of Estimates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Balance Sheet Account Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetail</Role>
      <ShortName>Balance Sheet Account Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Net Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/NetIncomeLossPerShare</Role>
      <ShortName>Net Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127108 - Disclosure - Commitment &amp; Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingencies</Role>
      <ShortName>Commitment &amp; Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2133109 - Disclosure - Out-License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/OutLicenseAgreement</Role>
      <ShortName>Out-License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies and Use of Estimates (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Balance Sheet Account Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetailTables</Role>
      <ShortName>Balance Sheet Account Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/BalanceSheetAccountDetail</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/StockholdersEquity</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/StockBasedCompensation</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Net Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/NetIncomeLossPerShareTables</Role>
      <ShortName>Net Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/NetIncomeLossPerShare</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2324305 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/FairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2328306 - Disclosure - Commitment &amp; Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingenciesTables</Role>
      <ShortName>Commitment &amp; Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/CommitmentContingencies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business and Presentation of Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails</Role>
      <ShortName>Description of Business and Presentation of Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails</Role>
      <ShortName>Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Balance Sheet Account Detail - Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails</Role>
      <ShortName>Balance Sheet Account Detail - Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Balance Sheet Account Detail - Other Long-Term Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Account Detail - Other Long-Term Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Stockholders' Equity - Shares Reserved for Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Shares Reserved for Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Stock-Based Compensation - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Net Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/NetIncomeLossPerShareDetails</Role>
      <ShortName>Net Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Net Income (Loss) Per Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Income (Loss) Per Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Fair Value Measurements - Changes in Fair Value of Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Changes in Fair Value of Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Commitment &amp; Contingencies - Facility Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails</Role>
      <ShortName>Commitment &amp; Contingencies - Facility Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Commitment &amp; Contingencies - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails</Role>
      <ShortName>Commitment &amp; Contingencies - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Commitment &amp; Contingencies - In-License Agreement for Lotilaner (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails</Role>
      <ShortName>Commitment &amp; Contingencies - In-License Agreement for Lotilaner (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Commitment &amp; Contingencies - Employment Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails</Role>
      <ShortName>Commitment &amp; Contingencies - Employment Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="tars-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Out-License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/OutLicenseAgreementDetails</Role>
      <ShortName>Out-License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/OutLicenseAgreement</ParentRole>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="tars-20210630.htm">tars-20210630.htm</File>
    <File>exhibit31111.htm</File>
    <File>exhibit31211.htm</File>
    <File>exhibit32111.htm</File>
    <File>exhibit32211.htm</File>
    <File>tars-20210630.xsd</File>
    <File>tars-20210630_cal.xml</File>
    <File>tars-20210630_def.xml</File>
    <File>tars-20210630_lab.xml</File>
    <File>tars-20210630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tars-20210630.htm": {
   "axisCustom": 0,
   "axisStandard": 14,
   "contextCount": 139,
   "dts": {
    "calculationLink": {
     "local": [
      "tars-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tars-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "tars-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tars-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tars-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "tars-20210630.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd"
     ]
    }
   },
   "elementCount": 341,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 2,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 7
   },
   "keyCustom": 26,
   "keyStandard": 261,
   "memberCustom": 13,
   "memberStandard": 23,
   "nsprefix": "tars",
   "nsuri": "http://tarsusrx.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://tarsusrx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Stockholders' Equity",
     "role": "http://tarsusrx.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Stock-Based Compensation",
     "role": "http://tarsusrx.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Net Income (Loss) Per Share",
     "role": "http://tarsusrx.com/role/NetIncomeLossPerShare",
     "shortName": "Net Income (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Fair Value Measurements",
     "role": "http://tarsusrx.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127108 - Disclosure - Commitment & Contingencies",
     "role": "http://tarsusrx.com/role/CommitmentContingencies",
     "shortName": "Commitment & Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133109 - Disclosure - Out-License Agreement",
     "role": "http://tarsusrx.com/role/OutLicenseAgreement",
     "shortName": "Out-License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Policies)",
     "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies",
     "shortName": "Summary of Significant Accounting Policies and Use of Estimates (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Balance Sheet Account Detail (Tables)",
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailTables",
     "shortName": "Balance Sheet Account Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://tarsusrx.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://tarsusrx.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Balance Sheets",
     "role": "http://tarsusrx.com/role/CondensedBalanceSheets",
     "shortName": "Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Net Income (Loss) Per Share (Tables)",
     "role": "http://tarsusrx.com/role/NetIncomeLossPerShareTables",
     "shortName": "Net Income (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324305 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://tarsusrx.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328306 - Disclosure - Commitment & Contingencies (Tables)",
     "role": "http://tarsusrx.com/role/CommitmentContingenciesTables",
     "shortName": "Commitment & Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business and Presentation of Financial Statements (Details)",
     "role": "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails",
     "shortName": "Description of Business and Presentation of Financial Statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)",
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails",
     "shortName": "Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i5e6394dd3d154e6eb7f0921e8d91a105_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepositAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Balance Sheet Account Detail - Other Assets (Details)",
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails",
     "shortName": "Balance Sheet Account Detail - Other Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepositAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)",
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Balance Sheet Account Detail - Other Long-Term Liabilities (Details)",
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails",
     "shortName": "Balance Sheet Account Detail - Other Long-Term Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "role": "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Stockholders' Equity - Shares Reserved for Issuance (Details)",
     "role": "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails",
     "shortName": "Stockholders' Equity - Shares Reserved for Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Balance Sheets (Parenthetical)",
     "role": "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Stock-Based Compensation - Expense (Details)",
     "role": "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Net Income (Loss) Per Share (Details)",
     "role": "http://tarsusrx.com/role/NetIncomeLossPerShareDetails",
     "shortName": "Net Income (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "ib790f0e6092341f4a52bec6af062bad6_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Net Income (Loss) Per Share - Antidilutive Securities (Details)",
     "role": "http://tarsusrx.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesDetails",
     "shortName": "Net Income (Loss) Per Share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "ib790f0e6092341f4a52bec6af062bad6_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)",
     "role": "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i17e969dac4d6411dbb826ee3db9998d9_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Fair Value Measurements - Changes in Fair Value of Derivative Liability (Details)",
     "role": "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails",
     "shortName": "Fair Value Measurements - Changes in Fair Value of Derivative Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i5e6394dd3d154e6eb7f0921e8d91a105_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "ie05ece3c0fcc4ccaa63406a8de30a51b_I20210131",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Commitment & Contingencies - Facility Leases (Details)",
     "role": "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails",
     "shortName": "Commitment & Contingencies - Facility Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "ie05ece3c0fcc4ccaa63406a8de30a51b_I20210131",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Commitment & Contingencies - Lease Cost (Details)",
     "role": "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails",
     "shortName": "Commitment & Contingencies - Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Commitment & Contingencies - In-License Agreement for Lotilaner (Details)",
     "role": "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
     "shortName": "Commitment & Contingencies - In-License Agreement for Lotilaner (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i120ab40354ce4e18abe9a05184afca4c_D20200901-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "tars:NumberOfEmploymentArrangementsWithExecutiveOfficers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "arrangement",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Commitment & Contingencies - Employment Arrangements (Details)",
     "role": "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails",
     "shortName": "Commitment & Contingencies - Employment Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "id5386c319aba4c61a7bf6efd8331dd95_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "tars:NumberOfEmploymentArrangementsWithExecutiveOfficers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "arrangement",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Statements of Operations and Comprehensive Loss",
     "role": "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "ifd6493a38f7e4dd0a18cc6fc9b45e0cc_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Out-License Agreement (Details)",
     "role": "http://tarsusrx.com/role/OutLicenseAgreementDetails",
     "shortName": "Out-License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "iaa0fee81cd004ce9a21528b56b335914_D20210601-20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "tars:CollaborativeArrangementMilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i582e67cbd8fa41379c4ab2acf8ad6e1c_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Statements of Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit",
     "shortName": "Condensed Statements of Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i54f251974ca94b0e9b65707daf81e0f4_D20200101-20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Statements of Cash Flows",
     "role": "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
     "shortName": "Condensed Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business and Presentation of Financial Statements",
     "role": "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements",
     "shortName": "Description of Business and Presentation of Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates",
     "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates",
     "shortName": "Summary of Significant Accounting Policies and Use of Estimates",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Balance Sheet Account Detail",
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetail",
     "shortName": "Balance Sheet Account Detail",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20210630.htm",
      "contextRef": "i8f9e5481fbdf44e0b17941cba64dbffb_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 38,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Smaller Reporting Company"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r41",
      "r43",
      "r85",
      "r86",
      "r184",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r183",
      "r194",
      "r234",
      "r235",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r357",
      "r359",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r183",
      "r194",
      "r234",
      "r235",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r357",
      "r359",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r153",
      "r222",
      "r224",
      "r333",
      "r356",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r153",
      "r222",
      "r224",
      "r333",
      "r356",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r183",
      "r194",
      "r225",
      "r234",
      "r235",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r357",
      "r359",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r183",
      "r194",
      "r225",
      "r234",
      "r235",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r357",
      "r359",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r42",
      "r43",
      "r85",
      "r86",
      "r184",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_AccruedClinicalStudiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Studies, Current",
        "label": "Accrued Clinical Studies, Current",
        "terseLabel": "Accrued clinical studies"
       }
      }
     },
     "localname": "AccruedClinicalStudiesCurrent",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services",
        "label": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services",
        "terseLabel": "Additional shares to be issued upon 18-month anniversary of contract execution, share price (usd per share)"
       }
      }
     },
     "localname": "AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services",
        "label": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services",
        "terseLabel": "Additional shares to be issued upon 18-month anniversary of contract execution (shares)"
       }
      }
     },
     "localname": "AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services",
        "label": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services",
        "terseLabel": "Additional shares to be issued upon 18-month anniversary of contract execution, value"
       }
      }
     },
     "localname": "AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_ClinicalMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Milestones",
        "label": "Clinical Milestones [Member]",
        "terseLabel": "Clinical milestones"
       }
      }
     },
     "localname": "ClinicalMilestonesMember",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration",
        "label": "Collaboration [Member]",
        "terseLabel": "Collaboration"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_CollaborativeArrangementMaximumMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Milestone Payment",
        "label": "Collaborative Arrangement, Maximum Milestone Payment",
        "terseLabel": "Maximum milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumMilestonePayment",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_CollaborativeArrangementMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Milestone Payment",
        "label": "Collaborative Arrangement, Milestone Payment",
        "terseLabel": "Milestone payment achieved"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePayment",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_CommercialAndSalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial And Sales Milestones",
        "label": "Commercial And Sales Milestones [Member]",
        "terseLabel": "Commercial and sales milestones"
       }
      }
     },
     "localname": "CommercialAndSalesMilestonesMember",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved For Future Issuance, Annual Percentage Increase",
        "label": "Common Stock, Capital Shares Reserved For Future Issuance, Annual Percentage Increase",
        "terseLabel": "Common stock reserved for issuance, increase percentage on first business day of each of next ten fiscal years"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant",
        "terseLabel": "Restricted stock units outstanding"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Available For Future Grant",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Available For Future Grant",
        "terseLabel": "Stock options reserved for future grant (shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsAvailableForFutureGrant",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding",
        "terseLabel": "Stock options issued and outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_CommonStockNumberOfVotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Number Of Votes",
        "label": "Common Stock, Number Of Votes",
        "terseLabel": "Common stock voting rights, number of votes"
       }
      }
     },
     "localname": "CommonStockNumberOfVotes",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "tars_CommonStockSharesSubjectToRepurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Shares Subject To Repurchase",
        "label": "Common Stock, Shares Subject To Repurchase",
        "terseLabel": "Common stock, subject to repurchase (shares)"
       }
      }
     },
     "localname": "CommonStockSharesSubjectToRepurchase",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decapitalization Of Operating Lease, Right Of Use Asset, Lease Termination",
        "label": "Decapitalization Of Operating Lease, Right Of Use Asset, Lease Termination",
        "negatedLabel": "Derecognition of right-of-use asset upon lease termination"
       }
      }
     },
     "localname": "DecapitalizationOfOperatingLeaseRightOfUseAssetLeaseTermination",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_DevelopmentAndRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Regulatory Milestone",
        "label": "Development And Regulatory Milestone [Member]",
        "terseLabel": "Development and Regulatory Milestone"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestoneMember",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_ElancoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Elanco",
        "label": "Elanco [Member]",
        "terseLabel": "Elanco"
       }
      }
     },
     "localname": "ElancoMember",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_EquityIncentivePlan2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan 2016",
        "label": "Equity Incentive Plan 2016 [Member]",
        "terseLabel": "2016 Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2016Member",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_EquityIncentivePlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan 2020",
        "label": "Equity Incentive Plan 2020 [Member]",
        "terseLabel": "2020 Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2020Member",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_EquityWarrantRights": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Warrant Rights",
        "label": "Equity Warrant Rights",
        "terseLabel": "Equity warrant rights*"
       }
      }
     },
     "localname": "EquityWarrantRights",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_EquityWarrantsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Warrants, Fair Value Disclosure",
        "label": "Equity Warrants, Fair Value Disclosure",
        "terseLabel": "Equity warrant rights"
       }
      }
     },
     "localname": "EquityWarrantsFairValueDisclosure",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_IrvineOfficeAndFacilitiesLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Irvine Office And Facilities Lease",
        "label": "Irvine Office And Facilities Lease [Member]",
        "terseLabel": "Irvine office and laboratory facility"
       }
      }
     },
     "localname": "IrvineOfficeAndFacilitiesLeaseMember",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_LesseeOperatingLeaseNumberOfContractsNotImpaired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Contracts Not Impaired",
        "label": "Lessee, Operating Lease, Number Of Contracts Not Impaired",
        "terseLabel": "Number of leases not impaired"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfContractsNotImpaired",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "tars_LesseeOperatingLeaseNumberOfLeaseContracts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Lease Contracts",
        "label": "Lessee, Operating Lease, Number Of Lease Contracts",
        "terseLabel": "Number of leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfLeaseContracts",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "tars_LianBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LianBio",
        "label": "LianBio [Member]",
        "terseLabel": "LianBio"
       }
      }
     },
     "localname": "LianBioMember",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_LicenseAndCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Collaboration",
        "label": "License And Collaboration [Member]",
        "terseLabel": "License fees and Collaboration"
       }
      }
     },
     "localname": "LicenseAndCollaborationMember",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_NumberOfEmploymentArrangementsWithExecutiveOfficers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Employment Arrangements With Executive Officers",
        "label": "Number Of Employment Arrangements With Executive Officers",
        "terseLabel": "Number of employment arrangements with executive officers"
       }
      }
     },
     "localname": "NumberOfEmploymentArrangementsWithExecutiveOfficers",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "tars_OtherFacilityLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Facility Leases",
        "label": "Other Facility Leases [Member]",
        "terseLabel": "Other facility leases"
       }
      }
     },
     "localname": "OtherFacilityLeasesMember",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_ProceedsFromEarlyExerciseOfStockOptions": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Early Exercise Of Stock Options",
        "label": "Proceeds From Early Exercise Of Stock Options",
        "terseLabel": "Proceeds from exercise of stock options prior to vesting"
       }
      }
     },
     "localname": "ProceedsFromEarlyExerciseOfStockOptions",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_SalesMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestone",
        "label": "Sales Milestone [Member]",
        "terseLabel": "Sales-Based Milestone"
       }
      }
     },
     "localname": "SalesMilestoneMember",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon All Other Separations",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon All Other Separations",
        "terseLabel": "Exercise period from termination upon all other separations"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Death",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Death",
        "terseLabel": "Exercise period from termination upon death"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Disability",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Disability",
        "terseLabel": "Exercise period from termination upon disability"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Minimum Exercise Price, Percent Of Fair Market Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Minimum Exercise Price, Percent Of Fair Market Value",
        "terseLabel": "Minimum exercise price, percent of fair market value of common stock on grant date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePricePercentOfFairMarketValue",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Early-Exercised Option",
        "label": "Share-based Payment Arrangement, Early-Exercised Option [Member]",
        "terseLabel": "Early-exercised and unvested stock options"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEarlyExercisedOptionMember",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Lapse Of Repurchase Rights",
        "label": "Stock Issued During Period, Shares, Lapse Of Repurchase Rights",
        "terseLabel": "Lapse of repurchase rights related to common stock issued pursuant to early exercises (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesLapseOfRepurchaseRights",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Lapse Of Repurchase Rights",
        "label": "Stock Issued During Period, Value, Lapse Of Repurchase Rights",
        "terseLabel": "Lapse of repurchase rights related to common stock issued pursuant to early exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueLapseOfRepurchaseRights",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_UpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment",
        "label": "Upfront Payment",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "UpfrontPayment",
     "nsuri": "http://tarsusrx.com/20210630",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and other accrued liabilities",
        "totalLabel": "Accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails",
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r7",
      "r29"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade accounts payable and other"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r16",
      "r156",
      "r157"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r11",
      "r336",
      "r346"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r27",
      "r163"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "(Less): Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r253",
      "r320"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r250",
      "r251",
      "r252",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r236",
      "r238",
      "r255",
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Recognition of stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r238",
      "r247",
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of net income (loss) per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r83",
      "r136",
      "r145",
      "r151",
      "r159",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r274",
      "r276",
      "r292",
      "r318",
      "r320",
      "r335",
      "r345"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets:",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r39",
      "r83",
      "r159",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r274",
      "r276",
      "r292",
      "r318",
      "r320"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r239",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r87",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business and Presentation of Financial Statements"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Additions of property and equipment in accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r24",
      "r72"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets",
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r8",
      "r73",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r67",
      "r72",
      "r77"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash \u2014 end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash \u2014 beginning of year",
        "totalLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r67",
      "r295"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r270",
      "r271",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Out-License Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "License agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r34",
      "r170",
      "r338",
      "r351"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r171",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitment &amp; Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total shares of common stock reserved (in shares)",
        "totalLabel": "Total shares of common stock reserved (shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock dividends declared (usd per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r88",
      "r89",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical",
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical",
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (shares)",
        "periodStartLabel": "Beginning balance (shares)",
        "terseLabel": "Common stock, outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical",
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit",
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r320"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 200,000,000 shares authorized; 20,704,104 shares issued and 20,573,951 outstanding, which excludes 130,153 shares subject to repurchase at June\u00a030, 2021 (unaudited); 20,502,576 shares issued and 20,323,301 outstanding, which excludes 179,375 shares subject to repurchase at December\u00a031, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r46",
      "r48",
      "r49",
      "r56",
      "r340",
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r130",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r220",
      "r221",
      "r223"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r13",
      "r14",
      "r204",
      "r210",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Common stock issued upon conversion of preferred stock (shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r59",
      "r83",
      "r159",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r292"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of license fees and collaboration revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current",
        "terseLabel": "Employee stock option early exercise liability, current portion"
       }
      }
     },
     "localname": "DeferredCompensationShareBasedArrangementsLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent",
        "terseLabel": "Employee stock option early exercise liability, non-current portion"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent",
        "terseLabel": "Liability for early exercise of stock options"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositAssets": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.",
        "label": "Deposit Assets",
        "terseLabel": "Deposits"
       }
      }
     },
     "localname": "DepositAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r70",
      "r161"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r57",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r101",
      "r104",
      "r116",
      "r119",
      "r120",
      "r124",
      "r125",
      "r281",
      "r282",
      "r341",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (usd per share)",
        "verboseLabel": "Net income (loss) per share attributable to common stockholders - basic (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/NetIncomeLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic EPS"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r57",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r104",
      "r116",
      "r119",
      "r120",
      "r124",
      "r125",
      "r281",
      "r282",
      "r341",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (usd per share)",
        "verboseLabel": "Net income (loss) per share attributable to common stockholders - diluted (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/NetIncomeLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted EPS"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetIncomeLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "negatedTerseLabel": "Change in fair value of derivative assets",
        "terseLabel": "Change in fair value of equity warrant rights"
       }
      }
     },
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Unexercised stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesDetails",
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r51",
      "r52",
      "r53",
      "r88",
      "r89",
      "r90",
      "r92",
      "r98",
      "r100",
      "r127",
      "r160",
      "r209",
      "r217",
      "r250",
      "r251",
      "r252",
      "r266",
      "r267",
      "r280",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r360",
      "r361",
      "r362",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r283",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r283",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Financial instruments measured at fair value"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r284",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r185",
      "r226",
      "r227",
      "r232",
      "r233",
      "r284",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r226",
      "r227",
      "r232",
      "r233",
      "r284",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r284",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r285",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r285",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Changes in fair value of derivative liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Revaluation of equity warrant rights"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Initial fair value estimate of equity warrant rights upon issuance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r71",
      "r293",
      "r294"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedTerseLabel": "Unrealized gain from transactions denominated in a foreign currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r304"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease",
        "negatedTerseLabel": "Loss on lease termination"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails",
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r165",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails",
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails",
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r84",
      "r99",
      "r100",
      "r135",
      "r261",
      "r268",
      "r269",
      "r355"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r50",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedTerseLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Common stock options (shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income (expense), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Issuance of common stock pursuant to in-license agreement"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r315",
      "r317"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of lease cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Future contractual lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future lease payments, undiscounted"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021 (remaining six months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "(Less): Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30",
      "r83",
      "r146",
      "r159",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r275",
      "r276",
      "r277",
      "r292",
      "r318",
      "r319"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r83",
      "r159",
      "r292",
      "r320",
      "r337",
      "r349"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, preferred stock and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES, PREFERRED STOCK AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r32",
      "r83",
      "r159",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r275",
      "r276",
      "r277",
      "r292",
      "r318",
      "r319",
      "r320"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]",
        "terseLabel": "License fees"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows From Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows From Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r67",
      "r68",
      "r71"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r45",
      "r47",
      "r53",
      "r55",
      "r71",
      "r83",
      "r91",
      "r93",
      "r94",
      "r95",
      "r96",
      "r99",
      "r100",
      "r113",
      "r136",
      "r144",
      "r147",
      "r150",
      "r152",
      "r159",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r282",
      "r292",
      "r339",
      "r352"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://tarsusrx.com/role/NetIncomeLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net income (loss)",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit",
      "http://tarsusrx.com/role/NetIncomeLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r96",
      "r101",
      "r102",
      "r115",
      "r120",
      "r136",
      "r144",
      "r147",
      "r150",
      "r152"
     ],
     "calculation": {
      "http://tarsusrx.com/role/NetIncomeLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income available to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetIncomeLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r103",
      "r108",
      "r109",
      "r110",
      "r111",
      "r115",
      "r120"
     ],
     "calculation": {
      "http://tarsusrx.com/role/NetIncomeLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income available to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetIncomeLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued or Effective Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosures Noncash Investing and Financing Activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing nonoperating income (expense).",
        "label": "Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r136",
      "r144",
      "r147",
      "r150",
      "r152"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations before other (expense) income and income taxes"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r309",
      "r317"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Impairment of operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of operating lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, non-current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r314",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Estimated incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r313",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Noncurrent",
        "terseLabel": "Other long term assets"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "totalLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails",
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "auth_ref": [
      "r60",
      "r70",
      "r161"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.",
        "label": "Other Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "OtherDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails",
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other liabilities.",
        "label": "Other Liabilities [Table Text Block]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherMachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services.",
        "label": "Other Machinery and Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "OtherMachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters' option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payments of issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r239",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock",
        "verboseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit",
      "http://tarsusrx.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred stock, outstanding (shares)",
        "periodStartLabel": "Preferred stock, outstanding (shares)",
        "terseLabel": "Preferred stock, outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical",
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14",
      "r320"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.0001 par value; 10,000,000 authorized at June\u00a030, 2021 and December\u00a031, 2020; no shares issued and outstanding at June\u00a030, 2021 and December\u00a031, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r22",
      "r23"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r65",
      "r249"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of vested stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r27",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r26",
      "r162"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r164",
      "r320",
      "r343",
      "r350"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation",
        "totalLabel": "Property and equipment, net of accumulated depreciation and amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails",
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r25",
      "r164",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r9",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and equipment, net of accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r9",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r258",
      "r332",
      "r370"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r8",
      "r72",
      "r77",
      "r334",
      "r347"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r3",
      "r8",
      "r77"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r217",
      "r253",
      "r320",
      "r348",
      "r363",
      "r364"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets",
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r88",
      "r89",
      "r90",
      "r92",
      "r98",
      "r100",
      "r160",
      "r250",
      "r251",
      "r252",
      "r266",
      "r267",
      "r280",
      "r360",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r54",
      "r83",
      "r133",
      "r134",
      "r143",
      "r148",
      "r149",
      "r153",
      "r154",
      "r155",
      "r159",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r292",
      "r342"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r312",
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use asset obtained in exchange for operating lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails",
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Stock issued, net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails",
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Stock issued (shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "verboseLabel": "Price per share (usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Net loss per share, basis and diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r238",
      "r246",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r238",
      "r246",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Schedule of Other Assets [Table Text Block]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r27",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r239",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r35",
      "r81",
      "r128",
      "r129",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r197",
      "r201",
      "r207",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r189",
      "r190",
      "r191",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Stock details"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Operating Segment"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Service condition period for full vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r237",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r239",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Common stock issued for license agreement, share price (usd per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Maximum contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r310",
      "r317"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r78",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies and Use of Estimates"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r37",
      "r51",
      "r52",
      "r53",
      "r88",
      "r89",
      "r90",
      "r92",
      "r98",
      "r100",
      "r127",
      "r160",
      "r209",
      "r217",
      "r250",
      "r251",
      "r252",
      "r266",
      "r267",
      "r280",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r360",
      "r361",
      "r362",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r127",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Shares issued as consideration for in-license rights (shares)",
        "verboseLabel": "Common stock issued for license agreement (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r209",
      "r217",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of vested stock options (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "netLabel": "Stock issued to licensor pursuant to execution of out-license agreement",
        "terseLabel": "Shares issued as consideration for in-license rights",
        "verboseLabel": "Common stock issued for license agreement, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r37",
      "r209",
      "r217"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of vested stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r83",
      "r158",
      "r159",
      "r292",
      "r320"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets",
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r82",
      "r193",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r208",
      "r217",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r302",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails",
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Account Detail"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r114",
      "r117",
      "r118"
     ],
     "calculation": {
      "http://tarsusrx.com/role/NetIncomeLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "terseLabel": "Less: undistributed income allocated to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetIncomeLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted": {
     "auth_ref": [
      "r112",
      "r114",
      "r117",
      "r118"
     ],
     "calculation": {
      "http://tarsusrx.com/role/NetIncomeLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted",
        "terseLabel": "Less: undistributed income reallocated to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetIncomeLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r311",
      "r317"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r103",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (shares)",
        "verboseLabel": "Diluted weighted average shares outstanding (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/NetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted-average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r101",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "netLabel": "Basic weighted average shares outstanding (shares)",
        "terseLabel": "Basic (shares)",
        "verboseLabel": "Basic weighted average shares outstanding (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/NetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2740-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "65",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2793-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "66",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2814-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "http://asc.fasb.org/subtopic&trid=2229187"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r371": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r372": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r373": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r374": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r375": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r376": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r377": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0001819790-21-000027-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001819790-21-000027-xbrl.zip
M4$L#!!0    (  F-!%/D9$^V30@  /(M   0    97AH:6)I=#,Q,3$Q+FAT
M;>U:[W/:.!/^_OX5.CIOF\P8@_G1 $DS0X!>F>DE.4*F=Y]N9%O&FLB6*\D0
M[J]_5Y(=2" M;YM>DN8Z4X*M76DE/;O[K-#1+\.SP?3/\Q&*5<+0^>7)Q_$
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MUG4%? ]8'D*?@- UJ#B >JHC;08 TSZC?8FQE5,4N)-WA@:_"TW!XFB)G($
M()X#+,UPTM@38!FCB/&%+-U!D!F5"JH=A;!^:>T&*YTU5,O2F UK?PY@MUXR
ML*>W4/!&%J M>)L.=SR**#SNR7T#CC'"@A@8 JRHSXB&"R* ?9]1&6L-+99
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MI#(C/O.6K3<V\VD$ [J ,?=)\*8<8> J$15LEBE&[#M%0]"F].<B-Q+[\5A
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M#D?]X:1W"H/W@_Z9,_QS@*]193"%WNCX$_G)<-3#1WQ:RQ^]MY.SZ>RL-W+
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MJ8ADVO59A4 DFH/]U>9&P%/9<\T;0Y1V7E+A&"VFYS&/(2#-D9-\GDJ@/DG
M[T([=$T3Y+OF6^"X]?II/[TO88%'848$TQ%C4BS90%+Q-*VOB U FY5WBS8*
M3U?$TQF'B0D^.&D44BQH;)T1F)LH$Z'6W"S:.#QU%$]^)';!4(*5H!Z<)8:%
MMH(0J[CBR(O I[$1]P*+>"IC,0@-G"/#V*!HD[44<21\*DVI-'/S$/NZ"6S
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M(G2%:IQTJ@_*V_?7#QZJVTJA;F_Z_NMC6JUH]/AAM()OCKTI[MV]/F$H1>B
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MJ/L&2<_;^=9]CI0Y,U">QE>AML6#G!5WVYE73V4>\E2C[65%S_6]3;1ZJK=
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MKU+][62Z5 NLSP7KUZJ+48!UZAQ!GF*#0(01&2DC"M@[P5S"-L!R9$OH2OM
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M;_$=GWI6FP368Y4IF2W3UN"LTJM</2X__%A]IZ8IV!W->C*CZHCC+'90=S@
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M^,GY>/*U;LVHFLR9Y2*H&CU6Q$&MR#<.L[,75<1<CW"7:_"&"Z"[0F:,HYO
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M^%/@-1';Y;8J@C;^&JI6=^;A\Z1NQM/B-3<F1761-K+:)M5RC4?,VFU9Z>K
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M]-U)TN[Q9/3MQ-=$!_1Z<2T,W5XOWI=>;-FNE%.=1)PH'3)"PT@2'O& , R
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M+;,X UQ30<WL8%XM 1(/VS) RBW!T]NT#!#9%LGHZFO%DZWLABT#?A)9LV0
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M6%<A]WY[F@VY7XYWOUZ*ZNCME\6NSL[^CX-_ON2&PO\915[[-#3T [4M51(
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M0]6/<9+=42A-/ F^F-QW7^$7E\[+0/4&!;ZK2E</Z.W?X</X<R,P8R/H^(-
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M+@QE\J)ZH/427*[)$IY1LDC3GQS7;<*=S06,"GE,$1C NTHV[,8>[]]=^:#
M/T-;,5C,WC43/#U?F D=PMF""FZ3WU4O*OGOCYT;S1=S:7.^YG*^R-4Y7V'
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M-K^^#/IF=&&'>%"PU,XW?Q+I<]NH^OC<\,RAC>K2I%-)A3[-\+VD4L-BZLD
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M5:+%<$E;'42>'H6J B'6H==S9<00?!@8Z[Q*_VAJ)K&N?QDB$;JHU*01PET
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MY*$5>L+[@6Z? 54X +,TCUO-4FQJ0GV./D:??' 33CJ<N)#(>;OS%Y8#K!"
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M-\V+P R]49-,4=F0>0I57=.O*4AN3$BC&,T,#S.""G6O$002 D*1]6QPW H
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M:N\0:YN1G(%G)EZ"X'KP%_"Q)J&"M?>F998Q5-/42E0Z033!6P233=0$_DY
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M[@G2>A,?^9YM-LY6O6;+V)6@:OY <&#^A4K&Z>*+3"/2PJGIM7E#> =Q[X#
MW;,@]"+,S&_IG7=^V#O:Z+5'X.)&1?IERI5UB10WH. B,KJ8&:)'K$?8NO6
MB'2P0+N*"DB]L<;LW$'Q+XW0>V>!*+^?G>I1([%7(+&?UTCLV[&6)T-BW_H+
M;M$03#.71X.Y@W(#<^95M]%]V.6&YF2?,)W9[B/;'=1>PJC@6@6BZV!>2?<I
M? G1C\%J]'.E+<9B4<;*8R1Y9?Z>9KF/7DK*4,FOVH5R%X.O> @<8XY>2)[@
M2"*"_0:#%\T_W&?QC%:CR;LR#S(F'_][\4BP"A/0_+PLE:1Q%*G"':%'NKB"
M,,>8#*PV[G\[[O&6X)C@[.GEKKRW4WHOHZ 7)KT"FSB>HFT"Y^,GH#_I8M)
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M[GIJ>DGTD^@5C7A^@"X!1Q]BFE("2N=L+?)B+Q2X\ZXSHL@\59\1@?\%]TU
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M,>O&CW JU?%+ZM-XA)GA>XR:XF4/9WZC^(Y.I5$["[(0SIWLN.;;+T'ZS?G
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M!*=P6<P<W,I3N%=%2D.PP*' 9D-[L_U%V!&!8*+G$] (468';G$ G!GSZ-H
M #$Q'K76VIA %7,B?07*3I60D6QDHP*0[)CQ8I!X."^'(!+"D%J!XZE'R 2H
M'<P@T5(GJ6\F[32<RU)O*^KMV2V:-=M +@PQ#X)5S#75 6X-M&J&[TO4V4")
MP-_QHG'B7A@,I=E6H[41.I*UI 9AO]$V9<L60O#2$S:A-#.*H@Q(:R8V(+83
MDN)@C%-WP^ ;=;GRU%8+2MT@\5![:O4S&\XOP"]\MXV X>"8D'7PD/*HP SQ
MR#/B.1JE4:"\?TU4&G2N\=OQR_=L7=^R#$=]@"L#'Q;YZ4 .G]%QK87,3\K
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M^)L$H2?#E'#15\:Y^6#6<U/X"EO.9Y\&@^.?!9GQ9H0#@>Q+>?>XK +$O@R
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MZ1YE.,B]]P 7'!Z>A"11\)'N ];EKGJX5$)H*",ET%B<[> ,D)AQ%K",,Z&
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MR$XXD">.PZ) TF!PRWS(5T0!]R@(\RZ$I".P5R476)2U>>QW;#W[F4(^D:2
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M406.6UP_$E=MD3,FY-N':8&5$<E.JVL79B^E2&H92 G9@I@9Y@IX.VJE_F3
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MI42<19R;*M02JI5O7^@G#.-?3_WZZ7]02P,$%     @ "8T$4VGL]-YL&0
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M\_S\:+U:P[P>6#+1'",%OZ'. J5:L)B9KUV><@ R:\4H[E-?4M\$<4QAZ+?
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M*YX!)M*.M-DHU:I*=S.D#X1330W4H(CDAA+F)V?)>,Q9%HI76:@=X%3-(,C
M%'(*<I+3J5$&P1(T>SM[;D*'7=5[-.?0)$@_]\/XZY65>'9Z$ESP1=5^1#'5
M(CARWH-TJF8?9E9"X>@;156K(!WL_'EG8R]AS^Y*;^LHOPUG].45YVNQJ[8.
MPJ;'T?=C/-#9=#=&O2/>[M BA^%.W297/'&PVM&:F-!!X#[0$(H\6(N%QT;U
M[P?BS'W'UX>BS":&:$"5U^].%AOJVBLIO*'EE]LZBUI;]^@+<.E*UD)KT>A>
MK$L(!_!/.[;/S=XJ6RFWP?;;"3G$SP>#T:QD=5Z3=0%,Q9B2=B!##;9"[9Y5
MM ;A*;K'>CMYHZNO5D)Z<"SH1ODKQWYG9UB_A$$8)OS]%''Z/*71^7 Z/RMY
M-Z[7N4V_AF&N\=;L#ONW.!T5^JWSL_-!F-;+_SZ-,?5G&T8[G&EUCF'',ZZV
M.KEQYN6*+#+Q7,MME?;18\G,.^M19,^S[G6.9M<<J/E;WQ&JZ?,KK_X6V%GA
MO+8A@-$U[\M3U!TYTQ2)&ZF3M\XWVMZ_']ON&6 KWO#/<>U<02X"11^E7GVI
MR5FPWH$+W$')5F>O0RZE38!_-Z[]SZX=L^1VBEAG9FBP\*X<?S07SM0^S,_/
M1N-I_W]FGZ\4IL=+\#XH#S%R3ZZH"1"E0# H,Y?:*E7:[%UW)<&#(]Y!3-LD
MDW4%L'J+KQ8,C;8:DB6_1'%IR$-1&CB%/19M9LSO>?X^R.7*AYK#-C5!@X.V
MJ]SN87"J:./!%UUO]XP)0J$_M&$\<EX(:)L8\2J*!V?^K57<XO0KG6(^K_'0
M2J'GFZY&<ED835,Y):2%M7!P2E%8Y$O4P=3V;&T:C*^+<%^'&HW)T<0@QW+D
ML5*D7[Y^H$?,]M^DMT6SB" =*Z#R+'<T99 BQ6A%"*Q94<6]X YV#-*$%.NN
M2EL:9Y^^2P6XV+I9!V+34Y(U0![FF*1S Z]+H!VM<R BU4[%GIPM"+:626.*
MX%,Q$!2:8@2Y8^M=BO7]$.B>,Y-CX,\F1FG FU?G8U+T^;A>3O&J_Z5^=5&@
M(*K#QI( IS.K/:\MU')ZDMS9;*2IQ4Q-Z+(:TQ%YSMN:<-1$_RV.7$KI)[R4
M][*43>;,3:X)"C0<E''@E8[ LQ(R).,8MO&:E\)Y>'S87>L-)HF3Z2F.?POI
ME *"\=>K4E_@2\)B$?5>P=I_4S@#/DH)1JBHM?/9^C:;>_<A>X $Z=(6#;9;
MWM2V4S6Y\?79I_'H\[QDZ>*XL+B$+EM0Q01RYD6%%@L$@2PZ9-IBFU8D=X!Z
M> SIR@+MBPYO)\)^*YE]/2RC\=FNQ[$;OF''P]9=Y+EQE&J+-\DP[0*S2C$,
MGK,2,HUFKJ,W94D2\9WOVK%881 FDT6&P;==(2%Y+L@D>!D,*,82>.%K6P-A
MR#5VVMDV&QM+X73>1^SY^?1T-.[_#^:>RK((<KY(TARA9F/7$PX+*$D'A0>6
M;9O(Z0Y0^Y^X=F?!O3=G;*GS!N[O!SS[-!J'\=?YX+H-KZ!Q3@B:ET5-B')U
M3THE<*%DF84LL='59O< >PBTZ%+WW5]5>4G9BZ+5_QQ-<=+3WJ40N82L128?
MW3N(P45@Q?H2DBRF^/N6JSO?\#U;MCO5M;U/Z67_<S_3.CRY*#=]B6E ?^6>
M<('"<,L @ZG[0%&1,R8#&)F4XI(BL$9M4M9!]SU3HYD5&APNWEJOYO5_Y*Y[
ME@,*8JSG!,MGFHOH#Z*N9@Q1"=9F5V0%H ?&AZUUW: 8[LYVLYQG5;*GH,JD
M2D]>(.K$0&9I26X1+&MS>>-Q7;ZV!S)LJ_46=PU=GF7.\/WR=2;^_/C2!_)A
MHR)HGBF"IB/$PB+D* Q+(11?&O7F70UJ7WD%W;.@*TT?2_; ZIH='4(]7_(@
M4D'2$M(Z5V\>]0PMQGJ58*.TM>,KF.S*YFO736ZB^\/4OJV#\$?=Y/9&W;P(
M;AN+'(8[)MG, RV6)B152W8$1&<=.,Q21DRAA$8KTO=6-]F8,IL8HFG=I$HZ
M"I(5Z+T!%/H(+F<#B>14W'B>1*.;ZH^Z;G(C^ZRLF]Q$N2MW,;L]</GEYI6>
M30Y=-GM+%P<O.\AUX_ E"BERD+KPZ%7.+!3'L[ Y!\&=R:&WQ?MVG-AKT'/[
MA6-B[4><9RQ]^Y5WX6O]Z'F]X>>;XQV3B1A](>J%!(K<(PB")C;THGCFDQ2-
MTGEVQ]YAS'[U;MO)>YS@^//L>K17YS7UIFXQU +%GF6!JXP(3)! JO8=#*(.
M8(HS@P@L!B-:!_+K03W W+E?+MZQ%=# F!V>)-W<\UX/[?/A\#P,WE& 5)O
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M)%A-;[6A%HL1T< ;PT!+A4QK6:0UZTS$]-0KDS!]=W,"OO;:Q^F*;:_Y#A,
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M-*J-:[,6O(=$F>[ML7*.Z6SG[2U.YPIY,YI<-K%_/ISV<W]P7L'_CNE\3*_
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MTD2:S.TCH> ]<=DQ,G 3ZS5@WF^C(7Z=7U/_ZGR8+U")(+5%R^LU6+1VFV#
M>5),U#IPZ4ILQ:GE>/;O0NW/IJ/.#=*^C]Y2!_/%:4W!FO2'ES\=E9<X)MW4
M!+#+R_JZ3EW:\+4M4I=VD?Q&ZI*.C*8<E&B25<SR*&WB62MGDI.ZI.6^_88
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M?5-5K77$Y7M9;P#N%_SOI"R)/C59EI]$^;U@HGI?OIR3XK&:I1&)&"$(!I'
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MG6LXEVQJAL*OY$?QN'X$K#4"UXIH[+=![@;.XL)Y[.$8X[X:UA*#7:W CEJ
M/H/=YUK50*V;(O^-=J!1S_'%MTO$W=^;.Y%N_&MWEZ">O+5WVL% 8N_<@=HE
MI"T:H4L+K9[O:65S4F+4UI3F]<8_K4MHT4K\7T$C,_C22>W09<T*);=ST:CG
M<>>9#1A'<\CJY4%G)W/U]Z6>;M_%SMQLE^9?B[FH5LN%:.?G+"4X8SA+81IR
M!E$D)"0HTB[K..)!*'/"F,6)B%7G4S5?'CLY=4B,1;;-00-@=%3A#5;O!Q [
MDN_:'G>@ WLC?6=_>,3:ZH3 &^:C[?L=8F^[A1\$WH6-N5V;8VZW!VE[L(D>
MUL9 "TI\U:U\%'71O\77IB+18=TLFC(4!2F""8G4TA B"?-(,BAD3#)=4C$G
M5GD'C'J=VIJPO95JQ;?<RQHA;6BKNL;/MZW:R LV H]3ILP*)K?&JE'/XQJK
M-F <&:M6+P\P5NLR]*\)JTLRUI>(75)R0F(NLUS"4)^VH8CGD(I(P"S,,,9<
MJB_.W"P]V\WDR$8+"F0K:9-%R<;V/(^G@97I!"7/E-( U G9. H8I'>W0<K"
M1G2"V$C6X$GD')E[%W'H->S.OSV>"7=1@SUC[?+33@):+8^RSKP]H=E[%&/I
MXZSJ @P^0RMO<QYU0>$+(957GCEI7\-[U0[7;;V>DZ^S"%.6LRB!.$@#B/(P
MA#B5"&**2,0SG&:8FSH![[4\M<5Z(QS0TIF[^>[#U3^WKP+!\VPVU-_*>?>D
MKH,<=O=;&LU)]Z0"NXZYIQ\8ZH7_NIB+\J6:RE^7Y?,L1"P.<DY@%J6)VK G
M$A+"$YACPM,LEC+-(CO_^[WVIS8!6W_R6D;0"6GK;K^/X.79>"4NGN>D'20#
M_.I/*GZ%1_U^>R/[TI]4YMB+_O1CM_)KO?].BKDNE;%Y^J\ZW?DL9QE/ Q[#
M*"$A5$R (*&,0,&X3'B6A!P9G=9YEW1J-++OW5KN.L3)QB'NJQ;[9@ZNYP;<
MZ.)H&L/H_9;)N8?C1FGP>OM:K?=4AG]L;U<'G\$?U^%UP.=P Z?7"T/DW^_U
MG !_,-?7"SBZ]WZ]U.$ 6Z-NOO&J?;4N]>%]DS*Z%NXM>:K$>_E1/*DY]ZU+
M:%[-!)%)P$4*!6*YKM840QPE 0SS".-0QI1QHPW$8 FF9AO48FI7JW(C:%NF
M&G3I/E?+_5I.;7C,;DDG0<KY,Q _1,D*?5X]P)(8-)P&%H+O0?)]Q5A#WH8C
M- JTSJI=KN<[T(RAHO2M'DUQ!9N;E4'X6RS1OL=AI*77TWC8K:778-F[1@YJ
M>+RU[QJ]]]:TJQIR457G[T*W*?C]=_73K^*CT/F<=N-,PYE4"U,<"0[#)",0
M21:I[:Y:JK(LC%B<)7DHQ/!".Y<%F-I*U4D,2".R6I]:F=MB//9Q&-9C8G9/
MY1-IW]?/AR'J&]1;\<%&_N:).H;=5]T><^@\EO(Q$.*&U7W,(>HO^&/1SC#^
M>TV*\F]DOA8[*<G;G';\_>*C8.M2$_$+4A75;XLEU9L+O6%XLWA:K]2O%3CJ
MK7IUW[J5Y8)$F"0$QG&NBZ]&6*?^"F"*0I&&L<B0G0.?#R&GQJ,OOVG7RPH4
M"R"5NN"[UE?O -18%M\;7]IYJ[[A98/7,3;CW%N/G&=>UNJ!6K^[W?(+759(
M#M3N;*,DJ+6\ [MZ@EI1L*\I^/*Y_IT7+T6?(^*4[KT(.NJ2X!/JPV7#:U\#
M36OMK537J:O>J>;;0BQYPH5@40 9)\I^Q@F%)$$)%(E$+"&(L91:V<^G>ID:
MN3=.<'4E2LO*-J=!S'@>)CG', UU93Z<)3!' L$8\9#D$D4DBV>KY8K,QP)Q
MT]<?!T3#7<.UT/C>&M2H- +>@:V(#HW_/@3<6O@G>QK7C.]3]LA6[WUX8(@,
M^R;X>J[KBNMCCQ<]8<]5&_?\XC#NN38?9@&+"$&)0CD3R@K/J2*)((R@B-(@
M5MB$H; J1>),LJFQ<Z=8'=ILD+^@ZDU@T%IOEN5.W V[&:W=9#!]'\J/.X[V
M 4*N,7<;1.1,NG$#C5R#>A2,Y+R#H=6:ETP(7KU6$.S>X3ZTUWM\QB45" D&
M<4HD1"R03=KU*%#6HJXL''&K!*@7>YP:D7<" _V9;.X]-1U\%]6J*VC;N5S9
MEK"]!+\9\3H%U3.A[N.Y[YFRD==E(5M#:!R7LKW4Z\C%; U!."YG:_KB,/YY
M2:IO^O\Z9<AW,M=T]U'-JK)@:F;I7]PO^/X/=IYL+O+>+%BI#ZY?B>9/]>_Y
M6F=<>_C!ZN//CV35^JG,\H 2C$0*&=&%+!%%D.IC@QQ105F2!D&2V&QQQQ5_
M:GOG=V(%BE9\\!-O%?A9GS8SI>I=_5\@MAK7:5;+#1[U[^T(<^3OQ8Q]I_L5
M>*;RE_4HZ_^"'8WNP%;9YI=ZV ]_MO=" P)XL_F8.AQ^O@,;*$"'!=!@M-Z-
M[A:*VXRBTU5G9!5&7<)N,SR'Z^&-I+@F O<S^?'P0V\LQ(NF#/HLRG&2BD!
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M(RN7(<?R38VD'%S?OAWJ@^1ZZ,U8\(8#.OVK>).QM"9:3X@[)6?7,HY*Z)X
M/EP$?'4S<.$X%>@QBWA* Q''$+%8G] 2!',I"$Q%3G,9*RO4+F;X9"]3(_$F
MUNFG=<6W 6B6UN5I-!.=88+$&0R)/O(* @E)&,00QS@)(I%'G(K9=U'2Y6AX
M[O;F#U$=T%<LV%+M0'_2@7T_;X$%9+4J"[I>U5==JZ7V3]O8^=^6<_4%5P#6
MX7]>QL1PE;L69]]'Y.="]APN.WT0N%T\3O8T[A+0I^P1D?<^/##1@ZC4M& K
MM1J0ZIOV 5%_:%?=[V1>>X5T;DXI412=L A*QC!$81+ G,L0IH3F&0UQ&D96
MU0Y,.YX::1]<CR\E8$KPN_J_=4Z;5O[:6"LW2M:_M\S48#HT9M3B W#/;+,5
M&6AA6_M7_65';"^.9[98N4VM8-KYN'D4+"$Y2II@^_XP/E,6P)O: 'BKEO_[
M[Z28UY'#RYV3D':Q;R.+9Q'"(0D(@WD<*F,)"::,I32',I1QRBD/0I[;W ]:
M2S"UJ\0=(XITXN\:3'KI:36P(S3[L3%C-J^(>Z8X#?:;UF)]6UNL][N8[YZJ
MMCK<=9D1W-'=8 "=\IZ]%*,2X&"0#IEP>$/^"Q1_5B,J9@(%(H]Y"N,@(1"E
M60CS  4P0BR,21($*;>R]:PEF)K1I[Y8Y*]$<0.Z&==YA=(SUPTJ4EPK<9LJ
MQ7OXW:Q,<2/%9.L4[X%T3:'B_89\6W_-H4P>BBR-200)5_]!@@20YKF 29C1
M-),$)U+XL?WL#R3__V'YV1R6>41[@E:?XV.V@>#=R.*[P='<0("&6WO7'.>M
M2%F=9-LFY<=[6?]#QW?I/78UBS-"21P1*%#$( J#'-*$8$CR)(A%G"&1&J6G
MMNQW:G9=(Z4^Q*MSJAJRFBW8_6SF$<);V7,MK.]EFP]U([P??/F2K;4E49_(
MW@+G/0'^$'@;+Q<#46N6"?URS?U!&@<U\]LV-PKC#]2Q8_JAKP^^L%'&,M,G
MJ*]TZ=IEG5.E=1&9Q3FG1)(8,A)S[8*=0A(C @,>IR13OPJ%[2W-^=ZFQN:=
ML$WVUJVXUM<N/0 ;W[6X@<W_!<L6L1U).Y<CIS<JEQ%Q?8W2T^/8=R>7E3]Q
M86+PDAV)5.5*YV7B:U;'^[<>054;?1"35.!,1I"FV@DG1Q3F+.$P03*+.0W"
M,$(FY-';R]1(HQ6TG@&MI):Q'/V@]A.&,Z@\$\4@E(Q)P@B%/G)0#>P0@_K7
M(2GT]S *&1@IV9& V</#+(A70@I=+V37_:_V)ZE=4'<\3ZO-45T;D*DD>;=L
MJHTL5K.,ITF292$D&5*VA@QB2&6<P8@G><B"/ NX44)6QW)-C6 VPM:E(A2E
MSY^!^"%*5E1U%O3: 0TLG^HJ27:FBJN1-#-J;C ^GEFMTPCLJ@1V_;%WM=J[
MIV@UJPEQJYL[>\DQV$XM*U>RC6J#.0;TT%ISW?S E)CKIZ=YW0V9OR#J6]?N
MWD*LMKF<=I(A8DXS3I,$Y@FG$.% [151Q*'$<2)BS$7*[+)<6G0^-9)NY06U
MP%VQ1[4C6I%B;IF\TF8(S(C7%[">V757;+ /\([DX(N?#)(#,'.;%-)&@''S
M/ Z YBAUXY VKDP;UV86TIW^O5A].THH5.V[YE;[^8<VM%NW-4OS5 9(IC!$
M/(4H34)(8S60F4 BHQ@1%HC94QW^\FE%RI49!7J1U69*'TKL;W;7Z<:^-^G&
MJ/A:++1K>EWDLQ9A8#8XIV.<I2)A/)8PC$,UQE&D%CB>91!G&>4"2ZI^WX[Q
MPX+_H4:XDW><\16Z&.N41M9LW;SY6'E>8'<S_NVH"'Y7.I[([%<=I/:[.TX'
MN-VKULUZ2/KG8RC\9/YS*NEMTO_Y /ML#D OG=DG GS5WL5^5J^J%2"30<HP
MS+@(( H%@3C"NG!0D'$F QXF1M=AAPU/;?O2R0:T<.9I_?:PZN?4:Q#P?8IC
MI+Q5DKY3F@Y*RK?7T&A)^$Z)OYMT[^3O!S@<?2)S4?U:J/^LE@M% '6YJ1RG
MF8AQJ(QJAB *0@%Q0F-(9()S2A@)<J,$8&=[F-KDJV6$=40]V(AJX>ER$L7^
MV>@$&]_;?RW>%A#PI9'0\%+M/#(6WC[7(C227\\!4HZ<=OJ4[W7/.?GB>(XX
M?7+ON=ST/CC$?;)@^FJ]SH,_5S]=EO6X=Y]=0"7A*((!8@*B+$\@R2F"DD4,
MX93%)#>Z[;K<U=3XK1462"&Z&A [,MNX]/4";,!XSF#S3'T=8O>'8 TAP0N?
MI87OHROTQG)W/(>B*Z]&$SSZ'1E[6QC1=]%$DWUW1:,WAAW8_I44"^WL_G[Q
M692/Q:+-*E1[0<YHP%@840P3(;C.QHQA+G@,!9-92@6F>8IF"_&5Z*+/YG=/
M?7T:?=IY\VD?]>SQ\]:%YQ4EU)[G8+45V^Z K1=MLW.RJ\$;AU6UF%VXC,)M
M1U9].%E+Z^[ R@03I^=.O1V.>GQDHOKA*9#1.P/OM$_G*]O>J+]XWC[2QA3>
M_TY*_G:381 %2/$+0MJQ,84H)R',PR#3*1[20'#).2)6-]U7BS0U&V_7YV7/
M&69'*4"?]WQC-KD*M697Y)-T,,!F/#?NL/G>7H\S8O87[\Y =GL=?[U8XU[2
M.X/QZ.K>7<MN,D"V62XVZ:SR%*,PYAB&(H\AHAF&E)(8QCGE- R3) OP-;D@
M#_J;&A6WXH&'#Y^NRSMXB*L923I$RS,#GLI%V('G(RF8(3)>4Q0>]GG39(5G
M +B4MO#<:P/-P^+KHI %TT7&&[<]U=>'Y;S0-2RWGG8<YUD<,083'"80,:K]
M?0(*&0UB+!%+9&QG AIU.S5N^;1^?"3EL]XO[2@ MAJ 3H7ZH.^WQD/]H5H5
MCVI;;.F=;C@RAK:;<[Q]VV<7\/7D]F@%DUL+RZSK<:TH*SB.+"6[MX<6+6S]
MP#^*IV6I>_BT(JMU-6-$>V!'!*:1#J\A.(=8)B$D',N,,1SPT-AWH:^CJ7%4
M(^LFP&(C+6C$M2U:> ;=?M9QB9EO*V@@7 .*%O9C<471PC,-CURTL%^]XZ*%
M%YX?9LZ\7WT3Y:^$?5.;K?+Y?L%UBM0Z\K>]\(D3DO&4$1@SSB#*8[6Y#\(8
MIBC)>)BG44"MBEY?ZG!J]*":K],L#XCLOXBMF2GB$C'/Y%"+"C:RUD;=1MK+
MEY'6YH<I-$X-CXN=CFIRF$)P:&P8OS<X,YY.N/RA7'XON. OGI5MS]\L-@E+
M[G7QU;J \RP):<XREL$P2Y3AP0(,<[4]@ED4I'$8)AAIAK%*BF?8M177C)0/
MK\[K_M3*K@]4?UKKH]1B\3-8;O+PD(T*UGGQ3$?%C)O\8.V9I33,=5KW#[LP
M_];!O$UW='\9YB%Y\"P1<YT"S[3[L;/?6<)R(O&=;0L# \36Y:)8K4OMS?"Z
M^*'_5K4+>D0(CI.$09FB$**$,4C33!\E9UDF<" %MRIC>;ZKJ9E)&TGK-5^V
MLEK&[IP'UHR-W,#EF7WVD>K$]& <74;#;2#+^>[&C4:YJ/912,GE-P:X=[Y4
MOR@8F6\\1KMOF:$TQ(G(82RI#A)!"))8)C"1*0V0H%*:Y3'I[65J_-#)"1XW
M@EKX))[%LI\7G"'DF1(VX&QE'.*Y>18E"Z=-%VB-Y*]Y C5'GIJ70.AUTCS[
M\GC^F9?DWW/-O/CPT"H0=1+*:O6YSC^\N7Z)4D3BG",H>2(@XAF#A"82"K71
MBU+,2!I:90$YT\_D^&_Y^*2PU06DNNR_@"FI;:L\G ;5S#QR )5G(FSSRVH9
MP9=:2N#EVNH"$HYK+YSN:^0*"[T*']=1Z']\Z-739_+C#5>3H+[ETJM#D[)V
MQD.61 F5,$>A3B,;)# /==F_"*>YE$3B2-C=/9WI:6JTT-ZF*&G!OKAMCF7;
MVZ=S )M>/SF ;9S[)WO$!EQ 74#CBANH<RV/? 5U0<'C.ZA++SBLT;SQ(R,B
M2N( Y3"A20H122*8)P&"&14<,9PG"!O5#C#J;6H$T=1LOMHW;Q]1,W/!&4Z^
M&>%<C>!1O/).HN*_;/ T//).*F]41MB5-]Z:5N)_KQ4C/7Q7_WF[\=!/(Q:%
M<8AAR$*A"[S'$"=JUT$YRK-4RBRTVV:<ZVAJ?+&5$]2"7A,G<0Y;,_IP@9AG
MYA@&UH#<@/U(.,X#>*:SD7/^]:M\G-_OPO-7>+=\%$P4=5Z@2M\1M3F($Q%0
M&:$4$J;/(5@H(0ES95I(U9*,49(R:NW7<K*KJ5%$XZ11;D4=X-5R&E,S8G"#
ME&=J:$#:D?(.*#DW>9@=N[#THN'>>>5T=^.[K?2J?=)AI?^-JTXJFW(Y:S+7
M$:5M,06<THSR5, \(!PB%&40RTC"/$2Y2' 4*.MBP&'EB:ZF1A+[A9V4J'7\
MLV6E"@.$K4XNK\1MC,/+ 9 -/;WL0</' >:I[FYQAMFC]IECS+XW!A?%6I4%
M6PFN74YT5@OUAW:@^T[F^HQ_1A%-LQ!QF-%4W_%*#'%.,IAE+.2*4@*$C9*2
MF78X-?K8REL[M%E7Q.I'UXPT7&+FF3IVX*H=T^JL1_HO.^(ZK8UE!(SK\EC]
MG8Y=(<L(@A-%LLS>\U!LKXX$>IZE69+C)*$0"Y%KFT19)QE+(&-Q*I,HY4(8
M5<VRZ'."['*ZC)R^LK+<SIA ;LPW+H'T3SF]I?CNFM#!9_"E_=/+1:P%9N,5
MZVO[G4[)OGT@K KW';PZC);^+HJOWW0(]7=1DJ^;.J/U:6[U?KVJ5NHC:C,K
MLUD6(!0$!,& 1+0Y6<%"64%,_32B.,P)-KK,'=3[U*BJN8CXJ2YE7_UL1TUV
ML$<IE31*(QA*IM-8J(^>D%3M5;,(XYP+'-%TIEJBRYL#ORN%;^A_;Y4 I-$"
M-$,!EEOYQQD>GH0H" E$:H6&** 1S%.<0DR3*$@#% 4\FBV$8>$/]T.S24CG
MNY#'M(;%;&GW-A,\+_*=W* 5O*O<K?,Q-'CO"-_>FKI;W >AYG29MY-@U 5_
M$#B'2_^P1IRF49HQB@))XPBJ38DB-BE#M>1@"G.2(L5KA#%D=49ZII^I+>Q=
MYI^?UA77E6H: K/DJG.8<IQ(%,9J!8]8IG,Q1)!R$D 2Q$D8X1C'C-JMY0Y0
M'6?5UL%YQ8(M'P7X:5[GWMR "\A*;;[I>E4[AJZ60#WUN%PT%4V_+>?J6ZX
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M"_U-C;B:VW8N5J28V_HW7$#6C+$<XN69H3I)ZS+C-6ST&=32MME/@9?@$T.
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M6Z!PTL9K^1,<H9-V/N&?/F#N?C=GRY_GJZ;/09E#HM+<S+_0%K_0H@2,9CF
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M\U3KTGWC'4)U:'UR9M1UW; ]T6=SVWO=B@ZJ<B!))E4.>0E4696KR# @+&5
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M$"8"D$QI((N\@%!23C3S.UR+]BF-<^#V\D+'</L%G8W*7?+=FA1S<#R<+C$
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MR!N6LT,C_R<,([*W2[&VVYQ7JO[S[?+]_K#J)7N8&U(X'*4B#FE.,@[24FJ
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M!(SZ.5\R[>E7>_&:81_G+ZNE>OR%K?^JMF]V2[EIEL,9DX7("@(*Q@A LE2
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M]COD\U1@:@2SUW_O@ZP^G%5=1*=QO@VN:.L]."A+2\(*!(C920.4<P&(X7V
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M@YRCA=T!8C;T3U0R6K-D('I"M^(B09#:@&;&),VY#Z5EAKH'9WC E/1>XNS
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MR!J-SQX%+VT*AYZB4\#-*)0D_F:Q?FU>QQ=O<;%NNC91WC-",2T.&02MO.#
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M4![_U8Q(PDLB+I$92,&F-NW)QA RM7(0"_E+GA4;K=5>J#9)GBT$'7\L??[
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M X .H;]^T;E>?G>9LQR5CZ5 CDA+CVM6.V07T(II95!*+]O<IMF+S'&OTG2
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ML\MV],_2:OIENII>&XK@L[.LCE?'%*OIE:DVUU$@LU \.(W)M]D#]Z>UDR+
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MGJQ=\XF,6A:A(@29:-/0!"5G(Z]].86DC4.C;S8<_%"B>VL-\Y20'5RI709
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M:>3YFT=K^Q[X'"_Z'C!T1?[OX92^O-8X_,7\-$QG$UI.2O'$P6KG-F<7@?M
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M*7WLN8UN(#]$?1]WCIWP7HE,, D\U59X'&)B",)DSKD*GN<VW89[N7,\4).
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M#+WWT:VL][0.?<9!F8U>Y@):U#(D:@[.:@^6>VX+=U*61E>W/^<XZ.VX4SU
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M_NL?_P=02P$"% ,4    "  )C013Y&1/MDT(  #R+0  $
M@ $     97AH:6)I=#,Q,3$Q+FAT;5!+ 0(4 Q0    (  F-!%/=8X[@5P@
M /(N   0              "  7L(  !E>&AI8FET,S$R,3$N:'1M4$L! A0#
M%     @ "8T$4V+J%K[(!0  >28  !               ( ! !$  &5X:&EB
M:70S,C$Q,2YH=&U02P$"% ,4    "  )C013IR6@A<L%   _)@  $
M        @ 'V%@  97AH:6)I=#,R,C$Q+FAT;5!+ 0(4 Q0    (  F-!%,X
M>-1<B* ! .SG$  1              "  >\<  !T87)S+3(P,C$P-C,P+FAT
M;5!+ 0(4 Q0    (  F-!%,H<UC5A0P  ,YZ   1              "  ::]
M 0!T87)S+3(P,C$P-C,P+GAS9%!+ 0(4 Q0    (  F-!%-I[/3>;!D  (?V
M   5              "  5K* 0!T87)S+3(P,C$P-C,P7V-A;"YX;6Q02P$"
M% ,4    "  )C013P\;PSY8P  "E# ( %0              @ 'YXP$ =&%R
M<RTR,#(Q,#8S,%]D968N>&UL4$L! A0#%     @ "8T$4V1NT4Y#G0  O8,&
M !4              ( !PA0" '1A<G,M,C R,3 V,S!?;&%B+GAM;%!+ 0(4
M Q0    (  F-!%.-R*NG 5P  .<D!  5              "  3BR @!T87)S
G+3(P,C$P-C,P7W!R92YX;6Q02P4&      H "@"" @  ; X#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
